| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
AbbVie Inc.$248.08
-1.83 (-0.73%)
A 91Pipeline Score Fair Value Pharma · Commercial
Market Cap
380.57 B
EPS
2.03
P/E Ratio
106.24 $
Value Trade
1.23 B
SEC Financials
Q1 2026Dilution Risk
Revenue
15.00 B
R&D Expenses
2.47 B
Operating CF
3.83 B
Total Assets
136.46 B
Total Liabilities
136.46 B
Equity
-6.66 B
D/E Ratio
12,345
1.22 %
Week
5.13 %
1 Month
-4.15 %
3 Month
-6.44 %
6 Month
83.54 %
5 Year
482.97 %
All Time
Cash Data
Cash Position
9.39 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
5.78 M
52 Week Range
181.73 - 244.81
% held by Insiders
0.12 %
% held by Institutions
77.4 %
Enterprise Value
444.08 B
Total Shares
1.77 B
Short %
1.24 %
Float Shares
1.77 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AbbVie Inc.
2659Total events
16Upcoming
1148Tier-1 (high impact)
2013 – 2030Coverage
Upcoming catalysts 16
Sep 2026
T1EU Approval
Expected European Commission decision on upadacitinib for severe alopecia areata
2027
T2Quarterly Update
Raised long-term outlook for Skyrizi and Rinvoq: combined 2027 revenues >$27 billion
2027
T2Quarterly Update
Raised long-term outlook for Skyrizi and Rinvoq: combined 2027 revenues >$27 billion
2030
T2Timing Guidance
Transaction expected to be accretive to adjusted diluted EPS beginning in 2030
TBD
T1FDA Filing Accepted
AbbVie and Genmab to engage global regulatory authorities to discuss next steps
TBD
T2Other Regulator Milestone
AbbVie and Genmab to engage global regulatory authorities to discuss next steps
TBD
T2Other Regulator Milestone
Marketing authorization submissions under review in multiple other countries
TBD
T1Full Results
Full results to be published in upcoming medical journal and shared at future medical congresses
TBD
T2Other Regulator Milestone
Marketing authorization submissions under review in multiple other countries
Event history 2643
Jul 6, 2026
▲EU ApprovalEpcoritamabApprovedEx-US Regulatory
EC approval of TEPKINLY + lenalidomide + rituximab for R/R FL
relapsed or refractory follicular lymphomasource ↗
Q3 2026
◆EU ApprovalMAVIRETApprovedEx-US Regulatory
Expected EC approval decision for MAVIRET in acute HCV
acute hepatitis C infectionsource ↗
Jul 2026
▲Product LaunchBoeyPost-Market
Commercial launch of Boey in Europe
moderate to severe glabellar linessource ↗
Jun 30, 2026
▲Milestone PaymentCorporate
Fourth R&D milestone achieved under AbbVie collaboration; $10M payment triggered
neurological diseasessource ↗
Jun 29, 2026
▲CHMP Positive OpinionUpadacitinibApprovedEx-US Regulatory
Positive CHMP opinion for upadacitinib in non-segmental vitiligo
non-segmental vitiligosource ↗
Jun 29, 2026
▲Topline ReadoutEpcoritamabApprovedClinical Data
Topline results from Phase 3 EPCORE DLBCL-4 trial announced
relapsed or refractory diffuse large B-cell lymphomasource ↗
Jun 29, 2026
▲Primary Endpoint MetEpcoritamabApprovedClinical Data
Phase 3 EPCORE DLBCL-4 trial met primary endpoint of PFS with epcoritamab plus lenalidomide vs R-GemOx
relapsed or refractory diffuse large B-cell lymphomasource ↗
Jun 29, 2026
▲CHMP Positive OpinionUpadacitinibApprovedEx-US Regulatory
Positive CHMP opinion for upadacitinib in non-segmental vitiligo
non-segmental vitiligosource ↗
Jun 23, 2026
▲EU ApprovalSKYRIZIApprovedEx-US Regulatory
European Commission approval of SKYRIZI for pediatric plaque psoriasis
moderate to severe plaque psoriasis in pediatric patients 6 years and oldersource ↗
Jun 23, 2026
▲EU ApprovalMAVIRETApprovedEx-US Regulatory
European Commission approval of MAVIRET for acute HCV infection
acute hepatitis C virus infectionsource ↗
Jun 23, 2026
▲Primary Endpoint MetMAVIRETApprovedClinical Data
Phase 3 M20-350 study met primary endpoint of SVR12
acute hepatitis C virus infectionsource ↗
Jun 23, 2026
▲Full ResultsMAVIRETApprovedClinical Data
Full results of Phase 3 M20-350 study disclosed in press release
acute hepatitis C virus infectionsource ↗
Drug Pipeline Intelligence
A91
Pipeline Score $91.3B
Pipeline ValueFair Value
Valuation Signal304
Drugs Scored0.8x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 911)
Percentile RankAbbVie Inc. earns an A-grade pipeline score (91/100), with $91.3B risk-adjusted pipeline value, led by MGd in Metastatic Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGd Small molecule | Metastatic Cancer | Phase 3 | NCT00003563 | 42% | $21.4B | COMPLETED | 430 | - | - | Jun 1, 2005 | - | Oct 31, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
epcoritamab BreakthroughPriorityAccelerated | relapsed or refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p-value <0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p-value <0.0001 Read More | AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Read More | |
epcoritamab BreakthroughPriorityAccelerated | relapsed or refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p-value <0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p-value <0.0001 Read More | AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Read More | |
epcoritamab BreakthroughPriorityAccelerated | relapsed or refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p-value <0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p-value <0.0001 Read More | AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABBV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ABBV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABBVAbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
AbbVie announced that the European Commission has approved TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. This marks the first bispecific therapy approved in Europe for this condition, demonstrating significant improvements in progression-free survival and overall response rates in the Phase 3 EPCORE FL-1 trial. The treatment offers a chemotherapy-free option, with a notable 74% of patients achieving a complete response.
Read more →ABBVAbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
AbbVie announced that the European Commission has approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for treating adult patients with relapsed or refractory follicular lymphoma. This approval is based on the Phase 3 EPCORE FL-1 trial, which demonstrated significant improvements in progression-free survival and overall response rates. TEPKINLY offers a chemotherapy-free treatment option, marking a significant advancement in the management of this persistent cancer.
Read more →ABBVMidera Food Processing and Centrus Energy Set to Join S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: Midera Food Processing Inc. (NASD: MFP) will replace Redwood Trust Inc....
S&P Dow Jones Indices announced changes to the S&P SmallCap 600, with Midera Food Processing replacing Redwood Trust effective July 8, 2026, and Centrus Energy replacing Whitestone REIT effective July 14, 2026. These adjustments are part of ongoing market evaluations and reflect the evolving landscape of small-cap stocks.
Read more →ABBVNxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nxera Pharma has successfully reached a fourth R&D milestone in its collaboration with AbbVie, leading to a $10 million payment. This milestone is part of a multi-target discovery effort focused on neurological diseases, utilizing Nxera's NxWave platform. The collaboration has yielded a total of $40 million in payments to date and has the potential for up to $1.2 billion in future milestones.
Read more →ABBVS&P Cotality Case-Shiller Index Reports Annual Gain in April 2026 S&P Dow Jones Indices (S&P DJI) today released the April 2026 results for the S&P Cotality Case-Shiller Indices....
The S&P Cotality Case-Shiller U.S. National Home Price Index recorded a 0.8% annual gain for April 2026, despite ongoing declines in real home values due to inflation. Chicago showed the strongest growth at 6.5%, while Seattle experienced a 2.3% drop. The report highlights significant regional disparities in housing trends and ongoing affordability challenges.
Read more →ABBVAllison Transmission Holdings Set to Join S&P MidCap 400 and Goodyear Tire & Rubber to Join S&P SmallCap 600 Allison Transmission Holdings Inc. (NYSE: ALSN) will replace Goodyear Tire & Rubber Co. (NASD: GT) in the S&P MidCap 400, and Goodyear Tire & Rubber...
Allison Transmission Holdings Inc. will replace Goodyear Tire & Rubber Co. in the S&P MidCap 400, effective July 6, 2026. Concurrently, Goodyear will take the place of Stellar Bancorp in the S&P SmallCap 600. This change follows Prosperity Bancshares' acquisition of Stellar Bancorp, set to close on July 1.
Read more →ABBVAbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, showing that the combination of epcoritamab and lenalidomide significantly improves progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint, reducing the risk of disease progression and death by 60%. AbbVie plans to engage with regulatory authorities regarding next steps.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie has received a positive opinion from the CHMP recommending the approval of upadacitinib (RINVOQ) for treating severe alopecia areata in adults and adolescents. The recommendation is based on data from the Phase 3 UP-AA clinical program, where the drug met its primary and key secondary endpoints. A final decision from the European Commission is anticipated soon.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie has received a positive opinion from the CHMP for upadacitinib (RINVOQ) to treat adults and adolescents with non-segmental vitiligo. This recommendation is based on Phase 3 Viti-Up studies, where the drug met its co-primary endpoints for skin repigmentation. If approved, it will be the first systemic medication for this condition, addressing a significant unmet need.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment...
AbbVie has received a positive opinion from the CHMP for upadacitinib (RINVOQ) as a treatment for non-segmental vitiligo in adults and adolescents. This approval could mark the first systemic medication for this autoimmune condition. The recommendation is based on Phase 3 clinical trial results showing significant repigmentation improvements. A final decision from the European Commission is anticipated soon.
Read more →ABBVAbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell...
AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, which evaluated the combination of epcoritamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial demonstrated a significant improvement in progression-free survival, reducing the risk of disease progression and death by 60%. The safety profile was consistent with existing data on the individual treatments, highlighting the potential of this combination therapy.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
AbbVie announced that the European Medicines Agency's CHMP has issued a positive opinion for upadacitinib (RINVOQ) for treating severe alopecia areata in adults and adolescents. The decision is based on data from the Phase 3 UP-AA clinical program, where the drug met its primary and key secondary endpoints. A final decision from the European Commission is anticipated soon.
Read more →ABBVAbbVie to Host Second-Quarter 2026 Earnings Conference Call
AbbVie will announce its second-quarter 2026 financial results on July 31, 2026, before the market opens. The company will host a live webcast of the earnings conference call at 8 a.m. Central time, which will be available on its Investor Relations website. An archived version will also be accessible later that day.
Read more →ABBVGulfport Energy and Mobility Global Set to Join S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: Gulfport Energy Corp. (NYSE: GPOR) will replace Select Medical...
S&P Dow Jones Indices has announced changes to the S&P SmallCap 600, with Gulfport Energy Corp. and Mobility Global Inc. set to join the index. Gulfport will replace Select Medical Holdings, which is being acquired, while Mobility Global will replace Core Laboratories, which no longer fits the small-cap criteria. These changes will take effect on July 1 and July 2, 2026, respectively.
Read more →ABBVSKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of...
AbbVie announced that the FDA has approved SKYRIZI (risankizumab-rzaa) for pediatric patients aged six and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe for patients weighing less than 40 kg, making SKYRIZI the first IL-23 inhibitor available for this demographic. The approval aims to improve treatment access and disease management for affected children.
Read more →ABBVNETSTREIT Set to Join S&P SmallCap 600 NETSTREIT Corp. (NYSE: NTST) will replace ProAssurance Corp. (NYSE: PRA) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, ...
NETSTREIT Corp. will replace ProAssurance Corp. in the S&P SmallCap 600, effective June 29, 2026. This change comes as ProAssurance is being acquired by The Doctors Company in a cash deal. The inclusion of NETSTREIT in the index highlights its growing significance in the real estate sector.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence...
Allergan Aesthetics, part of AbbVie, has announced the 2026 cohort for The Confidence Collective, a program aimed at empowering women entrepreneurs. This year, 250 women were selected to receive mentorship and resources, with 20 participants eligible for $20,000 grants. The initiative highlights the importance of support for women in business and aims to foster community and growth.
Read more →ABBVAbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds
AbbVie and Galderma control 80% of AI citation share in aesthetic medicine, according to the 2026 AI Visibility Index. The index highlights the dominance of these brands in a rapidly growing market valued at $25 billion. Notably, Botox scored the highest among brands, reflecting its strong association with wrinkle treatments. The findings emphasize the importance of AI visibility for patient acquisition in the sector.
Read more →ABBVAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
AbbVie announced that the European Commission has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This approval allows for earlier treatment initiation, potentially reducing liver disease progression risks. MAVIRET is now the only EU-approved therapy for both acute and chronic HCV infections, supporting efforts to eliminate HCV as a public health threat.
Read more →ABBVAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
AbbVie announced that the European Commission has approved SKYRIZI (risankizumab) for treating pediatric patients aged six and older with moderate to severe plaque psoriasis. This approval is based on data from pivotal Phase 3 trials and introduces a new 55 mg pre-filled syringe for weight-based dosing. The decision aims to provide effective treatment options for children, who often experience significant quality of life impacts due to the disease.
Read more →ABBVAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and...
AbbVie has received European Commission approval for SKYRIZI (risankizumab) to treat children and adolescents aged six and older with moderate to severe plaque psoriasis. This approval is based on pivotal Phase 3 trials and introduces a new 55 mg pre-filled syringe for patients under 40 kg. The treatment aims to address the significant impact of psoriasis on children's quality of life.
Read more →ABBVAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey® is the first and only rapid-onset and...
Allergan Aesthetics has received Health Canada approval for Boey® (trenibotulinumtoxinE), the first botulinum neurotoxin serotype E for aesthetic use. This rapid-onset treatment is designed for the temporary improvement of glabellar lines, with effects visible as soon as eight hours post-treatment. The approval represents a significant advancement in aesthetic medicine, providing a differentiated option for patients seeking facial injectables.
Read more →ABBVHoneywell Aerospace Set to Join S&P 500 & S&P 100; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600: Honeywell Aerospace Inc. (NASD:...
S&P Dow Jones Indices announced significant changes to its indices, including the addition of Honeywell Aerospace to the S&P 500 and S&P 100, effective June 29, 2026. Conagra Brands will replace Grid Dynamics Holdings in the S&P SmallCap 600. Other notable changes include Toast Inc. and IES Holdings Inc. joining the S&P MidCap 400.
Read more →ABBVAlphabet Set to Join and Honeywell International to Remain in Dow Jones Industrial Average Alphabet Inc. (NASD:GOOGL) will replace Verizon Communications Inc. (NYSE:VZ) in the Dow Jones Industrial Average (DJIA) effective prior to the...
Alphabet Inc. will replace Verizon Communications in the Dow Jones Industrial Average effective June 29, 2026. This change aims to enhance the index's representation of the technology sector. Additionally, Honeywell International will spin off Honeywell Aerospace but will retain its position in the DJIA under a new name. The adjustment is part of a routine update to maintain the index's accuracy.
Read more →ABBV▲ +6.2%on this newsshared move
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and...
AbbVie has announced its acquisition of Apogee Therapeutics for approximately $10.9 billion, aimed at enhancing its immunology portfolio. The acquisition includes Apogee's promising pipeline, notably the monoclonal antibody zumilokibart, which is in late-stage development for atopic dermatitis. This strategic move is expected to accelerate AbbVie's presence in the respiratory space and create long-term value for shareholders.
Read more →ABBV▲ +6.2%on this newsshared move
AbbVie Declares Quarterly Dividend
AbbVie Inc. has announced a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to stockholders of record by July 15, 2026. Since its inception in 2013, AbbVie has raised its dividend by more than 330%, earning a spot in the S&P Dividend Aristocrats Index for consistent annual increases over 25 years.
Read more →ABBVAllergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to ...
Allergan Aesthetics, a subsidiary of AbbVie, announced FDA approval for SKINVIVE by JUVÉDERM®, an injectable treatment aimed at reducing neck wrinkles. This product is notable for being the first hyaluronic acid injectable approved specifically for neck line enhancement, designed for adults aged 21 and over. Clinical trials demonstrated significant improvements in participants, with results lasting approximately six months. However, some side effects were reported, including mild adverse events like redness and swelling, while safety data in darker skin tones remains limited.
Read more →ABBVAbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
AbbVie presented new Phase 3 data on venetoclax at the EHA 2026 Congress, highlighting nine-year results from the CLL14 trial. The findings show significant long-term efficacy and safety of venetoclax combined with obinutuzumab for first-line treatment of chronic lymphocytic leukemia. The study indicates a median progression-free survival of 6.4 years, compared to 3.2 years with chlorambucil-based therapy.
Read more →ABBVAbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA)...
AbbVie presented new Phase 3 data at the EHA 2026 Congress, highlighting the nine-year results of the CLL14 trial. The study showed that venetoclax combined with obinutuzumab significantly improves progression-free survival in previously untreated chronic lymphocytic leukemia patients. The findings support the use of this regimen as a fixed-duration treatment option, offering patients extended time without treatment.
Read more →ABBVFirst Advantage Set to Join S&P SmallCap 600 First Advantage Corporation (NASD: FA) will replace Kennedy-Wilson Holdings Inc. (NYSE: KW) in the S&P SmallCap 600 effective prior to the opening of ...
First Advantage Corporation will replace Kennedy-Wilson Holdings Inc. in the S&P SmallCap 600 index effective June 16, 2026. This change comes as Kennedy-Wilson is being acquired by a consortium led by its CEO. The move is expected to enhance First Advantage's market presence and investor interest.
Read more →ABBVAllergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want, the latest installment in The Aesthetics Evolution ...
Allergan Aesthetics, a subsidiary of AbbVie, has launched the latest report in its Aesthetics Evolution series titled 'What Consumers Really Want'. This report delves into changing consumer perspectives on aesthetics, emphasizing their desire for a transformative experience rather than a transactional one. It highlights insights from extensive consumer research and expert interviews, aiming to enhance innovation and education in the aesthetics field. The report also builds on previous findings related to hyaluronic acid injectables, setting industry standards for consumer expectations.
Read more →ABBVAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical...
AbbVie presented new data at the EHA 2026 Congress, showcasing advancements in its blood cancer portfolio. The company highlighted 21 oral and poster presentations, including promising results for the investigational compound etentamig and established therapies like epcoritamab and venetoclax. These findings emphasize AbbVie's ongoing commitment to enhancing treatment outcomes for patients with various blood cancers.
Read more →ABBVAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
AbbVie presented new data at the EHA 2026 Congress, emphasizing its leadership in blood cancer research. The company highlighted advancements in therapies for multiple myeloma, follicular lymphoma, and other hematologic cancers. Key findings included promising results for the investigational compound etentamig and the approved therapies epcoritamab and venetoclax, showcasing their potential to improve patient outcomes.
Read more →ABBVSirius XM Holdings Set to Join S&P MidCap 400 Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on...
Sirius XM Holdings Inc. will replace Masimo Corp. in the S&P MidCap 400 effective June 11, 2026. This change follows Danaher Corp.'s acquisition of Masimo, which is pending final conditions. The addition of Sirius XM highlights its growth in the communication services sector.
Read more →ABBVMarvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of...
S&P Dow Jones Indices announced changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices, effective June 22, 2026. Marvell Technology and Flex will be added to the S&P 500, while several companies will be removed. The adjustments aim to better reflect the market capitalization of the indices.
Read more →ABBVS&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results S&P Dow Jones Indices ("S&P DJI") conducted a consultation with market participants on potential changes to the S&P U.S. Indices Methodology and Dow...
S&P Dow Jones Indices conducted a consultation regarding potential changes to its U.S. Indices Methodology for MegaCap companies. Following feedback from market participants, the Index Committee decided to maintain the current eligibility criteria for the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices. This decision aims to preserve the core principles of the indices while ensuring they remain representative benchmarks for the U.S. equity market.
Read more →ABBVAbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
AbbVie has received European Commission approval for AQUIPTA (atogepant) as an acute treatment for migraines in adults. This marks the second indication for AQUIPTA in the EU, complementing its preventive treatment approval. Clinical trials demonstrated AQUIPTA's effectiveness, showing significant pain relief and sustained effects. The approval aims to meet the needs of individuals suffering from migraines across Europe.
Read more →ABBVAbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AbbVie will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The management will engage in a fireside chat at 9:40 a.m. Central time, which will be accessible via a live audio webcast. An archived version will be available later the same day.
Read more →ABBVAbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic LeukemiaUSA - EnglishUSA - English
AbbVie has received European Commission authorization for an expanded label for VENCLYXTO (venetoclax), allowing its use in combination with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia (CLL). This decision supports the evolving treatment landscape, offering patients more targeted, oral therapy options. The new combinations aim to enhance patient outcomes and quality of life by providing the possibility of treatment-free intervals.
Read more →ABBVU.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
AbbVie announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first antibody-drug conjugate approved for this aggressive blood cancer. The approval is supported by data from the Phase 1/2 CADENZA trial, showing significant response rates in newly diagnosed patients. DECNUPAZ offers a new treatment avenue for patients with limited options.
Read more →ABBVU.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the...
AbbVie announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for treating adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first antibody-drug conjugate approved for this aggressive blood cancer, which has historically had limited treatment options. The approval is based on promising results from the Phase 1/2 CADENZA trial, showing significant response rates.
Read more →ABBVFedEx Freight Holding Company Set to Join S&P 500; EPAM Systems and Dave to Join S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: FedEx Freight Holding Company (NYSE: FDXF) will replace EPAM...
S&P Dow Jones Indices announced changes to the S&P 500 and S&P SmallCap 600 indices. FedEx Freight Holding Company will replace EPAM Systems in the S&P 500, while EPAM Systems will take the place of Shutterstock in the SmallCap 600. Additionally, Dave Inc. will replace American Woodmark in the SmallCap 600. These changes are effective on June 1 and June 2, 2026.
Read more →ABBVFedEx Freight Holding Set to Join Dow Jones Transportation Average FedEx Freight Holding Company Inc. (NYSE:FDXF) will replace American Airlines Group Inc. (NASD:AAL) in the Dow Jones Transportation Average (DJTA)...
FedEx Freight Holding Company Inc. will replace American Airlines Group in the Dow Jones Transportation Average effective June 1, 2026. This change comes as part of a spin-off from FedEx Corp., which will continue to be part of the index. The adjustment is aimed at improving the index's representation of the transportation sector.
Read more →ABBVS&P U.S. Indices Eligible Exchanges Methodology Update S&P Dow Jones Indices ("S&P DJI") announces a methodology change to the S&P U.S. Indices' list of eligible exchanges. To support the indices'...
S&P Dow Jones Indices announced an update to its methodology, adding the Texas Stock Exchange as an eligible exchange for the S&P U.S. Indices. This change will take effect with the commencement of continuous trading on July 6, 2026. The addition aims to enhance the measurement of U.S.-domiciled stocks, although no immediate impact on the indices is anticipated.
Read more →ABBVS&P Cotality Case-Shiller Index Reports Annual Gain in March 2026 The S&P Cotality Case-Shiller U.S. National Home Price NSA Index posted a 0.7% annual gain for March 2026, down from a 0.8% rise in the previous...
The S&P Cotality Case-Shiller U.S. National Home Price NSA Index reported a 0.7% annual gain for March 2026, a slight decrease from the previous month's 0.8%. Over half of major U.S. metropolitan areas experienced year-over-year price declines, with Seattle showing the largest drop at 2.5%. The ongoing inflation has led to negative real home price returns for ten months, indicating a significant slowdown in the housing market.
Read more →ABBVDow Jones Industrial Average® Celebrates 130 Years as Iconic American Benchmark Legacy of Excellence: The Dow Jones Industrial Average® (DJIA®) turns 130, cementing its status as a symbol of American business strength,...
The Dow Jones Industrial Average (DJIA) marks its 130th anniversary, showcasing its evolution from 12 industrial companies to a benchmark of 30 leading firms. Celebrated as a symbol of American business strength, the DJIA recently closed above 50,000 for the first time, reinforcing its relevance in global markets. S&P Dow Jones Indices plans global events to honor this milestone throughout 2026.
Read more →ABBVAbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C InfectionUSA - EnglishUSA - DeutschBrazil - PortuguêsUSA - EnglishLatin America - españolUSA - FrançaisUSA - español
AbbVie announced a positive opinion from the CHMP recommending MAVIRET for treating acute hepatitis C infection. This oral therapy is aimed at both adults and children aged 3 and older. The final decision from the European Commission is expected in Q3 2026. The treatment demonstrated a 96% cure rate in clinical trials, highlighting its efficacy.
Read more →ABBVAbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AbbVie announced new data at the ASCO 2026 Annual Meeting, highlighting advancements in its oncology pipeline. The presentations cover various cancer types, showcasing the potential of its antibody-drug conjugate and T-cell engager platforms. Key findings emphasize AbbVie's strategy to tackle cancer's complexity through diverse therapeutic approaches.
Read more →ABBVAbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago...
AbbVie announced new data at the 2026 ASCO Annual Meeting, showcasing its oncology pipeline's potential across solid tumors and blood cancers. Key findings include promising response rates for investigational therapies like ABBV-969 and ABBV-706 in prostate and small cell lung cancers. The company emphasizes its commitment to innovative cancer treatments addressing critical patient needs.
Read more →ABBVAllergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's...
AbbVie subsidiary Allergan Aesthetics has received a positive opinion from the CHMP for its product Boey® (trenibotulinumtoxinE), aimed at treating moderate to severe glabellar lines in adults. The endorsement is based on promising results from two pivotal Phase 3 clinical trials that met all primary and secondary endpoints. If approved, Allergan plans to train healthcare professionals and prepare for a commercial launch in the coming months while waiting for marketing submissions in other countries. The company emphasizes the product's rapid onset and good safety profile.
Read more →ABBVAbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie will participate in the Bank of America Securities Healthcare Conference on May 13, 2026. The management team will engage in a fireside chat at 1:20 p.m. Central Time, which will be available via a live audio webcast. An archived version will also be accessible later that day.
Read more →ABBVAbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting new long-term data on risankizumab and upadacitinib for treating inflammatory bowel diseases. The findings emphasize the efficacy, safety, and durability of these treatments, with significant improvements in patient quality of life and low switch rates. The data reinforces AbbVie's commitment to advancing IBD care.
Read more →ABBVAllergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
Allergan Aesthetics has launched a philanthropic initiative for Skin Cancer Awareness Month, donating $10 to The Skin Cancer Foundation for each new member who joins its loyalty program, Allē, through referrals in May. The company aims to raise up to $100,000 while promoting skin health education and prevention. Members will also receive discounts on treatments, fostering community involvement.
Read more →ABBVAbbVie Reports First-Quarter 2026 Financial Results Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent;...
AbbVie has reported its first-quarter financial results for 2026, noting a strong performance in key growth areas. Despite a significant drop in GAAP diluted EPS, the company saw an increase in adjusted diluted EPS, leading to an upward revision of its full-year guidance. CEO Robert A. Michael expressed optimism about AbbVie's pipeline progress and potential for long-term growth amidst current challenges.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports First-Quarter 2026 Financial Results Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent
AbbVie announced its first-quarter financial results for 2026, demonstrating a strong overall performance with net revenues of $15.002 billion, a 12.4% increase. The immunology portfolio, particularly Skyrizi and Rinvoq, performed exceptionally well, contributing to the positive revenue trends. However, the GAAP diluted EPS experienced a 45.8% decline, and revenues from Humira starkly dropped by 38.6%. Notably, AbbVie raised its adjusted diluted EPS guidance and is advancing multiple applications in the pipeline, including those for Crohn's disease and alopecia areata treatment.
Read more →ABBVAbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
AbbVie has submitted an application to the FDA for upadacitinib (RINVOQ) to treat severe alopecia areata in adults and adolescents. The application is based on positive results from the Phase 3 UP-AA clinical program, which demonstrated substantial scalp hair growth. The treatment aims to alleviate the significant impact of this autoimmune disease on patients' lives.
Read more →ABBVAbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
AbbVie has submitted a regulatory application to the FDA for SKYRIZI (risankizumab-rzaa) to be used as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This application is backed by positive results from the Phase 3 AFFIRM study, which demonstrated the efficacy and safety of the treatment. If approved, this will provide patients with an additional option for managing their condition.
Read more →ABBVAbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the...
AbbVie announced it received a Complete Response Letter from the FDA regarding its Biologics License Application for trenibotulinumtoxinE (TrenibotE). The letter requests additional information about manufacturing processes but does not raise any concerns regarding the safety or efficacy of the product. AbbVie intends to respond promptly to the FDA's comments and remains confident in the application. Regulatory reviews in other countries for TrenibotE are still progressing well.
Read more →ABBVAbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus AbbVie (NYSE: ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The...
AbbVie has announced a significant investment of $1.4 billion to establish a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. This facility will focus on immunology, neuroscience, and oncology medicines, combining advanced manufacturing techniques with artificial intelligence. Construction is expected to begin this year, with the campus set for completion by 2028 and will create 734 jobs, alongside support for over 2,000 construction jobs. This marks AbbVie's first major expansion into North Carolina, aimed at enhancing its manufacturing footprint in the U.S.
Read more →ABBVErin Lichy Gets Real About Her Natrelle® Breast Augmentation Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is...
Erin Lichy, a New York-based entrepreneur, has partnered with Allergan Aesthetics, an AbbVie company, to share her personal experience with Natrelle® breast augmentation. Emphasizing the importance of education and individual goals, Lichy highlights her journey from consultation to post-operative results. Her initiative aims to encourage other women to prioritize their aesthetic aspirations and consider their options transparently. The Natrelle® brand boasts a 50-year legacy in breast aesthetics, providing a range of safe implant options tailored to women's needs.
Read more →ABBVAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
AbbVie presented late-breaking Phase 2 data for mirvetuximab soravtansine-gynx at the 2026 SGO Annual Meeting. The study showed promising efficacy and safety in patients with platinum-sensitive ovarian cancer. The combination therapy demonstrated strong responses, particularly in patients previously treated with PARP inhibitors. Further investigation is warranted to explore this novel treatment approach.
Read more →ABBVHaisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
Haisco Pharmaceutical Group has entered an exclusive licensing agreement with AbbVie to develop novel pain treatments. This partnership allows AbbVie to develop and commercialize multiple compounds globally, excluding certain regions in Asia. Haisco will receive an upfront payment and potential milestone payments, enhancing its international presence and R&D capabilities.
Read more →ABBVAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab...
AbbVie presented late-breaking Phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE) at the 2026 SGO Annual Meeting. The trial showed a 62.7% objective response rate in patients with platinum-sensitive ovarian cancer. The safety profile was consistent with earlier studies, indicating a promising treatment option for this patient population.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through The Confidence Collective for Fourth Year Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that applications are now open for The Confidence Collective: Empowering Women...
Allergan Aesthetics, a subsidiary of AbbVie, has opened applications for its initiative, The Confidence Collective, aimed at empowering women entrepreneurs. The program will select 250 women to receive resources, coaching, and community support, with 20 of them awarded $20,000 grants. This initiative seeks to tackle systemic barriers faced by women in entrepreneurship, such as financial literacy and access to capital. Past participants have reported significant personal and professional growth through the program, showcasing its potential impact on their businesses and communities.
Read more →ABBV/C O R R E C T I O N -- AbbVie/
AbbVie, through Allergan Aesthetics, has announced the fourth annual CoolMonth, featuring exclusive offers on CoolSculpting treatments. This initiative aims to promote body contouring as spring approaches, with many considering aesthetic treatments. The FDA-cleared CoolSculpting is designed to eliminate stubborn fat with minimal downtime, making it a popular choice for those looking to enhance their appearance.
Read more →ABBVAbbVie to Host First-Quarter 2026 Earnings Conference Call
AbbVie will announce its first-quarter 2026 financial results on April 29, 2026, before market opening. A live webcast of the earnings conference call will take place at 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived version will be available later that day.
Read more →ABBVDocument AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
AbbVie Inc. has updated its guidance for the first quarter and full year of 2026, factoring in acquired IPR D and milestones expense. The adjusted diluted EPS for Q1 2026 is projected between $2.56 and $2.60, reflecting a significant expense of $744 million. For the full year, the guidance indicates an adjusted diluted EPS range of $13.96 to $14.16. Notably, the company's guidance excludes any potential expenses incurred after the first quarter, underscoring the uncertainty of future financial impacts.
Read more →ABBVAllergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
Allergan Aesthetics, a subsidiary of AbbVie, is launching its fourth annual CoolMonth, offering exclusive deals on CoolSculpting treatments. From April 1 to April 30, first-time users can receive $400 off their initial treatment. The initiative aims to motivate individuals to achieve their body contouring goals ahead of summer, with CoolSculpting being a trusted, FDA-cleared option for fat reduction.
Read more →ABBVAbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
AbbVie announced it will present new research at the 2026 AAD Annual Meeting, highlighting advancements in immune-mediated skin diseases. The company will showcase 24 abstracts, including a late-breaking presentation, emphasizing sustained treatment efficacy and safety. The findings aim to reshape treatment paradigms and improve patient outcomes in dermatology.
Read more →ABBVAllergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and...
Allergan Aesthetics, a subsidiary of AbbVie, presented findings at the 2026 American Academy of Dermatology Meeting, focusing on the investigational neurotoxin TrenibotulinumtoxinE (TrenibotE) and its favorable safety profile. The presentation also highlighted the growing population of GLP-1 treated patients expressing aesthetic concerns. TrenibotE, which shows rapid efficacy for glabellar lines, if approved, would be a first-in-class offering. Allergan aims to enhance patient trust through continual research and innovation in the aesthetic domain.
Read more →ABBVAllergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco Research reveals an industry mindset shift towards 'undetectable†' aesthetics, as people seek a natural-looking, personalized approach and a subtle,...
Allergan Aesthetics has announced the launch of the 'Undetectable Era' in the hyaluronic acid injectable market at the AMWC 2026 in Monaco. This new approach emphasizes subtle, natural-looking results sought by modern consumers who prefer enhancements that are not visibly noticeable. Research from Allergan indicates that there is a significant shift among patients toward desiring treatments that respect their natural beauty. The JUVÉDERM® Collection of Fillers is positioned to meet this demand, with a focus on personalized, holistic applications by skilled practitioners.
Read more →ABBVAllergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) - Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines ...
Allergan Aesthetics, a division of AbbVie, is set to present 21 scientific e-posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress in Monaco. These e-posters focus primarily on the investigational neurotoxin trenibotulinumtoxinE (TrenibotE), highlighting its rapid efficacy and safety in treating glabellar lines. Other data presented will reinforce BOTOX's leading role in facial aesthetics and patient satisfaction. The presentations reflect Allergan's commitment to evidence-based innovation in aesthetic medicine.
Read more →ABBVAbbVie Named Official Pharmaceutical Partner of Major League Baseball
AbbVie has partnered with Major League Baseball (MLB) as its Official Pharmaceutical Partner, launching the 'Striking Out Cancer' campaign for the 2026 season. This initiative will donate $20 for every strikeout, aiming to raise up to $1 million per season for cancer research. The campaign, which began in collaboration with the Chicago Cubs, will now be a league-wide effort to enhance cancer awareness and advocacy.
Read more →ABBVAllergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced new global consumer research...
Allergan Aesthetics, part of AbbVie, has announced new findings from global consumer research showcasing changing patient expectations in medical aesthetics. With a trend towards multimodal treatment plans, 62% of consumers find multiple treatments appealing and 74% aim to improve facial skin quality within the year. At the upcoming AMWC 2026, the company will present a new report, 'Layered Beauty: The New Aesthetic Mindset,' and discuss advancements in treatment strategies. These updates reflect an evolving approach to personalized aesthetic care that integrates various modalities.
Read more →ABBVAllergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index Allergan Aesthetics, an AbbVie company, today announced the launch of the Skin Quality Index (SQI), a unified vocabulary developed to standardize how ...
Allergan Aesthetics, a subsidiary of AbbVie, has launched the Skin Quality Index (SQI) to standardize communication about skin quality among patients and healthcare providers. This initiative aims to resolve discrepancies in terminology that have previously hindered effective consultations and treatment planning in aesthetics. Backed by extensive research published in Dermatologic Surgery, the SQI introduces 15 consensus terms across four core dimensions of skin health. Additionally, educational resources have been made available to facilitate better understanding for both patients and providers.
Read more →ABBVAbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie announced positive topline results from a Phase 1 study of ABBV-295, a long-acting amylin analog for obesity. The study showed significant weight loss in participants with a favorable safety profile. Adverse events were mainly mild gastrointestinal issues. Full data will be presented at a future scientific conference.
Read more →ABBVALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration 67% of patients say...
Allergan Aesthetics, a subsidiary of AbbVie, has reported a notable rise in demand for Medical Weight Loss (MWL) treatments, highlighting how these treatments are shifting patient priorities towards aesthetic care. The data suggests that patients are increasingly seeking solutions for facial volume restoration and overall balance after significant weight loss. This trend indicates a new patient demographic entering aesthetic practices, focused on personalized treatment plans. Furthermore, physicians note that the integration of MWL and aesthetics is changing the landscape of treatment preferences and consumer behavior.
Read more →ABBVAbbVie to Present at the Leerink Partners Global Healthcare Conference
AbbVie will participate in the Leerink Partners Global Healthcare Conference on March 10, 2026. The management team will engage in a fireside chat at 10:20 a.m. Central Time, which will be available via a live audio webcast. An archived version of the session will also be accessible later that day.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
AbbVie announced positive topline results from the Phase 3 AFFIRM study, which evaluated the efficacy and safety of risankizumab (SKYRIZI) in patients with moderately to severely active Crohn's disease. The study demonstrated that a higher percentage of patients achieved clinical remission and endoscopic response compared to placebo. The safety profile of risankizumab was consistent with previous studies, with no new safety risks reported.
Read more →ABBVAbbVie to Present at the TD Cowen 46th Annual Health Care Conference
AbbVie will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The management team will engage in a fireside chat at 10:10 a.m. Central Time. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later in the day.
Read more →ABBVAbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
AbbVie announced a $380 million investment to construct two new active pharmaceutical ingredient manufacturing facilities in North Chicago, Illinois. The facilities will utilize advanced manufacturing technologies and AI to support the production of next-generation medications. Construction is set to begin in spring 2026, with operations expected by 2029, creating 300 new jobs in the area.
Read more →ABBVU.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
AbbVie announced that the FDA has approved the combination treatment of VENCLEXTA (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL). This approval, based on data from the Phase 3 AMPLIFY trial, establishes the regimen as the first all-oral, fixed-duration option for CLL patients. The combination has demonstrated superior efficacy compared to traditional chemoimmunotherapy.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable May 15,...
AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, to stockholders of record by April 15, 2026. This announcement highlights AbbVie's strong track record, having increased its dividend by more than 330 percent since its formation in 2013. As a member of the S&P Dividend Aristocrats Index, AbbVie is recognized for consistently enhancing shareholder value through annual dividend increases over an extended timeframe. The company's ongoing mission is to deliver innovative solutions for serious health challenges across various therapeutic areas.
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
AbbVie reported strong financial results for the fourth quarter and full year 2025, highlighting record net sales and a robust growth outlook for 2026. CEO Robert A. Michael emphasized the company's diversified growth platform and ongoing investments in innovation. The adjusted diluted EPS guidance for 2026 is set between $14.37 and $14.57.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent Adjusted Diluted EPS of $10.00, a Decrease of 1.
AbbVie's financial results for the full year and fourth quarter of 2025 show an overall increase in net revenues driven by strong sales in its immunology and neuroscience portfolios. Despite a decrease in diluted earnings per share and a drop in revenues for Humira and certain aesthetics products, AbbVie reported record net sales and expects continued growth in 2026. The company also announced several FDA approvals and strategic partnerships aimed at enhancing their treatment offerings and expanding their pipeline.
Read more →ABBVAllergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Allergan Aesthetics, a subsidiary of AbbVie, has launched the Faces of Natrelle® Testimonial Program, inviting women to share their experiences with Natrelle® breast implants. This initiative aims to educate and empower others considering breast surgery by highlighting diverse personal stories. Participants may receive incentives for their contributions, promoting a cultural shift towards transparency in cosmetic procedures.
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
AbbVie has submitted regulatory applications to the FDA and EMA for upadacitinib (RINVOQ) to treat non-segmental vitiligo in adults and adolescents. The submissions are based on positive results from the Viti-Up studies, which evaluated the drug's safety and efficacy. Currently, there are no approved systemic treatments for vitiligo, highlighting the significance of this development.
Read more →ABBVAbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
AbbVie has launched the Love in Mind initiative to address the emotional impact of migraine on romantic relationships. The initiative is based on a survey revealing how migraine affects the social and emotional lives of those diagnosed. Public figures, such as Jessie James Decker, share their experiences to raise awareness and encourage open communication about migraine management.
Read more →ABBVAllergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
Allergan Aesthetics, a subsidiary of AbbVie, presented new data at the IMCAS 2026 World Congress, focusing on its facial injectables portfolio. Key highlights included efficacy and safety data for TrenibotulinumtoxinE, a first-in-class neurotoxin, and positive results from Phase 4 studies on BOTOX® Cosmetic. The company emphasized its commitment to innovation and personalized treatment approaches.
Read more →ABBVAbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab, a bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma. The trial showed improved progression-free survival and response rates compared to standard chemoimmunotherapy. However, overall survival did not show significant improvement. The study involved 483 patients and will inform future regulatory submissions.
Read more →ABBVAbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing...
AbbVie has entered into a definitive agreement to acquire a device manufacturing facility from West Pharmaceutical Services in Tempe, Arizona. This acquisition aims to significantly enhance AbbVie's drug delivery device manufacturing capabilities and capacity, with planned investments exceeding $175 million. AbbVie will also hire around 200 employees at this new location, as part of its commitment to expanding manufacturing operations in the United States. The transaction is expected to close by mid-2026, pending closing conditions.
Read more →ABBVAbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a ...
AbbVie and RemeGen have entered into an exclusive licensing agreement for the development of RC148, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. RC148 is currently under evaluation in various advanced cancer types and has demonstrated initial favorable outcomes in clinical trials. This partnership allows AbbVie to leverage RemeGen's innovative therapy and further expand its oncology offerings. RemeGen will receive an immediate payment along with potential milestone payments and royalties under the deal.
Read more →ABBVAbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans...
AbbVie has reached a voluntary agreement with the Trump administration to enhance access and affordability of medications for Americans. This agreement will commit AbbVie to invest $100 billion in U.S.-based research and development over the next decade and aims to provide lower prices in Medicaid. Furthermore, AbbVie plans to expand its direct-to-patient offerings through the establishment of TrumpRx, which will provide critical medications to millions of Americans. The specifics of the agreement remain confidential, and AbbVie acknowledges potential risks and uncertainties surrounding its implementation.
Read more →ABBVAbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
AbbVie will announce its full-year and fourth-quarter 2025 financial results on February 4, 2026. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time. This event will be accessible via AbbVie's Investor Relations website, with an archived edition available later.
Read more →ABBVAbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
AbbVie is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management will engage in a fireside chat at 10:15 a.m. Central time, which will be available via a live audio webcast. An archived version of the session will also be accessible later that day.
Read more →ABBVAbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To...
AbbVie ASEAN has achieved the #15 position in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list. This recognition emphasizes the company's strong workplace culture and commitment to employee experience across Singapore, Malaysia, Thailand, and the Philippines. The ranking is based on employee feedback and culture audits, underscoring AbbVie's focus on trust and collaboration.
Read more →ABBVAbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts gathered to address platinum resistance in advanced ovarian cancer with...
At the AbbVie-sponsored symposium during the ESMO Asia Congress 2025, experts highlighted the urgent need for new strategies to tackle platinum-resistant advanced ovarian cancer. The discussion emphasized the challenges of defining platinum resistance and the potential of Antibody Drug Conjugates (ADCs) as innovative treatment options. With a significant unmet medical need, the symposium aimed to improve patient outcomes and explore evolving perspectives on treatment eligibility.
Read more →ABBVAbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
AbbVie announced it will present new data at the 2025 ASH Congress, focusing on advancements in treatments for various blood cancers, including multiple myeloma and chronic lymphocytic leukemia. The presentations will feature both investigational compounds and approved therapies, showcasing AbbVie's commitment to innovation in oncology. Key data will highlight efficacy and safety profiles across their blood cancer portfolio.
Read more →ABBVÀ l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraineUSA - FrançaisUSA - EnglishUSA - españolUSA - Deutsch
AbbVie announced positive results from the Phase 3 ECLIPSE study, showing that atogepant significantly outperformed placebo in providing pain relief for acute migraine treatment. The study met its primary and key secondary endpoints, demonstrating a notable reduction in migraine symptoms. These findings will be presented at the upcoming European Headache Congress, highlighting AbbVie's commitment to enhancing treatment options for migraine sufferers.
Read more →ABBVAbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegenUSA - DeutschUSA - EnglishUSA - español
AbbVie announced positive preliminary results from its Phase 3 ECLIPSE study, demonstrating Atogepant's effectiveness in treating acute migraine compared to placebo. The study achieved its primary and secondary endpoints, showing significant pain relief within two hours of treatment. These findings were presented at the European Headache Congress, highlighting AbbVie's commitment to improving migraine treatment options.
Read more →ABBVAbbVie presentará datos de fase 3 de ECLIPSE en el 19º Congreso Europeo de CefaleasUSA - españolUSA - English
AbbVie announced positive results from the Phase 3 ECLIPSE study, demonstrating that Atogepant (AQUIPTA®) significantly outperformed placebo in achieving pain elimination for acute migraine treatment. The study's findings will be presented at the 19th European Headache Congress in Lisbon. AbbVie aims to expand treatment options for migraine patients in Europe with potential EMA approval.
Read more →ABBVAbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
AbbVie announced positive results from the Phase 3 ECLIPSE study of atogepant, demonstrating its superiority over placebo in achieving pain freedom for migraine treatment. The study met its primary and key secondary endpoints, with significant improvements noted. These findings will be presented at the European Headache Congress, highlighting AbbVie's commitment to enhancing migraine care options.
Read more →ABBVSKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
AbbVie announced that Canada's Drug Agency has recommended SKYRIZI (risankizumab) for reimbursement for adults with moderately to severely active ulcerative colitis. This decision follows consultations with clinicians and patient organizations. Additionally, AbbVie has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance, indicating progress in patient access to this treatment.
Read more →ABBVL’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne
AbbVie announced positive developments for ulcerative colitis treatment in Canada. Health Canada recommended conditional reimbursement for SKYRIZI® (risankizumab) for adults with moderate to severe cases who have not responded to traditional therapies. Additionally, AbbVie signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance to facilitate the drug's use. This decision aims to improve patient access to effective treatment options.
Read more →ABBVAbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
AbbVie will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The management will engage in a fireside chat at 7:30 a.m. Central time. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later.
Read more →ABBVAbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
AbbVie announced FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma. This therapy is the first bispecific antibody combination approved for this indication, showing superior efficacy in the Phase 3 EPCORE FL-1 trial. Approximately 74% of patients achieved complete responses, marking a significant advancement in treatment options.
Read more →ABBVAbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
AbbVie has launched 'Second Winds', a short film that portrays the inspiring journeys of three individuals living with chronic lymphocytic leukemia (CLL). The film emphasizes their resilience and the support they receive from family and community. Premiered in Los Angeles, it aims to raise awareness about CLL and the importance of hope and determination in facing cancer.
Read more →ABBVAbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
AbbVie has announced the 20 recipients of its second annual Migraine Career Catalyst Award, aimed at supporting individuals living with migraines in their professional development. Each winner received $2,500 to invest in opportunities that advance their careers. The initiative seeks to raise awareness about the impact of migraines on work life and empower affected individuals.
Read more →ABBVAllergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Allergan Aesthetics, a subsidiary of AbbVie, will present significant data at the 2025 ASDS Annual Meeting, showcasing advancements in aesthetic treatments. Key presentations include Phase 3 results for a new botulinum toxin and findings from a Phase 4 study on BOTOX® Cosmetic. The event will feature expert panels and educational programs aimed at enhancing clinical practices in aesthetics.
Read more →ABBVAbbVie Reports Third-Quarter 2025 Financial Results
AbbVie announced its financial results for the third quarter of 2025, showcasing strong performance with a notable increase in adjusted diluted EPS guidance. The company declared a 5.5% increase in its quarterly cash dividend, emphasizing its commitment to returning value to shareholders. Despite some challenges, including a decline in Humira's revenue, AbbVie maintains a positive outlook for its portfolio and pipeline.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Third-Quarter 2025 Financial Results Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent
AbbVie reported its third-quarter 2025 financial results, highlighting a net revenue increase of 9.1%, with notable performance from its immunology portfolio. Diluted earnings per share on a GAAP basis fell sharply by 88.6%, while adjusted diluted EPS revealed a 38% decrease. Despite challenges, AbbVie raised its 2025 EPS guidance, reflecting confidence in its future performance. Positive topline data for Rinvoq in various clinical settings supports the overall growth outlook.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
AbbVie announced positive topline results from two Phase 3 studies evaluating upadacitinib for non-segmental vitiligo. The studies showed significant efficacy in achieving co-primary endpoints, with approximately 70% of subjects meeting the criteria. The safety profile was consistent with previous indications, with no new safety signals identified. This marks a significant advancement in treatment options for vitiligo, a condition currently lacking approved systemic therapies.
Read more →ABBVAllergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM Today, Allergan Aesthetics, an AbbVie company, announces their continued partnership with Girls Inc. for the 7th year with programming and funding...
Allergan Aesthetics, an AbbVie company, has announced its ongoing partnership with Girls Inc. for the seventh consecutive year, focusing on mentorship and support for young women pursuing careers in STEM fields. Through initiatives like the AMI Atlanta Training Center Experience and the SkinSpirit Gives campaign, the program aims to equip girls with the necessary tools and encouragement to succeed in science and technology. The initiative addresses current disparities in STEM job representation for women and is set to inspire over 120,000 girls in the U.S. and Canada.
Read more →ABBVThe Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced this year's grant recipients of The Confidence Project: Empowering Women...
Allergan Aesthetics, a subsidiary of AbbVie, announced the grant recipients for its Confidence Project aimed at empowering women entrepreneurs. This year's program selected 20 recipients who each received a $20,000 grant after completing a 12-week training program. The initiative emphasizes community building and support among female entrepreneurs, highlighted in a recent virtual summit celebrating their achievements.
Read more →ABBVRINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
AbbVie announced positive topline results from the SELECT-SWITCH study, showing that RINVOQ (upadacitinib) significantly outperformed HUMIRA (adalimumab) in achieving low disease activity and remission in rheumatoid arthritis patients who had failed prior TNF inhibitor therapy. The study met its primary endpoint at week 12, with no new safety risks identified. These findings support the use of upadacitinib as an effective alternative treatment option.
Read more →ABBVAbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
AbbVie has finalized its acquisition of Gilgamesh Pharmaceuticals' bretisilocin, a novel treatment currently in Phase 2 trials for moderate-to-severe major depressive disorder. This acquisition aims to accelerate the development of bretisilocin, which is designed to overcome challenges faced by traditional psychedelic treatments. AbbVie expresses optimism about the compound's potential to improve mental health outcomes.
Read more →ABBVU.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
AbbVie announced that the FDA has approved an updated indication for RINVOQ (upadacitinib) for treating adults with moderately to severely active ulcerative colitis and Crohn's disease. The new indication allows RINVOQ to be used prior to TNF blockers for patients who have received at least one systemic therapy and for whom TNF blockers are inadvisable. This change aims to provide more treatment options for patients with inflammatory bowel disease.
Read more →ABBVAbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
AbbVie will present new data on its antibody-drug conjugate platform at the ESMO 2025 Congress in Berlin. The data includes results from investigational and approved ADCs, such as Temab-A and ABBV-706, targeting difficult-to-treat solid tumors. The presentations aim to highlight the potential of these therapies in addressing unmet medical needs in oncology.
Read more →ABBVSkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that...
Allergan Aesthetics, a subsidiary of AbbVie, has unveiled reimagined packaging for its SkinMedica® products, focusing on sustainability and user-friendliness. Along with this redesign, they introduced the HA5® Hydra Collagen Water Burst Moisturizer, promising up to 24 hours of hydration and support for a healthy skin barrier. This launch highlights SkinMedica's commitment to innovative skincare solutions tailored to current consumer demands. The packaging updates will gradually be applied to all SkinMedica® products over the next year.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the ...
AbbVie announced positive topline results from the Phase 2 ELATE trial assessing onabotulinumtoxinA (BOTOX) for upper limb essential tremor. The study met its primary endpoint, showing significant improvements in the Tremor Disability Scale-Revised for the treatment group compared to placebo. Additionally, all secondary endpoints were met, further supporting the therapy's efficacy. However, the use of BOTOX for this condition remains unapproved by regulatory authorities, and muscular weakness was the most common adverse event noted in the trial. The findings will be presented at the upcoming International Congress of Parkinson's Disease and Movement Disorders.
Read more →ABBVAbbVie to Host Third-Quarter 2025 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a...
AbbVie is set to announce its third-quarter 2025 financial results on October 31, 2025, prior to the market opening. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time. This event reflects AbbVie's ongoing commitment to transparency with investors and stakeholders as it continues to focus on delivering innovative healthcare solutions.
Read more →ABBV▲ +5.5%on this newsshared move
Natrelle® Awarded Supplier Agreement from Vizient Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that Natrelle® has been named a supplier by Vizient, Inc., the nation's largest...
AbbVie’s Allergan Aesthetics announced that Natrelle® has been designated as a supplier for Vizient, providing clients with broad access to the largest selection of breast implants. This partnership aims to enhance operational efficiencies and support healthcare providers with competitive pricing and a simplified procurement process. The agreement emphasizes Allergan's commitment to patient-centered outcomes but also highlights potential risks associated with breast implant surgery. Patients receiving implants face various complications and health concerns that can arise over time, underscoring the importance of informed decision-making.
Read more →ABBVAbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.,...
AbbVie has announced the commencement of a $70 million expansion at its Bioresearch Center in Worcester, Massachusetts, aimed at increasing its biologics manufacturing and R&D capabilities. This initiative is part of a larger commitment to invest over $10 billion in the U.S. to support innovation in biologics and respond to growing global demand. The expansion will add manufacturing areas and a new building for laboratory, warehouse, and office space, enhancing the company's capacity for oncology and immunology medicines. The project is expected to create new jobs and strengthen AbbVie's presence in the U.S. market.
Read more →ABBVAbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
AbbVie has announced the submission of a Biologics License Application (BLA) for its investigational drug Pivekimab sunirine (PVEK) to the U.S. FDA. This submission is based on data from the global Phase 1/2 CADENZA trial focusing on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare blood cancer. PVEK is a CD123-targeting antibody-drug conjugate designed to improve treatment outcomes for patients with BPDCN, especially in cases of relapsed or refractory disease. AbbVie is committed to advancing therapies in oncology with the potential to transform care for patients with difficult-to-treat cancers.
Read more →ABBVAbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility...
AbbVie has begun construction on a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois, marking a significant step in its expansion efforts. The company plans to invest over $10 billion in U.S. manufacturing over the next decade, focusing on enhancing capabilities in immunology, oncology, and neuroscience. This facility will allow for the domestic production of certain APIs currently made overseas, furthering AbbVie's commitment to improving patient outcomes in the U.S. and around the world. The investment will also create additional jobs and strengthen AbbVie's existing manufacturing footprint in the region.
Read more →ABBVAbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx) AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S.,...
AbbVie has announced its pricing strategy for ELAHERE (mirvetuximab soravtansine-gynx) in the U.K., aligning the list price with that in the U.S. This drug is a first-in-class treatment developed for adult patients with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian cancer. The company is currently discussing the drug's value with the National Institute for Health and Care Excellence (NICE) to ensure fair pricing, given its role in meeting a significant unmet medical need. ELAHERE has recently received regulatory approvals in both the U.S. and Europe, marking a significant advancement in oncology treatment options.
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon,...
AbbVie has submitted a New Drug Application to the FDA for tavapadon, a new oral treatment for Parkinson's disease. This submission is based on positive results from the TEMPO clinical trial program, which included multiple Phase 3 studies showing significant efficacy and safety in improving motor symptoms. The application aims to provide a new therapeutic option for patients struggling with current treatments. AbbVie is committed to addressing the challenges of Parkinson's disease with innovative solutions.
Read more →ABBVAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience,...
Allergan Aesthetics, a subsidiary of AbbVie, is poised to present its AA Signature™ multimodal treatment approach at the AMWC in Dubai from October 1 to 3, 2025. This innovative approach focuses on addressing individual patient needs while improving skin quality and aesthetics through a variety of advanced products. The initiative aims to cater to the growing demand for natural and personalized aesthetic treatments. Additionally, the event will feature renowned experts discussing the latest advancements and techniques in aesthetic medicine.
Read more →ABBVAllergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality SKINVIVE® to launch in 35 additional markets worldwide from September taking the total to 57 international launches in 2025. Research highlights 94%...
Allergan Aesthetics, a subsidiary of AbbVie, announced the expansion of SKINVIVE by JUVÉDERM into 35 additional global markets, increasing its total international launches to 57 in 2025. This initiative reflects a strategic commitment to enhancing skin quality worldwide, emphasizing consumer preferences for health-focused solutions in aesthetics. Research highlights a significant interest among patients for treatments prioritizing smooth and hydrated skin, aligning with evolving trends in the beauty sector. Aesthetic professionals will benefit from innovative techniques and a robust product portfolio aimed at addressing patient needs effectively.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Unveils The One & Only Campaign Featuring Real People and Their Distinctive Stories Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of The One & Only campaign, a ...
Allergan Aesthetics, a subsidiary of AbbVie, has launched a new multichannel marketing campaign for BOTOX® Cosmetic called 'The One & Only.' This initiative highlights the importance of self-expression and features real patients sharing their experiences with the product. BOTOX® Cosmetic remains the leading neurotoxin globally, celebrating over 100 million vials sold and a significant number of repeat clients. The campaign is set to run across various platforms, aiming to underscore that there is no substitute for the authentic results of BOTOX® Cosmetic.
Read more →ABBVAbbVie Declares Quarterly Dividend NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share....
AbbVie Inc., based in North Chicago, has declared a quarterly cash dividend of $1.64 per share, payable on November 14, 2025. This announcement highlights the company’s long-standing commitment to rewarding its shareholders, evidenced by a 310% increase in dividends since 2013. AbbVie is also distinguished as a member of the S&P Dividend Aristocrats Index, which includes companies that have raised their dividends for at least 25 years consecutively. The company focuses on delivering innovative medicines across various therapeutic areas.
Read more →ABBVAllergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers Allergan Aesthetics, an AbbVie company, has launched the Naturally You with Injectable Hyaluronic Acid Fillers campaign, aimed to providing clear,...
Allergan Aesthetics, a subsidiary of AbbVie, has launched the 'Naturally You with Injectable Hyaluronic Acid Fillers' campaign aimed at educating consumers about HA fillers. This initiative emphasizes correcting misinformation surrounding these products and highlights their efficacy in achieving safe, natural results. Central to the campaign is 'The Hyaluronic Acid Injectable Fillers Report,' which provides valuable insights from research and expert interviews. The campaign seeks to reshape perceptions and collaborate with healthcare professionals to improve public understanding of HA injectable fillers.
Read more →ABBVAbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and...
AbbVie announced updated results from the Phase 2 EPCORE NHL-6 trial, evaluating the outpatient use of epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that 92% of the patients were successfully monitored in an outpatient setting, with manageable instances of cytokine release syndrome and neurotoxicity. The overall response rate was reported at 64.3% in patients with one prior therapy and 60.0% in those with multiple therapies. The findings suggest a potential shift towards outpatient treatment for this patient population.
Read more →ABBVAbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will...
AbbVie will be participating in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. During the conference, management will engage in a fireside chat at 9:00 a.m. Central time. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session posted later the same day. The company's focus is on addressing serious health issues across various therapeutic areas, including immunology and oncology.
Read more →ABBVAbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company...
AbbVie has been recognized as one of the Best Workplaces in Asia for 2025, ranking No. 7, up from No. 8 last year. This accolade is based on a survey of over 3.2 million employees across Asia and the Middle East, highlighting the company's commitment to fostering a positive workplace culture. AbbVie emphasizes respect and inclusion, empowering employees to contribute effectively.
Read more →ABBVAbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ( Gilgamesh ) today announced a definitive agreement under which AbbVie will acquire...
AbbVie has announced its acquisition of Gilgamesh Pharmaceuticals' investigational therapy, bretisilocin, aimed at treating major depressive disorder. This novel psychedelic compound, a 5-HT receptor agonist, has demonstrated significant therapeutic benefits and a shorter psychoactive experience compared to existing treatments. Recent Phase 2a study results showcased a statistically significant reduction in depressive symptoms. The acquisition is valued at up to $1.2 billion and aligns with AbbVie's ongoing commitment to developing innovative psychiatric solutions.
Read more →ABBVAbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint,...
AbbVie announced positive topline results from its Phase 3 UP-AA trial evaluating upadacitinib (RINVOQ) for severe alopecia areata. In the second study, notable percentages of patients achieved significant scalp hair coverage with both tested doses, surpassing results seen in the placebo group. Safety data showed a favorable profile with low occurrence of serious adverse events. AbbVie is positioned to submit these findings to regulatory bodies as they advance towards potential approval.
Read more →ABBVAbbVie Completes Acquisition of Capstan Therapeutics AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is ...
AbbVie has completed its acquisition of Capstan Therapeutics, integrating Capstan and its innovative technology into its operations. The lead asset, CPTX2309, is currently in Phase 1 trials and targets B cell-mediated autoimmune diseases, designed to induce rapid B cell depletion without chemotherapy. This acquisition enhances AbbVie's capacity to deliver innovative treatments and further their mission of improving patient care.
Read more →ABBVSkinMedica® Unveils Its Newest Hydration Hero Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today the newest addition to the SkinMedica® HA5® Hydra Collagen portfolio. Featuring...
Allergan Aesthetics, an AbbVie company, has unveiled the HA 5® Hydra Collagen Hydrating Foaming Cleanser, part of its SkinMedica® portfolio. The cleanser features a unique blend of hyaluronic acid and vegan hydra collagen, designed to improve skin hydration and promote skin barrier health. Clinical studies indicate effective makeup removal and a significant hydration boost when used alongside the HA 5® Hydra Collagen Replenish + Restore Hydrator. The product aims to address the needs of consumers with dehydrated and sensitive skin while enhancing overall skincare routines.
Read more →ABBVAbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S....
AbbVie has announced a $195 million investment to enhance its active pharmaceutical ingredient manufacturing at its North Chicago facility. This investment is part of a larger commitment exceeding $10 billion to bolster U.S. manufacturing and innovation in pharmaceuticals. The new facility will emphasize the production of neuroscience, immunology, and oncology medicines and is set to be operational by 2027. The expansion highlights AbbVie's dedication to maintaining its footprint in Illinois and supporting thousands of jobs across the state.
Read more →ABBVGet Ready, JUVÉDERM® Day is Calling! Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM® Day, Wednesday, August 20. This year's holiday marks the ...
Allergan Aesthetics, part of AbbVie, announced the return of JUVÉDERM® Day set for August 20, 2025. This celebration marks the third annual event aimed at promoting aesthetic treatments, featuring exclusive offers for Allē Members. The JUVÉDERM® Collection is recognized as the leading hyaluronic acid filler in the U.S., providing an important component in personalized aesthetic treatment plans. The event aims to facilitate conversations about treatment options and encourage participation from consumers.
Read more →ABBVAllergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is launching its Faces of Natrelle® campaign – a powerful tribute to resilience and authenticity....
Allergan Aesthetics, a division of AbbVie, has launched its Faces of Natrelle campaign, showcasing real stories of nine women who share their breast augmentation and reconstruction journeys. This initiative aims to empower women and reshape perceptions surrounding breast procedures through authenticity and resilience. The campaign includes insights on the broad range of Natrelle breast implant options while also addressing important safety information and potential complications associated with breast implant surgery.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Second-Quarter 2025 Financial Results Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent Adjusted Diluted EPS of $2.97, an Increase of 12.1 Perce
AbbVie has reported its financial results for the second quarter of 2025, showcasing a net revenue of $15.423 billion, reflecting a 6.6% increase. Despite a drop in diluted EPS and Humira revenues, the company highlighted robust growth in its immunology and neuroscience portfolios. AbbVie gained FDA approvals for Rinvoq in treating giant cell arteritis and made strides in its R&D with promising results from its clinical programs. Additionally, an acquisition of Capstan Therapeutics will enhance its pipeline in innovative therapies.
Read more →ABBVAbbVie Reports Second-Quarter 2025 Financial Results Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent;...
AbbVie has announced its financial results for the second quarter of 2025, reporting an adjusted diluted EPS increase of 12.1% to $2.97, while GAAP-based diluted EPS dropped 32.5% to $0.52. The company has raised its full-year adjusted EPS guidance, reflecting optimism fueled by strong performance across its diversified growth platform and recent pipeline successes. However, the revenue from its flagship product, Humira, saw a significant decline of 66% compared to the previous year.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...
AbbVie announced positive topline results from the Phase 3 UP-AA clinical trial of upadacitinib (RINVOQ) for treating severe alopecia areata. In the trial, significant percentages of patients achieved substantial scalp hair coverage at week 24, with 44.6% and 54.3% of patients reaching 80% or more hair coverage for the 15 mg and 30 mg doses, respectively. The results highlight the potential of upadacitinib as a new therapeutic option, though the treatment is not yet approved for use in this indication. Efficacy was accompanied by a generally manageable safety profile, though some serious adverse events were noted.
Read more →ABBVAbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the...
AbbVie has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for the combination treatment of VENCLEXTA (venetoclax) and acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL). This submission is based on favorable findings from the Phase 3 AMPLIFY trial, which demonstrated the combination therapy's effectiveness in improving progression-free survival compared to traditional chemoimmunotherapy. If approved, this combination could significantly alter treatment approaches for CLL by allowing a fixed-duration oral regimen.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project:...
AbbVie’s Allergan Aesthetics has announced the 2025 class of entrepreneurs for The Confidence Project, a program aimed at empowering women business owners. Selected participants will engage in a Virtual Community Summit and an intensive "Boostcamp," focusing on business development and mentorship. Ultimately, 20 entrepreneurs will receive a $20,000 grant each to help propel their businesses. The initiative reflects Allergan Aesthetics' commitment to fostering successful women entrepreneurs across diverse industries.
Read more →ABBVAbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation's annual global volunteering programme, held in ...
AbbVie employees across Asia participated in the tenth Week of Possibilities, contributing over 3,000 volunteer hours to support vulnerable communities. The initiative involved 880 employees from seven countries, focusing on various projects including education, health, and environmental sustainability. The program highlights AbbVie's commitment to health equity and community engagement.
Read more →ABBVAbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an...
AbbVie and Ichnos Glenmark Innovation have entered an exclusive licensing agreement for ISB 2001, a trispecific antibody targeting multiple myeloma. Currently in Phase 1 trials, ISB 2001 has demonstrated a 79% overall response rate in heavily pretreated patients. AbbVie will develop and commercialize the drug across several regions, receiving an upfront payment of $700 million.
Read more →ABBVAbbVie to Host Second-Quarter 2025 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a...
AbbVie has announced it will release its second-quarter 2025 financial results on July 31, 2025. Prior to market opening, the company plans to host a live webcast for the earnings conference call at 8 a.m. Central Time. The event will be available for later viewing on AbbVie's Investor Relations website. AbbVie continues its mission to address serious health issues across various therapeutic areas.
Read more →ABBVU.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin ...
Allergan Aesthetics, a subsidiary of AbbVie, announced that the U.S. FDA has accepted its supplemental premarket approval application for SKINVIVE by JUVÉDERM®, which aims to improve neck appearance by reducing neck lines. Currently approved for enhancing cheek skin smoothness, this injectable hyaluronic acid treatment could expand aesthetic treatment options for patients concerned about their necks. Clinical data suggests that a significant majority of patients experienced improvements, with minimal adverse effects noted. The approval process reflects a growing focus on comprehensive lower face and neck aesthetic treatments.
Read more →ABBVAbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ( Capstan ), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of...
AbbVie has announced its acquisition of Capstan Therapeutics for up to $2.1 billion, aiming to enhance its immunology portfolio. Capstan's lead candidate, CPTX2309, is a Phase 1 anti-CD19 CAR-T therapy designed for B cell-mediated autoimmune diseases. This transaction includes Capstan's proprietary tLNP platform technology, potentially transforming treatment modalities in cell therapy. The deal is expected to close pending regulatory approvals and customary conditions.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August...
AbbVie Inc. (NYSE: ABBV) announced a quarterly cash dividend of $1.64 per share, payable on August 15, 2025, to stockholders of record by July 15, 2025. The company has seen significant growth, having increased its dividend by 310 percent since its inception in 2013. AbbVie is recognized as a member of the S&P Dividend Aristocrats Index, highlighting its strong performance in consistently raising dividends over the years. The company focuses on delivering innovative medicines across various therapeutic areas including immunology and oncology.
Read more →ABBVAbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to ...
AbbVie has announced positive topline results from its Phase 3 TEMPLE study, which compared the efficacy and safety of atogepant (QULIPTA®) against topiramate for migraine prevention. The study found that atogepant had a much lower rate of treatment discontinuation due to adverse events, with only 12.1% of patients discontinuing compared to 29.6% for topiramate. Furthermore, over 64% of patients using atogepant experienced a ≥50% reduction in mean monthly migraine days, marking a significant improvement in clinical outcomes. Full study results will be presented at an upcoming medical meeting.
Read more →ABBVAbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly...
AbbVie announced that its global Phase 3 VERONA trial, testing venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndromes, did not achieve its primary endpoint of overall survival. The trial reported a hazard ratio of 0.908 with a p-value of 0.3772, indicating the treatment was not statistically significant in improving survival. No new safety signals emerged from the trial, and results will be shared at a future medical congress. Despite this setback, current approvals for venetoclax remain unaffected.
Read more →ABBVU.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic...
AbbVie has received FDA approval for an expanded indication of its drug MAVYRET (glecaprevir/pibrentasvir), which is now the first and only treatment approved for adults and children aged three and older with acute hepatitis C virus (HCV) infection. This pangenotypic oral therapy shortens treatment duration to just eight weeks and demonstrates a 96% cure rate. This expansion aims to address the significant medical need among patients with acute HCV, particularly as current health guidance advocates for universal treatment to curb the disease's spread globally. Additionally, AbbVie emphasizes the importance of early treatment to prevent debilitating liver disease or complications.
Read more →ABBVAbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional ...
AbbVie has opened entries for the second annual AbbVie Migraine Career Catalyst Award contest, which will provide 20 individuals living with migraine each a $2,500 grant to support their personal and professional goals. This initiative aims to help reduce stigma surrounding migraines and works towards improving workplace environments for affected individuals. The contest encourages participants to share their experiences with migraine and how the award could benefit their careers. Last year's winners successfully utilized their awards to enhance their professional development and create supportive workspaces.
Read more →ABBVAbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will...
AbbVie will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. Management will engage in a fireside chat at 10:20 a.m. Central time, with a live audio webcast accessible via AbbVie's Investor Relations website. An archived edition of the session will be available later the same day. AbbVie aims to provide innovative medicines across several therapeutic areas, including immunology, oncology, neuroscience, and eye care.
Read more →ABBVAbbVie Partners with Chicago Cubs on Striking Out Cancer AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called Striking ...
AbbVie has partnered with the Chicago Cubs for a campaign called 'Striking Out Cancer' to support cancer advocacy. For every strikeout by a Cubs pitcher at home during the 2025 season, AbbVie will donate $233, symbolizing the number of cancer diagnoses per hour in the U.S. The funds will be directed to Cubs Charities and organizations such as Conquer Cancer, enhancing efforts to combat cancer. This initiative aligns with AbbVie's goal of addressing serious health issues through innovative medicines.
Read more →ABBVAbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters...
AbbVie presented pivotal data from its oncology portfolio at the ASCO Annual Meeting 2025, emphasizing advancements in antibody-drug conjugates (ADCs). The data showcased the potential effectiveness and manageable safety of investigational drugs like telisotuzumab adizutecan in advanced cancer types. Key presentations highlighted ongoing trials aiming to transform treatment outcomes for patients with challenging solid tumors and blood cancers. AbbVie's commitment to innovation in oncology is reinforced by their comprehensive pipeline targeting significant unmet medical needs.
Read more →ABBV▼ -5.6%on this news
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug...
AbbVie announced the FDA's accelerated approval of EMRELIS (telisotuzumab vedotin-tllv) for adults with previously treated advanced non-small cell lung cancer (NSCLC) who have high c-Met protein overexpression. This marks a significant advancement as EMRELIS is the first approved treatment targeting this specific patient population, which has historically faced poor prognosis and limited options. The approval is based on encouraging data from the Phase 2 LUMINOSITY study, which showed a 35% overall response rate. However, continued approval will depend on confirmation of clinical benefits in further trials.
Read more →ABBV▼ -5.6%on this news
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today...
AbbVie and ADARx Pharmaceuticals have announced a collaboration to develop next-generation siRNA therapies targeting multiple therapeutic areas, including neuroscience, immunology, and oncology. The partnership will leverage AbbVie's expertise in biotherapeutics and ADARx's proprietary RNA technology, aiming to enhance mRNA silencing capabilities. The agreement includes a $335 million upfront payment for ADARx, with additional contingent payments possible. However, both companies acknowledge challenges related to effective siRNA delivery and potential competition in the biotech sector.
Read more →ABBVAbbVie to Present at the Bank of America Securities Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate...
AbbVie (NYSE: ABBV) is set to participate in the Bank of America Securities Healthcare Conference on May 14, 2025. Management will engage in a fireside chat at 12:00 p.m. Central time, which will also be available via a live audio webcast. This presents an opportunity for investors and stakeholders to understand AbbVie's ongoing efforts in addressing healthcare challenges through innovative medicine.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through The Confidence Project Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the...
Allergan Aesthetics, under AbbVie, has announced the continuation of BOTOX® Cosmetic's initiative, The Confidence Project, aimed at empowering women entrepreneurs. The program allows business owners to apply for support, including mentorship and potential grants, from May 1 through May 9, 2025. This year, the project will expand its reach to 250 founders, offering them access to resources and a chance to pitch for one of 20 grants of $20,000. The initiative highlights the importance of mentorship in the growth of women-led businesses.
Read more →ABBVRINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the...
AbbVie has received U.S. FDA approval for RINVOQ (upadacitinib) for the treatment of giant cell arteritis (GCA), marking it as the first oral JAK inhibitor approved for this condition. The approval follows a successful Phase 3 SELECT-GCA trial, where RINVOQ showed a significant ability to achieve sustained remission in patients. This approval adds to the drug's growing list of indications and underscores AbbVie's commitment to addressing unmet medical needs in the field of immune-mediated diseases. As GCA can lead to severe complications, this new treatment option provides healthcare professionals and patients with a promising alternative to current therapies, especially in terms of reducing steroid usage.
Read more →ABBVAbbVie Reports First-Quarter 2025 Financial Results Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent;...
AbbVie reported better-than-expected financial results for the first quarter of 2025, with adjusted diluted EPS increasing 6.5% to $2.46, despite a GAAP EPS decline. The company raised its full-year adjusted EPS guidance to between $12.09 and $12.29, indicating confidence in ongoing business fundamentals and pipeline advancements. However, it faced challenges with a 6.5% drop in GAAP EPS and potential impacts from trade policies and acquired expenses. Overall, AbbVie's outlook remains strong, bolstered by robust revenue growth in its immunology and oncology segments.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports First-Quarter 2025 Financial Results Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent T
AbbVie reported their first-quarter 2025 financial results, revealing net revenues of $13.343 billion, an 8.4% increase compared to last year. Revenues from the immunology portfolio led this growth, particularly driven by strong performances from Skyrizi and Rinvoq. The company raised its adjusted diluted EPS guidance, indicating positive future expectations. However, there was a noted decline in aesthetics product revenues and a decrease in GAAP diluted EPS. Additionally, AbbVie has secured new approvals for Rinvoq and plans for innovative treatments through collaborations and applications.
Read more →ABBVAbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
AbbVie has submitted a Biologics License Application (BLA) to the U.S. FDA for trenibotulinumtoxinE (TrenibotE) to treat glabellar lines. TrenibotE is notable for its rapid onset, with effects seen as soon as 8 hours post-administration, and a short duration of 2-3 weeks. The submission is backed by clinical data from over 2,100 patients in Phase 3 studies, indicating positive efficacy and safety profiles. If approved, it will be the first serotype E neurotoxin available in the market, aiming to address patient concerns about the aesthetics of neurotoxin treatments.
Read more →ABBV▼ -5.8%on this news
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis...
AbbVie announced that the European Commission has granted marketing authorization for RINVOQ (upadacitinib) for the treatment of adult patients with giant cell arteritis (GCA). This marked the first approval of an oral Janus kinase (JAK) inhibitor for GCA in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval was supported by data from the Phase 3 SELECT-GCA trial, which showed significant efficacy and a favorable safety profile of RINVOQ in patients with this condition. This development is expected to offer a crucial treatment option for older patients suffering from GCA.
Read more →ABBVAbbVie to Host First-Quarter 2025 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a...
AbbVie (NYSE: ABBV) is set to announce its first-quarter 2025 financial results on April 25, 2025, prior to market opening. The earnings conference call will begin at 8 a.m. Central time and will be accessible via a live webcast. This event is part of AbbVie's ongoing commitment to engage with its investors and stakeholders regarding its financial performance and business developments.
Read more →ABBVAbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming...
AbbVie is set to present new data from its early oncology research at the upcoming AACR Annual Meeting, highlighting investigational compounds ABBV-969 and ABBV-514. These presentations focus on addressing hard-to-treat tumor types and exploring treatment resistance through real-world-data analyses. The early-stage studies aim to establish a foundation for innovative cancer therapies, reflecting AbbVie's commitment to improving treatment options for patients with demanding medical needs.
Read more →ABBVAllergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve...
Allergan Aesthetics, a subsidiary of AbbVie, is set to highlight its commitment to innovation and patient-centric care at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco. The launch of the new AA Signature program aims to enhance treatment planning through a personalized approach. The event will honor the 10th anniversary of MD Codes™, which has played a pivotal role in improving aesthetic treatment techniques. Various expert-led symposiums will address significant scientific advances in the field of aging and aesthetics.
Read more →ABBVELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE®...
AbbVie announced the final analysis of the Phase 3 MIRASOL trial for ELAHERE, an innovative treatment for folate receptor alpha-positive platinum-resistant ovarian cancer. Results indicated significant improvements in both progression-free and overall survival compared to standard chemotherapy. Despite presenting some adverse events, ELAHERE's safety profile appears favorable when compared to conventional treatments. The therapy has already gained full approval from the FDA and is under review in several other countries.
Read more →ABBVAbbVie to Present at the Leerink Partners Global Healthcare Conference AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in...
AbbVie (NYSE: ABBV) is set to present at the Leerink Partners Global Healthcare Conference on March 11, 2025, with a fireside chat scheduled for 7:40 a.m. Central time. The event will be accessible through a live audio webcast on AbbVie's Investor Relations website, followed by an archived version later that day. AbbVie aims to showcase its mission of delivering innovative medicines across key therapeutic areas, including immunology and oncology.
Read more →ABBVAbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery...
AbbVie and Gubra A/S have entered into a license agreement to develop GUB014295, a long-acting amylin analog aimed at treating obesity. Currently undergoing a Phase 1 clinical trial, this drug could represent a significant advancement in obesity management, which poses a global health concern. AbbVie will lead the development and commercialization efforts, with substantial financial incentives outlined for Gubra, including an upfront payment and milestone payments. The collaboration signifies AbbVie's commitment to exploring new therapeutic areas and enhancing patient care.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults...
AbbVie has obtained a positive opinion from the CHMP regarding upadacitinib (RINVOQ) for treating adults with giant cell arteritis (GCA). This opinion is based on results from the pivotal Phase 3 SELECT-GCA trial, which assessed the drug's efficacy and safety in a cohort of patients aged 50 and older. This development aims to enhance treatment options for patients suffering from GCA, which causes serious symptoms including headaches and vision problems. Upadacitinib is already approved for various other immune-mediated inflammatory diseases in the EU.
Read more →ABBVAbbVie to Present at the TD Cowen's 45th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025. Management will participate in ...
AbbVie (NYSE: ABBV) will be presenting at the TD Cowen's 45th Annual Health Care Conference on March 5, 2025. During the event, management will engage in a fireside chat scheduled for 8:10 a.m. Central time. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie is committed to discovering and delivering innovative medicines across various therapeutic areas, including immunology, oncology, neuroscience, and eye care.
Read more →ABBVAbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors - Richard A. Gonzalez to retire from the board of directors effective
AbbVie has announced the appointment of Robert A. Michael as the new chairman of the board, effective July 1, 2025, succeeding Richard A. Gonzalez, who is retiring. The board expressed strong confidence in Michael's leadership qualities and vision for the company's future. Michael, who has served as CEO and has been integral to AbbVie's success, aims to build on the company's track record. Alongside this transition, Glenn F. Tilton will also retire from AbbVie's board on the same date.
Read more →ABBVAbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the ...
AbbVie announced that CEO Robert A. Michael will assume the position of chairman of the board effective July 1, 2025, succeeding Richard A. Gonzalez. The board expressed confidence in Michael's leadership capabilities, highlighting his integrity and commitment to the company's mission. Gonzalez has served as chairman since AbbVie's formation in 2013 and has expressed gratitude for his time with the company. Additionally, Glenn F. Tilton will retire from the board on the same date as Michael's new appointment.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May 15,...
AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share, which will be paid on May 15, 2025, to shareholders recorded by April 15, 2025. Since its establishment in 2013, AbbVie has significantly increased its dividend by 310%. The company is known for being a part of the S&P Dividend Aristocrats Index, which highlights firms that have consistently raised their dividends for at least 25 years.
Read more →ABBVAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated...
AbbVie has entered into a collaboration and option-to-license agreement with Xilio Therapeutics to develop novel tumor-activated immunotherapies. Under the agreement, Xilio will receive $52 million in upfront payments and could earn up to $2.1 billion in contingent payments. The collaboration aims to leverage Xilio's proprietary technology to create targeted cancer treatments, exemplifying AbbVie's commitment to advancing oncology research. Both companies will work together to enhance the development of T-cell engagers as part of their efforts to improve patient outcomes in cancer care.
Read more →ABBVAllergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new state-of-the-art training...
Allergan Aesthetics, a subsidiary of AbbVie, has announced the opening of three new training centers in the U.S. through its Allergan Medical Institute (AMI). These state-of-the-art centers will provide tailored training to licensed aesthetics providers, enhancing their skills in delivering safe and effective outcomes. The initiative aims to expand the reach of AMI's high-caliber educational programs, leveraging innovative products and clinical techniques. The first center in Orange County, California, is set to open in 2025, followed by locations in Atlanta and Austin.
Read more →ABBVU.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first...
The U.S. FDA has granted approval to AbbVie's EMBLAVEO (aztreonam and avibactam) for treating adults with complicated intra-abdominal infections who lack alternative treatment options. This antibiotic is the first fixed-dose combination of a monobactam and β-lactamase inhibitor, specifically targeting Gram-negative bacteria associated with high antimicrobial resistance rates. The approval follows limited clinical safety and efficacy data and positions EMBLAVEO as a crucial option for healthcare providers dealing with challenging infections.
Read more →ABBVAllergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a nationwide open casting call in search of the next Faces of Natrelle®, encouraging...
Allergan Aesthetics, a subsidiary of AbbVie, has launched the 'Faces of Natrelle®' campaign with an open casting call for women who have experienced breast reconstruction or augmentation. Running until February 28, 2025, the campaign seeks to celebrate women's stories and promote inclusivity in the beauty space. This initiative is part of the Natrelle® For Every BODY platform and emphasizes empowerment and transparency about breast surgery.
Read more →ABBVAllergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons Allergan Aesthetics, an AbbVie company, is continuing its dedication to the LIMITLESS initiative by expanding the content of its Presidential Series...
Allergan Aesthetics, a subsidiary of AbbVie, has released two new videos as part of its LIMITLESS initiative, celebrating women surgeons. These videos feature interviews with Dr. Caroline Glicksman and Dr. Melinda Haws, reflecting on their career journeys and goals for the aesthetics industry. The LIMITLESS initiative aims to inspire and promote leadership roles for women in healthcare through storytelling, mentorship, and networking. The fourth season of the LIMITLESS podcast is also set to launch in early 2025, complementing the new video releases.
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These...
AbbVie has announced its financial results for the fourth quarter and full year ending December 31, 2024. The company reported a diluted EPS of $2.39, reflecting a 12.1% decrease compared to the previous year. Despite this decline, AbbVie noted significant progress in its pipeline and strategic advancements, entering 2025 with momentum. The company projects adjusted diluted EPS for 2025 to be between $12.12 and $12.32 and has raised its revenue expectations for its flagship products Skyrizi and Rinvoq.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent Adjusted Diluted EPS of $10.12, a Decrease of 8
AbbVie announced its financial results for the fourth quarter and full year 2024, highlighting a significant revenue increase but facing challenges with declining Humira sales. Total net revenues rose to $56.334 billion, driven by growth in their oncology and neuroscience portfolios. Notably, AbbVie received marketing authorization for Elahere, a treatment for ovarian cancer, and reported strong pipeline advancements. Despite these positives, diluted EPS saw a decline, and the company reported a loss per share in the fourth quarter due to an impairment charge.
Read more →ABBVAllergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil...
Allergan Aesthetics, a part of AbbVie, has launched the AA Signature program at the IMCAS World Congress 2025. This new initiative focuses on providing personalized and patient-centric aesthetic treatment plans by combining multiple facial treatments using Allergan's product portfolio. Research indicates that clinics adopting this multimodal approach experience significantly higher patient retention rates. The program also equips healthcare professionals with advanced education and training to optimize treatment outcomes.
Read more →ABBVAllergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025 New AA (Allergan Aesthetics) Signature Program provides a personalized approach to treatment planning, in combination with Allergan Aesthetics'...
Allergan Aesthetics, an AbbVie subsidiary, has launched its AA Signature Program, aimed at improving treatment planning for aesthetic procedures at the IMCAS World Congress 2025. This initiative emphasizes a personalized approach for healthcare professionals, enhancing patient retention and addressing various facial needs. The congress will feature expert-led symposiums and live demonstrations, showcasing innovative techniques and the application of Allergan's product portfolio. Additionally, serious side effects associated with the use of certain products have been highlighted as part of the safety considerations for practitioners.
Read more →ABBVAbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for...
AbbVie and Neomorph have announced a collaboration to develop molecular glue degraders aimed at targets in oncology and immunology. This innovative class of small molecules intends to degrade proteins that contribute to cancer growth and immune system issues, which have been historically difficult to target. Neomorph will receive an upfront payment and may earn up to $1.64 billion through future milestones and sales. The partnership highlights a commitment to advancing drug discovery technologies and addressing serious health challenges.
Read more →ABBVAbbVie Completes Acquisition of Nimble Therapeutics AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is...
AbbVie has completed the acquisition of Nimble Therapeutics, enhancing its immunology pipeline. Nimble's lead asset is an oral peptide IL23R inhibitor currently in preclinical development for psoriasis. The integration of Nimble’s proprietary technology is expected to drive rapid discovery and optimization of oral peptide candidates. Jonathon Sedgwick from AbbVie has expressed enthusiasm about incorporating Nimble's capabilities to better serve patients with autoimmune diseases.
Read more →ABBVAbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement ...
AbbVie and Simcere Zaiming have entered a partnership to develop SIM0500, a novel trispecific antibody currently in Phase 1 trials for multiple myeloma. This drug targets multiple antigens using Simcere's proprietary T-cell engager technology, showing promising preclinical efficacy. The deal includes an upfront payment and potential milestone payments totaling up to $1.055 billion, plus royalties based on sales in various territories. This collaboration aims to address significant unmet medical needs in treating multiple myeloma.
Read more →ABBVAbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related...
AbbVie and REGENXBIO have announced new developments regarding the ABBV-RGX-314 clinical program focused on wet age-related macular degeneration and diabetic retinopathy. Trials for ABBV-RGX-314's efficacy and safety are scheduled for release in 2026, with plans for a Phase 3 clinical program utilizing SCS Microinjector for treatment delivery. This program aims to provide a potential one-time gene therapy solution to alleviate the treatment burden associated with current frequent dosing practices for these debilitating conditions.
Read more →ABBVAbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in...
AbbVie (NYSE: ABBV) is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will include a fireside chat with management scheduled for 10:15 a.m. Central time. Investors can access a live audio webcast of the session through AbbVie's Investor Relations website, with an archived edition available later in the day. The company aims to address serious health issues across various therapeutic areas.
Read more →ABBVCoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an...
AbbVie subsidiary Allergan Aesthetics has launched its third annual CoolMonth event, promoting CoolSculpting® Elite as a leading option for body contouring. The program encourages consumers to explore non-invasive fat reduction treatments through special promotions starting in January. Experts emphasize the importance of CoolSculpting® for targeting stubborn fat areas, particularly as the new year begins and self-care goals are prioritized. The event invites participants to discuss treatment plans to achieve visible results by spring and summer.
Read more →ABBVAbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens....
AbbVie will announce its full-year and fourth-quarter 2024 financial results on January 31, 2025, prior to market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived session will be available the same day, providing investors with insights into the company's financial performance.
Read more →ABBVAbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset,...
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics for $200 million. This acquisition focuses on Nimble's lead investigational oral peptide IL23R inhibitor, aimed at treating psoriasis and inflammatory bowel disease, among other autoimmune conditions. AbbVie believes this addition will significantly enhance its existing immunology pipeline while addressing unmet medical needs in autoimmune disease treatment. The deal also includes Nimble's proprietary peptide synthesis and optimization platform, expected to bolster drug discovery efforts.
Read more →ABBVAbbVie Completes Acquisition of Aliada Therapeutics AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is...
AbbVie has officially completed its acquisition of Aliada Therapeutics, integrating the latter's lead investigational asset, ALIA-1758, which is currently in a Phase 1 clinical trial for Alzheimer's disease. ALIA-1758 employs a novel blood-brain barrier-crossing technology aimed at improving drug delivery to the central nervous system. AbbVie sees this acquisition as a key step in advancing treatments for Alzheimer's and enhancing its neuroscience development efforts. The company recognizes the significant public health challenges posed by Alzheimer’s, especially given an aging population.
Read more →ABBVAbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant...
AbbVie announced positive topline results from its Phase 3 TEMPO-2 trial for tavapadon, a D1/D5 partial agonist treatment for early Parkinson's disease. The trial met its primary endpoint with a significant improvement in symptoms compared to placebo. Additionally, a key secondary endpoint was also achieved, indicating clinical relevance. AbbVie is on track to submit a New Drug Application to the FDA in 2025.
Read more →ABBVTwo Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging...
AbbVie announced promising results from two clinical trials evaluating epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL). The Phase 1b/2 NHL-2 trial reported a 100% overall response rate when epcoritamab was combined with R-CHOP, with 87% achieving complete responses. The Phase 2 NHL-1 trial results highlighted durable responses in challenging-to-treat relapsed or refractory patients. Despite encouraging efficacy, the trials noted significant treatment-emergent adverse events, including fatalities related to COVID-19.
Read more →ABBVAbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the...
AbbVie has released its latest Emotional Impact Report highlighting the mental health impacts of chronic lymphocytic leukemia (CLL) on underrepresented patient groups, specifically Black, Hispanic, and Asian individuals. The survey reveals that these groups experience higher emotional distress and unmet needs regarding treatment support and education. Moreover, communication gaps persist between patients and healthcare providers, with many patients feeling unsupported in managing their emotional wellbeing. AbbVie aims to work with advocacy stakeholders to enhance awareness and solutions tailored to the emotional needs of these patients.
Read more →ABBVInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational epcoritamab, a...
AbbVie announced encouraging results from the Phase 1b/2 EPCORE NHL-2 trial evaluating epcoritamab, a bispecific antibody, combined with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma. The trial demonstrated a notable overall response rate of 96% and a complete response rate of 87%, suggesting strong efficacy. These results were presented at the American Society of Hematology's Annual Meeting. However, the treatment remains unapproved in major markets, and further studies are necessary to solidify epcoritamab's role in therapy.
Read more →ABBVHalf of Australians live with chronic health conditions, over a third forced to leave their jobs as a result A new report released today has found that of the one in two Australians living with a chronic health condition/s, over a third (37%) have left a job ...
A new report by AbbVie reveals that half of Australians live with chronic health conditions, with over a third having left their jobs due to these conditions. Key reasons include workplace stress and lack of support. The report highlights the stigma faced by these individuals and emphasizes the need for improved workplace policies and support systems. Positive sentiments from the workforce indicate a desire to assist those affected.
Read more →ABBVAbbVie to Present at Citi's 2024 Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice...
AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on December 3, 2024. Key executives, including the CFO and head of R&D, will present at the event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later. This participation reflects AbbVie's commitment to addressing significant health issues across various therapeutic areas.
Read more →ABBVAllergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all ...
Allergan Aesthetics, a subsidiary of AbbVie, has launched the AMI Business Education initiative, offering free online business training for healthcare practitioners. This new program aims to empower providers by enhancing their operational skills alongside their clinical expertise. The courses focus on practical business principles tailored to the aesthetics industry and are accessible via the AMI Online platform. This launch signifies Allergan Aesthetics' commitment to supporting the growth and development of aesthetics practices through educational resources.
Read more →ABBVAbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the...
AbbVie announced that the European Commission granted marketing authorization for ELAHERE (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer in adults with specific biomarkers. This approval marks the first folate receptor alpha-targeted therapy in the EU for this indication, addressing a significant need after a long gap in new treatment options. The approval is based on promising data from the Phase 3 MIRASOL trial, which evaluated the drug's effectiveness against standard chemotherapy options. ELAHERE's unique mechanism and approval could enhance treatment outcomes for patients facing this challenging diagnosis.
Read more →ABBVAbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest designed...
AbbVie has announced the winners of the inaugural AbbVie Migraine Career Catalyst Award, aimed at supporting the career aspirations of individuals living with migraine. The 20 award recipients, selected from various submissions, come from diverse professional backgrounds and exemplify resilience despite the challenges posed by their condition. The awards not only acknowledge their struggles but also provide financial assistance to help them in their professional journeys. This initiative reflects AbbVie's dedication to enhancing the quality of life for those affected by migraine and fostering professional growth.
Read more →ABBV▼ -12.6%on this newsshared move
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for...
AbbVie announced disappointing results from its two Phase 2 EMPOWER trials assessing emraclidine as a treatment for schizophrenia. The trials failed to show a statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) score compared to placebo. Despite being well-tolerated with a safety profile similar to previous trials, the lack of primary endpoint achievement raises concerns about the efficacy of emraclidine. AbbVie is currently analyzing the data to determine future steps in its development strategy for this drug.
Read more →ABBVAllergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the sixth annual BOTOX® Cosmetic Day will be Wednesday, November 20. This holiday ...
Allergan Aesthetics, a subsidiary of AbbVie, has announced the sixth annual BOTOX Cosmetic Day, which will take place on November 20. This celebration honors the healthcare providers and patients that contribute to BOTOX's status as the leading neurotoxin globally. Notably, the recent FDA approval expands BOTOX's indications, allowing treatment for new areas, which is expected to enhance its appeal and usage. The event will feature exclusive offers through the Allē loyalty rewards program, marking another effort to engage patients and promote BOTOX treatments.
Read more →ABBVAbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic...
AbbVie and EvolveImmune Therapeutics have announced a collaboration to develop next-generation cancer biotherapeutics. This partnership will utilize EvolveImmune's T-cell engager platform to create novel therapies aimed at treating various solid and hematologic malignancies. Under the agreement, AbbVie will provide $65 million upfront, alongside potential option fees and milestone payments totaling up to $1.4 billion. The collaboration highlights AbbVie's commitment to advancing innovative technologies in oncology.
Read more →ABBV▲ +6.4%on this newsshared move
AbbVie Reports Third-Quarter 2024 Financial Results Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent;...
AbbVie reported its financial results for the third quarter of 2024, revealing a GAAP diluted EPS of $0.88, down 12.0% year-over-year, while the adjusted diluted EPS rose by 1.7% to $3.00. The company has raised its adjusted diluted EPS guidance for the full year 2024 to a range of $10.90 to $10.94. AbbVie also announced a 5.8% increase in its quarterly cash dividend, reflecting its commitment to returning value to shareholders. Despite strong performance in certain areas, revenue from its key product Humira continued to decline, raising concerns among analysts.
Read more →ABBV▲ +6.4%on this newsshared move
Document PRESS RELEASE AbbVie Reports Third-Quarter 2024 Financial Results Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent
AbbVie reported its third-quarter 2024 financial results, highlighting a net revenue of $14.460 billion, which is a 3.8% increase from the previous year. Notable growth was observed in the immunology and neuroscience portfolios, particularly for drugs like Skyrizi and Rinvoq, while Humira revenues experienced a significant decline. The company successfully completed its acquisition of Cerevel, expanding its portfolio with new treatments for neurological conditions. Additionally, AbbVie raised its 2024 adjusted diluted EPS guidance and announced a dividend increase for shareholders.
Read more →ABBVSkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM In its sixth year of partnership with Girls Inc., Allergan Aesthetics, an AbbVie company, will be joined by SkinSpirit, a premier destination for...
SkinSpirit has partnered with Allergan Aesthetics to support Girls Inc. in empowering young girls, particularly in STEM fields. In its first year of collaboration, SkinSpirit will contribute a $5,000 donation and encourage client donations over two weeks, with proceeds directly funding STEM programming. This initiative aims to inspire girls to pursue careers in science, technology, engineering, and mathematics, further enhancing development opportunities among young women. The campaign will be promoted through various channels, including media coverage and social media engagement.
Read more →ABBVAbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company...
AbbVie has announced its intent to acquire Aliada Therapeutics for $1.4 billion, aiming to enhance its focus on Alzheimer's disease and neurological treatments. Aliada's innovative blood-brain barrier-crossing technology could improve delivery for CNS therapies, with their lead product, ALIA-1758, in Phase 1 trials. The acquisition is expected to close in the fourth quarter of 2024, pending regulatory approvals. This move aligns with AbbVie's commitment to advancing treatment options for serious neurological diseases.
Read more →ABBVAbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel...
AbbVie and Gedeon Richter have announced a new collaboration focused on discovering and developing novel targets for neuropsychiatric conditions. This agreement builds upon a long-standing partnership that includes successful products like cariprazine. The collaboration will involve shared financing for research and development activities, with Richter receiving an upfront payment of $25 million, potentially augmented by future milestone payments. AbbVie retains worldwide commercialization rights outside of certain traditional markets for Richter.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the...
Allergan Aesthetics, a subsidiary of AbbVie, announced the FDA approval of BOTOX® Cosmetic for treating moderate to severe platysma bands in adults. This makes BOTOX® the first product to include this treatment area, expanding its use beyond facial applications. Clinical studies demonstrated a significant satisfaction rate among patients, with many reporting enhanced appearance in neck and jawline definition post-treatment. This approval offers patients a new non-surgical option for aesthetic improvement.
Read more →ABBVU.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first ...
The U.S. FDA has granted approval for AbbVie's VYALEV (foscarbidopa and foslevodopa), establishing it as the first subcutaneous 24-hour infusion levodopa-based therapy for adults with advanced Parkinson's disease. This innovative treatment aims to improve motor symptom control by providing continuous levodopa delivery, addressing limitations of previous oral medications. Clinical studies have showcased significant improvements in motor fluctuations among patients. However, some adverse reactions were reported, and patients must await further insurance coverage to access the treatment.
Read more →ABBVAllergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present data highlighting efficacy, safety and patient-reported outcomes across its facial...
Allergan Aesthetics, a subsidiary of AbbVie, is set to present new data at the 2024 American Society for Dermatologic Surgery (ASDS) Annual Meeting. The presentations will focus on the efficacy, safety, and patient outcomes of their facial injectables, highlighting their commitment to innovation and understanding patient needs. Key discussions will also address trends in social media and ethical practices within the aesthetics industry. A large 4,000-subject study aims to provide insights into different demographic perceptions of aesthetic treatments.
Read more →ABBVAllergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM Today Allergan Aesthetics, an AbbVie company, announces the sixth consecutive year of partnership with Girls Inc. The partnership supports high...
Allergan Aesthetics, part of AbbVie, is celebrating its sixth year of partnership with Girls Inc., focusing on promoting mentorship in STEM fields for girls. The initiative highlights the importance of role models and safe programming for young women, aiming to increase confidence and inspire future career pursuits. To further engage the community, Allergan Aesthetics will launch a social media campaign encouraging individuals to mentor girls in their lives. This partnership seeks to bridge the gender gap in the STEM workforce by connecting young girls with successful women leaders.
Read more →ABBVAvailable Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing. Following its...
Allergan Aesthetics, a subsidiary of AbbVie, announced the national launch of JUVÉDERM VOLUMA XC, the first hyaluronic acid filler approved for treating moderate to severe temple hollowing in adults over 21. Following its FDA approval in March 2024, the product aims to address a common aesthetic concern and has garnered high patient satisfaction ratings. The company is focusing on training providers for safe and effective administration of the product, ensuring patients receive optimal results. The product adds to the extensive JUVÉDERM collection, known for its versatility in aesthetic treatments.
Read more →ABBVAbbVie to Host Third-Quarter 2024 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens. AbbVie will host...
AbbVie will announce its third-quarter 2024 financial results on October 30, 2024, before market opening. The company will hold a live webcast of its earnings conference call at 8 a.m. Central time, which will be accessible through its Investor Relations website. An archived edition of the session will also be available later that day. The announcement reflects AbbVie's ongoing commitment to transparency and engagement with investors.
Read more →ABBVAbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer - Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC)...
AbbVie has announced the submission of a Biologics License Application (BLA) to the FDA for accelerated approval of telisotuzumab vedotin (Teliso-V) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) exhibiting overexpression of the c-Met protein. The submission is supported by data from the ongoing Phase 2 LUMINOSITY trial, which aims to evaluate the safety and efficacy of Teliso-V for this particular patient demographic. If approved, Teliso-V will be a first-in-class treatment addressing a significant unmet medical need in an area with limited existing therapies.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early...
AbbVie has announced positive topline results from its Phase 3 TEMPO-1 trial evaluating Tavapadon as a monotherapy for early Parkinson's disease. The trial showed significant improvements in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores, indicating efficacy in patients compared to placebo. Tavapadon is a D1/D5 dopamine receptor partial agonist, and its safety profile appeared consistent with earlier trials. AbbVie plans to present full results at future medical meetings and will continue to support regulatory submissions for Tavapadon as a treatment for Parkinson's disease.
Read more →ABBVNew Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement New post-hoc analysis demonstrated efficacy of RINVOQ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of...
AbbVie announced positive results from a post-hoc analysis of its RINVOQ (upadacitinib) in the treatment of moderate-to-severe atopic dermatitis (AD), particularly focusing on patients with head and neck involvement. The analysis, based on the Measure Up 1 and 2 Phase 3 studies, indicated that patients receiving upadacitinib achieved better outcomes in severe disease measures compared to the placebo. Key clinical endpoints included near-complete skin clearance and significant improvements in quality of life metrics. These findings underscore the potential of RINVOQ as a critical treatment option in areas of high disease burden.
Read more →ABBVEmpowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is proud to announce the next exciting phase of its 2024 BOTOX® Cosmetic grant program dedicated...
Allergan Aesthetics, part of AbbVie, has launched its 2024 BOTOX® Cosmetic grant program aimed at supporting women entrepreneurs. This initiative features crowdfunding campaigns to empower 20 grant recipients by providing financial backing and essential skills through mentorship and training. The program seeks to close the gap in venture capital funding for women-led businesses, enabling them to thrive and contribute to their communities. Grant recipients will have access to resources and coaching designed to navigate the complexities of crowdfunding effectively.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a...
AbbVie has received a positive opinion from the EMA's CHMP for mirvetuximab soravtansine, which is aimed at treating certain adult patients with platinum-resistant ovarian cancer. This treatment has already been granted full FDA approval in the United States, and is currently undergoing marketing authorization reviews in various countries. The Phase 3 MIRASOL trial demonstrated the drug's efficacy and safety. However, while it addresses significant unmet needs, patients may experience serious side effects, necessitating careful monitoring.
Read more →ABBVAllergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that BOTOX® Cosmetic (onabotulinumtoxinA) is now available for the treatment of...
Allergan Aesthetics, a subsidiary of AbbVie, has launched BOTOX® Cosmetic for the treatment of masseter muscle prominence (MMP) in China. The treatment was recently approved by the China National Medical Product Administration and is backed by robust clinical evidence showing significant effectiveness and sustained results. This launch marks the first neurotoxin approval for MMP in China, highlighting a critical advancement in non-invasive aesthetic treatments for a condition affecting many adults, particularly within the Asian population. With planned global applications, this approval is seen as a significant milestone for the BOTOX brand.
Read more →ABBVAbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high...
AbbVie is highlighting advancements in its solid tumor pipeline at the ESMO Congress 2024, showcasing new data from crucial trials. Notably, the Phase 2 PICCOLO trial for mirvetuximab soravtansine demonstrated an objective response rate of 51.9% in patients with platinum-sensitive ovarian cancer. Additionally, patient-reported outcomes for the c-Met targeted ADCs, Teliso-V and ABBV-400, will be presented, with plans for accelerated approval for Teliso-V by Q3 2024. Featuring ongoing research across multiple tumor types, AbbVie aims to address urgent patient needs with innovative therapies.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable November ...
AbbVie Inc. has announced a quarterly cash dividend of $1.55 per share, payable on November 15, 2024, to stockholders of record by October 15, 2024. The company has demonstrated a consistent commitment to returning value to shareholders, increasing its dividend by over 285% since its founding in 2013. AbbVie is also recognized as a member of the S&P Dividend Aristocrats Index, which highlights its historical dividend growth.
Read more →ABBVAbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic,...
AbbVie has announced the recipients of the 2024-2025 AbbVie Immunology Scholarship, which supports students living with chronic immune-mediated diseases. A total of 45 scholarships have been awarded across various therapeutic areas, including dermatology, gastroenterology, and rheumatology. The initiative is designed to alleviate financial burdens and encourage academic achievement among these students. AbbVie aims to promote resilience and hope through this scholarship program, reflecting its commitment to patient care and empowerment for those affected by chronic conditions.
Read more →ABBVSkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE:...
Allergan Aesthetics, part of AbbVie, has introduced the SkinMedica® HA 5® Hydra Collagen Replenish + Restore Hydrator, an advanced hydration product. It features double the hyaluronic acid compared to the original and incorporates new technology to improve skin moisture retention. Clinical studies highlight that users report three times more radiance and hydration after just one use. The product is suitable for all skin types and offers up to 48 hours of hydration.
Read more →ABBVEuropean Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as...
AbbVie announced that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) to treat adults with relapsed or refractory follicular lymphoma after two or more prior therapies. This antibody, previously approved for diffuse large B-cell lymphoma, is the first subcutaneous therapy of its kind for follicular lymphoma in the EU. The approval is derived from promising clinical trial data, showing high rates of overall and complete responses. However, concerns about adverse reactions, particularly cytokine release syndrome, persist.
Read more →ABBVAbbVie Completes Acquisition of Cerevel Therapeutics Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and...
AbbVie has successfully completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience pipeline. This acquisition includes key clinical-stage assets that target significant neurological and psychiatric conditions. AbbVie expects this strategic move to boost its long-term performance, providing innovative treatments for conditions like schizophrenia and Parkinson's disease. Financially, the acquisition is anticipated to have a dilutive impact on earnings per share in the near term but is expected to contribute positively in the long run.
Read more →ABBVAllergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first...
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the upcoming second annual JUVÉDERM® Day on August 21, 2024. Building on the success of the inaugural event, which saw a record number of treatments, this year's celebration will feature exclusive deals through the Allē loyalty program. The event aims to further engage consumers by promoting the JUVÉDERM® Collection of Fillers and addressing aesthetic goals. JUVÉDERM® Day is recognized as an official holiday, and the loyalty program supports both consumer education and practice operations in the aesthetics industry.
Read more →ABBVAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with...
AbbVie announced that the European Commission has approved SKYRIZI® (risankizumab) for treating adults with moderately to severely active ulcerative colitis. This approval is significant as it addresses a critical need for patients unresponsive to conventional or biologic therapies. The decision is backed by positive results from Phase 3 trials, demonstrating improvements in clinical remission and mucosal healing. SKYRIZI shows promise in enhancing patient care by providing an additional treatment option within AbbVie's diversified inflammatory bowel disease portfolio.
Read more →ABBVAbbVie Reports Second-Quarter 2024 Financial Results Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent;...
AbbVie announced its financial results for the second quarter of 2024, reporting a diluted EPS of $0.77, which represents a 32.5% decrease compared to the previous year. Despite this decline, the company raised its adjusted diluted EPS guidance for the full year from $10.61 - $10.81 to $10.71 - $10.91. AbbVie's growth in key products, particularly beyond Humira, is a focus for future success. The CEO emphasized that the company's performance is ahead of expectations, showcasing a promising long-term outlook.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Second-Quarter 2024 Financial Results Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent
AbbVie reported its second-quarter financial results for 2024, showing a total revenue of $14.462 billion, which represents a growth of 4.3% compared to prior periods. While diluted EPS on a GAAP basis decreased by 32.5% to $0.77, the company raised its adjusted EPS guidance for the year. Key growth was noted in the immunology, oncology, and neuroscience portfolios, despite a significant decline in Humira revenue. The company is also advancing its pipeline, with approvals for Skyrizi and a new indication for Rinvoq under review.
Read more →ABBVAbbVie Employees Volunteer to Make an Impact on over 1100 Lives in Asia with 9th Annual "Week of Possibilities" AbbVie employees in Asia participated in its ninth annual Week of Possibilities (WOP) volunteering program, which unites employees around the world...
AbbVie employees in Asia participated in the ninth annual Week of Possibilities, engaging in volunteer projects to enhance health equity and support local communities. Over 900 employees contributed to various initiatives, including environmental sustainability and welfare activities for children and seniors. The program reflects AbbVie's commitment to social responsibility and community engagement across multiple Asian countries.
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...
AbbVie has submitted regulatory applications to the FDA and EMA for upadacitinib (RINVOQ) to treat adults with giant cell arteritis (GCA). This autoimmune disease currently lacks sufficient approved treatment options, often relying on glucocorticoids that patients find difficult to discontinue. The applications are backed by data from the Phase 3 SELECT-GCA study that demonstrated the efficacy and safety of upadacitinib among GCA patients. The development has the potential to offer new hope for those affected by this condition.
Read more →ABBVAbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global...
AbbVie has appointed Roopal Thakkar, M.D. as Executive Vice President and Chief Scientific Officer, overseeing its global R&D organization of over 14,000 members. Dr. Thakkar has been with AbbVie since 2003, previously holding senior roles in clinical development and regulatory affairs. He aims to leverage AbbVie's robust pipeline of more than 90 drug and device programs to drive the company's growth and innovation in critical therapeutic areas. AbbVie’s mission focuses on delivering solutions to serious health issues while also advancing its aesthetics portfolio.
Read more →ABBVAbbVie to Host Second-Quarter 2024 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a...
AbbVie will announce its financial results for the second quarter of 2024 on July 25, 2024, prior to market opening. A live webcast of the earnings conference call will be held at 8 a.m. Central time, and will be accessible via AbbVie's Investor Relations website. An archived version will be available later the same day, highlighting AbbVie's commitment to transparency with its stakeholders.
Read more →ABBVRobert A. Michael Assumes Role as AbbVie Chief Executive Officer AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of...
AbbVie announced that Robert A. Michael has been appointed as the new Chief Executive Officer, succeeding Richard A. Gonzalez, who has transitioned to executive chairman. Michael, who has served in multiple leadership roles within the company, expressed his commitment to AbbVie's mission of delivering innovative medicines and enhancing the company's impact on patients. The board has conveyed confidence in Michael's ability to lead the organization into its next phase of growth and maintains a strong strategy for the future.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a...
AbbVie announced the positive opinion from the CHMP for epcoritamab (TEPKINLY®) as a treatment for adults with relapsed/refractory follicular lymphoma (FL). This recognition addresses a significant unmet need in Europe for patients who have exhausted other therapies. Data from the Phase 1/2 EPCORE NHL-1 trial supports this decision, demonstrating efficacy and a manageable safety profile. AbbVie and Genmab will collaborate on the further commercialization of this investigational therapy across various markets.
Read more →ABBVAbbVie Acquires Celsius Therapeutics AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ( Celsius ), a privately held biotechnology company pioneering new...
AbbVie (NYSE: ABBV) has announced the acquisition of Celsius Therapeutics, a company specializing in innovative therapies for inflammatory diseases. This acquisition includes Celsius' lead candidate, CEL383, an investigational anti-TREM1 antibody that has completed a Phase 1 clinical trial for inflammatory bowel disease (IBD). The acquisition valued at $250 million in cash positions AbbVie to further explore the therapeutic potential of TREM1 inhibition for patients with IBD. Both companies express optimism about advancing the development of CEL383 to help more patients achieve remission.
Read more →ABBVIntroducing Allē Payment Plans, Powered by Cherry Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay...
AbbVie (NYSE: ABBV) has launched Allē Payment Plans through Allergan Aesthetics, designed to make aesthetic treatments more affordable for consumers. This initiative allows patients to pay for treatments like BOTOX® and JUVÉDERM® over time, addressing cost barriers that prevent many from seeking such services. The national rollout is supported by insights from a pilot program that indicated significant interest from new patients. The collaboration with Cherry aims to enhance the accessibility of care by providing seamless payment solutions in aesthetic practices.
Read more →ABBVU.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only...
AbbVie has received FDA approval for EPKINLY (epcoritamab-bysp) as a treatment for adults with relapsed or refractory follicular lymphoma after multiple therapies. This approval marks EPKINLY as the first and only bispecific antibody for this indication, promising deep and durable responses. The treatment can be administered subcutaneously, providing convenience for patients. However, its continued approval is contingent upon further studies to confirm its clinical benefits.
Read more →ABBVAbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not...
AbbVie announced the receipt of a Complete Response Letter from the FDA regarding its New Drug Application for ABBV-951, a treatment for motor fluctuations in advanced Parkinson's disease. The letter cites issues observed during an inspection at a third-party manufacturing facility, though it does not pertain to the safety or effectiveness of the drug itself. AbbVie remains committed to collaborating with the FDA to expedite the approval process despite this regulatory obstacle. ABBV-951 is already approved in 34 countries and used by over 2,100 patients globally.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable August...
AbbVie Inc. has announced a quarterly cash dividend of $1.55 per share, payable on August 15, 2024, to shareholders of record by July 15, 2024. Since its establishment in 2013, AbbVie has significantly increased its dividend payouts by more than 285%. The company is recognized as a member of the S&P Dividend Aristocrats Index, representing firms with a strong track record of dividend increases over the years. AbbVie continues to focus on developing innovative medicines across various therapeutic areas.
Read more →ABBVAbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director,...
AbbVie has appointed Roxanne S. Austin as the new lead independent director of its Board of Directors, effective July 1, 2024. She succeeds Glenn F. Tilton, who has served in this role since 2013 and will remain on the board. CEO Richard A. Gonzalez praised Austin's leadership ability and experience, expressing confidence in her capacity to guide AbbVie through a critical period of executive transition. The unanimous support from the independent directors emphasizes the board's cohesive approach to leadership.
Read more →ABBVU.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately...
AbbVie announced that the U.S. FDA has approved SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis. This makes SKYRIZI the first IL-23 specific inhibitor to gain approval for both ulcerative colitis and Crohn's disease, expanding AbbVie's portfolio in inflammatory bowel diseases. The approval is significant given the rising number of ulcerative colitis patients in the U.S., estimated to be over 1 million. Dosing includes a 12-week induction period and maintenance therapy, although it carries potential risks such as serious allergic reactions and infections.
Read more →ABBVAbbVie Recommends Shareholders Reject Tutanota's Mini-Tender Offer AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited mini-tender offer, dated May 28, 2024, to purchase...
AbbVie has advised its shareholders to reject an unsolicited mini-tender offer from Tutanota LLC, which aims to buy up to 250,000 shares at $165.00 each. This offer is contingent on the market price of AbbVie’s stock exceeding the offer price prior to its expiration on June 28, 2024. AbbVie warns that shareholders could sell their shares at a below-market price and encourages caution regarding the offer, highlighting the lack of investor protections associated with mini-tender offers. The company emphasizes that it is not associated with Tutanota and suggests shareholders consult with their brokers before taking action.
Read more →ABBVAbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation...
AbbVie and FutureGen Biopharmaceutical have entered a global license agreement to develop FG-M701, a next-generation TL1A antibody aimed at treating inflammatory bowel disease (IBD). This collaboration seeks to leverage AbbVie's extensive expertise in autoimmune therapies and FutureGen's innovative drug development technologies. FG-M701, still in preclinical development, promises improved efficacy and dosing frequency over existing treatments. The financial agreement includes an immediate $150 million payment to FutureGen, with the potential for additional billions based on future clinical milestones.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX® Cosmetic grant recipients. Each inspiring woman...
Allergan Aesthetics, an AbbVie company, announced the 2024 recipients of the BOTOX® Cosmetic grant program, awarding $25,000 each to twenty women entrepreneurs. This year's program saw nearly 11,000 applications, highlighting the increasing need for such initiatives. Recipients will benefit from mentorship, community access, and a ten-week Crowdfunding Coaching Accelerator program. The initiative aims to address funding disparities faced by women entrepreneurs, especially those from BIPOC communities.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine...
AbbVie has announced positive topline results from its Phase 2 PICCOLO trial for mirvetuximab soravtansine, which targets platinum-sensitive ovarian cancer patients with high folate receptor-alpha expression. The trial reported a significant objective response rate of 51.9%, and a median duration of response of 8.25 months. The safety profile of the drug was consistent with prior studies, showing no new safety concerns. Full details will be shared at an upcoming medical meeting, supporting the drug's potential as a treatment alternative in this challenging patient population.
Read more →ABBVSkinMedica® Celebrates 25 Years of Empowering Radiant Skin Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To...
Allergan Aesthetics, part of AbbVie, is celebrating the 25th anniversary of SkinMedica, a brand known for its science-based skincare products. To commemorate this milestone, the company is offering double points for purchases made by Allē members from June 1 to June 25, 2024, alongside a chance to win $5,000. SkinMedica's range of products has continuously evolved, garnering a loyal following and recognition in the aesthetics industry. Leadership reflects on the brand's journey and potential for future innovation.
Read more →ABBVAbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career,...
AbbVie has initiated the Migraine Career Catalyst Award, a novel contest aimed at supporting the professional aspirations of individuals living with migraine. The initiative allows participants to submit essays, videos, or audio clips detailing their experiences and career goals, with twenty winners receiving up to $2,500 for career support. This effort is designed to address the significant impact of migraine on work life and contribute to the empowerment of those affected by this condition. The submission period will remain open until September 3, 2024, with winners announced by mid-November 2024.
Read more →ABBVAbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a ...
AbbVie announced the start of its CERVINO Phase 3 clinical trial for investigational drug ABBV-383, a bispecific antibody targeting B-cell maturation antigen for patients with relapsed/refractory multiple myeloma. The trial aims to evaluate the efficacy of ABBV-383 versus standard therapies with a focus on treatment simplicity through monthly dosing. Approximately 380 patients will be enrolled at 140 sites globally. AbbVie continues to enhance its oncology pipeline to address unmet needs in blood cancer treatment.
Read more →ABBVRINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and ...
AbbVie announced the approval of RINVOQ (upadacitinib) for use in pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis and psoriatic arthritis. This announcement includes the introduction of a new weight-based oral solution called RINVOQ LQ. The approval is significant as it provides additional treatment options for children who have not responded adequately to previous therapies. AbbVie emphasized the ongoing need for effective treatments for these chronic inflammatory conditions that can severely impact a child's quality of life.
Read more →ABBVRefer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics...
Allergan Aesthetics, a subsidiary of AbbVie, has introduced a 'Refer a Friend' feature for its Allē Loyalty Rewards Program. This initiative allows members to refer friends and family, with both parties receiving discounts on a range of Allergan products. The program aims to leverage the power of word-of-mouth marketing, with a survey indicating that many consumers prefer referrals from trusted sources. This new feature aims to drive customer engagement and growth in the aesthetics market.
Read more →ABBVAbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael,...
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. Key executives, including president Robert A. Michael and CFO Scott T. Reents, will present during the event. The presentation will be available via live audio webcast, reflecting AbbVie's commitment to transparency and investor engagement. The company's mission focuses on delivering innovative solutions in various therapeutic areas, signaling its ongoing dedication to addressing health challenges.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab ...
AbbVie has received a positive opinion from the CHMP for its drug risankizumab (SKYRIZI) for treating adults with moderately to severely active ulcerative colitis (UC). This recommendation is based on the results of two pivotal Phase 3 trials, INSPIRE and COMMAND, which demonstrated that the treatment can lead to long-term management goals beyond mere symptom control. The findings suggest that risankizumab not only targets immediate symptoms but also supports endoscopic mucosal healing. However, the approval is still pending in the European Union, with safety and efficacy under continuous evaluation.
Read more →ABBVAbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a...
AbbVie is set to showcase new data from its antibody-drug conjugate platforms at the ASCO 2024 Annual Meeting, highlighting advancements in its solid tumor pipeline. The Phase 1 study results for ABBV-400, aimed at colorectal cancer, suggest promising antitumor activity, particularly in patients with high c-Met expression. Additionally, early results for ABBV-706 indicate significant effectiveness against small cell lung cancer. Despite the positive data, notable safety concerns include several treatment-emergent adverse events, leading to discontinuations in some cases.
Read more →ABBVAbbVie Completes Acquisition of Landos Biopharma AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the...
AbbVie has finalized its acquisition of Landos Biopharma, incorporating Landos' lead investigational asset NX-13 into its pipeline. NX-13, an oral NLRX1 agonist, is currently in Phase 2 trials aimed at treating moderate to severe ulcerative colitis and Crohn's disease. This acquisition is expected to enhance AbbVie's capabilities in immunology and improve treatment options for patients suffering from inflammatory bowel diseases. Financially, AbbVie has agreed to purchase Landos at $20.42 per share, which includes contingent value rights based on clinical milestones.
Read more →ABBVAbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to...
AbbVie is set to present 15 abstracts at the 2024 Digestive Disease Week, highlighting new data on treatments for Crohn's disease and ulcerative colitis. Among the notable presentations are findings from the SEQUENCE trial comparing risankizumab with ustekinumab, along with significant safety and efficacy data from the INSPIRE and COMMAND studies. AbbVie's efforts reflect its commitment to enhancing patient care in chronic inflammatory bowel diseases. The presentations will take place from May 18-21, 2024, in Washington, D.C.
Read more →ABBVAbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation...
AbbVie and Gilgamesh Pharmaceuticals have entered a collaboration agreement to develop next-generation therapies targeting psychiatric disorders. The partnership will combine AbbVie's expertise in psychiatry with Gilgamesh's innovative research platform to identify novel neuroplastogens. These new compounds aim to offer clinical benefits while minimizing the psychoactive effects associated with first-generation treatments. The collaboration includes an upfront payment of $65 million to Gilgamesh and potential future earnings of up to $1.95 billion, underlining the significance of this agreement in advancing mental health treatment options.
Read more →ABBVAbbVie to Present at the Bank of America Securities Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024. Robert A. Michael, president ...
AbbVie (NYSE: ABBV) is scheduled to participate in the Bank of America Securities Healthcare Conference on May 15, 2024. Key executives, including the president and chief operating officer, will present during the session. A live audio webcast of the presentation will be available through AbbVie's Investor Relations website, with an archived edition accessible later that day. The event reflects AbbVie's commitment to innovation in various therapeutic areas.
Read more →ABBVAbbVie Reports First-Quarter 2024 Financial Results Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent;...
AbbVie announced its first-quarter financial results for 2024, reporting a GAAP diluted EPS of $0.77, which reflects a significant increase of 492.3% year-over-year. Despite this strong performance, the adjusted diluted EPS decreased by 6.1%. The company's growth continues to be driven by its ex-Humira platform, prompting an upward revision of its full-year EPS outlook. CEO Richard A. Gonzalez praised the company's organizational achievements while emphasizing their commitment to operational excellence and patient impact.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports First-Quarter 2024 Financial Results Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent
AbbVie reported its financial results for Q1 2024, highlighting a diluted EPS of $0.77 on a GAAP basis, reflecting a dramatic increase of 492.3%. However, adjusted diluted EPS saw a decrease of 6.1%, primarily due to Humira biosimilar competition affecting its immunology segment. The company successfully completed its acquisition of ImmunoGen, enhancing its oncology portfolio with the drug Elahere. Despite some revenue declines in certain portfolios, AbbVie raised its full-year adjusted EPS guidance, indicating strong operational performance.
Read more →ABBVNew Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and...
AbbVie announced positive topline results from the LEVEL UP study, which evaluated upadacitinib against dupilumab in treating moderate-to-severe atopic dermatitis. The study demonstrated that upadacitinib achieved superior efficacy on primary and all secondary endpoints for patients inadequately responding to systemic therapies. Results highlighted that a significantly higher proportion of patients on upadacitinib experienced both significant skin clearance and reduced itch. The safety profile of upadacitinib was consistent with findings from earlier studies, with no new safety signals identified.
Read more →ABBVAllergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest...
Allergan Aesthetics, a subsidiary of AbbVie, has launched an open casting call inviting consumers to participate in upcoming campaigns for brands like BOTOX® Cosmetic and JUVÉDERM® fillers. This initiative aims to elevate authentic patient voices and promote diversity within the aesthetic industry. The campaign follows the successful 'See Yourself' campaign, which included a diverse range of individuals sharing their aesthetic journeys. The casting call runs until June 4, 2024, allowing both existing patients and others interested in aesthetic treatments to apply.
Read more →ABBVPhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis − Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib...
AbbVie announced positive results from the Phase 3 SELECT-GCA study, which evaluated upadacitinib (RINVOQ) for patients with giant cell arteritis (GCA). The study demonstrated that 46% of patients receiving upadacitinib in combination with a steroid taper achieved sustained remission from week 12 to 52, compared to 29% in the placebo group. Key secondary endpoints were also met, showing significant improvements in remission rates and lower disease flare rates. The drug's safety profile remained consistent with other approved uses, with no new safety concerns reported.
Read more →ABBVAbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine - Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic...
AbbVie announced promising interim analysis results from a 156-week extension study of atogepant, showcasing long-term safety, tolerability, and efficacy for preventing chronic and episodic migraines. The study found that 70% of participants experienced a significant reduction in monthly migraine days during the treatment period. No new safety concerns were identified, continuing to affirm the drug's established safety profile. AbbVie plans to present these findings at the upcoming American Academy of Neurology Annual Meeting, indicating ongoing research interests in migraine treatment.
Read more →ABBVSkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic....
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has introduced new Acne Clarifying Treatment and Pore Purifying Gel Cleanser under the SkinMedica brand. These products aim to effectively address acne while maintaining skin health. Clinical studies indicate that users experience clearer skin without excessive dryness. The treatments incorporate ingredients that soothe and preserve the skin barrier, enhancing the overall efficacy for acne-prone individuals.
Read more →ABBV▼ -5.3%on this newsshared move
AbbVie to Host First-Quarter 2024 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens. AbbVie will host a...
AbbVie (NYSE: ABBV) will release its first-quarter 2024 financial results on April 26, 2024, before the market opens. The company will also host a live webcast of their earnings conference call at 8 a.m. Central time, which will be accessible via its Investor Relations website. An archived edition of the call will be made available later that day for those unable to attend the live event.
Read more →ABBVAllergan Aesthetics Announces the Return of CoolMonth with CoolSculpting® Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite. From April...
Allergan Aesthetics, a subsidiary of AbbVie, is launching its second annual CoolMonth, running from April 1 to April 30, 2024, promoting CoolSculpting® Elite. The campaign is designed to drive consumer interest in non-invasive body contouring treatments, following a successful previous year with over 62,000 procedures. The initiative includes CoolSavings promotions aimed at encouraging consumers to consult healthcare providers for treatment options. The CoolSculpting® technologies are FDA-cleared for treating specific areas, although certain risks and side effects are associated with the procedure.
Read more →ABBVAllergan Aesthetics Launches Moving the Needle on Ethics to Elevate the Conversation Around Ethics in Aesthetics Allergan Aesthetics, an AbbVie (NYSE: ABBV) Company, announces Moving the Needle on Ethics- its collaboration with medical aesthetics experts from...
Allergan Aesthetics, a division of AbbVie, has launched the 'Moving the Needle on Ethics' initiative to elevate discussions surrounding ethics in the aesthetics industry. This effort includes a collection of global interviews and research, aiming to foster transparency and integrity amidst increasing global demand for aesthetic treatments. The initiative also includes a training program on ethics for aesthetic practitioners, set to begin in 2024, reinforcing the importance of patient safety and establishing high ethical standards within the industry.
Read more →ABBVAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases AbbVie Inc. (NYSE: ABBV) ( AbbVie ) and Landos Biopharma, Inc. (NASDAQ: LABP) ( Landos ) today announced a definitive agreement under which AbbVie...
AbbVie has announced its plan to acquire Landos Biopharma for $137.5 million, with an additional contingent value right based on clinical milestones. The acquisition focuses on Landos' NX-13, an innovative oral treatment aimed at addressing autoimmune diseases like ulcerative colitis and Crohn's disease. The transaction is expected to enhance AbbVie's capabilities in immunology, with the acquisition set to close in the second quarter of 2024, pending shareholder approval and regulatory conditions. Landos' NX-13 is currently in Phase 2 trials to evaluate its safety and efficacy in patients.
Read more →ABBVU.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab...
AbbVie announced that the FDA has granted full approval for ELAHERE (mirvetuximab soravtansine-gynx) for eligible ovarian cancer patients. This approval is based on data from the MIRASOL Phase 3 trial, which demonstrated an overall survival benefit and a reduction in cancer progression risk. ELAHERE is the first and only approved antibody-drug conjugate for this challenging indication, providing a new treatment option for patients with platinum-resistant ovarian cancer.
Read more →ABBVALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024 -- Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions...
Allergan Aesthetics is set to showcase its commitment to innovation and individuality at the AMWC 2024. The event will include expert-led symposia focusing on personalized aesthetic treatments, live injection demonstrations, and discussions on emerging trends in the industry. Seventeen posters exhibiting new clinical data on toxins and fillers will further highlight the company's expansive portfolio. A new initiative aimed at addressing ethics in aesthetic medicine will also be launched during the congress.
Read more →ABBVAbbVie to Present at the Barclays 26th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024. Robert A. Michael,...
AbbVie announced its participation in the Barclays 26th Annual Global Healthcare Conference scheduled for March 14, 2024. Key executives, including the president and chief operating officer, will present at 8:00 a.m. Central time. The event will be accessible via a live audio webcast and will be archived for future viewing. AbbVie emphasizes its mission to deliver innovative solutions in various therapeutic areas, including immunology and oncology.
Read more →ABBVAbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking...
AbbVie and Allergan Aesthetics announced the presentation of 29 abstracts at the 2024 American Academy of Dermatology Annual Meeting in San Diego. The data presented emphasizes the efficacy, safety, and durability of their dermatology and aesthetics portfolios, showcasing their commitment to advancing medical treatments. Key highlights include results from phase trials on various dermatological conditions such as atopic dermatitis and psoriasis. This presentation reaffirms their dedication to improving patient outcomes and redefining treatment standards.
Read more →ABBVJUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple...
Allergan Aesthetics, a subsidiary of AbbVie, has received FDA approval for JUVÉDERM VOLUMA XC, the first hyaluronic acid dermal filler specifically for temple hollowing in adults over 21. The approval signifies a major advancement in facial aesthetics, offering patients a solution to improve moderate to severe volume loss in the temple area. Clinical trials demonstrated high patient satisfaction, with over 80% of subjects noticing significant improvement in their appearance after treatment. Following the approval, Allergan will implement a training program for providers to ensure safe application of the new filler in aesthetic practices.
Read more →ABBVAbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a...
AbbVie and OSE Immunotherapeutics have announced a strategic partnership to develop OSE-230, a monoclonal antibody targeting chronic inflammation. Under the agreement, OSE Immunotherapeutics will receive an upfront payment of $48 million, with additional potential milestone payments totaling up to $665 million. AbbVie aims to leverage its expertise in immunology to advance the development of OSE-230, which operates through a novel mechanism of action by activating ChemR23. This partnership signifies a major step forward for OSE Immunotherapeutics and their innovative research and development capabilities.
Read more →ABBVAbbVie to Present at the TD Cowen 44th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. Robert A. Michael, president and...
AbbVie (NYSE: ABBV) is set to participate in the TD Cowen 44th Annual Health Care Conference on March 5, 2024. High-level executives, including President Robert A. Michael, will provide insights during the presentation. A live audio webcast will be available for investors to access the session, alongside an archived version later in the day. This participation underscores AbbVie's commitment to addressing significant health issues and seeking innovative solutions.
Read more →ABBVU.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics...
AbbVie announced that the FDA has granted Priority Review for epcoritamab, a bispecific antibody for treating relapsed or refractory follicular lymphoma after multiple therapies. The designation shortens the review time, reflecting the treatment's potential to improve patient outcomes. Results from the Phase 1/2 EPCORE NHL-1 trial showed promising treatment responses. This designation follows the Breakthrough Therapy Designation received in November 2023.
Read more →ABBVAbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of...
AbbVie and Tentarix Biotherapeutics have announced a multi-year collaboration to develop conditionally-active, multi-specific biologics targeting oncology and immunology. This partnership will leverage AbbVie’s expertise with Tentarix’s Tentacles™ platform, aimed at improving immune modulation while reducing safety issues. AbbVie will invest $64 million in upfront payments for two therapeutic programs, with an option for further acquisition following candidate nomination. Both companies express optimism about accelerating innovative therapies to meet critical patient needs.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program...
AbbVie’s Allergan Aesthetics has opened applications for the 2024 BOTOX Cosmetic grant program, aiming to support women entrepreneurs. This year, the program will award 20 grants of $25,000 each, alongside vital mentorship and community resources, to help bridge the Confidence Gap in business. The program, in its second year, is a collaboration with IFundWomen and focuses on providing women with the tools and funding to succeed in their ventures. The application deadline is March 19, 2024, with recipients announced in the spring.
Read more →ABBVAbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief...
AbbVie has announced the appointment of Robert A. Michael as its new CEO, succeeding Richard A. Gonzalez, who will transition to the role of executive chairman. Michael, currently the president and COO, is recognized for his significant contributions to the company's strategy and growth. The board has expressed confidence in his ability to lead AbbVie into its next chapter, especially as the company continues to perform well and maintain a strong product pipeline. Gonzalez's tenure saw substantial growth for AbbVie, including a market value increase from $54 billion to over $300 billion.
Read more →ABBVAbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer - Richard A. Gonzalez to retire as AbbVie CEO to become executive chairman - Transition will occur on
AbbVie has announced the appointment of Robert A. Michael as its new Chief Executive Officer, set to take effect on July 1, 2024. He will succeed Richard A. Gonzalez, who will transition to the role of executive chairman after leading the company since its formation in 2013. The board expressed confidence in Michael's ability to drive AbbVie's future success, citing his significant contributions and experience. This planned succession reflects AbbVie's strong management team and commitment to long-term growth.
Read more →ABBVAbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) – A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of...
AbbVie announced the acceptance of 17 abstracts for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO), emphasizing its dedication to enhancing the lives of patients with inflammatory bowel diseases (IBD). Among the highlights are data from pivotal studies comparing risankizumab and upadacitinib, aimed at improving treatment outcomes for Crohn's disease and ulcerative colitis. The research reflects AbbVie's ongoing commitment to advance standards of care in this field, as physicians emphasize the need for continuous improvement in treatment paradigms.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable May 15,...
AbbVie Inc. has declared a quarterly cash dividend of $1.55 per share, payable on May 15, 2024, to stockholders recorded by April 15, 2024. Since its founding in 2013, the company has increased its dividend significantly, reflecting a robust financial performance. AbbVie is recognized as a member of the S&P Dividend Aristocrats Index, which highlights its consistent ability to increase dividends over the years. The company focuses on delivering innovative medicines in various therapeutic areas, contributing positively to healthcare.
Read more →ABBVAbbVie Completes Acquisition of ImmunoGen Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant...
AbbVie has completed the acquisition of ImmunoGen, integrating its innovative ADC ELAHERE, which is the first FDA-approved agent for platinum-resistant ovarian cancer. This acquisition is set to enhance AbbVie's oncology offerings and is anticipated to contribute positively to its revenue and EPS beginning in 2027. However, challenges related to integration, business relationships, and significant transaction costs pose potential risks to AbbVie as it navigates this new merger.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent Adjusted Diluted EPS of $11.11, a Decrease of 1
AbbVie reported its financial results for 2023, revealing significant declines in EPS and revenues driven largely by biosimilar competition affecting its immunology portfolio. The company's total net revenues were $54.318 billion, a drop of 6.4 percent compared to the previous year. Despite these challenges, AbbVie announced acquisitions of ImmunoGen and Cerevel Therapeutics, expected to strengthen their oncology and neuroscience pipelines. Additionally, AbbVie provided a positive guidance for adjusted diluted EPS in 2024, indicating potential growth amidst current revenue pressures.
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These ...
AbbVie reported its financial results for 2023, highlighting a significant drop in diluted EPS by 59.0% on a GAAP basis and a 19.3% decrease in adjusted diluted EPS. However, the company noted strong performance in its non-Humira growth sector and an increase in expectations for revenues from Skyrizi and Rinvoq. AbbVie anticipates modest revenue growth in 2024 as it manages the effects of Humira's market erosion. Additionally, the firm has outlined plans for acquisitions of ImmunoGen and Cerevel Therapeutics, which could influence its financial landscape going forward.
Read more →ABBVAllergan Aesthetics Releases Decoding the Future of Aesthetic Individuality Exploring the Power of Self-Expression Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments, released the Decoding the Future of ...
Allergan Aesthetics, part of AbbVie, has released the report "Decoding the Future of Aesthetic Individuality" to explore consumer individuality in aesthetics. The report aims to understand patients' personal definitions of individuality and enhance personalized aesthetics treatments. It builds on previous research and incorporates social listening and expert interviews. The findings underscore the importance of tailored approaches in aesthetic consultations as consumer needs evolve.
Read more →ABBVAllergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024 Allergan Aesthetics, the industry leader in aesthetics globally, continues to bring best-in-class programming highlighting Individuality, Innovation, ...
Allergan Aesthetics is set to showcase its commitment to individuality, innovation, and integrity at the IMCAS World Congress 2024 in Paris from February 1-3. The event will feature several key activities, including a symposium on individualized aesthetics and new clinical data presentations. The congress emphasizes originality through the theme 'True Originals,' highlighting the industry’s focus on personalized aesthetic solutions. Additionally, Allergan will host various expert-led sessions, enhancing the educational landscape within the aesthetics field.
Read more →ABBVAbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its...
AbbVie has announced a $223 million expansion of its manufacturing facility in Singapore, aimed at increasing biologics capacity. This investment will create over 100 new jobs and enhance the company's ability to support its growing pipeline of immunology and oncology products. Construction is set to begin immediately, with operations expected to start in 2026.
Read more →ABBVAllē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S. Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of...
Allē, the loyalty rewards program by Allergan Aesthetics (a subsidiary of AbbVie), has garnered a 92% satisfaction rate based on a recent consumer survey. The program serves over six million members across 19,000 practices, establishing itself as the leading player in the aesthetics loyalty space in the United States. Allē aims to educate consumers on aesthetic treatments and empower them along their treatment journey. It also offers tools for providers to enhance patient engagement and retention.
Read more →ABBVAbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union AbbVie (NYSE: ABBV) today announced the launch of PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced...
AbbVie has launched PRODUODOPA (foslevodopa/foscarbidopa), marking a significant advancement in the treatment of advanced Parkinson's disease within the European Union. This is the first subcutaneous 24-hour infusion of levodopa-based therapy, aimed at patients experiencing severe motor fluctuations. Clinical studies indicated that it significantly improves both 'On' and 'Off' times, enhancing patients' daily functionality. While most adverse events were mild, there are concerns regarding infusion site reactions that may affect patient adherence to the new treatment.
Read more →ABBVLutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3 Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly ...
AbbVie announced that its investigational drug lutikizumab (ABT-981) showed promising Phase 2 trial results in adults with moderate to severe hidradenitis suppurativa (HS) who previously failed anti-TNF therapy. The drug achieved higher response rates than placebo, with 59.5% of participants on the 300 mg weekly regimen achieving a primary efficacy endpoint. Given the positive results, AbbVie plans to progress the lutikizumab program to Phase 3 trials. Despite some adverse events, the treatment was generally well-tolerated, signaling potential efficacy in a challenging-to-treat patient population.
Read more →ABBVAbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024, before the market opens....
AbbVie is scheduled to announce its financial results for both full-year and fourth-quarter 2023 on February 2, 2024. The announcement will occur before the market opens, followed by a live webcast of the earnings call at 8 a.m. CT. Investors and interested parties can access the webcast through AbbVie's Investor Relations website. Additionally, an archived version of the session will be available later in the day.
Read more →ABBVAbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license...
AbbVie has entered strategic collaboration with Umoja Biopharma to develop novel in-situ CAR-T cell therapies for oncology. The agreement includes exclusive options to license Umoja's CD19-targeted candidates and further develop additional candidates. This partnership aims to leverage Umoja's VivoVec platform, which allows T cells to generate their own CAR-T cells within the body, addressing some challenges associated with traditional methods. The agreements could result in Umoja earning up to $1.44 billion in aggregate from AbbVie as they advance their therapeutic candidates into clinical stages.
Read more →ABBVAbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. Robert A. Michael,...
AbbVie (NYSE: ABBV) is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Key executives, including Robert A. Michael and Scott T. Reents, will participate in the presentation scheduled for 10:15 a.m. Central time. The event aims to showcase AbbVie's dedication to developing innovative medicines across various therapeutic areas. A live audio webcast will be available, along with an archived edition later that day.
Read more →ABBVNew Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL)...
AbbVie and Genmab reported positive results from the Phase 1/2 EPCORE NHL-1 study for their investigational bispecific antibody, epcoritamab, showing significant efficacy in patients with relapsed/refractory follicular lymphoma. The therapy achieved an 82% overall response rate and a 63% complete response rate, suggesting strong and durable effectiveness. Safety data demonstrated that while cytokine release syndrome was prevalent, an optimized dosing regimen helped mitigate these effects. The FDA has granted Breakthrough Therapy Designation for epcoritamab, reinforcing its potential as a treatment option.
Read more →ABBVAbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant...
AbbVie has announced its intention to acquire Cerevel Therapeutics for $45 per share, valuing the deal at approximately $8.7 billion. This acquisition is set to enhance AbbVie's neuroscience portfolio with a range of promising clinical-stage and preclinical candidates targeting neurological and psychiatric disorders, including schizophrenia and Parkinson's disease. The transaction is expected to close in mid-2024, pending shareholder and regulatory approvals. AbbVie CEO Richard Gonzalez emphasized the growth potential of this acquisition, which could significantly impact patient care over the coming decade.
Read more →ABBVAbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatri
AbbVie has announced its definitive agreement to acquire Cerevel Therapeutics for $8.7 billion, aiming to enhance its neuroscience pipeline. The acquisition will add multiple clinical-stage and preclinical candidates focused on conditions such as schizophrenia and Parkinson's disease. AbbVie anticipates that this investment will allow for significant growth opportunities in the coming decade and is expected to close by mid-2024, pending regulatory and shareholder approvals. The deal includes promising assets like emraclidine, which has shown efficacy in treating schizophrenia and related conditions.
Read more →ABBVAbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic...
AbbVie and BigHat Biosciences have announced a research collaboration to discover and develop next-generation therapeutic antibodies targeting oncology and neuroscience. BigHat will leverage its Milliner™ platform, which combines machine learning with a high-speed lab, to optimize antibody design. The collaboration could accelerate AbbVie's drug development pipeline, with BigHat set to receive an upfront payment of $30 million and potential milestone payments totaling approximately $325 million.
Read more →ABBVAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug...
AbbVie has entered into a definitive agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx). This acquisition aims to strengthen AbbVie's presence in the oncology market, particularly in treating platinum-resistant ovarian cancer. The transaction, valued at approximately $10.1 billion, is expected to close in mid-2024 pending regulatory and shareholder approvals. ELAHERE, a first-in-class antibody-drug conjugate, offers promising potential for expansion into broader therapeutic areas.
Read more →ABBVAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE ( mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio Proposed acquisition will accelerate AbbVie's entry into the com
AbbVie has announced a definitive agreement to acquire ImmunoGen, including its leading cancer therapy ELAHERE, for approximately $10.1 billion. The acquisition aims to strengthen AbbVie's presence in the oncology market, particularly targeting solid tumors and expanding its antibody-drug conjugate (ADC) portfolio. Both companies' boards have approved the transaction, which is expected to close in mid-2024 pending shareholder and regulatory approvals. This integration is anticipated to enhance treatment options for ovarian cancer patients and potentially provide long-term revenue growth for AbbVie.
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC) AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in...
AbbVie announced topline results from the Phase 2 LUMINOSITY trial for telisotuzumab-vedotin (Teliso-V) targeting patients with c-Met overexpressing non-small cell lung cancer. The trial showed an overall response rate of 35% among c-Met High patients, with a median overall survival of 14.6 months. The safety profile was consistent, with no new safety concerns reported. AbbVie is continuing with other trials aimed at establishing Teliso-V's broader impact in oncology, signaling a potential pathway to accelerated approval.
Read more →ABBVAbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an...
AbbVie announced significant progress for epcoritamab, as it received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory follicular lymphoma. The European Medicines Agency also validated a Type II application, indicating the drug is closer to potential approval for this indication. This move emphasizes AbbVie’s commitment to developing therapies for complex blood cancers with limited treatment options. Ongoing and future clinical trials will further assess the drug’s safety and efficacy, with challenges remaining regarding side effects and regulatory approval.
Read more →ABBVFifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever Allergan Aesthetics, an AbbVie company (NYSE: ABBV), celebrated the fifth annual BOTOX® Cosmetic Day like never before, achieving record-breaking...
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), celebrated its fifth annual BOTOX Cosmetic Day, setting new records for participation and engagement. The event featured offers such as Buy-One-Get-One gift cards, allowing Allē members to benefit while promoting the product's continued leadership in the aesthetic market. BOTOX Cosmetic remains the only FDA-approved neurotoxin for several cosmetic lines, underpinning its market success. The company anticipates ongoing growth and celebration of this significant event in the future.
Read more →ABBVResults Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine - More patients treated with UBRELVY® 100 mg during the prodrome avoided the development of moderate or severe headache within 24 hours post-dose vs. ...
AbbVie has announced promising results for UBRELVY (ubrogepant) in a Phase 3 clinical trial published in The Lancet. The study demonstrated that patients who received UBRELVY 100 mg during the prodrome phase of migraine significantly avoided the onset of moderate to severe headaches within 24 hours compared to a placebo. This makes UBRELVY the first migraine treatment to show effectiveness during the prodrome phase. The findings offer new hope for the nearly 40 million Americans affected by migraines.
Read more →ABBVNatrelle® Unveils New For Every BODY Campaign Allergan Aesthetics, an AbbVie company (NYSE: ABBV), embraces the immensely personal choice that patients experience when choosing breast surgery....
Allergan Aesthetics, a company of AbbVie, has launched the 'For Every BODY' campaign to spotlight its diverse Natrelle® breast implant portfolio. This initiative emphasizes patient stories and aims to provide transparency about breast augmentation outcomes. The Natrelle® collection includes 300 customization options, catering to varied patient needs. While the campaign highlights the positive aspects of breast augmentation, it also includes important safety information regarding potential complications associated with implants.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX® Cosmetic Day on Wednesday, November 15. To commemorate...
AbbVie’s Allergan Aesthetics is set to celebrate the fifth annual BOTOX Cosmetic Day on November 15, enhancing its offerings for both new and existing Allē members. This year, customers can expect exclusive promotions and a partnership with Snapchat to create an interactive AR Lens that educates users about BOTOX. Last year's event saw significant participation, prompting over half a million BOTOX treatments, with this year's expectations even higher. BOTOX Cosmetic remains a leading product in the aesthetics market, recognized as the most awarded aesthetic neurotoxin in the U.S.
Read more →ABBVAbbVie Reports Third-Quarter 2023 Financial Results Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent;...
AbbVie has reported its financial results for the third quarter of 2023, noting continued growth in its non-Humira product category, which is contributing to double-digit growth. The company raised its full-year adjusted diluted EPS guidance and announced a 4.7% increase in its quarterly dividend. Despite a decrease in both GAAP and adjusted diluted EPS, AbbVie remains confident in its long-term outlook. The negative impact from IPR&D and milestone costs remains a concern, but overall confidence in growth persists.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Third-Quarter 2023 Financial Results Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent
AbbVie reported its third-quarter 2023 financial results, indicating a diluted EPS of $1.00 on a GAAP basis, a significant decline of 54.8% from the previous year. While overall net revenues fell by 6.0% to $13.927 billion, the company saw substantial growth in its neuroscience portfolio, which increased by 22.1%. AbbVie is optimistic about its future, raising both its 2023 and 2024 adjusted diluted EPS guidance while announcing a 4.7% dividend increase. However, the immunology portfolio remained a concern with a year-over-year revenue decrease of 11.3%.
Read more →ABBVAllergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating...
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has reported positive topline results from two pivotal Phase 3 studies evaluating trenibotulinumtoxinE (BoNT/E) for moderate to severe glabellar lines. The studies, involving 947 adult subjects across multiple locations, demonstrated significant efficacy compared to placebo with rapid onset and a short duration of effect. If approved, BoNT/E will be the first neurotoxin of its kind available for patients seeking aesthetic treatments, with safety profiles similar to placebo. Further results will be presented at future medical meetings.
Read more →ABBVAllergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project Yesterday, on Breast Reconstruction Awareness Day (National BRA Day), Allergan Aesthetics, an AbbVie company (NYSE: ABBV), launched Reblossom, a...
On October 19, 2023, Allergan Aesthetics launched the Reblossom Project on Breast Reconstruction Awareness Day. This initiative features a coffee table book that highlights the stories of 12 women who have undergone breast cancer journeys. The book's proceeds will benefit Living Beyond Breast Cancer. Allergan Aesthetics continues to support patients through various initiatives and partnerships to elevate voices within the breast cancer community.
Read more →ABBVAbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active...
AbbVie has announced positive results from the Phase 3 SEQUENCE study, which compared risankizumab (SKYRIZI) to ustekinumab (STELARA) for treating adults with moderately to severely active Crohn's disease. The study met all primary and secondary endpoints, demonstrating that risankizumab is superior in achieving clinical and endoscopic remission. These findings offer physicians critical data to aid in treatment decisions, enhancing care for patients with Crohn's disease. The safety profile for risankizumab remains consistent, with no new risks identified during the study.
Read more →ABBVAbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3 AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo (NSV) met the...
AbbVie announced that its Phase 2b trial for upadacitinib (RINVOQ) in adults with non-segmental vitiligo met its primary endpoint, demonstrating significant efficacy in skin re-pigmentation. The study observed a greater percentage change from baseline in the Facial Vitiligo Area Scoring Index at both week 24 and week 52 for higher doses compared to placebo. AbbVie plans to progress the clinical program to Phase 3, addressing a high unmet need in vitiligo treatment, as no systemic options are currently available and vitiligo significantly impacts patients' lives.
Read more →ABBVAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) ...
AbbVie has released new analyses from three Phase 3 studies demonstrating the long-term efficacy and safety of RINVOQ (upadacitinib) in treating moderate to severe atopic dermatitis in adults and adolescents aged 12 and older. The studies reported that a higher proportion of patients achieved significant improvements in skin clearance and reduced itch compared to placebo, with effects maintained over 140 weeks. These results, highlighting an acceptable safety profile, were presented at the 32nd EADV Congress in Berlin, reinforcing AbbVie's commitment to delivering effective treatments for chronic skin conditions.
Read more →ABBVAbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023 – Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn's disease ...
AbbVie is set to showcase significant data pertaining to Crohn's disease and ulcerative colitis at the UEG Week 2023 Congress in Copenhagen, Denmark. A total of 23 abstracts will be presented, including a late-breaking study comparing SKYRIZI to STELARA. The research aims to highlight AbbVie's ongoing commitment to improving treatment standards and outcomes for patients with inflammatory bowel diseases. The findings may provide valuable insights into the efficacy of therapies in managing these challenging gastrointestinal conditions.
Read more →ABBVAbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage...
AbbVie announced the completion of its acquisition of Mitokinin, a company developing a PINK1 activator aimed at addressing mitochondrial dysfunction in Parkinson's disease. This move strengthens AbbVie's neuroscience pipeline with a promising treatment option that may alter disease progression. The acquisition involves an initial payment of $110 million, with potential additional payments upon achieving specific milestones. AbbVie views this as a significant opportunity to address the unmet medical needs of Parkinson's patients.
Read more →ABBVAbbVie to Host Third-Quarter 2023 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie will host a...
AbbVie has announced it will disclose its third-quarter 2023 financial results on October 27, 2023, prior to market opening. This will be accompanied by a live webcast at 8 a.m. CT accessible through its Investor Relations website. An archived version of the session will be available later in the day, allowing investors to review the financial outcomes and updates. AbbVie emphasizes its commitment to delivering innovative solutions in key therapeutic areas.
Read more →ABBVNature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and...
AbbVie, in collaboration with the Broad Institute and Calico Life Sciences, announced the publication of research on ABBV-CLS-484, a potential first-in-class inhibitor for cancer immunotherapy. The findings highlight this investigational drug's dual mechanism, enhancing anti-tumor immunity and showing efficacy in preclinical models, particularly in tumors resistant to existing therapies. Additionally, ABBV-CLS-484 is currently undergoing a Phase 1 clinical trial for solid tumors, representing a significant advancement in cancer treatment strategies.
Read more →ABBVAllergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a...
Allergan Aesthetics, an AbbVie company, has announced its fifth year of collaboration with Girls Inc. to support Project Accelerate, a program aiming to empower young women in STEM fields. This initiative will help address workforce inequality by providing mentorship and opportunities for college-aged girls from underrepresented populations. The program includes a virtual panel and discussions on career journeys in STEM, guided by experienced women professionals. This partnership aims to cultivate the next generation of female leaders in science, technology, engineering, and mathematics, responding directly to the needs voiced by young women seeking support as they navigate their educational and career paths.
Read more →ABBVAbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus ...
AbbVie announced data from its Phase 3 CANOVA study assessing venetoclax combined with dexamethasone for relapsed or refractory multiple myeloma. While patients treated with the combination showed improved median progression-free survival (PFS) compared to another regimen, the results lacked statistical significance. The safety profile of the combination was consistent with existing safety data, with no new safety signals identified. The company plans to discuss the findings with health authorities as they continue to seek ways to improve treatment outcomes for multiple myeloma patients.
Read more →ABBVAbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as...
AbbVie announced that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma. This marks a significant milestone as TEPKINLY becomes the first subcutaneous bispecific antibody approved for this patient population in the EU. The authorization is based on encouraging study results indicating an overall response rate of 62%. However, the treatment is associated with risks of cytokine release syndrome and serious infections, necessitating careful patient management.
Read more →ABBVAllergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from the second of three Phase 3 clinical studies...
Allergan Aesthetics, a subsidiary of AbbVie, announced positive topline results from a Phase 3 clinical study of onabotulinumtoxinA (BOTOX Cosmetic) for treating moderate to severe platysma prominence. The study met all primary and secondary endpoints, demonstrating statistically significant improvements. The results support the potential of onabotulinumtoxinA as a treatment option and will be included in an upcoming FDA submission. This product could become the first neurotoxin approved for this indication, adding to Allergan's portfolio in aesthetics.
Read more →ABBVAbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship Thriving Students AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships. Following this...
AbbVie has launched a public voting period for its 2023 Thriving Undergraduate and Graduate Scholarships, aimed at supporting students living with cystic fibrosis. The voting will determine two recipients who will each receive $25,000 in scholarships. This initiative follows AbbVie's tradition of providing financial assistance and recognizing achievements in the CF community, with over $3.9 million awarded since the program's inception. The winners will be announced in early November 2023.
Read more →ABBVAbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment ...
AbbVie announced positive results from its Phase 3 SEQUENCE clinical trial, which compared SKYRIZI (risankizumab) to ustekinumab in Crohn's disease patients. The trial showed that risankizumab met both primary endpoints, with significant improvements in clinical and endoscopic remission rates. The safety profile of risankizumab was consistent with prior research, indicating no new safety issues. Full results from the study are expected to be presented at a forthcoming medical meeting and submitted for publication.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable November ...
AbbVie Inc. has declared a quarterly cash dividend of $1.48 per share, payable on November 15, 2023, to shareholders on record by October 13, 2023. Since its founding in 2013, AbbVie has increased its dividend significantly by 270%. The company is recognized as a member of the S&P Dividend Aristocrats Index, underscoring its ongoing commitment to dividend increases over the years.
Read more →ABBVJoin BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the next chapter of the BOTOX® Cosmetic and IFundWomen grant program with the...
AbbVie, through its Allergan Aesthetics division, has announced the next phase of its grant program in collaboration with IFundWomen, dedicated to supporting women entrepreneurs. Each selected entrepreneur will receive a $25,000 grant, mentorship, and access to a Crowdfunding Accelerator Program. The initiative aims to promote visibility and funding opportunities for women-led businesses, working towards closing the 'Confidence Gap.' The program emphasizes community involvement in uplifting women entrepreneurs and provides essential resources for their growth.
Read more →ABBVAbbVie to Present at the Morgan Stanley Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. Robert A....
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023. Key executives including president Robert A. Michael and CFO Scott Reents will present at the event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later. AbbVie aims to innovate in therapeutic areas such as immunology, oncology, and neuroscience.
Read more →ABBVJournal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic) Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc ...
AbbVie’s Allergan Aesthetics announced the publication of positive results from a study in the Journal of Cosmetic Dermatology on onabotulinumtoxinA (BOTOX® Cosmetic). The year-long analysis indicated that about 90% of participants were satisfied with the natural appearance achieved post-treatment. Additionally, more than half of the patients noted improvements in their psychological well-being and self-perception 30 days after the treatment. The study highlights the effectiveness of BOTOX® in addressing upper facial lines in individuals who had not previously received neurotoxin treatments.
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted...
AbbVie has submitted regulatory applications to the FDA and EMA for risankizumab (SKYRIZI) aimed at treating adults with moderately to severely active ulcerative colitis. The applications are underpinned by positive Phase 3 clinical trial data demonstrating risankizumab's effectiveness in achieving clinical remission. Notably, the safety profile remains consistent with earlier findings, which bolsters confidence in the drug's use for this new indication. AbbVie aims to address the ongoing need for effective treatments in this therapeutic area.
Read more →ABBVAbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults AQUIPTA® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union...
AbbVie has received European Commission approval for AQUIPTA (atogepant), a once-daily oral treatment for adults suffering from migraines, particularly those experiencing four or more migraine days a month. This approval positions AQUIPTA as a unique offering in the EU market, fulfilling a significant unmet need for chronic and episodic migraine patients. Clinical trials demonstrated substantial efficacy, with participants experiencing a reduction in mean monthly migraine days. However, some adverse effects such as nausea and constipation were reported during trials.
Read more →ABBVAllergan Aesthetics Announces First Ever JUVÉDERM® Day Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes ...
Allergan Aesthetics, a subsidiary of AbbVie, has announced the inaugural JUVÉDERM® Day, set for August 16, 2023. This day aims to celebrate both consumers and aesthetics providers while offering exclusive promotions through the Allē loyalty program. The initiative also highlights the success of the JUVÉDERM® Collection, recognized as the leading dermal filler in the U.S. The event is officially recognized by the National Day Registry, allowing it to be celebrated annually.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Second-Quarter 2023 Financial Results Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Perc
AbbVie reported its financial results for the second quarter of 2023, showing a diluted EPS of $1.14 on a GAAP basis, which is a substantial increase of 123.5%. However, the total net revenues fell to $13.865 billion, a decrease of 4.9%, mainly driven by declining sales of Humira and the hematologic oncology portfolio. The company has raised its adjusted diluted EPS guidance for 2023, reflecting optimism driven by strong performance in its non-Humira products. Moreover, AbbVie announced FDA approvals for its products Rinvoq and Skyrizi, further enhancing its pipeline.
Read more →ABBVAbbVie Reports Second-Quarter 2023 Financial Results Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; ...
AbbVie announced its second-quarter 2023 financial results, revealing a diluted EPS of $1.14 on a GAAP basis, marking a significant 123.5% increase. However, the adjusted diluted EPS fell by 13.6% to $2.91. The company's performance was bolstered by its non-Humira business, which saw high single-digit sales growth, prompting AbbVie to raise its full-year earnings guidance. Nonetheless, the decline in Humira sales and the adjusted EPS decrease highlighted existing challenges in their product portfolio.
Read more →ABBVAbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical ...
AbbVie and Calibr have announced the expansion of their strategic collaboration, focusing on advancing several preclinical and early-stage clinical assets in immunology, oncology, and neuroscience. This partnership builds on their previous collaboration established in 2019 with Scripps Research. The goal is to explore new technologies and clinical indications that could lead to breakthrough medicines. While the partnership presents significant opportunities, AbbVie has stressed the risks associated with R&D, including competitive challenges and regulatory uncertainties.
Read more →ABBVSKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study An open-label, efficacy assessor-blinded study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with...
AbbVie announced positive results from the Phase 4 IMMpulse study published in the British Journal of Dermatology, showing that SKYRIZI (risankizumab) outperformed Otezla (apremilast) in treating adults with moderate plaque psoriasis. The study met its primary and secondary endpoints while demonstrating a safety profile consistent with prior studies. Notably, no new safety signals were identified, and patients on risankizumab reported higher treatment satisfaction compared to those on apremilast. This reinforces risankizumab's potential as an effective therapy for systemic-eligible psoriasis patients.
Read more →ABBVAbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa AbbVie (NYSE: ABBV) today announced that the first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ®) in adults ...
AbbVie has announced the dosing of the first patient in its Phase 3 Step-Up HS study for upadacitinib (RINVOQ) aimed at treating moderate to severe hidradenitis suppurativa. This trial marks a significant advancement as it is the first randomized Phase 3 trial for this chronic condition, which has limited therapeutic options. The study plans to enroll approximately 1,300 participants and will evaluate the treatment's efficacy and safety against placebo for patients who failed previous therapies. The development underscores AbbVie's ongoing efforts to innovate care in underserved patient populations.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) If approved, epcoritamab (TEPKINLY®) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the...
AbbVie has received a positive opinion from the CHMP for its investigational drug epcoritamab (TEPKINLY®), aimed at treating adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). If approved, it could be the first subcutaneous bispecific antibody to be conditionally approved as a monotherapy aimed at this condition. The application is supported by encouraging results from the pivotal EPCORE™ NHL-1 trial, which reported a 63.1% overall response rate. Despite these positives, epcoritamab is not yet available in the EU, and further evaluations are required.
Read more →ABBVAbbVie Employees Volunteer to Make an Impact on over 1,300 Lives in Asia with 8th Annual "Week of Possibilities" to Support Local Communities AbbVie employees in Asia participated in its eighth annual Week of Possibilities (WOP) volunteering program, which unites employees around the world...
AbbVie employees in Asia participated in the eighth annual Week of Possibilities, engaging in volunteer projects that benefited local communities. From June 7 to July 7, over 940 employees collaborated with non-profits to support educational programs, environmental initiatives, and care for disadvantaged groups. A total of 1,308 individuals were positively impacted by these efforts across several Asian countries.
Read more →ABBVAbbVie to Host Second-Quarter 2023 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023, before the market opens. AbbVie will host a...
AbbVie will announce its second-quarter 2023 financial results on July 27, 2023, prior to market opening. The company will hold a live webcast of the earnings conference call at 8 a.m. CT, which will also be archived later for accessibility. AbbVie emphasizes its mission to deliver innovative medicines that address various health issues across multiple therapeutic areas.
Read more →ABBVAbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™ NHL-1 ...
AbbVie and Genmab have reported positive topline results from the Phase 1/2 EPCORE NHL-1 clinical trial of epcoritamab, an investigational therapy for patients with relapsed/refractory follicular lymphoma. The study demonstrated an 82% overall response rate, exceeding prespecified efficacy thresholds. However, the safety profile noted cytokine release syndrome as a common treatment-emergent adverse event. Further data from this trial are expected to be presented at a future medical meeting, with regulatory discussions planned with global authorities.
Read more →ABBVAbbVie Employees Volunteer During 8th Annual Week of Possibilities to Support Communities Globally AbbVie kicks off its eighth Week of Possibilities today with more than 14,000 employees volunteering in more than 50 countries and territories to...
AbbVie has launched its eighth Week of Possibilities, engaging over 14,000 employees in volunteer activities across more than 50 countries. This annual initiative aims to support local communities through various hands-on projects, including school renovations and food bank assistance. The program is aligned with AbbVie's philanthropy strategy and is designed to address specific community needs. This year's efforts reflect a continued commitment to making a positive impact through collaborative partnerships with community organizations.
Read more →ABBVAbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a...
AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the approval of atogepant, a new treatment for adults with chronic and episodic migraine. This would make AbbVie the only company to provide a daily oral CGRP receptor antagonist for migraine treatment in the EU. The favorable opinion is based on pivotal Phase 3 studies which demonstrated significant reductions in monthly migraine days. If approved, atogepant could improve the quality of life for millions of individuals affected by migraines.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable August...
AbbVie Inc. has announced a quarterly cash dividend of $1.48 per share, which is payable on August 15, 2023, to shareholders on record as of July 14, 2023. The company has seen a significant dividend increase of 270 percent since its inception in 2013 and is recognized as a member of the S&P Dividend Aristocrats Index, reflecting a long history of annual dividend growth. AbbVie aims to address serious health challenges through innovative medicines across various therapeutic areas.
Read more →ABBVRisankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated...
AbbVie announced that its Phase 3 COMMAND study for risankizumab (SKYRIZI) achieved positive results, meeting both primary and key secondary endpoints for patients with moderately to severely active ulcerative colitis. At week 52, approximately 40% and 38% of patients receiving risankizumab doses of 180 mg and 360 mg, respectively, achieved clinical remission, compared to 25% in the control group. Additionally, significant improvements in endoscopic and histologic measures were observed in the treatment groups. Despite these positive outcomes, risankizumab is not yet approved for ulcerative colitis treatment.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the 20 incredible women entrepreneurs who will receive funding and mentorship...
Allergan Aesthetics, an AbbVie company, has announced 20 winners of the BOTOX® Cosmetic and IFundWomen grant program, selected from over 6,500 applications. Each recipient will receive funding and year-long mentorship to support their business ventures. This initiative aims to empower women entrepreneurs by addressing the 'Confidence Gap' and providing them with essential resources such as a Crowdfunding Accelerator Program. The program includes coaching on various business strategies, enhancing the potential for success among these entrepreneurs.
Read more →ABBVAbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of...
AbbVie announced new findings from Phase 3 trials demonstrating the sustained long-term efficacy and safety of VENCLYXTO/VENCLEXTA (venetoclax) in chronic lymphocytic leukemia (CLL) patients. The data highlights improvements in progression-free survival (PFS) and undetectable minimal residual disease rates compared to traditional treatments. The findings presented at the EHA Annual Congress show that patients can experience long-term disease control, even after ceasing treatment. Additionally, the safety profile of venetoclax combinations remains consistent across studies, with no new serious safety signals identified.
Read more →ABBVAbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael,...
AbbVie (NYSE: ABBV) is set to participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. Key executives including Robert A. Michael and Jeffrey R. Stewart will be presenting at the event. The presentation will be available via a live audio webcast on AbbVie's Investor Relations website, with an archived version accessible later on the same day. AbbVie's mission centers around delivering innovative treatments across various therapeutic areas, indicating their continual engagement in addressing health challenges.
Read more →ABBVPhase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus - At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the...
AbbVie announced positive results from the Phase 2 SLEek study evaluating upadacitinib (RINVOQ®) in patients with systemic lupus erythematosus (SLE). At week 24, upadacitinib administered alone or in combination met primary endpoints, demonstrating significant improvements in disease activity compared to placebo. The study also noted that the safety profile remained consistent with previous data, with no new safety signals. Despite the success of upadacitinib, ABBV-599 will not progress to the next trial phase due to insufficient efficacy.
Read more →ABBVNew England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL,...
AbbVie announced that the New England Journal of Medicine published results from its pivotal Phase 3 trials evaluating upadacitinib (RINVOQ) for Crohn’s disease. The studies demonstrated the safety and efficacy of upadacitinib compared to placebo, focusing on adult patients with moderately to severely active Crohn's who had inadequate responses to existing therapies. Following these positive results, upadacitinib has been approved in various countries, including the United States in May 2023, marking a significant advancement in treatment options for this condition.
Read more →ABBVAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress - Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination...
AbbVie presented new long-term data at the EULAR 2023 Congress, demonstrating the efficacy and safety of RINVOQ (upadacitinib) across various rheumatic diseases. The data, derived from the SELECT-COMPARE, SELECT-PsA 1, and SELECT-AXIS 2 studies, includes five-year results in rheumatoid arthritis and three-year results in psoriatic arthritis. Approximately 2,450 patients were involved, providing a robust dataset supporting RINVOQ's clinical effectiveness and safety. AbbVie aims to enhance treatment choices for healthcare providers by offering comprehensive insights into RINVOQ's performance in long-term care for affected patients.
Read more →ABBVEPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only ...
AbbVie announced that the U.S. FDA has approved EPKINLY (epcoritamab-bysp), a bispecific antibody designed for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is part of the FDA's Accelerated Approval program and is based on promising response rates. However, the continued approval of EPKINLY is anticipated to depend on further clinical confirmation of its benefits. The treatment provides a new option for patients with limited alternatives after exhausting prior therapies.
Read more →ABBVU.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults – The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by...
AbbVie has received FDA approval for RINVOQ (upadacitinib) as a once-daily treatment for adults with moderately to severely active Crohn's disease. The approval is based on the successful results from two induction studies and one maintenance study, demonstrating significant clinical response and endoscopic remission. This marks the seventh FDA indication for RINVOQ, which is now available for patients who have not responded to TNF blockers. The drug offers hope for better symptom management and reduction of intestinal damage in Crohn's disease patients.
Read more →ABBVSKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of SKINVIVE™ by JUVÉDERM® to improve skin smoothness of...
Allergan Aesthetics has received U.S. FDA approval for SKINVIVE™ by JUVÉDERM®, marking it as the first and only hyaluronic acid intradermal microdroplet injection for improving skin smoothness in adults. The product is designed to enhance skin quality with results lasting up to six months. Clinical studies show significant improvements in skin satisfaction among patients, although some experienced mild to moderate side effects. As part of the approval, providers will be required to undergo training before administering the treatment.
Read more →ABBVAbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week® AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, being...
AbbVie announced that it will present 29 abstracts focusing on its gastroenterology portfolio at the 2023 Digestive Disease Week. Key presentations include the efficacy and safety of upadacitinib for Crohn's disease and the investigational use of linaclotide for pediatric functional constipation. The findings underscore AbbVie's commitment to enhancing patient care through robust clinical research. It is important to note that upadacitinib's use in Crohn's disease is still under evaluation for FDA approval.
Read more →ABBVAbbVie to Present at the Bank of America Securities Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice...
AbbVie (NYSE: ABBV) is set to participate in the Bank of America Securities Healthcare Conference on May 9, 2023. Notable executives from the company, including Robert A. Michael and Scott Reents, will present at 10:00 a.m. Central time. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived session accessible later in the day. The event aims to showcase AbbVie's mission in delivering innovative medicines across various therapeutic areas.
Read more →ABBV▼ -8%on this newsshared move
Document PRESS RELEASE AbbVie Reports First-Quarter 2023 Financial Results Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent
AbbVie reported its first-quarter 2023 financial results, revealing a diluted EPS of $0.13, down 94.8% GAAP, and adjusted diluted EPS of $2.46, reflecting a 22.2% decrease. Total net revenues amounted to $12.225 billion, down 9.7% year-over-year. Despite challenges with Humira and other portfolios, significant growth was noted in Rinvoq and Skyrizi revenues. The company also announced positive developments, including the expansion of Rinvoq's indications for Crohn's disease and successful results from key clinical trials.
Read more →ABBV▼ -8%on this newsshared move
AbbVie Reports First-Quarter 2023 Financial Results Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent;...
AbbVie has released its first-quarter financial results for 2023, reporting a diluted EPS of $0.13, down 94.8% compared to the previous year, with an adjusted diluted EPS of $2.46, reflecting a 22.2% decrease. Despite these declines, the company exceeded revenue expectations, attributing this success to strong commercial execution across its diversified portfolio. AbbVie has raised its full-year 2023 adjusted EPS guidance to a range of $10.72 to $11.12, indicating confidence in its long-term growth prospects.
Read more →ABBVAbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who...
AbbVie announced positive results from the Phase 3 ELEVATE study evaluating atogepant for preventing episodic migraine in patients with prior treatment failure. The study showed that participants receiving atogepant experienced a statistically significant reduction in mean monthly migraine days compared to those receiving placebo. Furthermore, atogepant was well tolerated, with a safety profile consistent with earlier data. AbbVie plans to continue regulatory submissions for atogepant in international markets.
Read more →ABBVAllergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS Allergan Aesthetics, an AbbVie company, supports women plastic surgeons and the development of current and future leaders in science, healthcare, and ...
Allergan Aesthetics, part of AbbVie, has launched the LIMITLESS program to empower women in plastic surgery by providing education and mentorship. This initiative aims to highlight the achievements of women surgeons and inspire future leaders through various platforms including a docuseries, a podcast, and an annual summit. Key figures in surgery, such as Carrie Strom and Anu Bajaj, emphasize the importance of sharing experiences to combat biases and empower women in the field. The LIMITLESS Leaders Summit will take place in Seattle, offering networking and educational opportunities.
Read more →ABBVU.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic...
The U.S. FDA has approved AbbVie's QULIPTA (atogepant) for the preventive treatment of chronic migraine, marking it as the first oral CGRP receptor antagonist for this condition. This expansion follows positive results from the Phase 3 PROGRESS trial, demonstrating a significant reduction in migraine days. QULIPTA is already approved for episodic migraine and now offers a convenient once-daily option for those with chronic migraine, enhancing treatment accessibility and improving patient quality of life.
Read more →ABBVAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease – Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult...
AbbVie has received European Commission approval for RINVOQ® (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor to treat adults with moderately to severely active Crohn's disease. This approval adds to RINVOQ's indication list, marking its seventh approval in the EU. The efficacy of RINVOQ for this condition was demonstrated in clinical studies, showing significant improvements in endoscopic response and clinical remission compared to placebo. With this new indication, AbbVie continues to strengthen its offerings in the inflammatory bowel disease market.
Read more →ABBVAbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF...
AbbVie has announced the opening of the AbbVie Cystic Fibrosis Scholarship application for the 2023-2024 academic year, inviting eligible college students to apply. The program, in existence for over 30 years, has awarded more than $3.8 million to support students living with cystic fibrosis (CF). This year, a total of 40 students will receive $3,000 each, with the opportunity to compete for an additional $22,000. Recipients will be selected based on their academic achievements, essays, and public voting.
Read more →ABBVAbbVie to Host First-Quarter 2023 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. AbbVie will host a...
AbbVie is scheduled to release its first-quarter 2023 financial results on April 27, 2023, prior to the market opening. The announcement will be followed by a live earnings conference call hosted at 8 a.m. CT. Investors can access the call via AbbVie's Investor Relations website, with an archived version available later the same day. This event highlights AbbVie's ongoing operations and commitment to addressing various health issues through innovative products.
Read more →ABBVAbbVie avança estudo clínico de Fase 3 com upadacitinibe para tratamento de lúpus eritematoso sistêmico Resultados do estudo clínico de fase 2 denominado M19-130 ( SLEek ) com upadacitinibe em monoterapia, ou como uma terapia combinada (ABBV-599,) para...
AbbVie has announced the primary results of a Phase 2 study of upadacitinib, which showed effectiveness in treating moderate to severely active systemic lupus erythematosus (SLE). The study, involving 341 participants, achieved its primary endpoints at week 24, leading AbbVie to advance to Phase 3 clinical trials. However, upadacitinib is not yet approved for SLE, with its safety and efficacy still pending evaluation by regulatory bodies. The company aims to provide new treatment options for this challenging autoimmune disease.
Read more →ABBVCoolSculpting® Elite Announces First Ever CoolMonth Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and the parent company of CoolSculpting® Elite, announces the first ever CoolMonth, taking place...
AbbVie’s Allergan Aesthetics has announced the launch of CoolMonth, a promotional initiative from April, aimed at encouraging individuals to seek body contouring treatments. The program features a 'buy 4, get 4' deal to incentivize patients to start their CoolSculpting journeys ahead of summer. Clinical data indicates high patient satisfaction with the CoolSculpting treatment, which is FDA-cleared for various fat reduction applications. However, potential patients are advised to consult healthcare providers regarding contraindications and side effects associated with the treatments.
Read more →ABBVAllergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023 Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st...
Allergan Aesthetics, a subsidiary of AbbVie, will present its 'Discover Your 360°' approach at the AMWC 2023 in Monaco. This approach focuses on enhancing professionals' capacity to address the aesthetic needs of patients through innovative practices and educational initiatives. The event will include expert-led symposia discussing key industry themes, including the importance of individuality and ethics in aesthetics. Live demonstration sessions by leading practitioners will showcase Allergan's commitment to interactive learning and patient-centered care.
Read more →ABBVRisankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary...
AbbVie announced positive data from the Phase 3 INSPIRE study, revealing that risankizumab (SKYRIZI) met its primary endpoint of clinical remission for ulcerative colitis patients after 12 weeks. The study showed that 20.3% of participants receiving risankizumab achieved clinical remission, significantly outperforming the 6.2% in the placebo group. Furthermore, risankizumab demonstrated improvements in secondary endpoints such as endoscopic and histologic outcomes. However, regulatory approval for this indication is pending.
Read more →ABBVAbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic...
AbbVie has announced positive topline results from a Phase 2 trial of upadacitinib (RINVOQ) for treating moderately to severely active systemic lupus erythematosus. The study met its primary endpoint, which demonstrates the drug's potential effectiveness. As a result, AbbVie is advancing the clinical development of upadacitinib into Phase 3 trials. The safety profile observed during the study aligns with previous knowledge of the drug, indicating a focus on improving treatment options for this complex condition.
Read more →ABBVAbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug...
AbbVie announced that it has received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for ABBV-951, a treatment intended for motor fluctuations in advanced Parkinson's disease. The FDA's letter requests additional information regarding the delivery device but does not ask for further trials concerning the drug's efficacy or safety. AbbVie intends to address the FDA's requests and resubmit the NDA promptly, building on positive results from Phase 3 clinical trials. The company emphasizes their commitment to providing treatment options for patients with advanced Parkinson's disease.
Read more →ABBVAbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in ...
AbbVie has announced positive 52-week data from a study evaluating SKYRIZI (risankizumab) for moderate to severe plaque psoriasis patients who previously had suboptimal responses to IL-17 inhibitors. The study, presented at the AAD Annual Meeting, showed that 56.3% of participants achieved significant symptom reduction by week 16. Importantly, no new safety signals were observed during the analysis, indicating a favorable profile for SKYRIZI in this difficult-to-treat patient population. This data reinforces AbbVie’s commitment to improving psoriasis treatment standards.
Read more →ABBVAbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema AbbVie (NYSE: ABBV) today announced the launch of a new documentary film, Under My Skin: Untold Stories of Life with Eczema, which debuted at South ...
AbbVie has launched a documentary film titled "Under My Skin: Untold Stories of Life with Eczema," which debuted at the South by Southwest 2023 festival. The film, directed by Redglass Pictures, portrays the physical and emotional experiences of individuals with eczema, seeking to illuminate the deeper impact of the condition beyond superficial stereotypes. It aims to inspire viewers to understand and support those living with eczema by sharing real-life stories of resilience and coping strategies. The documentary is now available on YouTube and will be streamable on The Roku Channel starting April 1, 2023.
Read more →ABBVAbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy ...
AbbVie (NYSE: ABBV) is set to present over 20 abstracts, including a significant late-breaking presentation, at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. This presentation aims to demonstrate AbbVie's commitment to enhancing care for patients with immune-mediated skin conditions like psoriasis and atopic dermatitis. The showcased data reflects ongoing research and emphasizes AbbVie's strong position in dermatology innovation and patient outcome improvements.
Read more →ABBVAbbVie e Capsida Biotherapeutics Ampliam Parceria Estratégia para Desenvolvimento de Medicamentos-Alvo por Engenharia Genética para Doenças Oculares com Necessidades Não Atendidas A AbbVie (NYSE: ABBV) e a Capsida Biotherapeutics Inc. ( Capsida ) anunciaram (23/03/23) a ampliação de uma colaboração estratégica para...
AbbVie and Capsida Biotherapeutics announced an expansion of their strategic partnership to develop genetic medicines for underserved eye diseases. This collaboration builds on their previous work in neurodegenerative diseases and integrates AbbVie's extensive experience with Capsida's innovative adeno-associated virus platform. The deal includes an upfront payment of $70 million and potential earnings of up to $595 million based on specific performance milestones. This initiative aims to bring groundbreaking therapies to patients facing severe eye conditions.
Read more →ABBVAbbVie to Present at the Barclays Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. Robert A. Michael, vice chairman and...
AbbVie (NYSE: ABBV) will present at the Barclays Global Healthcare Conference on March 15, 2023. Key executives including Robert A. Michael, the vice chairman, will participate in the presentation. A live audio webcast of the event will be available on AbbVie's Investor Relations website, with an archived edition accessible later the same day. AbbVie emphasizes its mission to discover solutions for serious health issues across various therapeutic areas.
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs In honor of International Women's Day, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced that BOTOX® Cosmetic is partnering with...
Allergan Aesthetics, a subsidiary of AbbVie, announced a partnership with IFundWomen to address the confidence gap faced by women entrepreneurs. In honor of International Women's Day, this initiative will provide 20 grants of $25,000 along with coaching and mentorship. The program aims to empower women in various sectors by equipping them with essential resources and support. Applications for this grant program are open until April 7, 2023, with recipients to be announced in June.
Read more →ABBVAbbVie to Present at the Cowen 43rd Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Robert A. Michael, vice chairman and...
AbbVie (NYSE: ABBV) is scheduled to present at the Cowen 43rd Annual Health Care Conference on March 7, 2023. Key executives, including Robert A. Michael and Scott Reents, will be presenting at 8:10 a.m. Central time. Investors can access a live audio webcast of the presentation through AbbVie's Investor Relations website, which will later offer an archived edition. The company's commitment to innovative medicines across various therapeutic areas underscores its industry significance.
Read more →ABBVAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohn's disease is a chronic,...
AbbVie has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of upadacitinib (RINVOQ) for adults with moderately to severely active Crohn's disease. This recommendation is supported by data from Phase 3 studies, demonstrating that upadacitinib significantly improved clinical outcomes compared to placebo. The treatment is intended for patients who have not responded adequately to other conventional or biologic therapies. AbbVie is committed to providing innovative treatment options for inflammatory bowel diseases.
Read more →ABBVAbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO) A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance...
AbbVie announced its participation in the 18th Congress of European Crohn's and Colitis Organisation (ECCO) from March 1-4, 2023. The company is set to present 24 abstracts regarding its treatments, particularly focusing on SKYRIZI and RINVOQ for Crohn’s disease and ulcerative colitis. The presentations aim to underscore AbbVie's commitment to advancing research and improving patient care in the field of inflammatory bowel diseases. Experts emphasize the ongoing challenges faced by IBD patients, reinforcing the need for continued innovation in treatment options.
Read more →ABBVAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ( Capsida ) today announced an expanded strategic collaboration to develop genetic medicines for ...
AbbVie and Capsida Biotherapeutics have announced an expanded collaboration to develop genetic medicines aimed at treating serious eye diseases with high unmet needs. This partnership builds upon their previous work in neurodegenerative diseases and will leverage AbbVie's expertise in drug development alongside Capsida's advanced AAV engineering platform. Capsida stands to gain $70 million upfront, with additional potential earnings of up to $595 million linked to the successful progression of three targeted programs.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable May 15,...
AbbVie Inc. has declared a quarterly cash dividend of $1.48 per share, which is set to be paid on May 15, 2023, to shareholders recorded by April 14, 2023. The company's dividend has seen a significant increase of more than 270% since its establishment in 2013. AbbVie is listed among the S&P Dividend Aristocrats Index, highlighting its history of annual dividend growth over the past 25 years. The company is focused on developing innovative medicines across various therapeutic areas to address critical health issues.
Read more →ABBVAbbVie submete o anticorpo biespecifico epcoritamabe (DuoBody®-CD3xCD20) à análise da ANVISA para tratamento de linfoma de grandes células B recidivo/refratário Epcoritamabe (DuoBody®-CD3xCD20), se aprovado, pode se tornar o primeiro anticorpo biespecífico de administração subcutânea para o tratamento de...
AbbVie has submitted the bispecific antibody epcoritamabe (DuoBody®-CD3xCD20) for analysis by Brazil's ANVISA for the treatment of adult patients with recurrent/refractory diffuse large B-cell lymphoma. This submission is based on promising results from the phase 1b/2 GCT 3013-01 study, which assesses the efficacy and safety of this treatment. If approved, epcoritamabe will be the first bispecific antibody to be administered subcutaneously, potentially offering a new option for patients with limited therapeutic choices.
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent;...
AbbVie reported its financial results for the fourth quarter and full year of 2022, revealing a diluted EPS of $6.63 on a GAAP basis, representing a 2.8% increase. The company projects an adjusted diluted EPS for 2023 between $10.70 and $11.10. Despite stable performance and future growth plans, AbbVie faces potential challenges with the impending loss of exclusivity for its major product, Humira, along with declining revenues in certain therapeutic areas. Overall, the company remains optimistic about its diverse product portfolio and pipeline capabilities.
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent Adjusted Diluted EPS of $13.77, an Increase of
AbbVie has reported its financial results for 2022 and the fourth quarter, revealing a full-year diluted EPS of $6.63, which reflects a 2.8% increase. The company experienced strong trajectory in the immunology portfolio, generating $28.924 billion in revenue, highlighting significant growth in products like Skyrizi and Rinvoq. However, it faced declines in its hematologic oncology portfolio and experienced a significant decrease in fourth-quarter EPS. Looking ahead, AbbVie provided guidance for adjusted diluted EPS for 2023 between $10.70 and $11.10 and announced positive developments regarding drug approvals and pipeline advancements.
Read more →ABBVAllergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023 Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress...
Allergan Aesthetics, a subsidiary of AbbVie, announced its immersive initiative 'Discover your 360°' at the IMCAS 2023 World Congress. This comprehensive approach is designed to enhance both practitioner education and patient outcomes through innovative techniques and insights into cultural shifts in the aesthetics industry. The event will feature various expert-led sessions, including new perspectives on treatment and personalization of patient experiences. Notable speakers will address contemporary topics like Gender Inclusive Beauty and the evolution of aesthetics practices.
Read more →ABBVJUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM® VOLUX™ XC. The long-lasting ...
Allergan Aesthetics, a subsidiary of AbbVie, has announced the national launch of JUVÉDERM® VOLUX™ XC, a new hyaluronic acid filler designed for non-surgical jawline augmentation. The product is aimed at individuals over the age of 21 experiencing moderate to severe loss of jawline definition. Clinical trials indicate high patient satisfaction, and the filler can provide results lasting up to twelve months. Allergan also offers a loyalty rewards program, Allē, for consumers using their aesthetic products.
Read more →ABBVSkinMedica® Launches Even & Correct Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection....
Allergan Aesthetics, part of AbbVie, has launched the SkinMedica® Even & Correct Collection, targeting hyperpigmentation and uneven skin tone. The collection includes three products designed to be used individually or together for optimal results. Backed by clinical studies, the products promise visible improvements in skin conditions like melasma and post-inflammatory hyperpigmentation. They are also designed to cater to diverse skin types and are hydroquinone-free.
Read more →ABBVAbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets...
AbbVie and Anima Biotech have formed a collaboration to develop mRNA biology modulators targeting oncology and immunology. Anima's mRNA Lightning technology will be utilized to create these modulators, with AbbVie gaining exclusive licensing rights. Anima will receive an upfront payment of $42 million and could earn up to $540 million in potential milestones. This partnership aims to address 'undruggable' targets, enhancing AbbVie's drug development capabilities in critical therapeutic areas.
Read more →ABBVJ.P. Morgan Healthcare Conference |
At the J.P. Morgan Healthcare Conference, AbbVie highlighted its strong pipeline, showcasing a range of partnered assets and anticipated regulatory approvals that could drive significant growth. The company emphasized its robust capital allocation strategy, balancing growth investments with shareholder returns. AbbVie is positioned as a leader in the biopharma industry with a proven track record of executing on its financial commitments. Key upcoming events in 2023 and 2024 were discussed in relation to AbbVie's innovative products across different therapeutic areas.
Read more →ABBVAbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to...
AbbVie and Immunome have announced a strategic collaboration to discover up to 10 novel antibody-target pairs from specific tumor types, utilizing Immunome's Discovery Engine. AbbVie will provide a $30 million upfront payment and may contribute additional funds through various options and milestone payments. This partnership underscores both companies' commitment to developing pioneering oncology therapies aimed at treating solid tumors, with hopes of bringing innovative solutions to cancer patients.
Read more →ABBVAbbVie to Host Fourth-Quarter 2022 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host...
AbbVie will release its fourth-quarter 2022 financial results on February 9, 2023, prior to market opening. The company will conduct a live webcast of the earnings conference call at 8 a.m. CT, which will be accessible via its Investor Relations website. Additionally, an archived edition of the call will be available later in the day for those unable to attend the live session.
Read more →ABBVAbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman ...
AbbVie will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, with CEO Richard A. Gonzalez presenting. The event underscores AbbVie's dedication to innovation in therapeutics across multiple medical areas. A live audio webcast will be accessible for broader audience engagement, alongside an archived edition available later the same day. This conference is significant for stakeholders and investors interested in AbbVie's developments.
Read more →ABBVU.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder - Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major...
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement in symptoms when compared to placebo + ADT - Desig
Read more →ABBVAbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and...
NORTH CHICAGO, Ill. , Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 1
Read more →ABBVAbbVie firma colaboração estratégica com HotSpot Therapeutics para expandir portfólio de Imunologia A AbbVie (NYSE: ABBV) e a HotSpot Therapeutics, Inc., empresa de biotecnologia pioneira na descoberta e desenvolvimento de terapias alostéricas de...
A colaboração entre as duas empresas utiliza a plataforma de descoberta de medicamentos Smart Allostery™ da HotSpot para o desenvolvimento da primeira e única pequena molécula inibidora de IRF5 (fator regulatório de interferon 5), potencialmente para o tratamento de doenças autoi
Read more →ABBVAbbVie apresenta inovações para o tratamento de enxaqueca crônica durante 16º Congresso da Federação Europeia de Cefaleia A AbbVie (NYSE: ABBV) apresentou seu portfólio atual bem como terapias em fase de desenvolvimento para tratamento de enxaqueca crônica no 16º...
SÃO PAULO , 15 de dezembro de 2022 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) apresentou seu portfólio atual bem como terapias em fase de desenvolvimento para tratamento de enxaqueca crônica no 16º Congresso da Federação Europeia de Cefaleia 2022 ( EHC 202 2), que aconteceu em Viena,
Read more →ABBVAbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World)...
NORTH CHICAGO, Ill. , Dec. 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America). Addition
Read more →ABBVAbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous...
NORTH CHICAGO, Ill. , Dec. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients wit
Read more →ABBVAbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress...
-- Fifteen abstracts underscore AbbVie's commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study on neck pain with headache in people with and without migraine -- Results
Read more →ABBVAbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric...
NORTH CHICAGO, Ill. and BOSTON , Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today an
Read more →ABBVFDA Aceita Submissão de Análise Prioritária de Epcoritamabe (DuoBody®-CD3xCD20) para o Tratamento de Linfoma de Grandes Células B Recidivo/Refratário A submissão é fundamentada pelos dados do estudo de Fase I/II EPCORE™ NHL-1, que avalia a segurança e a eficácia preliminar de epicoritamabe,...
SÃO PAULO , 5 de dezembro de 2022 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou (21/11/22) que a agência regulatória dos EUA, Food and Drug Administration (FDA), aceitou o pedido para avaliação prioritária de epcoritamabe (DuoBody ® -CD3xCD20), um anticorpo biespecífico de admi
Read more →ABBVAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease - Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European...
- Third approved indication for SKYRIZI ® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) - A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal hea
Read more →ABBVAbbVie to Present at the Evercore ISI HealthCONx Conference AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice...
NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 5 th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022 . Rob Michael , vice chairman and president, Jeffrey R. Stewart , executive vice president, commer
Read more →ABBVAbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society...
- Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will pr
Read more →ABBVAbbVie to Present at the Piper Sandler Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Rob Michael, vice chairman ...
NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022 . Rob Michael , vice chairman and president, Jeffrey R. Stewart , executive vice president, commercial op
Read more →ABBVU.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License...
NORTH CHICAGO, Ill. , Nov. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bisp
Read more →ABBVFourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet Yesterday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), celebrated the fourth annual – and most successful – BOTOX® Cosmetic Day yet. Once...
A RECORD-BREAKING NUMBER OF CONSUMERS PARTICIPATED, WITH BOGO GIFT CARDS SELLING OUT IN JUST A FEW HOURS 11 IRVINE, Calif. , Nov. 17, 2022 /PRNewswire/ -- Yesterday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), celebrated the fourth annual – and most successful – BOTOX
Read more →ABBVNorth Chicago's New Neal Math and Science Academy Opens, Funded by a Donation from AbbVie AbbVie and the North Chicago Community Unit School District 187 today announced the opening of the new Neal Math and Science Academy, the district's...
– AbbVie donated $40 million to North Chicago Community Unit School District 187 in 2019 to fund rebuilding of the district's only middle school, Neal Math and Science Academy – The new school will open doors to students and teachers on November 28 NORTH CHICAGO, Ill. , Nov. 16,
Read more →ABBVAbbVie to Present at the Wolfe Research Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman ...
NORTH CHICAGO, Ill. , Nov. 9, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 4 th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022 . Rob Michael , vice chairman and president, Jeffrey R. Stewart , executive vice president, commercial op
Read more →ABBVAbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022 AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid...
NORTH CHICAGO, Ill. , Nov. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it would present new data across its rheumatology portfolio, including RINVOQ ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI ® (risanki
Read more →ABBVAbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft...
NORTH CHICAGO, Ill. , Nov. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial
Read more →ABBVAbbVie Anuncia Resultados Financeiros Globais do Terceiro Trimestre de 2022 A AbbVie (NYSE:ABBV) anunciou resultados financeiros referentes ao terceiro trimestre de 2022, no qual a companhia apresentou lucro líquido de...
SÃO PAULO , 7 de novembro de 2022 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou resultados financeiros referentes ao terceiro trimestre de 2022, no qual a companhia apresentou lucro líquido de US$14,812 bilhões, o que equivale a um aumento de 5.4% em base operacional. No períod
Read more →ABBVAllergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to provide education and support for breast health, restoration,...
PINK RIBBON STRONG 365 IS DEDICATED TO PROVIDING EDUCATIONAL INITIATIVES AND SHARING REAL STORIES TO SUPPORT PATIENTS, SURVIVORS, AND PREVIVORS IRVINE, Calif. , Nov. 3, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is continuing its commitment to pro
Read more →ABBVAllergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is inviting people across the country to take a Moment for You on Wednesday, November 16 and...
THE ICONIC BRAND ENCOURAGES PEOPLE TO TAKE A 'MOMENT FOR YOU' WITH TWO EXCLUSIVE OFFERS FOR FAMILY AND FRIENDS, POWERED BY ALLĒ IRVINE, Calif. , Nov. 2, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is inviting people across the country to take a "Mo
Read more →ABBVAbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL) AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for...
NORTH CHICAGO, Ill. , Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bispecific antibody,
Read more →ABBVAbbVie Reports Third-Quarter 2022 Financial Results Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent;...
NORTH CHICAGO, Ill. , Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2022 . "We continue to see strong momentum from our key immunology assets, Skyrizi and Rinvoq, and this performance – combined with stre
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Third-Quarter 2022 Financial Results Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percen
AbbVie Reports Third-Quarter 2022 Financial Results Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquir
Read more →ABBVAbbVie Adquire a Companhia DJS Antibodies, Fortalecendo seu Pipeline em Imunologia A AbbVie (NYSE: ABBV) anunciou a aquisição da DJS Antibodies Ltd ( DJS ), empresa privada de biotecnologia com sede no Reino Unido, dedicada à...
- DJS-002, da DJS Antibodies, é um anticorpo de primeira classe, que tem como alvo o LPAR1 ( receptor de ácido lisofosfatidico 1) , em estudos pré-clínicos para o tratamento de fibrose pulmonar idiopática e outras doenças fibróticas. - A plataforma proprietária HEPTAD da DJS amp
Read more →ABBVAbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting Data illustrates AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet need...
NORTH CHICAGO, Ill. , Oct. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022 , in Charlotte, N.C.
Read more →ABBVRINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral...
NORTH CHICAGO, Ill. , Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondy
Read more →ABBVAbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ( DJS ), a privately-held UK-based biotechnology company dedicated to...
-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company's proprietary HEPTAD platform will extend AbbVie's
Read more →ABBVAllergan Aesthetics and Girls Inc. Partner to Bridge the Gender Gap in STEM Today Allergan Aesthetics, an AbbVie company, announces its fourth-consecutive year of partnership with Girls Inc. to support the engagement of high...
-- A social media campaign kicks off in November with the goal of educating on the lack of female, diverse representation in STEM and raising up to $250,000 for Girls Inc. -- Girls from Girls Inc. affiliates in Houston , St. Louis and Chicago will participate in a 'Breaking Barr
Read more →ABBVABBVIE VICE CHAIRMAN OF EXTERNAL AFFAIRS AND CHIEF LEGAL OFFICER LAURA SCHUMACHER TO RETIRE Perry Siatis Named as Executive Vice President, General Counsel and Secretary
ABBVIE VICE CHAIRMAN OF EXTERNAL AFFAIRS AND CHIEF LEGAL OFFICER LAURA SCHUMACHER TO RETIRE Perry Siatis Named as Executive Vice President, General Counsel and Secretary NORTH CHICAGO, Ill., October 17, 2022 -- AbbVie (NYSE: ABBV) announced today that Laura J. Schumacher, vice
Read more →ABBVAllergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting –Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to...
– Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to advancing aesthetic medicine – Analyses of 15 years of post-marketing surveillance data demonstrate the global reported rate of delayed-
Read more →ABBVAbbVie to Host Third-Quarter 2022 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , Oct. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2022 financial results on Friday, October 28, 2022 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessib
Read more →ABBVAbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022 Final analyses from the U-ACHIEVE Phase 3 maintenance study of RINVOQ® (upadacitinib) in moderately to severely active ulcerative colitis Data...
NORTH CHICAGO, Ill. , Sept. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI ® ) in Crohn's disease and upadacitinib (RINVOQ ® ) in ulcerative colitis and Crohn's disease that will be presented as live pre
Read more →ABBVThe Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and skinbetter science® announce a new report from their DREAM (Driving Racial Equity in...
--Initiative Creates Groundbreaking New, Royalty Free Inclusive Image Gallery In Strategic Partnership with Shutterstock Studios-- IRVINE, Calif. and PHOENIX , Sept. 22, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), and skinbetter science ® an
Read more →ABBVAbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease - CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 - Crohn's disease is a chronic,...
NORTH CHICAGO, Ill. , Sept. 19, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CMHP) adopted a positive opinion recommending the approval of risankizumab (SKYRIZI ® , 600 mg intraveno
Read more →ABBVAbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress --Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the...
--Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease --Data will also be pr
Read more →ABBVAbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship Thriving Student Awards AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Graduate Scholarships. Following this...
NORTH CHICAGO, Ill. , Sept. 14, 2022 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Graduate Scholarships. Following this voting period, scholarships totaling $25,000 each will be awarded to two commen
Read more →ABBVAllergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who...
NEARLY 20,000 PEOPLE RESPONDED TO AN OPEN CASTING CALL FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN FOR THE NUMBER ONE SELLING PRODUCT OF ITS KIND IRVINE, Calif. , Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is unveiling the 25 re
Read more →ABBVNew Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in adult...
- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis 1 - Ongoing treatment with SKYRIZI demonstrated consistent long-term efficacy in psoriatic art
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable November ...
NORTH CHICAGO, Ill. , Sept. 9, 2022 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable November 15, 2022 , to stockholders of record at the close of business on October 14,
Read more →ABBVNew MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients MEASURE-AD was a real-world study of moderate to severe atopic dermatitis patients across 28 countries designed to assess the multidimensional...
NORTH CHICAGO, Ill. , Sept. 8, 2022 /PRNewswire/ -- An analysis from AbbVie's (NYSE: ABBV ) three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis (an immune-mediated skin disease) who are not receiving systemic therapy had g
Read more →ABBVAbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022 AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS)...
--Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine will be showcased as an oral presentation --Breadth of research underscores AbbVie's leadership and commitment to people living with migraine NORTH CHICAGO, Ill. , Sept. 8, 2
Read more →ABBVAllergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM® Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its manufacturing facility in France has reached the milestone of producing and ...
JUVÉDERM ® Collection of Fillers Continues Position as the World's Number One Chosen Dermal Filler Collection IRVINE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced its manufacturing facility in France has reached th
Read more →ABBVAbbVie to Present at the Morgan Stanley Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Rob Michael, vice ...
NORTH CHICAGO, Ill. , Sept. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 . Rob Michael , vice chairman and president, Jeff Stewart , executive vice president, commercial
Read more →ABBVSkinMedica® Launches Firm & Tone Lotion for Body Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Firm & Tone Lotion for Body, the first product from...
Powerful, Effective, Targeted Topical Treatment Formulated to Prevent and Address Visible Signs of Body Skin Aging IRVINE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announces the launch of SkinMedica ® Firm & Tone Lotion
Read more →ABBVAllergan Aesthetics publishes 'The Future of Aesthetics' global trends report Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, today announces the U.S. publication of 'The Future of...
-- Report is aimed at helping practitioners and the industry prepare for the future by supporting the evolving needs of patients -- -- North American medical aesthetic market expected to grow more than 10 percent annually through 2026* -- -- Built on robust research and analysi
Read more →ABBVAbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe...
NORTH CHICAGO, Ill. , Aug. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present 23 abstracts at the 31 st European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of
Read more →ABBVChildren with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib) The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after...
NORTH CHICAGO, Ill. , Aug. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA ® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease
Read more →ABBVExperience the JUVÉDERM® Difference with Allergan Aesthetics Allergan Aesthetics, an AbbVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM® difference. The JUVÉDERM® Collection of Fillers is ...
Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM ® Difference IRVINE, Calif. , Aug. 17, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), invites consumers to experience the JUVÉDERM ® difference. The JUVÉDERM ® Collection of Fillers
Read more →ABBVAbbVie Anuncia Resultados Financeiros do Segundo Trimestre de 2022 A AbbVie (NYSE:ABBV) anunciou resultados financeiros referentes ao segundo trimestre de 2022, no qual a companhia apresentou um faturamento líquido...
- No período, os investimentos em P&D foram de 11% da receita liquida - SÃO PAULO , 10 de agosto de 2022 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou resultados financeiros referentes ao segundo trimestre de 2022, no qual a companhia apresentou um faturamento líquido de US$ 1
Read more →ABBVFDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline...
JUVÉDERM ® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced the U.S. FDA approval of JUVÉ
Read more →ABBVAbbVie Reports Second-Quarter 2022 Financial Results Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; ...
NORTH CHICAGO, Ill. , July 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2022 . "We delivered another strong quarter with substantial progress for our new products and indications. Importantly, Skyrizi and Rinvoq
Read more →ABBVRINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the ...
NORTH CHICAGO, Ill. , July 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in a
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Second-Quarter 2022 Financial Results Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent Adjusted Diluted EPS of $3.37, an Increase of 11.2 Perc
AbbVie Reports Second-Quarter 2022 Financial Results Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent These Results Include an Unfavorable Impact of $0.14 Per Share related to Acqu
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...
NORTH CHICAGO, Ill. , July 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ ® , 45 mg [induction dose]
Read more →ABBVEuropean Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative...
NORTH CHICAGO, Ill. , July 26, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely act
Read more →ABBVAbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference – Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and...
– Data analyses of onabotulinumtoxinA (BOTOX ® ) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use – Study
Read more →ABBVAbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject®...
- Alliance will provide opportunity for AbbVie to further expand its diverse eye care portfolio and provide additional treatment options for glaucoma patients - Collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates goal to bring MINIjec
Read more →ABBVAbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine AbbVie (NYSE: ABBV) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant ...
NORTH CHICAGO, Ill. , July 18, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migr
Read more →ABBVAbbVie to Host Second-Quarter 2022 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2022 financial results on Friday, July 29, 2022 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible
Read more →ABBVDocument AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022 (Unaudited) (In millions, except per share data) Quarter Ended
Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022 (Unaudited) (In millions, except per share data) Quarter Ended June 30, 2022 Full-Year Ended December 31, 2022 Acquired IPR D and Milestones Expense Adjusted Di
Read more →ABBVCHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the...
NORTH CHICAGO, Ill. , June 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ ® 15 mg, once daily) for the treatment of active n
Read more →ABBVApproximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local...
– AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact – Week of Possibilities i
Read more →ABBVNew Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer AbbVie today shared findings from the newly launched Emotional Impact Report, a survey of more than 300 chronic lymphocytic leukemia (CLL) patients,...
- New insights uncover how patients and caregivers cope emotionally during phases of Chronic Lymphocytic Leukemia (CLL) - The findings also show majority of HCPs view treating CLL patients as different from treating other cancers - The emotional complexities of this slow-growing
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August...
NORTH CHICAGO, Ill. , June 23, 2022 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August 15, 2022 , to stockholders of record at the close of business on July 15, 2022
Read more →ABBVAbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine - Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTATM) in adult patients that met primary endpoint ...
- Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTA TM ) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo - If approved, atogepant
Read more →ABBVAllergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry -- Report is aimed at helping practitioners and the industry understand and prepare for the future by supporting the evolving needs of patients -- -- ...
-- Report is aimed at helping practitioners and the industry understand and prepare for the future by supporting the evolving needs of patients -- -- Built on robust market research and analysis of global social listening data, industry research, academic studies, and Allergan A
Read more →ABBVSKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults - Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical...
- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY 1-4 - As early as week 4
Read more →ABBVAbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress – Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients – Total patient population achieved...
– Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients – Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42
Read more →ABBVAbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib...
NORTH CHICAGO, Ill. , June 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult
Read more →ABBVNew Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment Five-year follow-up analysis of the Phase 3 CLL14 trial (median follow-up of 65.4 months) continues to demonstrate longer progression-free survival...
NORTH CHICAGO, Ill. , June 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced five-year follow-up results from the Phase 3 CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia (CLL) who had received one-year fixed
Read more →ABBVAbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific...
NORTH CHICAGO, Ill. , June 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver , June 9-12 . A total of 29 abstracts, including two
Read more →ABBVAbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022 Results from the SELECT-AXIS 2 non-radiographic axial spondyloarthritis (nr-axSpA) study demonstrated significantly greater improvements in signs and ...
NORTH CHICAGO, Ill. , June 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the presentation of full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ ® ), an oral therapy, in adult patients with active non-radiographic ax
Read more →ABBVThe Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and ...
NORTH CHICAGO, Ill. , May 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ ® ) in patients with
Read more →ABBVAbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference AbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022. Richard A. Gonzalez,...
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines tha
Read more →ABBVAbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress - SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib (RINVOQ®) in patients with non-radiographic axial spondyloarthritis, and in...
- SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib (RINVOQ ® ) in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) with an inadequate response to biologic disease-modify
Read more →ABBVAbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting In Study 3111-301-001, cariprazine (VRAYLAR®; 1.5mg/day) achieved the primary endpoint of statistically significant improvement on the...
NORTH CHICAGO, Ill. , May 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present positive data from a Phase 3 trial of cariprazine (VRAYLAR ® ; 1.5mg/day), Study 3111-301-001, for the adjunctive treatment of major depressive disorder (MDD) in patients with
Read more →ABBVCHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
NORTH CHICAGO, Ill. , May 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ ® , 45 mg [induction do
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951...
NORTH CHICAGO, Ill. , May 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients wi
Read more →ABBVAbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week® AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW)...
NORTH CHICAGO, Ill. , May 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022 , in San Diego and virtually. AbbVie's research t
Read more →ABBVAbbVie and Cugene Announce Collaboration in Autoimmune Diseases AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology...
- AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology - Cugene to complete a Phase 1a study in healthy v
Read more →ABBVAbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual...
NORTH CHICAGO, Ill. , May 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting ( June 3-7 ) and the European Hematology Association (EHA) Congress ( Jun
Read more →ABBVAbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education AbbVie today announced the 2022-2023 class of recipients of the AbbVie Immunology Scholarship, which provides financial support to students living...
Since 2016, the AbbVie Immunology Scholarship program has helped more than 300 students impacted by immune-mediated diseases across rheumatology, gastroenterology and dermatology NORTH CHICAGO, Ill. , May 12, 2022 /PRNewswire/ -- AbbVie today announced the 2022-2023 class of rec
Read more →ABBVUpadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease In patients with moderate to severe Crohn's disease who achieved clinical response to upadacitinib induction treatment, a significantly greater...
NORTH CHICAGO, Ill. , May 11, 2022 /PRNewswire/ -- AbbVie today announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a
Read more →ABBV▼ -6%on this news
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the...
NORTH CHICAGO, Ill. , April 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) who have had an i
Read more →ABBV▼ -6%on this news
AbbVie Reports First-Quarter 2022 Financial Results Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent;...
NORTH CHICAGO, Ill. , April 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2022 . "This year is off to a strong start. Our first quarter results highlight the diversity of our portfolio and include compelling perfo
Read more →ABBV▼ -6%on this news
Document PRESS RELEASE AbbVie Reports First-Quarter 2022 Financial Results Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent
AbbVie Reports First-Quarter 2022 Financial Results Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquire
Read more →ABBVAllergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first...
- Seven abstract presentations showcase ongoing research in presbyopia and glaucoma NORTH CHICAGO, Ill. , April 28, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, announced that it will present new data on VUITY ™ (pilocarpine HCl ophthalmic solution) 1.25%, the
Read more →ABBVAbbVie Inc. Reconciliation of Reported GAAP and Non-GAAP Results to Revised Non-GAAP Results (Unaudited) (In Millions, except per share data) Quarter Ended
Reconciliation of Reported GAAP and Non-GAAP Results to Revised Non-GAAP Results (Unaudited) (In Millions, except per share data) Reconciliation of Reported GAAP and Non-GAAP Results to Revised Non-GAAP Results (Unaudited) (In Millions, except per share data)
Read more →ABBVAllergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data from its leading eye care portfolio at the 2022 American Society...
- Seven abstract presentations reinforce leadership in eye care, including continued presbyopia and glaucoma treatment research NORTH CHICAGO, Ill. , April 19, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, announced that it will present new data from its leadin
Read more →ABBVAbbVie to Host First-Quarter 2022 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , April 14, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2022 financial results on Friday, April 29, 2022 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessib
Read more →ABBVBOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April...
Iconic Brand Was The First Product Of Its Kind To Receive U.S. Food And Drug Administration Approval In 2002 For Aesthetic Use And Is Honoring This Milestone By Celebrating Its Loyal Patients And Providers IRVINE, Calif. , April 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an A
Read more →ABBVAbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial ...
- Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities - Data from the clinical trial to be presented at a future medical meeting - Large B-cell lymphoma (LBCL) is a common form of non-Hodgkin's lymphoma (NHL)
Read more →ABBVAbbVie Celebrates 30th Anniversary of CF Scholarship with Opening of Application Period for Students with Cystic Fibrosis AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship program is now accepting applications for the 2022-2023 academic school year. ...
NORTH CHICAGO, Ill. , April 13, 2022 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship program is now accepting applications for the 2022-2023 academic school year. This year's program marks 30 years of honoring and supporting young adults wi
Read more →ABBVAbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis - Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer - Results are from an exploratory analysis of 34...
- Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer - Results are from an exploratory analysis of 34 myelofibrosis patients who received at least one dose of navitoclax in combination with ruxolitinib after suboptimal response or disease progre
Read more →ABBVAllergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia) VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily...
NORTH CHICAGO, Ill. , April 5, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% in ad
Read more →ABBVAbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting AbbVie (NYSE: ABBV) today announced that data from its neuroscience portfolio will be presented at the 2022 American Academy of Neurology (AAN)...
-- AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia NORTH
Read more →ABBVALLERGAN AESTHETICS BRINGS DATA, INNOVATION & INDUSTRY EXPERTISE TO THE 2022 AESTHETIC AND ANTI-AGING MEDICINE WORLD CONGRESS (AMWC) Allergan Aesthetics, an AbbVie company, will join industry colleagues and healthcare providers from around the globe for the 20th edition of AMWC in...
-Industry leader demonstrates commitment to the future of aesthetics with forward-facing, trends report- -Meeting will signify the launch of HArmonyCa ™ , hybrid injectable across Europe and in select EEMEA countries IRVINE, Calif. , March 29, 2022 /PRNewswire/ -- Allergan Aest
Read more →ABBVAbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations...
NORTH CHICAGO, Ill. , March 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-
Read more →ABBVRINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A ...
NORTH CHICAGO, Ill. , March 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an i
Read more →ABBVAbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19 AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global...
NORTH CHICAGO, Ill. , March 15, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for C
Read more →ABBVNow Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT® (alcaftadine ophthalmic solution 0.25%) is now available without a...
- Itchy allergy eyes affect an estimated 40% of Americans 1 - LASTACAFT is a once-daily eye drop that works within minutes against seasonal and year-round allergens to relieve itchy eyes - Previously available only by prescription, LASTACAFT is now available over the counter na
Read more →ABBVAbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and...
NORTH CHICAGO, Ill. and BUDAPEST, Hungary , March 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potenti
Read more →ABBVAbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin...
NORTH CHICAGO, Ill. , March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States ), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatmen
Read more →ABBVAbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech AbbVie (NYSE: ABBV) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. Under the terms of the resolution, AbbVie...
NORTH CHICAGO, Ill. , March 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in t
Read more →ABBVAbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience...
NORTH CHICAGO, Ill. , March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel mo
Read more →ABBVAbbVie to Present at the Cowen 42nd Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2021. Robert A. Michael, vice chairman,...
NORTH CHICAGO, Ill. , March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8, 2021 . Robert A. Michael , vice chairman, finance and commercial operations and chief financial officer, Michael E. Seve
Read more →ABBVAbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD) AbbVie (NYSE: ABBV), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for...
NORTH CHICAGO, Ill. , Feb. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA ® (ibrutinib) for the treatment of pediatric and adolescent patients
Read more →ABBVAbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S. AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI® (risankizumab-rzaa)...
NORTH CHICAGO, Ill. , Feb. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI ® (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in patients 16 years
Read more →ABBVSecond Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily)...
NORTH CHICAGO, Ill. , Feb. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c
Read more →ABBVAllergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan's leading portfolio of eye care treatments at the...
NORTH CHICAGO, Ill. , Feb. 24, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced new data to be presented from Allergan's leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN
Read more →ABBVAbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and...
NORTH CHICAGO, Ill. , Feb. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR ® ) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive d
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable May 16,...
NORTH CHICAGO, Ill. , Feb. 17, 2022 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable May 16, 2022 to stockholders of record at the close of business on April 15, 2022 .
Read more →ABBVFDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the FDA approval of JUVÉDERM® VOLBELLA® XC for improvement of infraorbital hollows in...
IRVINE, Calif. , Feb. 8, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announces the FDA approval of JUVÉDERM ® VOLBELLA ® XC for improvement of infraorbital hollows in adults over the age of 21. 2 According to clinical trial data, 90% of subjects rep
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021. We delivered another year of...
NORTH CHICAGO, Ill., Feb. 2, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter and full year ended December 31, 2021 . "We delivered another year of outstanding performance in 2021 with double-digit revenue and EPS growth that were well
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent Adjusted Diluted EPS of $12.70, an Increase o
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent Adjusted Diluted EPS of $12.70, an Increase of 20.3 Percent Delivers Full-Year Net Revenues of $56.197 Billion on a GAAP Basis
Read more →ABBVAbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO) AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and upadacitinib...
NORTH CHICAGO, Ill. , Feb. 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present further analyses on HUMIRA ® (adalimumab) and the investigational uses of risankizumab (SKYRIZI ® ) and upadacitinib (RINVOQ ® ) at the 17th Congress of European Crohn's and Colitis Organisation
Read more →ABBVAllergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA) Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share...
"The ' See Yourself ' campaign featuring real people, reached almost one billion adults in 2021. This year, our goal is to reach even more people," said Jasson Gilmore , Senior Vice President Digital & Consumer Marketing, Allergan Aesthetics. "The finalists from the open casting
Read more →ABBVU.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults ...
NORTH CHICAGO, Ill. , Jan. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that
Read more →ABBVU.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of moderate to...
NORTH CHICAGO, Ill. , Jan. 14, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older who
Read more →ABBVAbbVie Anuncia que FDA Outorgou ao Telisotuzumabe Vedotin a Classificação de Terapia Inovadora (BDT) para Câncer de Pulmão de Células Não Pequenas - O anticorpo terapêutico conjugado em fase de pesquisa está sendo estudado em pacientes com câncer de pulmão de células não pequenas (NSCLC), com o...
- O anticorpo terapêutico conjugado em fase de pesquisa está sendo estudado em pacientes com câncer de pulmão de células não pequenas ( NSCLC ), com o marcador tumoral c-Met em excesso, e previamente tratados. - O estudo da Fase 2 LUMINOSITY (M14-239) está em desenvolvimento e o
Read more →ABBVAbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 AbbVie (NYSE: ABBV) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab)...
NORTH CHICAGO, Ill. , Jan. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of great
Read more →ABBVAbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approvals for upadacitinib (RINVOQ®, 15 mg once daily) to the U.S....
NORTH CHICAGO, Ill. , Jan. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted applications seeking approvals for upadacitinib (RINVOQ ® , 15 mg once daily) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for t
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2021 financial results on Wednesday, February 2, 2022, before the market opens....
NORTH CHICAGO, Ill. , Jan. 5, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter and full-year 2021 financial results on Wednesday, February 2, 2022 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . I
Read more →ABBVAbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Members of AbbVie's executive ...
NORTH CHICAGO, Ill. , Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 . Members of AbbVie's executive leadership team will present virtually at 2:45 p.m. CT , including Robert A.
Read more →ABBVAbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to...
NORTH CHICAGO, Ill. , Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/
Read more →ABBVAllergan Aesthetics Completes Acquisition of Soliton Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY)....
IRVINE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY ). The addition of Soliton and its technology complements Allergan Aesthetics' portfoli
Read more →ABBVRINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the...
NORTH CHICAGO, Ill. , Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inad
Read more →ABBVUpadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily)...
NORTH CHICAGO, Ill. , Dec. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c
Read more →ABBVAbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S. AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the treatment...
NORTH CHICAGO, Ill. , Dec. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ ® (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This update follow
Read more →ABBVAbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab...
NORTH CHICAGO, Ill. , Nov. 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI ® , 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenanc
Read more →ABBVAbbVie to Present at the Evercore ISI Conference AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021. Michael Severino,...
NORTH CHICAGO, Ill. , Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 4 th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice preside
Read more →ABBVAbbVie to Present at the Piper Sandler Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021. Michael Severino, ...
NORTH CHICAGO, Ill. , Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Piper Sandler 33 rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice pres
Read more →ABBVAllergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting Allergan Aesthetics, an AbbVie company, (NYSE: ABBV) today announced that it will present six abstracts from its leading portfolio of aesthetic...
IRVINE, Calif. , Nov. 19, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, (NYSE: ABBV ) today announced that it will present six abstracts from its leading portfolio of aesthetic treatments and products at the American Society for Dermatologic Surgery (ASDS) meeting
Read more →ABBVNew Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission AbbVie (NYSE: ABBV) today announced the publication of results from a new literature review in Advances in Therapy. The literature review reported...
NORTH CHICAGO, Ill. , Nov. 18, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the publication of results from a new literature review in Advances in Therapy . The literature review reported that achieving clinical remission in rheumatoid arthritis (RA) is likely to be
Read more →ABBVAbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab, 150 mg, subcutaneous injection at week 0,...
NORTH CHICAGO, Ill. , Nov. 17, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Commission (EC) has approved SKYRIZI ® (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexa
Read more →ABBVAllergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day Let the countdown begin. Experience the interactive Multichannel News Release here:...
IRVINE, Calif. , Nov. 15, 2021 /PRNewswire/ -- Let the countdown begin. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8966951-allergan-aesthetics-alle-botox-cosmetic-day/ Allergan Aesthetics, an AbbVie company (NYSE: ABBV ),
Read more →ABBVAbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025 AbbVie (NYSE: ABBV) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology...
NORTH CHICAGO, Ill. and CHICAGO , Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research. To date, the collaboration has led to novel insights related
Read more →ABBVAbbVie to Present at the Wolfe Research Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021. Michael Severino, M.D., vice...
NORTH CHICAGO, Ill. , Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president and chief fin
Read more →ABBVAbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ®...
NORTH CHICAGO, Ill. , Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis
Read more →ABBVAbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021 AbbVie (NYSE: ABBV) today announced results from new post-hoc analyses from the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy...
NORTH CHICAGO, Ill. , Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from new post-hoc analyses from the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (RINVOQ ® ) on axial symptoms in adult patients with active psor
Read more →ABBVAllergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM ...
NORTH CHICAGO, Ill. , Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITY TM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the
Read more →ABBVAbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021 AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the...
NORTH CHICAGO, Ill. , Nov. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI ® ) in adult patients with active p
Read more →ABBVAbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology...
NORTH CHICAGO, Ill. , Nov. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology (ASH) Annual Meeting ( December 11-14 ) in Atlanta, Georgia . "We are dedicated t
Read more →ABBVAbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab) across...
NORTH CHICAGO, Ill. , Nov. 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the presentation of new data on RINVOQ ® (upadacitinib), SKYRIZI ® (risankizumab) and HUMIRA ® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Third-Quarter 2021 Financial Results Reports Third-Quarter Diluted EPS of $1.78 on a GAAP Basis, an Increase of 38.0 Percent Adjusted Diluted EPS of $3.33, an Increase of 17.7 Percen
AbbVie Reports Third-Quarter 2021 Financial Results Reports Third-Quarter Diluted EPS of $1.78 on a GAAP Basis, an Increase of 38.0 Percent Adjusted Diluted EPS of $3.33, an Increase of 17.7 Percent Delivers Third-Quarter Net Revenues of $14.342 Billion, an Increase of 11.2 Per
Read more →ABBVAbbVie Reports Third-Quarter 2021 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2021. We continue to deliver excellent results, with...
NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2021 . "We continue to deliver excellent results, with balanced performance across our portfolio driving double-digit operational sales a
Read more →ABBVAbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the...
NORTH CHICAGO, Ill. , Oct. 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR ® ) as an adjunctive treatment for pat
Read more →ABBVU.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) Allergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY™ (pilocarpine HCl ophthalmic...
NORTH CHICAGO, Ill. , Oct. 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY ™ (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-relate
Read more →ABBVAbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically...
NORTH CHICAGO, Ill. , Oct. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with
Read more →ABBVAllergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of...
NORTH CHICAGO, Ill. , Oct. 26, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of AGN-190584 (pilocarpine HCl ophthalmic solution 1.25%), an investigational novel
Read more →ABBVAbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the...
NORTH CHICAGO, Ill. , Oct. 15, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI ® , 150 mg, subcutaneous injection at week 0, wee
Read more →ABBVAllergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support...
IRVINE, Calif. , Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month. For the month of October and into 2022, Allergan A
Read more →ABBVAbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active...
NORTH CHICAGO, Ill. , Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis (nr-axSpA), showing upadacitinib (RINVOQ ® ; 1
Read more →ABBVAbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating...
NORTH CHICAGO, Ill. , Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the efficacy and safety of RINVOQ ® (upadacitinib; 15 mg, once daily) in patients
Read more →ABBVAbbVie to Host Third-Quarter 2021 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , Oct. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2021 financial results on Friday, October 29, 2021 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will b
Read more →ABBVAbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021 AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative...
NORTH CHICAGO, Ill. , Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI ® ) in Crohn's disease, upadacitinib (RINVOQ ® ) in ulcerative colitis and HUMIRA ® (adalimumab) in inflammatory bowel disease (IBD) will be pres
Read more →ABBVAbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress AbbVie (NYSE: ABBV) today announced new analyses from the Phase 3 RINVOQ® (upadacitinib) atopic dermatitis clinical trial program to be presented at...
NORTH CHICAGO, Ill. , Sept. 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new analyses from the Phase 3 RINVOQ ® (upadacitinib) atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Cong
Read more →ABBVAbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress AbbVie (NYSE: ABBV) today presented results from new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating risankizumab (SKYRIZI®, 150 mg)...
NORTH CHICAGO, Ill. , Sept. 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today presented results from new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating risankizumab (SKYRIZI ® , 150 mg) in adults with active psoriatic arthritis for one year (52 weeks). 1 These r
Read more →ABBVDREAM™ Initiative Releases, The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Allergan Aesthetics, an AbbVie company, and SkinBetter Science through their DREAMTM (Driving Racial Equity in Aesthetic Medicine) initiative are...
IRVINE, Calif. and PHOENIX, Sept. 29, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, and SkinBetter Science through their DREAM TM (Driving Racial Equity in Aesthetic Medicine) initiative are supporting the development and distribution of The Full Spectrum of Dermat
Read more →ABBVFDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of...
NORTH CHICAGO, Ill. , Sept. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults. 1 QULIPTA is the first and only oral calcitonin ge
Read more →ABBVAmericans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals From texting mishaps to lost reading glasses, the impact of age-related blurry near vision, or difficulty seeing things up close, on daily life can...
NORTH CHICAGO, Ill. , Sept. 27, 2021 /PRNewswire/ -- From texting mishaps to lost reading glasses, the impact of age-related blurry near vision, or difficulty seeing things up close, on daily life can be pervasive. People who struggle with this may have presbyopia, which affects
Read more →ABBVAbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and...
NORTH CHICAGO, Ill. , Sept. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ ® (upadacitinib) in atopic dermatitis and new data on SKYRI
Read more →ABBVAbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for...
NORTH CHICAGO, Ill. , Sept. 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) mai
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45...
NORTH CHICAGO, Ill. , Sept. 16, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely a
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable November ...
NORTH CHICAGO, Ill. , Sept. 10, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable November 15, 2021 to stockholders of record at the close of business on October 15,
Read more →ABBVAbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021 AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement...
NORTH CHICAGO, Ill. , Sept. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22 . Mo
Read more →ABBVClinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2...
NORTH CHICAGO, Ill. , and COPENHAGEN, Denmark , Sept, 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Genmab A/S (Nasdaq: GMAB ) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and c
Read more →ABBVAbbVie to Present at the Morgan Stanley Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard ...
NORTH CHICAGO, Ill. , Sept. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021 . Richard A. Gonzalez , chairman and chief executive officer, Michael Severino , M.D.,
Read more →ABBVAbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly ...
NORTH CHICAGO, Ill. , Sept. 8, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Fed
Read more →ABBVEuropean Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor,...
NORTH CHICAGO, Ill. , Aug. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Commission (EC) approved RINVOQ ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolesc
Read more →ABBVAbbVie Kicks Off Two-Week Public Voting Open for the 2021 AbbVie CF Scholarship Thriving Student Awards AbbVie today announced the start of its two-week public voting period for the 2021 Thriving Undergraduate and Thriving Graduate Scholarship. At the...
NORTH CHICAGO, Ill. , Aug. 18, 2021 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2021 Thriving Undergraduate and Thriving Graduate Scholarship. At the conclusion of this voting period, two commendable students living with cystic fi
Read more →ABBVNew England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine (NEJM) has published 12-week results from the Phase 3 ADVANCE trial...
NORTH CHICAGO, Ill. , Aug. 18, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the New England Journal of Medicine ( NEJM ) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet
Read more →ABBVSKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV) today announced that SKYRIZI® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a...
NORTH CHICAGO, Ill. , Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that SKYRIZI ® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaq
Read more →ABBVAbbVie e Calico Anunciam Nova Extensão de Colaboração em Doenças Relacionadas ao Envelhecimento A AbbVie (NYSE: ABBV) e a Calico Life Sciences anunciaram nova extensão da parceria para descobrir, desenvolver e levar ao mercado novas terapias...
SÃO PAULO, 5 de agosto de 2021 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) e a Calico Life Sciences anunciaram nova extensão da parceria para descobrir, desenvolver e levar ao mercado novas terapias para pacientes com doenças relacionadas ao envelhecimento, incluindo degeneração neuro
Read more →ABBVJAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and...
NORTH CHICAGO, Ill. , Aug. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ ® (upadacitinib, 30 mg, once daily) versus DUPIXENT ® (dupilum
Read more →ABBVAbbVie Reports Second-Quarter 2021 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2021. AbbVie delivered another strong quarter and our business...
NORTH CHICAGO, Ill., July 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2021 . "AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie's new
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Second-Quarter 2021 Financial Results Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis Adjusted Diluted EPS of $3.11 Delivers Second-Quarter Net Revenues of $13.959 Billio
AbbVie Reports Second-Quarter 2021 Financial Results Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis Adjusted Diluted EPS of $3.11 Delivers Second-Quarter Net Revenues of $13.959 Billion, an Increase of 33.9 Percent on a Reported Basis Second-Quarter Global Net Rev
Read more →ABBVFDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX®...
NORTH CHICAGO, Ill. , July 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX ® to include eight new muscles for the treatment of upper limb spasticity in adu
Read more →ABBVAbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , July 27, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related
Read more →ABBVNew Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating...
NORTH CHICAGO, Ill. , July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpin
Read more →ABBVDALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute...
NORTH CHICAGO, Ill. , July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from b
Read more →ABBVVenetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS) AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax...
NORTH CHICAGO, Ill. , July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA ® ) in combination with azacitidine for the potential treatment of a
Read more →ABBVAllergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021...
NORTH CHICAGO, Ill. , July 20, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) Annual Meeting be
Read more →ABBVResultados de Estudo de Fase 3 Indicam que Pacientes com Doença de Crohn Tratados com Risanquizumabe Alcançaram Resposta Endoscópica e Remissão Clínica em Um Ano - No estudo, uma proporção significativamente maior de pacientes com doença de Crohn tratados com risanquizumabe 360 mg SC obteve resposta...
- No estudo, uma proporção significativamente maior de pacientes com doença de Crohn tratados com risanquizumabe 360 mg SC obteve resposta endoscópica e remissão clínica em um ano (52 semanas) 1 - Os resultados de segurança neste estudo foram, de forma geral, consistentes com o
Read more →ABBVAbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S. AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) did not meet the Prescription Drug User Fee Act (PDUFA) action date...
NORTH CHICAGO, Ill. , July 16, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the U.S. Food and Drug Administration (FDA) did not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental New Drug Application (sNDA) for RINVOQ ® (upadacitinib) fo
Read more →ABBVAbbVie to Host Second-Quarter 2021 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2021 financial results on Friday, July 30, 2021 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be
Read more →ABBVAbbVie Apresenta Análise de Dados que Indicam que risanquizumabe Obtém Remissão Clínica e Resposta Endoscópica em 12 Semanas em Pacientes com Doença de Crohn Moderada a Grave Análises de dados apresentadas pela AbbVie (NYSE: ABBV) na Digestive Disease Week® (DDW) Virtual Conference 2021 mostraram que uma parcela maior de...
SAO PAULO , 7 de julho de 2021 /PRNewswire/ -- Análises de dados apresentadas pela AbbVie (NYSE: ABBV ) na Digestive Disease Week® (DDW) Virtual Conference 2021 mostraram que uma parcela maior de pacientes com doença de Crohn ativa moderada a grave tratados com duas diferentes do
Read more →ABBVNovos Dados Sobre VENCLEXTA®(venetoclax), da AbbVie, em Combinação Fixa De Tratamento, Demonstrou Sobrevida Livre De Progressão, em Pacientes Com Leucemia Linfocítica Crônica (LLC), Após Três Anos De Conclusão Do Tratamento A análise do seguimento de quatro anos de pacientes com LLC no estudo clínico de fase 3 CLL14 (seguimento mediano de 52,4 meses) demonstrou maior...
SÃO PAULO , 7 de Julho de 2021 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou (11 de junho) resultados da análise do seguimento de quatro anos de pacientes com LLC incluídos no estudo de fase 3 CLL14, os quais indicam que aqueles que receberam a combinação VENCLEXTA ® (venetocla
Read more →ABBVAberta Consulta Pública para Atualização de Protocolo Clínico de Diretrizes Terapêuticas (PCDT), com Inclusão de risanquizumabe, da AbbVie, para Pacientes com Psoríase Moderada a Grave Até 5 de julho de 2021, a CONITEC – Comissão Nacional de Incorporação de Novas Tecnologias recebe contribuições na consulta pública para atualização...
SÃO PAULO , 30 de junho de 2021 /PRNewswire/ -- Até 5 de julho de 2021, a CONITEC – Comissão Nacional de Incorporação de Novas Tecnologias recebe contribuições na consulta pública para atualização do Protocolo Clínico e Diretrizes Terapêuticas (PCDT) da Psoríase, com a inclusão d
Read more →ABBVUpadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients AbbVie (NYSE: ABBV) today announced that upadacitinib (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo...
NORTH CHICAGO, Ill. , June 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that upadacitinib (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all secondary endpoints at one-year (week 52) in the Phase 3 ulcerat
Read more →ABBVAbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) AbbVie today announced new data on upadacitinib (RINVOQ®) in ulcerative colitis and risankizumab (SKYRIZI®) in Crohn's disease will be presented as...
NORTH CHICAGO, Ill. , June 28, 2021 /PRNewswire/ -- AbbVie today announced new data on upadacitinib (RINVOQ ® ) in ulcerative colitis and risankizumab (SKYRIZI ® ) in Crohn's disease will be presented as oral presentations at the 16 th Congress of European Crohn's and Colitis Org
Read more →ABBVAbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S. AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the...
NORTH CHICAGO, Ill. , June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Appl
Read more →ABBVCHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
NORTH CHICAGO, Ill. , June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ ® (upadacitinib), an oral, selective
Read more →ABBVAbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., ...
NORTH CHICAGO, Ill. and NEWARK, Calif. , June 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the p
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable August...
NORTH CHICAGO, Ill. , June 17, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable August 16, 2021 to stockholders of record at the close of business on July 15, 2021 .
Read more →ABBVIMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA®...
NORTH CHICAGO, Ill. , June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® /VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus
Read more →ABBVNew Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated...
NORTH CHICAGO, Ill. , June 11, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated patients with chronic lymphocytic leukemia (CLL) with coexisting conditions who
Read more →ABBVAllergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is changing the way BOTOX® Cosmetic, the #1 selling neurotoxin treatment1, is connecting with...
Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8909451-allergan-aesthetics-botox-cosmetic-onabotulinumtoxina-new-campaign/ As people begin to embrace meeting up in-person again, society is feeling like they have a lot to celebrat
Read more →ABBVCAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA® (ibrutinib) in combination with...
NORTH CHICAGO, Ill. , June 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new data from the Phase 2 CAPTIVATE ( PCYC-1142 ) study investigating IMBRUVICA ® (ibrutinib) in combination with VENCLEXTA ® /VENCLYXTO ® (venetoclax), an all-oral, once-daily, chemotherapy-f
Read more →ABBVResults from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent IMBRUVICA...
NORTH CHICAGO, Ill. , June 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ), today announced extended long-term data from the Phase 3 RESONATE-2 study ( PCYC-1115/1116 ) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients
Read more →ABBVAbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with...
NORTH CHICAGO, Ill. , June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ ® (upadacitinib, 15 mg, once daily) resulted in sustained improvements in dis
Read more →ABBVNew Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe...
NORTH CHICAGO, Ill. , June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe rheumatoid arthritis on background methotrexate (MTX) treated with RINVOQ ® (upadacitin
Read more →ABBVPhase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg (subcutaneous...
NORTH CHICAGO, Ill. , June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg (subcutaneous [SC]; administered every eight weeks) achieved the co-primary endpoints of endo
Read more →ABBVAbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. Michael Severino, M.D.,...
NORTH CHICAGO, Ill. , June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president an
Read more →ABBVAbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific...
NORTH CHICAGO, Ill. , May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually June 3-6 . A total of 23 abstracts, including fou
Read more →ABBVAbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference AbbVie (NYSE: ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Wednesday, June 2, 2021. Michael Severino, M.D.,...
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines tha
Read more →ABBVAbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with a hypomethylating...
NORTH CHICAGO, Ill. , May 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly d
Read more →ABBVAbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology AbbVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including ...
NORTH CHICAGO, Ill. , May 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® , SKYRIZI ® , HUMIRA ® and its pipeline across multiple rheumatic dis
Read more →ABBVThe Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1,...
NORTH CHICAGO, Ill. , May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ ® (upadacitinib) in adults and adolesce
Read more →ABBVAbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater...
NORTH CHICAGO, Ill. , May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE: ABBV ) at Digestive Disease Week ® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treat
Read more →ABBVAbbVie to Present at the UBS Global Healthcare Virtual Conference AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Michael Severino, M.D., vice chairman...
NORTH CHICAGO, Ill. , May 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president and chief financi
Read more →ABBVAbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical...
NORTH CHICAGO, Ill. , May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting ( June 4-8 ) and the virtual European Hematology Associ
Read more →ABBVFDA Aceita Submissão de Atogepant Novo Medicamento da AbbVie para o Tratamento Preventivo de Enxaqueca A AbbVie (NYSE:ABBV) anunciou que a agência regulatória dos Estados Unidos, FDA (Food and Drug Administration) aceitou o pedido de submissão para...
SÃO PAULO, 13 de maio de 2021 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou que a agência regulatória dos Estados Unidos, FDA ( Food and Drug Administration ) aceitou o pedido de submissão para atogepant como sNDA . O atogepant é um antagonista do receptor de peptídeo relaciona
Read more →ABBVAbbVie to Present at the RBC Capital Markets Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021. Michael Severino, M.D., vice...
NORTH CHICAGO, Ill. , May 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president and chief
Read more →ABBVAllergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics ...
IRVINE, Calif. and HOUSTON , May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ) and Soliton (NASDAQ: SOLY ) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONIC TM , its Rapid Acoustic Pulse device
Read more →ABBVAbbVie Anuncia Resultados Financeiros do Primeiro Trimestre de 2021 A companhia farmacêutica AbbVie (NYSE: ABBV) anunciou, em 30 de abril de 2021, os resultados financeiros referentes ao primeiro trimestre (Q1) de...
SÃO PAULO, 7 de maio de 2021 /PRNewswire/ -- A companhia farmacêutica AbbVie (NYSE: ABBV ) anunciou, em 30 de abril de 2021, os resultados financeiros referentes ao primeiro trimestre (Q1) de 2021, encerrado em 31 de março de 2021. Neste período, a receita líquida da companhia f
Read more →ABBVAbbVie Reports First-Quarter 2021 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. We are off to an excellent start to 2021, with strong...
NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2021 . "We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and ea
Read more →ABBVDocument PRESS RELEASE AbbVie Reports First-Quarter 2021 Financial Results Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis Adjusted Diluted EPS of $2.95 Delivers First-Quarter Net Revenues of $13.010 Billion o
AbbVie Reports First-Quarter 2021 Financial Results Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis Adjusted Diluted EPS of $2.95 Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis Adjusted Net Reve
Read more →ABBVAllergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes ...
NORTH CHICAGO, Ill. , April 27, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (
Read more →ABBVAbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy AbbVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a...
The positive CHMP opinion represents the third for an extension of indications for VENCLYXTO. The opinion is based on results from the double-blind, placebo-controlled VIALE-A (M15-656) and the Phase 1b open-label, nonrandomized, multicenter M14-358 trial. "This positive CHMP op
Read more →ABBVNOTICE OF REDEMPTION TO THE HOLDERS OF AbbVie Inc. 0.500% Senior Notes due 2021 CUSIP No. 00287YDE6 (ISIN XS2117754247) / U0029QBK1 (ISIN XS2117754163) / 00287YDL0 (ISIN XS2125913603)* Pursuant to Section 11.4 of the Bas
NOTICE OF REDEMPTION TO THE HOLDERS OF 0.500% Senior Notes due 2021 CUSIP No. 00287YDE6 (ISIN XS2117754247) / U0029QBK1 (ISIN XS2117754163) / 00287YDL0 (ISIN XS2125913603)* Pursuant to Section 11.4 of the Base Indenture, dated as of November 8, 2012, between AbbVie Inc., a Del
Read more →ABBVAbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and ...
NORTH CHICAGO, Ill. , April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted applications seeking approval for SKYRIZI ® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI ® (risankizumab, 150 mg) to the Eu
Read more →ABBVAbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology...
NORTH CHICAGO, Ill. , April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22 . A total of 33 abst
Read more →ABBVAbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has ...
NORTH CHICAGO, Ill. , April 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA)
Read more →ABBVSkinMedica® Launches Neck Correct Cream for Neck and Décolleté Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Neck Correct Cream, the first product from the...
IRVINE, Calif. , April 1, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announces the launch of SkinMedica ® Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin
Read more →ABBVNew England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial...
NORTH CHICAGO, Ill. , April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic
Read more →ABBVAbbVie to Host First-Quarter 2021 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , March 31, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2021 financial results on Friday, April 30, 2021 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will b
Read more →ABBVU.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an...
Migraine is a complex, chronic disease with attacks that are often incapacitating and can include headache pain as well as neurologic and autonomic symptoms. 3 Migraine symptoms and severity range widely among individuals. The NDA is supported by data from a robust clinical prog
Read more →ABBVAbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has ...
NORTH CHICAGO, Ill. , March 17, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA)
Read more →ABBVAbbVie Calls on Students with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2021-2022 Academic School Year AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting...
NORTH CHICAGO, Ill. , March 17, 2021 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2021-2022 academic school year. Eligible undergraduate and
Read more →ABBVAllergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for...
NORTH CHICAGO, Ill. , Feb. 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the trea
Read more →ABBVHUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...
NORTH CHICAGO, Ill. , Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA ® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and
Read more →ABBVNew REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are...
NORTH CHICAGO, Ill. , Feb. 23, 2021 /PRNewswire/ -- From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day on some type of digital device. 1 As the relia
Read more →ABBVSecond Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and ...
NORTH CHICAGO, Ill. , Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH.
Read more →ABBVAbbVie to Present at the Cowen 41st Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021. Michael Severino, M.D., vice...
NORTH CHICAGO, Ill. , Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen 41 st Annual Health Care Conference on Wednesday, March 3, 2021 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president and chief fi
Read more →ABBVAbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the...
NORTH CHICAGO, Ill. and NEWPORT BEACH, Calif. and SEOUL , Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ), Evolus (NASDAQ: EOLS ) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable May 14,...
NORTH CHICAGO, Ill. , Feb. 18, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable May 14, 2021 to stockholders of record at the close of business on April 15, 2021 .
Read more →ABBVAbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice ...
NORTH CHICAGO, Ill. , Feb. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 10 th Annual SVB Leerink Global Healthcare Conference on Friday, February 26 . Michael Severino , M.D., vice chairman and president, Robert A. Michael , executive vice president and c
Read more →ABBVBOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of...
NORTH CHICAGO, Ill. , Feb. 10, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX ® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition
Read more →ABBVAbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they...
NORTH CHICAGO, Ill. and BERKELEY, Calif. , Feb. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis Adjusted Diluted EPS of $10.56 Delivers Full-Year Net Revenues of $45.804 B
AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis Adjusted Diluted EPS of $10.56 Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis Adjusted
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. We successfully completed the...
NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter and full year ended December 31, 2020 . "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 20
Read more →ABBVCoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting® Elite, its next generation fat reduction system...
IRVINE, Calif. , Jan. 26, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced the launch of CoolSculpting ® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. CoolSculpting ® E
Read more →ABBVEuropean Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and ...
NORTH CHICAGO, Ill. , Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA
Read more →ABBVAllergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins...
NORTH CHICAGO, Ill. , Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV ), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studie
Read more →ABBVrgan Healthcare Conference Richard Gonzalez Chairman and Chief Executive Officer
AbbVie's Partnered Assets Skyrizi developed in cooperation with Boehringer Ingelheim Imbruvica jointly developed and commercialized with Janssen Biotech Venclexta developed by AbbVie and Roche, commercialized by AbbVie and Genentech, a member of the Roche Group Epcoritamab, GEN10
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens....
NORTH CHICAGO, Ill. , Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Centr
Read more →ABBVAllergan Aesthetics Enters Into Option to Acquire Cypris Medical Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately...
IRVINE, Calif. , Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago . Following the completion of a clinica
Read more →ABBVRisankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab...
NORTH CHICAGO, Ill. , Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscop
Read more →ABBVAbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive ...
NORTH CHICAGO, Ill. , Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . Members of AbbVie's executive leadership team will present virtually at 3:30 p.m. Central time , including
Read more →ABBVRisankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and...
NORTH CHICAGO, Ill. , Jan. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, showing that significantly more patients treated with risankizumab (150
Read more →ABBVIMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM) AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA® (ibrutinib) Prescribing...
NORTH CHICAGO, Ill. , Dec. 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA ® (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVIC
Read more →ABBVAbbVie Apresenta Novos Dados de VENCLEXTA® (venetoclax) para Tratamento com Duração Fixa de Leucemia Linfocitica Crônica (LLC) A AbbVie (NYSE: ABBV) anunciou resultados atualizados dos estudos Fase 3 MURANO e CLL14 que avaliaram o tratamento com duração fixa de combinações de ...
SÃO PAULO, 14 de dezembro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou resultados atualizados dos estudos Fase 3 MURANO e CLL14 que avaliaram o tratamento com duração fixa de combinações de VENCLEXTA® (venetoclax) apresentados no 62º Encontro Anual da Sociedade America
Read more →ABBVCHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the...
NORTH CHICAGO, Ill. , Dec. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ ™ (upadacitinib, 15 mg), an oral, once daily selective and
Read more →ABBVRINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved...
NORTH CHICAGO, Ill. , Dec. 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the prop
Read more →ABBVAbbVie Announces Partners in $50 Million Program to Promote Health and Education Equity in Underserved Black Communities AbbVie, a research-based global biopharmaceutical company, is investing $50 million in a five-year program to support underserved Black communities...
NORTH CHICAGO, Ill. , Dec. 9, 2020 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, is investing $50 million in a five-year program to support underserved Black communities across the United States . AbbVie will collaborate with six nonprofit partners, i
Read more →ABBVUpadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis AbbVie (NYSE: ABBV) today announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met...
NORTH CHICAGO, Ill. , Dec. 9, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8, a
Read more →ABBVCombined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis...
NORTH CHICAGO, Ill. , Dec. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based therapies for the first-line t
Read more →ABBVAbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO®...
NORTH CHICAGO, Ill. , Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA ® /VENCLYXTO ® (venetoclax) fixed duration treatment combinations at the virtual 62 nd American Soci
Read more →ABBVIMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination...
NORTH CHICAGO, Ill. , Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA ® (ibrutinib) in combination with VENCLEXTA ® /VENCLYXTO ® (venetoclax) in previously untreated patients wit
Read more →ABBVAbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging...
Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Whereas conventional drug discovery methodologie
Read more →ABBVCONITEC Avalia Incorporação de Novo Tratamento Para Pacientes Adultos Com Artrite Reumatoide Ativa Moderada a Grave A artrite reumatoide (AR) é uma doença inflamatória, crônica e imunomediada, que afeta articulações e órgãos internos. Estima-se que cerca de 1 por...
SÃO PAULO, 1 de dezembro de 2020 /PRNewswire/ -- A AbbVie informa que RINVOQ ® (upadacitinibe), um inibidor oral da JAK1, de dose única diária, obteve recomendação preliminar favorável da CONITEC - Comissão Nacional de Incorporação de Novas Tecnologias, para incorporação no SUS -
Read more →ABBVAbbVie to Host Virtual Immunology Strategic Update AbbVie (NYSE: ABBV) will host a virtual immunology strategic update for investors on Monday, December 14, 2020 at 9:00 a.m. Central time. Richard A....
NORTH CHICAGO, Ill. , Dec. 1, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will host a virtual immunology strategic update for investors on Monday, December 14, 2020 at 9:00 a.m. Central time . Richard A. Gonzalez , chairman of the board and chief executive officer, and members of t
Read more →ABBVAbbVie Anuncia Resultados Financeiros do Terceiro Trimestre 2020 A AbbVie, companhia biofarmacêutica baseada em pesquisa, anunciou o crescimento de suas receitas globais em 52,1 por cento, chegando a US$ 12,9...
SÃO PAULO, 24 de novembro de 2020 /PRNewswire/ -- A AbbVie, companhia biofarmacêutica baseada em pesquisa, anunciou o crescimento de suas receitas globais em 52,1 por cento, chegando a US$ 12,9 bilhões no terceiro trimestre de 2020, encerrado em 30 de outubro. Neste período, as r
Read more →ABBVAbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2 at 1:40 p.m. CT and the Piper Sandler ...
NORTH CHICAGO, Ill. , Nov. 24, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2 at 1:40 p.m. CT and the Piper Sandler Virtual Healthcare Conference on Thursday, December 3 at 10 a.m. CT . Michael
Read more →ABBVAbbVie Announces Expiration and Final Results of Registered Exchange Offers
AbbVie Announces Expiration and Final Results of Registered Exchange Offers NORTH CHICAGO, Ill., November 18, 2020 - AbbVie Inc. (NYSE:ABBV) (" AbbVie ") announced today the expiration and final results of its offers to exchange (the " Registered Exchange Offers ") any and all o
Read more →ABBVAllergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating its second annual BOTOX® Cosmetic Day on Wednesday, November 18, 2020. The event...
IRVINE, Calif. , Nov. 16, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is celebrating its second annual BOTOX ® Cosmetic Day on Wednesday, November 18, 2020 . The event is dedicated to celebrating the iconic treatment that helped create the aesthetic
Read more →ABBVAbbVie to Present at the Wolfe Research Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice...
NORTH CHICAGO, Ill. , Nov. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020 . Michael Severino , M.D., vice chairman and president, and Robert A. Michael , executive vice president and chief
Read more →ABBVAbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting AbbVie (NYSE: ABBV) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer...
NORTH CHICAGO, Ill. , Nov. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeti
Read more →ABBVNovos Dados Demonstram que SKYRIZI®(risanquizumabe) Mantém a Pele Sem Lesões por Mais de Três Anos em Cerca de Dois Terços dos Pacientes com Psoríase Moderada a Grave A AbbVie (NYSE: ABBV) anuncia que aproximadamente 63% dos pacientes com psoríase em placas moderada a grave tratados com SKYRIZI® apresentaram...
SÃO PAULO, 3 de novembro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anuncia que aproximadamente 63% dos pacientes com psoríase em placas moderada a grave tratados com SKYRIZI ® apresentaram eliminação total das lesões por mais de três anos (172 semanas), conforme medido pelo
Read more →ABBVAbbVie Reports Third-Quarter 2020 Financial Results AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020. We continue to be very well positioned for the...
NORTH CHICAGO, Ill., Oct. 30, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2020 . "We continue to be very well positioned for the long-term. Results from key growth products – including Skyrizi, Rinvoq and Ubrelv
Read more →ABBVDocument PRESS RELEASE AbbVie Reports Third-Quarter 2020 Financial Results Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis Adjusted Diluted EPS of $2.83 Delivers Third-Quarter Net Revenues of $12.902 Billion o
AbbVie Reports Third-Quarter 2020 Financial Results Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis Adjusted Diluted EPS of $2.83 Delivers Third-Quarter Net Revenues of $12.902 Billion on a GAAP Basis, an Increase of 52.1 Percent on a Reported Basis Adjusted Net Reve
Read more →ABBVAbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual...
NORTH CHICAGO, Ill. , Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV ) at the 29 th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadac
Read more →ABBVAllergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability ...
NORTH CHICAGO, Ill. , Oct. 28, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the
Read more →ABBVAbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and...
NORTH CHICAGO, Ill. , Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College
Read more →ABBVAbbVie e I-Mab Firmam Parceria Global Estratégica para Terapia Diferenciada de Imuno-Oncologia A AbbVie (NYSE: ABBV) e a I-Mab (Nasdaq: IMAB) anunciaram amplo acordo de colaboração global para o desenvolvimento e comercialização de...
SÃO PAULO, 23 de outubro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) e a I-Mab (Nasdaq: IMAB ) anunciaram amplo acordo de colaboração global para o desenvolvimento e comercialização de lemzoparlimabe (também conhecido como TJC4), anticorpo monoclonal inovador anti-CD47 de
Read more →ABBVAbbVie Announces Commencement of Registered Exchange Offers
AbbVie Announces Commencement of Registered Exchange Offers NORTH CHICAGO, Ill., October 19, 2020 - AbbVie Inc. (NYSE:ABBV) (" AbbVie ") announced today the commencement of its offers to exchange (the " Registered Exchange Offers ") any and all of its outstanding (i) $30,000,000
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis AbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency...
NORTH CHICAGO, Ill. , Oct. 19, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ™ (upadacitinib) for the treatment of adults (
Read more →ABBVVENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML) AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in...
NORTH CHICAGO, Ill. , Oct. 16, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the tr
Read more →ABBVAllergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for...
IRVINE, Calif. , Oct. 9, 2020 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020 . The scheduled time
Read more →ABBVAllergan, an AbbVie Company, and Von Miller Encourage People with Glaucoma to Design Their Disease Management Plan More than 4 million people in the United States are expected to have glaucoma by 2030. This serious disease is one of the leading causes of...
NORTH CHICAGO, Ill. , Oct. 8, 2020 /PRNewswire/ -- More than 4 million people in the United States are expected to have glaucoma by 2030. This serious disease is one of the leading causes of blindness, yet patients do not know that elevated eye pressure is the only treatable risk
Read more →ABBVAllergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into an agreement with Luminera, a privately held,...
IRVINE, Calif. , Oct. 7, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced that it has entered into an agreement with Luminera, a privately held, aesthetics company based in Israel with a portfolio and pipeline of dermal filler products.
Read more →ABBVAbbVie to Host Third-Quarter 2020 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , Oct. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2020 financial results on Friday, October 30, 2020 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will b
Read more →ABBVUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (Dollar amounts presented in millions, except share data) The following unaudited pro forma condensed combined financial information gives effect to the acquis
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (Dollar amounts presented in millions, except share data) The following unaudited pro forma condensed combined financial information gives effect to the acquisition of Allergan plc ("Allergan") by Venice Subsidiary LL
Read more →ABBVAbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International Symposium AbbVie (NYSE: ABBV) today announced it will present results from several clinical trials, including new data from the Phase 3 ADVANCE trial,...
NORTH CHICAGO, Ill. , Oct. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present results from several clinical trials, including new data from the Phase 3 ADVANCE trial, evaluating the efficacy and safety of the investigational medicine atogepant, an orally
Read more →ABBVSkinMedica® Launches TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™ Today Allergan Aesthetics, an AbbVie company, announced the launch of SkinMedica® TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™ treatments....
IRVINE, Calif. , Sept. 30, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announced the launch of SkinMedica ® TNS ® Advanced+ Pro-Infusion Serum for DiamondGlow™ treatments. Offered by dermatologists, plastic surgeons and medical aestheticians nationwide, Dia
Read more →ABBVAbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for...
NORTH CHICAGO, Ill. , Sept. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord
Read more →ABBVAbbVie Submete Upadacitinibe para Pacientes Adultos com Espondilite Anquilosante à Avaliação Regulatória da FDA A AbbVie (NYSE: ABBV) apresentou pedido de nova indicação à agência regulatória dos EUA, Food and Drug Administration (FDA), para upadacitinibe (15...
SÃO PAULO, 25 de setembro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) apresentou pedido de nova indicação à agência regulatória dos EUA, Food and Drug Administration (FDA), para upadacitinibe (15 mg, uma vez ao dia), inibidor seletivo e reversível da Janus Quinase (JAK)1, para
Read more →ABBVCONITEC Recomenda Incorporação de SKYRIZI® (risanquizumabe) da AbbVie pelo SUS, Para Tratamento De Adultos Com Psoríase Em Placas Moderada a Grave A AbbVie, companhia biofarmacêutica global baseada em pesquisa, anuncia que SKYRIZI, anticorpo monoclonal de imunoglobulina humanizada G1 (IgG1)4,...
SÃO PAULO, 23 de setembro de 2020 /PRNewswire/ -- A AbbVie, companhia biofarmacêutica global baseada em pesquisa, anuncia que SKYRIZI, anticorpo monoclonal de imunoglobulina humanizada G1 (IgG1) 4 , teve incorporação pelo SUS - Sistema Único de Saúde recomendada pela CONITEC - Co
Read more →ABBVMalin Akerman Joins CoolSculpting® and CoolTone™ as U.S. Ambassador for the Allergan Aesthetics Body Contouring Portfolio Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the partnership between actress and producer Malin Akerman and the Allergan...
IRVINE, Calif. , Sept. 16, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced the partnership between actress and producer Malin Akerman and the Allergan Aesthetics body contouring portfolio. Akerman is named the first Allergan Aesthetics b
Read more →ABBVVoting for the 2020 AbbVie CF Scholarship Thriving Student Awards is Open to the Public Until September 30 AbbVie today announced the start of its annual public voting period for the 2020 Thriving Undergraduate and Thriving Graduate Scholarship. Following...
NORTH CHICAGO, Ill. , Sept. 16, 2020 /PRNewswire/ -- AbbVie today announced the start of its annual public voting period for the 2020 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships totaling $25,000 each will be given to two co
Read more →ABBVAllergan Aesthetics and Skinbetter Science Announce The DREAM Initiative™ To Advance Health Equity and Diversity in Aesthetics Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and Skinbetter Science® announced the launch of a new long-term, educational initiative –...
IRVINE, Calif. and PHOENIX , Sept. 14, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), and Skinbetter Science ® announced the launch of a new long-term, educational initiative – DREAM: Driving Racial Equity in Aesthetic Medicine ™ . The DREAM Init
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable November ...
NORTH CHICAGO, Ill. , Sept. 11, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15,
Read more →ABBVAbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders® AbbVie (NYSE: ABBV) today announced it will present results from several studies, including the DYSCOVER study evaluating the efficacy of DUODOPA®...
NORTH CHICAGO, Ill. , Sept. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced it will present results from several studies, including the DYSCOVER study evaluating the efficacy of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia
Read more →ABBVAbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the...
NORTH CHICAGO , Ill., and SHANGHAI , Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and I-Mab (Nasdaq: IMAB ) announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJ
Read more →ABBVAbbVie to Present at the Morgan Stanley Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020. Richard A....
NORTH CHICAGO, Ill. , Sept. 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16 , 2020. Richard A. Gonzalez , chairman and chief executive officer, will present at 10 a.m. Central
Read more →ABBVThe Lancet Oncology Publica Análise que Acompanhou por Três Anos Pacientes de Leucemia Linfocítica Crônica (LLC) Tratados com VENCLEXTA® (venetoclax) em Combinação com obinutuzumabe - Análise atualizada demonstrou que pacientes que receberam venetoclax por um período fixo, em combinação com obinutuzumabe, continuaram a apresentar ...
- Análise atualizada demonstrou que pacientes que receberam venetoclax por um período fixo, em combinação com obinutuzumabe, continuaram a apresentar taxas maiores de sobrevida livre de progressão da doença (SLP), por pelo menos 24 meses após o fim do tratamento 1 . - A SLP se m
Read more →ABBVNew England Journal of Medicine Publica Dados Positivos de Estudo de Fase 3 de Regime Combinado com Venetoclax para Leucemia Mieloide Aguda (LMA) Os dados de estudo fase 3 VIALE-A demonstram que venetoclax mais azacitidina reduziu o risco de morte em 34% em comparação com azacitidina mais...
SÃO PAULO, 1 de setembro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ) anunciou a publicação dos resultados do estudo clínico de Fase 3 VIALE-A em pacientes com LMA no New England Journal of Medicine (NEJM) . O estudo, que avaliou pacientes recém-diagnosticados com LMA que ainda
Read more →ABBV'Say No to Chronic Migraine Monday' Urges People Living with Chronic Migraine to Seek Help from a Headache Specialist Healthy living blogger Becca Ludlum knows all too well the physical and mental toll Chronic Migraine can have. She experienced self-described 'daily...
NORTH CHICAGO, Ill. , Aug. 31, 2020 /PRNewswire/ -- Healthy living blogger Becca Ludlum knows all too well the physical and mental toll Chronic Migraine can have. She experienced self-described 'daily unbreaking migraine attacks.' Her story is more common than you think. In the U
Read more →ABBVAbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for...
NORTH CHICAGO, Ill. , Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibito
Read more →ABBVAbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases AbbVie (NYSE: ABBV) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard ...
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. , Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapie
Read more →ABBVNew England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England...
NORTH CHICAGO, Ill. , Aug. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM) . The study, which evaluated newly-diagnosed AML patients
Read more →ABBVAbbVie Destina US$ 35 Milhões Para Apoiar Sistema de Saúde e Comunidades Afetadas pela COVID-19, com Aporte Adicional de Meio Milhão de Reais para Entidades Brasileiras No Brasil, este aporte será destinado a organizações e projetos que aumentem a capacidade de atendimento dos sistemas de saúde e ofereçam alimentação ...
SÃO PAULO, 4 de agosto de 2020 /PRNewswire/ -- A AbbVie, companhia biofarmacêutica de pesquisa, anuncia a criação do Fundo AbbVie Brasil de Combate à COVID-19 , com a contribuição de meio milhão de reais. Estes recursos serão destinados a projetos no Brasil que combatam o impacto
Read more →ABBVAbbVie Reports Second-Quarter 2020 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2020. AbbVie delivered another strong quarterly performance,...
NORTH CHICAGO, Ill., July 31, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2020. "AbbVie delivered another strong quarterly performance, ahead of our guidance. The adverse impact from COVID-19 on legacy AbbVie was le
Read more →ABBVAbbVie Reports Second-Quarter 2020 Financial Results
AbbVie Reports Second-Quarter 2020 Financial Results NORTH CHICAGO, Ill., July 31, 2020 - AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2020. "AbbVie delivered another strong quarterly performance, ahead of our guidance. The adverse impact
Read more →ABBVUpadacitinibe, da AbbVie, em Monoterapia, Demonstra Redução das Lesões de Pele e do Prurido em Estudo de Fase 3 para Dermatite Atópica Os primeiros resultados de um estudo de fase 3 que avaliou o uso de upadacitinibe para o tratamento da dermatite atópica moderada a grave, em adultos ...
SÃO PAULO, 30 de julho de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global baseada em pesquisa, anunciou que upadacitinibe, em monoterapia (15 mg ou 30 mg, uma vez ao dia), alcançou os objetivos primários de melhora de, pelo menos, 75 por cento no Índ
Read more →ABBVAbbVie Inc. Key Product Revenues Quarterly Trend Analysis (Unaudited, in millions) 1Q19 2Q19 3Q19 4Q19 FY19 1Q20 U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total U.S. Int'l. Total
Key Product Revenues Quarterly Trend Analysis (Unaudited, in millions) a Reflects profit sharing for Imbruvica international revenues. * Represents product(s) acquired as part of the Allergan acquisition. Key Product Revenues Quarterly Comparable Historical Trend Analysis a
Read more →ABBVAbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention AbbVie (NYSE: ABBV) today announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered...
NORTH CHICAGO, Ill. , July 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary en
Read more →ABBVThird Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients AbbVie (NYSE: ABBV) today announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and...
NORTH CHICAGO, Ill. , July 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of RINVOQ in a
Read more →ABBVRINVOQ™ (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis AbbVie (NYSE: ABBV) today announced upadacitinib (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up ...
NORTH CHICAGO, Ill. , July 21, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced upadacitinib (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic der
Read more →ABBVFDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
NORTH CHICAGO, Ill. , July 9, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX ® for the treatment of s
Read more →ABBVAbbVie to Host Second-Quarter 2020 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2020 financial results on Friday, July 31, 2020, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 7, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2020 financial results on Friday, July 31, 2020 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be
Read more →ABBVAbbVie Apresenta Dados de Estudo que Indicam Superioridade de SKYRIZI® (risanquizumabe) na Melhora das Lesões de Pele em Pacientes com Psoríase em Placas, em Comparação com Secuquinumabe, em 52 Semanas de Tratamento A AbbVie (NYSE: ABBV), companhia biofarmacêutica global baseada em pesquisa, anunciou novos dados de estudo de fase 3b, que indicam superioridade de...
SÃO PAULO, 1 de julho de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global baseada em pesquisa, anunciou novos dados de estudo de fase 3b , que indicam superioridade de SKYRIZI ® (risanquizumabe), em relação a secuquinumabe, na melhora completa das les
Read more →ABBVAllergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of...
NORTH CHICAGO, Ill. , June 26, 2020 /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV ), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced tha
Read more →ABBVIMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) will review...
NORTH CHICAGO, Ill. , June 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA ® (ibrutinib) in comb
Read more →ABBVFDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental...
NORTH CHICAGO, Ill. , June 22, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing informati
Read more →ABBVRINVOQ™ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced upadacitinib (15 mg and 30 mg, once daily) monotherapy met...
NORTH CHICAGO, Ill. , June 18, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced upadacitinib (15 mg and 30 mg, once daily) monotherapy met the co-primary endpoints of at least a 75 percent improvement in the Eczema Area
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable August...
NORTH CHICAGO, Ill. , June 17, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable August 14, 2020 to stockholders of record at the close of business on July 15, 2020 .
Read more →ABBVFDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® VOLUMA™ XC for the augmentation of the chin region ...
IRVINE, Calif. , June 15, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), announced the FDA approval of JUVÉDERM ® VOLUMA ™ XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. 1 As the category lead
Read more →ABBVAbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has 27 studies accepted to the virtual 2020 Annual...
NORTH CHICAGO, Ill. , June 15, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that it has 27 studies accepted to the virtual 2020 Annual Scientific Meeting of the American Headache Society (AHS). These abstracts highl
Read more →ABBVVENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the positive results from the VIALE-A (M15-656) trial, which...
NORTH CHICAGO, Ill. , June 13, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the positive results from the VIALE-A (M15-656) trial, which demonstrated that previously-untreated patients with acute myeloid leukemia (A
Read more →ABBVAbbVie Recommends Shareholders Reject TRC Capital's Mini-Tender Offer AbbVie (NYSE:ABBV) has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited mini-tender offer, dated...
NORTH CHICAGO, Ill. , June 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated June 1, 2020 , to purchase up to 1,500,000 shares of AbbVie common stock at $88
Read more →ABBVAbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior ...
NORTH CHICAGO, Ill. , June 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI ® (risankizumab-rzaa) to COSENTYX ® (secu
Read more →ABBVNovel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from a Phase 2a study of ABBV-3373, an...
NORTH CHICAGO, Ill. , June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new data from a Phase 2a study of ABBV-3373, an investigational anti-tumor necrosis factor (TNF) Glucocorticoid Receptor Modulator (GRM) st
Read more →ABBVAbbVie and Genmab Announce Broad Oncology Collaboration AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly...
NORTH CHICAGO, Illinois and COPENHAGEN, Denmark , June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Genmab A/S (Nasdaq: GMAB ) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stag
Read more →ABBVAbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new Phase 3 data from the SELECT-CHOICE clinical trial,...
NORTH CHICAGO, Ill. , June 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new Phase 3 data from the SELECT-CHOICE clinical trial, showing that RINVOQ™ (upadacitinib, 15 mg, once daily) met the primary endpoint of n
Read more →ABBVAbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19 AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a...
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. and UTRECHT , Netherlands and ROTTERDAM, Netherlands and SUZHOU, China , June 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered in
Read more →ABBVNew Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib...
NORTH CHICAGO, Ill. , June 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at
Read more →ABBVAbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the virtual Goldman Sachs 41st Annual Global Healthcare...
NORTH CHICAGO, Ill. , June 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 . Richard A. Gonzalez , chairman and chie
Read more →ABBVAbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has submitted applications for a new indication to...
NORTH CHICAGO, Ill. , June 1, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) f
Read more →ABBVAllergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is initiating a new digital campaign to improve device tracking and further identify and reach...
IRVINE, Calif. , June 1, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is initiating a new digital campaign to improve device tracking and further identify and reach breast implant patients who have, or have had, BIOCELL ® breast implants and/or tissu
Read more →ABBVAbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today...
NORTH CHICAGO , Ill. and BEIJING , June 1, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commerci
Read more →ABBVFDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA)...
NORTH CHICAGO, Ill. , May 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX ), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagol
Read more →ABBVAbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new safety and efficacy results for...
NORTH CHICAGO, Ill. , May 27, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that it will present new safety and efficacy results for RINVOQ™ (upadacitinib) in adult patients with moderate to severe active rheumatoid
Read more →ABBVAbbVie Announces 26 Nonprofits Selected for the COVID-19 Community Resilience Fund AbbVie, a research-based global biopharmaceutical company, today announced donations to 26 nonprofit organizations totaling $5 million to support...
NORTH CHICAGO, Ill. , May 21, 2020 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced donations to 26 nonprofit organizations totaling $5 million to support immediate COVID-19 relief efforts. Through support from the newly created AbbVie CO
Read more →ABBVAbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from studies evaluating the BCL-2...
NORTH CHICAGO, Ill. , May 15, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data from studies evaluating the BCL-2 inhibitor venetoclax (VENCLEXTA®/ VENCLYXTO®), among others, from clinical trials acr
Read more →ABBVAbbVie to Present at the UBS Virtual Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May...
NORTH CHICAGO, Ill. , May 14, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May 20, 2020 . Michael Severino , M.D., vice chairman and president and Robert A. Mi
Read more →ABBVAbbVie Announces Final Results of Exchange Offers for Allergan Notes
AbbVie Announces Final Results of Exchange Offers for Allergan Notes NORTH CHICAGO, Ill., May 13, 2020 - AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the final results of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and al
Read more →ABBVAbbVie Completes Transformative Acquisition of Allergan Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aes
AbbVie Completes Transformative Acquisition of Allergan NORTH CHICAGO, Ill., May 8, 2020 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from
Read more →ABBVAbbVie Completes Transformative Acquisition of Allergan AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc...
NORTH CHICAGO, Ill. , May 8, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by th
Read more →ABBVAbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes and Expects No Further Extensions of Expiration Date AbbVie Inc. (NYSE:ABBV) ( AbbVie ) announced today the extension of the expiration date of the offers to exchange (each, an Exchange Offer and,...
NORTH CHICAGO, Ill. , May 5, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV ) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain seri
Read more →ABBVAbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan NORTH CHICAGO, Ill. and DUBLIN
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan NORTH CHICAGO, Ill. and DUBLIN , May 5, 2020 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pha
Read more →ABBVAbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today...
NORTH CHICAGO , Ill. and DUBLIN, May 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN ), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted
Read more →ABBVAbbVie Reports First-Quarter 2020 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2020. During this challenging time, we are doing everything...
NORTH CHICAGO, Ill., May 1, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2020. "During this challenging time, we are doing everything possible to ensure our employees remain safe, our patients receive their medicines
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of April 27, 2020 its issued...
NORTH CHICAGO, Ill. , April 29, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of April 27, 2020 its issued share capital, excluding treasury shares, is comprised of 1,476,742,215 shares o
Read more →ABBVAbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes NORTH CHICAGO, Ill., Apr. 27, 2020 - AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectivel
Read more →ABBVIMBRUVICA® (ibrutinib) Receives 11th FDA Approval AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the ...
NORTH CHICAGO, Ill. , April 21, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA ® (ibrutinib) in combination with rituximab for the treatme
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of April 13, 2020 its issued...
NORTH CHICAGO, Ill. , April 15, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of April 13, 2020 its issued share capital, excluding treasury shares, is comprised of 1,476,730,009 shares o
Read more →ABBVAbbVie Invites Students with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2020-2021 Academic School Year AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting...
NORTH CHICAGO, Ill. , April 8, 2020 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2020-2021 academic school year. Undergraduate and graduate s
Read more →ABBVAbbVie Inc. - Form 8.1 - Dealings By Offerors, Offerees Or Parties Acting In Concert With Them For Themselves Or For Discretionary Clients IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY OFFERORS,...
NORTH CHICAGO, Ill. , April 2, 2020 /PRNewswire/ -- Related Links 21 %
Read more →ABBVAbbVie to Host First-Quarter 2020 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2020 financial results on Friday, May 1,...
NORTH CHICAGO, Ill. , April 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its first-quarter 2020 financial results on Friday, May 1, 2020 , before the market opens. AbbVie will host a live webcast of the earnings co
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 30, 2020 its issued...
NORTH CHICAGO, Ill. , April 1, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 30, 2020 its issued share capital, excluding treasury shares, is comprised of 1,476,674,661 shares of
Read more →ABBVAbbVie Anuncia Resultados Positivos De Estudo De Fase 3 De VENCLEXTA® (Venetoclax) Em Combinação Com Azacitidina Em Pacientes Com Leucemia Mieloide Aguda (LMA) - O estudo VIALE-A alcançou seus dois desfechos primários e demonstrou melhora estatisticamente significativa em sobrevida global e na taxa de...
- O estudo VIALE-A alcançou seus dois desfechos primários e demonstrou melhora estatisticamente significativa em sobrevida global e na taxa de remissão completa (CR + CRi - Remissão Completa + Remissão Completa com Recuperação Incompleta). Os resultados completos serão apresentad
Read more →ABBVAbbVie Donates $35 Million for COVID-19 Relief to Support Healthcare Systems, Patients and Communities AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced a donation of $35 million to support COVID-19 relief efforts....
NORTH CHICAGO, Ill. , March 31, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced a donation of $35 million to support COVID-19 relief efforts. In the U.S., AbbVie's funds will be used to support healthcare capacity for
Read more →ABBVAbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director AbbVie issued the following form today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER...
NORTH CHICAGO, Ill. , March 30, 2020 /PRNewswire/ -- AbbVie issued the following form today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WIT
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in...
NORTH CHICAGO, Ill. , March 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the VIALE-A (M15-656) trial of VENCLEXTA ® (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 16, 2020 its issued...
NORTH CHICAGO, Ill. , March 18, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 16, 2020 its issued share capital, excluding treasury shares, is comprised of 1,476,672,808 shares o
Read more →ABBVAbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today...
NORTH CHICAGO, Ill. and DUBLIN , March 17, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN ), a leading global pharmaceutical company, today announced that they have entered into a consent decree agreement
Read more →ABBVAbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved VENCLYXTO®...
NORTH CHICAGO, Ill. , March 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with obinutuzumab for the treatment of adult patien
Read more →ABBVAbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19 AbbVie (NYSE:ABBV) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the...
NORTH CHICAGO, Ill. , March 9, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to dete
Read more →ABBVEuropean Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has approved a change to the...
NORTH CHICAGO, Ill. , March 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Commission has approved a change to the marketing authorization for MAVIRET ® (glecaprevir/pibrentasvir) to shorten once-
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 2, 2020 its issued...
NORTH CHICAGO, Ill. , March 4, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 2, 2020 its issued share capital, excluding treasury shares, is comprised of 1,482,464,688 shares of
Read more →ABBVAbbVie Inc. - Form 8.1 - Share Buyback AbbVie issued the following forms today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER ...
NORTH CHICAGO, Ill. , March 3, 2020 /PRNewswire/ -- AbbVie issued the following forms today. Related Links 21 %
Read more →ABBVAbbVie and Allergan Receive Final European Approval to Close Pending Transaction AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today...
NORTH CHICAGO, Ill. and DUBLIN , March 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN ), a leading global pharmaceutical company, today announced that the European Commission has approved the divestitur
Read more →ABBVAbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director AbbVie issued the following forms today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER ...
NORTH CHICAGO, Ill. , March 2, 2020 /PRNewswire/ -- AbbVie issued the following forms today. Related Links 21 %
Read more →ABBVAbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in...
NORTH CHICAGO, Ill. , Feb. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA ® ) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with pla
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 21, 2020 its issued ...
NORTH CHICAGO, Ill. , Feb. 25, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 21, 2020 its issued share capital, excluding treasury shares, is comprised of 1,481,908,359 shares
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable May 15,...
NORTH CHICAGO, Ill. , Feb. 20, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable May 15, 2020 to stockholders of record at the close of business on April 15, 2020 .
Read more →ABBVAbbVie to Present at the Cowen 40th Annual Health Care Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Cowen 40th Annual Health Care Conference on...
NORTH CHICAGO, Ill. , Feb. 19, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Cowen 40 th Annual Health Care Conference on Wednesday, March 4 , 2020. Michael Severino , M.D., vice chairman and president and Ro
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 17, 2020 its issued ...
NORTH CHICAGO, Ill. , Feb. 19, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 17, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,512,883 shares
Read more →ABBVAbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9th Annual Global Healthcare Conference...
NORTH CHICAGO, Ill. , Feb. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9 th Annual Global Healthcare Conference on Tuesday, February 25. Michael Severino , M.D., vice chairman and president
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2019. Our strong performance this quarter...
NORTH CHICAGO, Ill., Feb. 7, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter and full year ended December 31, 2019. "Our strong performance this quarter completes another excellent year for AbbVie," said Richard A. Gonzalez , chairman
Read more →ABBVRINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1...
NORTH CHICAGO, Ill. , Feb. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. In this study, both doses of RINVOQ TM (upadacitinib; 15 mg and 30 m
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 3, 2020 its issued...
NORTH CHICAGO, Ill. , Feb. 5, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 3, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,156,683 shares o
Read more →ABBVAbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human...
NORTH CHICAGO, Ill. , Jan. 31, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a change to
Read more →ABBVAbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use...
"The positive CHMP opinion for this new indication in chronic lymphocytic leukemia is an important step forward for patients and underscores the growing utility of VENCLYXTO in treating this common blood cancer," said Neil Gallagher , M.D., Ph.D., chief medical officer and vice p
Read more →ABBVAbbVie Anuncia Aprovação da ANVISA para VENCLEXTA™ (venetoclax) como Tratamento Livre de Quimioterapia e Duração Fixa para Pacientes com Leucemia Linfocítica Crônica (LLC) sem Tratamento Prévio A aprovação foi baseada no estudo CLL 14 – um estudo de fase 3 que avaliou VENCLEXTA, em combinação com obinutuzumabe, como um tratamento oral, sem...
SÃO PAULO, 29 de janeiro de 2020 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global baseada em pesquisa e desenvolvimento, anunciou a aprovação, pela agência regulatória ANVISA, de VENCLEXTA (venetoclax), em combinação com obinutuzumabe, para tratamento de p
Read more →ABBVAbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today...
NORTH CHICAGO, Ill. and DUBLIN , Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN ), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements to dive
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 20, 2020 its issued...
NORTH CHICAGO, Ill. , Jan. 22, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 20, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,155,708 shares
Read more →ABBVNew Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI™ met both primary and all ranked secondary...
NORTH CHICAGO, Ill. , Jan. 14, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that SKYRIZI ™ met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx ® in a head-to-head P
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on...
NORTH CHICAGO, Ill. , Jan. 13, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on Friday, February 7, 2020 before the market opens. AbbVie will host a live webcast
Read more →ABBVAbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the creation of a new global business, Allergan Aesthetics,...
NORTH CHICAGO, Ill. , Jan. 8, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, ef
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 6, 2020 its issued...
NORTH CHICAGO, Ill. , Jan. 8, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 6, 2020 its issued share capital, excluding treasury shares, is comprised of 1,478,912,545 shares of
Read more →ABBVAbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 38th Annual J.P. Morgan Healthcare Conference on...
NORTH CHICAGO, Ill. , Jan. 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 . Richard A. Gonzalez , chairman and chief executive of
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 18, 2019 its issued ...
NORTH CHICAGO, Ill. , Dec. 20, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 18, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,875,921 shares
Read more →ABBVAbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved RINVOQ™...
NORTH CHICAGO, Ill. , Dec. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved RINVOQ ™ (upadacitinib) for the treatment of adult patients with moderate to severe active r
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 9, 2019 its issued...
NORTH CHICAGO, Ill. , Dec. 11, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 9, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,867,665 shares
Read more →ABBVAbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical...
NORTH CHICAGO, Ill. and LA JOLLA, Calif. , Dec. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to d
Read more →ABBVNew Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting...
NORTH CHICAGO, Ill. , Dec. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCL
Read more →ABBVIMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical...
NORTH CHICAGO, Ill. , Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, 1 evaluating IMBRUVICA ® (ibrutinib) in combination with VENCLEXTA ® /VENCLY
Read more →ABBVExtended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3...
NORTH CHICAGO, Ill. , Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research G
Read more →ABBVMore than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier...
NORTH CHICAGO, Ill. , Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA ® (ibrutinib) monotherapy compared to later lines of therapy
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 25, 2019 its issued ...
NORTH CHICAGO, Ill. , Nov. 27, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 25, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,862,394 shares
Read more →ABBVAbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, ...
NORTH CHICAGO, Ill. , Nov. 21, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, will be presented during the upcoming American Society of Hematology (ASH) An
Read more →ABBVAbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes AbbVie Inc. (NYSE:ABBV) ( AbbVie ) announced today the extension of the expiration date of the offers to exchange (each, an Exchange Offer and,...
NORTH CHICAGO, Ill. , Nov. 18, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV ) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain se
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 11, 2019 its issued ...
NORTH CHICAGO, Ill. , Nov. 13, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 11, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,830,254 shares
Read more →ABBVAbbVie Prices $30 Billion of Senior Unsecured Notes
AbbVie Prices $30 Billion of Senior Unsecured Notes NORTH CHICAGO, III., Nov. 12, 2019 - AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that it has priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal a
Read more →ABBVNew Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which ...
NORTH CHICAGO, Ill. , Nov. 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult patients with active ankylosing spondylitis (AS) treated
Read more →ABBVAbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA)...
NORTH CHICAGO, Ill. , Nov. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA ® (ibrutinib) in co
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 6, 2019 its issued...
NORTH CHICAGO, Ill. , Nov. 8, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 6, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,830,254 shares o
Read more →ABBVto AbbVie's Current Report on Form 8-K filed
TABLE OF CONTENTS UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 AND SEPTEMBER 30, 2018 PART I. FINANCIAL INFORMATION CONSOLIDATED BALANCE SHEETS (Unaudited; in millions, except par value) See accompanying
Read more →ABBVAbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes
AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes NORTH CHICAGO, Ill., Nov. 7, 2019 - AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that the requisite number of consents have been received to adopt certain propos
Read more →ABBVSOURCES AND USES OF FUNDS AND PRO FORMA DEBT The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Acquisition, assuming they occurred on
SOURCES AND USES OF FUNDS AND PRO FORMA DEBT The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Acquisition, assuming they occurred on September 30, 2019, and based on estimated amounts outstanding on
Read more →ABBVAbbVie Announces Launch of Private Offering of Senior Unsecured Notes AbbVie Inc. (NYSE:ABBV) ( AbbVie ) announced today that it has launched a private offering (the Offering ) of senior unsecured notes (the Notes )....
NORTH CHICAGO, Ill. , Nov. 6, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV ) ("AbbVie") announced today that it has launched a private offering (the "Offering") of senior unsecured notes (the "Notes"). The Offering is being conducted in connection with AbbVie's previously announ
Read more →ABBVAbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of RINVOQ™...
NORTH CHICAGO, Ill. , Nov. 4, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA® (adalimumab) and SKYRIZI™ (risankizumab) at the 2019 American
Read more →ABBVAbbVie Reports Third-Quarter 2019 Financial Results
AbbVie Reports Third-Quarter 2019 Financial Results NORTH CHICAGO, Ill., November 1, 2019 - AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2019. "Strong performance from our Immunology and Hematologic Oncology portfolios led our growth
Read more →ABBVAbbVie Reports Third-Quarter 2019 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2019. Strong performance from our Immunology and...
NORTH CHICAGO, Ill., Nov. 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2019. "Strong performance from our Immunology and Hematologic Oncology portfolios led our growth this quarter. We are also making excellen
Read more →ABBVRINVOQ™ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line data from the SELECT-PsA 2 Phase 3 study....
NORTH CHICAGO, Ill. , Oct. 31, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both doses of RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 28, 2019 its issued...
NORTH CHICAGO, Ill. , Oct. 30, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 28, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,821,109 shares
Read more →ABBVAbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the launch of Let Me Be Clear, an empowerment platform for...
NORTH CHICAGO, Ill. , Oct. 29, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the launch of Let Me Be Clear , an empowerment platform for people living with psoriasis. The initiative, which launches on World Psoriasis
Read more →ABBVAbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes
AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes NORTH CHICAGO, Ill., Oct. 25, 2019 - AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the commencement, in connection with its previously announced acquisition of Allergan plc (NYSE:A
Read more →ABBVAbbVie to Present at the Wolfe Research Inaugural Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Wolfe Research Inaugural Healthcare Conference on...
NORTH CHICAGO, Ill. , Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Wolfe Research Inaugural Healthcare Conference on Wednesday, November 6. Richard A. Gonzalez , chairman and chief executive officer
Read more →ABBVAbbVie Announces Collaboration with Cystic Fibrosis Foundation AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation, announced today a strategic collaboration ...
NORTH CHICAGO, Ill. , Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation, announced today a strategic collaboration in which AbbVie will develop a cystic fibrosis transmembrane conductance regu
Read more →ABBVAbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for...
NORTH CHICAGO, Ill. , Oct. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ ™ (u
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 14, 2019 its issued...
NORTH CHICAGO, Ill. , Oct. 16, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 14, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,820,152 shares
Read more →ABBVAbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and...
NORTH CHICAGO, Ill. , Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult patients with moderate
Read more →ABBVAbbVie to Host Third-Quarter 2019 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1...
NORTH CHICAGO, Ill. , Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market opens. AbbVie will host a live webcast of the earnings confer
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 30, 2019 its...
NORTH CHICAGO, Ill. , Oct. 2, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 30, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,782,106 shares
Read more →ABBVAbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE: AGN) have each...
NORTH CHICAGO, Ill. , Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE: AGN ) have each received a Request for Additional Information (Second Request) from the Fede
Read more →ABBVUpadacitinibe, inibidor oral da JAK da AbbVie, é aprovado pelo FDA (EUA) para o tratamento de artrite reumatoide moderada a grave A AbbVie (NYSE: ABBV), companhia biofarmacêutica global baseada em pesquisa, anunciou a aprovação pelo FDA de upadacitinibe, um inibidor oral da...
SÃO PAULO, 27 de setembro de 2019 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global baseada em pesquisa, anunciou a aprovação pelo FDA de upadacitinibe, um inibidor oral da Janus Kinase 1 (JAK1), de dose única diária (15 mg), para o tratamento de adultos co
Read more →ABBVAbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted...
NORTH CHICAGO, Ill. , Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET ® (glecaprevir/pibrentasvir) to shorten the once-daily tr
Read more →ABBVAbbVie Announces Public Voting Open for the 2019 AbbVie CF Scholarship Thriving Student Awards, Given to Two Exceptional Students Living with Cystic Fibrosis AbbVie, a research-based global biopharmaceutical company, today announced the start of its public voting period for the 2019 Thriving Undergraduate...
NORTH CHICAGO, Ill. , Sept. 25, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced the start of its public voting period for the 2019 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships
Read more →ABBVAbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders® AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from...
NORTH CHICAGO, Ill. , Sept. 23, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from two late-breaking abstracts, including final data from the Phase 1b study eval
Read more →ABBVAbbVie Inc. - Despatch of Option Holder Proposal Letters In accordance with Rule 15(c) of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. ( AbbVie ) and Allergan plc ( Allergan )...
NORTH CHICAGO, Ill. , Sept. 20, 2019 /PRNewswire/ -- In accordance with Rule 15(c) of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. (" AbbVie ") and Allergan plc (" Allergan ") announce that letters dated 20 September 2019 containing details of the proposal
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 16, 2019 its...
NORTH CHICAGO, Ill. , Sept. 18, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 16, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,779,037 shar
Read more →ABBVThe Directors AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064 United States Morgan Stanley & Co International plc 25 Cabot Square Canary Wharf London E14 4QA 16 September 2019 Dear Ladies and Gentlemen AbbVie I
1 North Waukegan Road North Chicago, IL 60064 Morgan Stanley & Co International plc 25 Cabot Square 16 September 2019 Dear Ladies and Gentlemen AbbVie Inc. Profit Forecast We report on the profit forecasts comprising the statements by AbbVie Inc. (" AbbVie ") and its subsi
Read more →ABBVINDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Reports of Independent Registered Public Accounting Firm 2 Consolidated Balance Sheets of Allergan plc as of
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Allergan plc Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Allergan plc and i
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable November 15,...
NORTH CHICAGO, Ill. , Sept. 6, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable November 15, 2019 to stockholders of record at the close of business on October 15, 2019 .
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 2, 2019 its issued ...
NORTH CHICAGO, Ill. , Sept. 4, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 2, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,773,465 shares
Read more →ABBVAbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program AbbVie (NYSE: ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line...
NORTH CHICAGO, Ill. , Aug. 29, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated n
Read more →ABBVAbbVie to Present at the Morgan Stanley Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare...
NORTH CHICAGO, Ill. , Aug. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17 th Annual Global Healthcare Conference on Tuesday, September 10 , 2019. Richard A. Gonzalez , chairman and chief
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 19, 2019 its issued...
NORTH CHICAGO, Ill. , Aug. 21, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 19, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,768,075 shares o
Read more →ABBVAbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
NORTH CHICAGO, Ill. , Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibito
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 5, 2019 its issued...
NORTH CHICAGO, Ill. , Aug. 7, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 5, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,483,918 shares of
Read more →ABBVAbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today...
NORTH CHICAGO, Ill. , Aug. 5, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug A
Read more →ABBVAbbVie Reports Second-Quarter 2019 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2019. We continue to see strong momentum in our business, as we ...
NORTH CHICAGO, Ill., July 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2019. "We continue to see strong momentum in our business, as we delivered revenue and adjusted EPS ahead of our expectations for the quarter
Read more →ABBVAbbVie Reports Second-Quarter 2019 Financial Results
AbbVie Reports Second-Quarter 2019 Financial Results NORTH CHICAGO, Ill., July 26, 2019 - AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2019. "We continue to see strong momentum in our business, as we delivered revenue and adjusted EPS ahe
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 22, 2019 its issued...
NORTH CHICAGO, Ill. , July 24, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 22, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,481,177 shares of
Read more →ABBVAbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel...
NORTH CHICAGO, Ill. , July 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that it has acquired Seattle -based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the tre
Read more →ABBVAbbVie to Host Second-Quarter 2019 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26...
NORTH CHICAGO, Ill. , July 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before the market opens. AbbVie will host a live webcast of the earnings confere
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 8, 2019 its issued...
NORTH CHICAGO, Ill. , July 10, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 8, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,373,039 shares of c
Read more →ABBVAbbVie Apresenta Resultados de Vários Estudos Clínicos com Medicamentos em Fase de Pesquisa para Mais de 15 Tipos de Câncer em Encontros Médicos Internacionais A AbbVie (NYSE: ABBV), companhia biofarmacêutica global baseada em pesquisa e desenvolvimento, anunciou a apresentação de cerca de 40 abstracts de...
SÃO PAULO, 27 de junho de 2019 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global baseada em pesquisa e desenvolvimento, anunciou a apresentação de cerca de 40 abstracts de dados atualizados de seu portfólio de oncologia, compreendendo medicamentos já aprova
Read more →ABBVAbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of June 24, 2019 its issued...
NORTH CHICAGO, Ill. , June 26, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of June 24, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,365,231 shares of
Read more →ABBVAbbVie to Acquire Allergan in Transformative Move for Both Companies AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN) announced that the companies have entered into a definitive transaction agreement under which...
NORTH CHICAGO , Ill. and DUBLIN , June 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV ) and Allergan plc (NYSE: AGN ) announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a
Read more →ABBVNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.5 OF THE IRISH TAKEOVER RU
Read more →ABBVAbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted...
NORTH CHICAGO, Ill. , June 24, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluatin
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable August 15,...
NORTH CHICAGO, Ill. , June 20, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable August 15, 2019 to stockholders of record at the close of business on July 15, 2019 . Sinc
Read more →ABBVNew Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and ...
NORTH CHICAGO, Ill. , June 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily (15 mg
Read more →ABBVNew Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated...
NORTH CHICAGO, Ill. , June 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated with SKYRIZI™ (risankizumab) experienced complete skin clearance at week 94. 1
Read more →ABBVAbbVie Employees to Help Underserved Communities in Sixth-Annual Week of Possibilities AbbVie, a research-based global biopharmaceutical company, kicks off its sixth annual Week of Possibilities global employee volunteering program this ...
NORTH CHICAGO, Ill. , June 10, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, kicks off its sixth annual Week of Possibilities global employee volunteering program this week. Approximately 9,000 AbbVie employees will work with leading nonprofit gr
Read more →ABBVAbbVie to Present at the Goldman Sachs Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare...
NORTH CHICAGO, Ill. , June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019 . Michael Severino , vice chairman and president
Read more →ABBVAbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia - Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of...
- Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine - Patients treated with venetoclax plus obinutuzumab lived significantly longer without their disease progressing, and sus
Read more →ABBVAbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present more than 40 data updates across its oncology ...
NORTH CHICAGO, Ill. , May 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present more than 40 data updates across its oncology portfolio during the upcoming American Society of Clinical Oncology (ASCO) Ann
Read more →ABBVAbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin...
NORTH CHICAGO, Ill. , May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblas
Read more →ABBVAbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
NORTH CHICAGO, Ill. , May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previou
Read more →ABBVAbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the...
NORTH CHICAGO, Ill. , May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a non-exclusive license to its HUMIRA-related intelle
Read more →ABBVAbbVie to Present at the UBS Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21,...
NORTH CHICAGO, Ill. , May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Michael Severino , vice chairman and president, will present at 7:30 a.m
Read more →ABBVAbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference...
NORTH CHICAGO, Ill. , May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 . Michael Severino , vice chairman and president, will
Read more →ABBVAbbVie apresenta Resultados Financeiros do primeiro trimestre de 2019 A AbbVie (NYSE:ABBV), companhia biofarmacêutica global, anunciou os resultados financeiros do T1 2019, encerrado em 31 de março de 2019. O anúncio...
SÃO PAULO, 30 de abril de 2019 /PRNewswire/ -- A AbbVie (NYSE: ABBV ), companhia biofarmacêutica global, anunciou os resultados financeiros do T1 2019, encerrado em 31 de março de 2019. O anúncio foi feito em Chicago , EUA, sede mundial da companhia. "Estamos vivenciando o iníci
Read more →ABBVEuropean Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved SKYRIZI™...
NORTH CHICAGO, Ill. , April 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult p
Read more →ABBVAbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present six abstracts, ...
NORTH CHICAGO, Ill. , April 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present six abstracts, including data evaluating investigational medicines from its neuroscience pi
Read more →ABBVAbbVie Reports First -Quarter 2019 Financial Results Reports First -Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent First -Quarter Net Revenues We
AbbVie Reports First-Quarter 2019 Financial Results NORTH CHICAGO, Ill., April 25, 2019 - AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2019. "We are off to another excellent start, including first quarter sales and earnings above expectat
Read more →ABBVAbbVie Reports First-Quarter 2019 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2019. We are off to another excellent start, including first...
NORTH CHICAGO, Ill., April 25, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2019. "We are off to another excellent start, including first quarter sales and earnings above expectations," said Richard A. Gonzalez , cha
Read more →ABBVAbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
NORTH CHICAGO, Ill. , April 23, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treat
Read more →ABBVAbbVie Announces Call for Entries for the AbbVie CF Scholarship for the 2019-2020 Academic School Year AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting...
NORTH CHICAGO, Ill. , April 17, 2019 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2019-2020 academic school year. Undergraduate and graduate
Read more →ABBVAbbVie to Host First-Quarter 2019 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25...
NORTH CHICAGO, Ill. , April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens. AbbVie will host a live webcast of the earnings confe
Read more →ABBVAbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare...
NORTH CHICAGO, Ill. , March 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor,
Read more →ABBVAbbVie Donates $40 Million to Rebuild North Chicago Middle School AbbVie, a research-based global biopharmaceutical company, today announced a donation of $40 million to North Chicago Community Unit School District...
NORTH CHICAGO, Ill. , March 21, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $40 million to North Chicago Community Unit School District (CUSD) 187 to fund the rebuilding of the district's only middle school: Neal M
Read more →ABBVAbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a...
NORTH CHICAGO, Ill. , March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax (VENCLEXTA®/VE
Read more →ABBVAbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a...
NORTH CHICAGO, Ill. , March 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in combinati
Read more →ABBVAbbVie to Present at the Barclays Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday,...
NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Michael Severino , vice chairman and president, will present a
Read more →ABBVAbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for...
NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SKYRIZI™ (r
Read more →ABBVAbbVie to Present at the Cowen Health Care Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 39th Annual Cowen Health Care Conference on Tuesday,...
NORTH CHICAGO, Ill. , Feb. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 39 th Annual Cowen Health Care Conference on Tuesday, March 12, 2019 . Richard A. Gonzalez , chairman and chief executive officer,
Read more →ABBVAbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present 19 abstracts during the 2019 American Academy ...
NORTH CHICAGO, Ill. , Feb. 25, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5 , in Washington, D.C. , includ
Read more →ABBVAbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused ...
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. , Feb. 22, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR ), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neuro
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE:ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable May 15, 2019 to ...
NORTH CHICAGO, Ill. , Feb. 21, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable May 15, 2019 to stockholders of record at the close of business on April 15, 2019 . Since t
Read more →ABBVAbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted...
The NDA is supported by data from the global upadacitinib SELECT Phase 3 rheumatoid arthritis program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis across five of six Phase 3 studies. 3-7 In all SELECT Phase 3 studies, upadacitinib met all prima
Read more →ABBVAbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop ...
NORTH CHICAGO, Ill. and MENLO PARK, Calif. , Feb. 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunothe
Read more →ABBVAbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the ...
NORTH CHICAGO, Ill. , Jan. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA ® (ibrutinib) in combination with obinutuzumab (GAZYVA ® ) f
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results NORTH CHICAGO, Ill., January 25, 2019 - AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2018. "We delivered exceptional performance in 2018, including opera
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2018. We delivered exceptional performance in ...
NORTH CHICAGO, Ill., Jan. 25, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter and full year ended December 31, 2018. "We delivered exceptional performance in 2018, including operational revenue growth of more than 15 percent and EPS g
Read more →ABBVAbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial (PCYC-1137) of...
NORTH CHICAGO, Ill. , Jan. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial (PCYC-1137) of ibrutinib (IMBRUVICA ® ) in combination with chemotherapy agents nab-paclitaxel and g
Read more →ABBVAbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc. ( Tizona ), a privately held immunotherapy...
NORTH CHICAGO , Ill. and SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc. ("Tizona"), a privately held immunotherapy company, announced today that they have entered in
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2018 financial results on...
NORTH CHICAGO, Ill. , Jan. 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens. AbbVie will host a live webcast o
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food ...
NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA)
Read more →ABBVAbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37th annual J.P. Morgan Healthcare Conference on...
NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President
Read more →ABBVAbbVie Announces Executive Leadership Changes AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to...
NORTH CHICAGO, Ill. , Dec. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy. Ef
Read more →ABBVAbbVie Announces Executive Leadership Changes
AbbVie Announces Executive Leadership Changes NORTH CHICAGO, Ill., Dec. 17, 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its
Read more →ABBVAbbVie Announces $5 Billion Increase to Stock Repurchase Program The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may...
NORTH CHICAGO, Ill. , Dec. 13, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may be made from time to time at management's discretion. The stock repurchase au
Read more →ABBVPhase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the decision to stop enrollment for the TAHOE trial, a Phase...
"Patients are our first priority and we are deeply grateful to the patients and physicians who participated in this trial," said Michael Severino , M.D., executive vice president, research and development and chief scientific officer, AbbVie. "We remain committed to discovering a
Read more →ABBVIMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today shared results from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN),...
NORTH CHICAGO, Ill. , Dec. 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today shared results from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), National Cancer Institute (NCI)-sponsored, Phase 3 study (E1912) evaluating IMB
Read more →ABBVIMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from the Phase 3 iLLUMINATE (PCYC-1130) trial,...
NORTH CHICAGO, Ill. , Dec. 3, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced results from the Phase 3 iLLUMINATE (PCYC-1130) trial, evaluating the chemotherapy-free, anti-CD20 combination of IMBRUVICA ® (ibrutinib) pl
Read more →ABBVAbbVie Donates $50 Million To St. Jude Children's Research Hospital® To Expand Family-Centered Care AbbVie, a research-based global biopharmaceutical company, today announced a historic $50 million donation to St. Jude Children's Research Hospital®. ...
NORTH CHICAGO, Ill. and MEMPHIS, Tenn. , Dec. 3, 2018 /PRNewswire/ -- AbbVie , a research-based global biopharmaceutical company, today announced a historic $50 million donation to St. Jude Children's Research Hospital ® . This donation will enable St. Jude to accelerate plans to
Read more →ABBVIMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the results of up to seven years of clinical trial follow-up...
NORTH CHICAGO, Ill. , Dec. 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the results of up to seven years of clinical trial follow-up for IMBRUVICA ® (ibrutinib) monotherapy in chronic lymphocytic leukemia/small l
Read more →ABBVAbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of...
NORTH CHICAGO, Ill. , Dec. 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA ® or VENCLYXTO ® ) in combination with rituximab (VenR). The resu
Read more →ABBVAbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the...
NORTH CHICAGO, Ill. , Nov. 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates t
Read more →ABBVAbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted...
NORTH CHICAGO, Ill. , Nov. 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA ® (venetoclax tablets) in combination with a
Read more →ABBVUPDATED AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral...
NORTH CHICAGO, Ill. , Nov. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upc
Read more →ABBVAbbVie Donates $55 Million to Three Education Nonprofits Supporting Underserved Youth in Chicago & Across America AbbVie, a research-based global biopharmaceutical company, today announced a $55 million total donation to three leading nonprofits working to...
NORTH CHICAGO, Ill. , Nov. 16, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a $55 million total donation to three leading nonprofits working to address the achievement gap for children in underserved areas: Communities In Schools
Read more →ABBVAbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today...
NORTH CHICAGO, Ill. , Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today presented for the first time additional results from two replicate pivotal Phase 3
Read more →ABBVAbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus...
NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET™ (glecaprevir/pibrentasvir), in treatment-naïve patients
Read more →ABBVAbbVie to Present at the Evercore ISI Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday,...
NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday, November 27, 2018. Bill Chase , executive vice president, finance and administration
Read more →ABBVAbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from two studies that assessed HCV...
NORTH CHICAGO, Ill. , Nov. 9, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data from two studies that assessed HCV screening and diagnosis practices and linkage to care in the United States (US) at T
Read more →ABBVAbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the...
NORTH CHICAGO, Ill. , Nov. 6, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates
Read more →ABBVAbbVie Reports Third -Quarter 2018 Financial Results Reports Third -Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent Delivers Third -Quarter Net Re
AbbVie Reports Third-Quarter 2018 Financial Results NORTH CHICAGO, Ill., November 2, 2018 - AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2018. "We delivered another exceptional quarter, with results well ahead of our expectations, inc
Read more →ABBVAbbVie Reports Third-Quarter 2018 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2018. We delivered another exceptional quarter, with...
NORTH CHICAGO, Ill., Nov. 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2018. "We delivered another exceptional quarter, with results well ahead of our expectations, including operational revenue growth above 1
Read more →ABBVAbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II...
NORTH CHICAGO, Ill. , Nov. 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II variation application for VENCLYXTO ® (venetoclax) in combination with rituximab
Read more →ABBVAbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized clinical...
NORTH CHICAGO, Ill. , Oct. 31, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized clinical trial evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chloramb
Read more →ABBVAbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial...
NORTH CHICAGO, Ill. , Oct. 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and de
Read more →ABBVAbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from the ongoing Phase 3...
NORTH CHICAGO, Ill. , Oct. 23, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from the ongoing Phase 3 SELECT-MONOTHERAPY trial evaluating upadacitinib (15 mg and 30 mg, once-daily),
Read more →ABBVPositive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3...
NORTH CHICAGO, Ill. , Oct. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b /3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhib
Read more →ABBVAbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin...
NORTH CHICAGO, Ill. and WALTHAM, Mass. , Oct. 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered int
Read more →ABBVAbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi AbbVie (NYSE: ABBV) announced today global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed...
NORTH CHICAGO, Ill. , Oct. 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie wil
Read more →ABBVAbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its...
NORTH CHICAGO, Ill. , Oct. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for IMBRUVICA ® (
Read more →ABBVAbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present new data across investigational medicines and ...
NORTH CHICAGO, Ill. , Oct. 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present new data across investigational medicines and HUMIRA ® (adalimumab) at United European Gastroenterology (UEG) Week 2018 fro
Read more →ABBVAbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today a global resolution of all intellectual property-related...
NORTH CHICAGO, Ill. , Oct. 11, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product. Under the
Read more →ABBVAbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of upadacitinib,...
NORTH CHICAGO, Ill. , Oct. 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of upadacitinib, an investigational oral JAK1-selective inhibitor, and HUMIRA® (adalimumab) at th
Read more →ABBVAbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization's...
NORTH CHICAGO, Ill. , Sept. 21, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization's efforts to alleviate the financial burden of cancer on pediatric patients and fam
Read more →ABBVAbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use...
In 2016, VENCLYXTO was approved by the EC as a monotherapy for the treatment of R/R CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, and for the treatment of CLL in the absence of 17p
Read more →ABBVAbbVie to Host Third-Quarter 2018 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2...
NORTH CHICAGO, Ill. , Sept. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2 2018 , before the market opens. AbbVie will host a live webcast of the earnin
Read more →ABBVAbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including...
NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data ev
Read more →ABBVAbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 ...
NORTH CHICAGO, Ill. , Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) in
Read more →ABBVMinimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the...
NORTH CHICAGO, Ill. , Sept. 11, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA ® (venetoclax tablets) in combination with rituximab to i
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018...
NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 . Since
Read more →ABBVPublic Voting is Open for the 2018 AbbVie CF Scholarship Thriving Student Awards, Given to Two Exceptional Students Living with Cystic Fibrosis AbbVie, a research-based global biopharmaceutical company, today announced its annual call for the public to vote for students living with cystic...
NORTH CHICAGO, Ill. , Sept. 5, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced its annual call for the public to vote for students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive s
Read more →ABBVAbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new data across investigational...
NORTH CHICAGO, Ill. , Sept. 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA ® (adalimumab) at the 27 th European Academy of Dermatology and V
Read more →ABBVAbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16th Annual Global Healthcare...
NORTH CHICAGO, Ill. , Aug. 28, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16 th Annual Global Healthcare Conference on Wednesday, September 12, 2018. Bill Chase , executive vice president an
Read more →ABBVAbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
NORTH CHICAGO, Ill. , Aug. 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA ® (ibrutinib) plus rituximab (RITUXAN ® ) for the treatment of adult pa
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced...
NORTH CHICAGO, Ill. , Aug. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed
Read more →ABBVAbbVie Announces $100 Million Donation to Ronald McDonald House Charities to Support Hospitalized Children and Their Families AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to Ronald McDonald House Charities (RMHC). This ...
NORTH CHICAGO, Ill. , Aug. 20, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to Ronald McDonald House Charities (RMHC). This donation, the largest single gift in RMHC's history, will provide housing and
Read more →ABBVAbbVie Reports Second -Quarter 2018 Financial Results Reports Second -Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent Delivers Second -Quarter Net
AbbVie Reports Second-Quarter 2018 Financial Results NORTH CHICAGO, Ill., July 27, 2018 - AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2018. "We are extremely pleased with the strong momentum of our business in the quarter and progress ye
Read more →ABBVAbbVie Reports Second-Quarter 2018 Financial Results AbbVie (NYSE: ABBV) announced financial results for the second quarter ended June 30, 2018. We are extremely pleased with the strong momentum of our ...
NORTH CHICAGO, Ill., July 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2018. "We are extremely pleased with the strong momentum of our business in the quarter and progress year-to-date. We've driven strong commer
Read more →ABBVAbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced...
NORTH CHICAGO, Ill. , July 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix),
Read more →ABBVAbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the...
NORTH CHICAGO, Ill. , July 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to
Read more →ABBVAbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy – Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are...
– Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy – Median survival is five to 10 months in older AML patients who are ineligible for intensive
Read more →ABBVAbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program - The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for...
- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. Fourteen Phase 3 company-sponsored studies are ongoing. - The DBL3001 study targeted a subtype
Read more →ABBVAbbVie to Host Second-Quarter 2018 Earnings Conference Call AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27,...
NORTH CHICAGO, Ill. , July 10, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018 , before the market opens. AbbVie will host a live webcast of the earning
Read more →ABBVAbbVie and Calico Announce Extension of Groundbreaking Collaboration AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , June 26, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today announced an extension of their collaboration to di
Read more →ABBVAbbVie and Calibr announce collaboration for next generation T-cell therapies AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today...
NORTH CHICAGO, Ill. and LA JOLLA, Calif. , June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed
Read more →ABBVIMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
NORTH CHICAGO, Ill. , June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for IMBRUVICA ® (ib
Read more →ABBV8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual Week of Possibilities AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual Week of Possibilities global...
NORTH CHICAGO, Ill. , June 19, 2018 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees wi
Read more →ABBVAbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis...
NORTH CHICAGO, Ill. , June 15, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018...
NORTH CHICAGO, Ill. , June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018 to stockholders of record at the close of business on July 13, 2018 . Since
Read more →ABBVAbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European...
NORTH CHICAGO, Ill. , June 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials e
Read more →ABBVAbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved,...
NORTH CHICAGO, Ill. , June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA® (venetoclax tablets) in combination with rituxim
Read more →ABBVUpadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both ...
NORTH CHICAGO, Ill. , June 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints
Read more →ABBVAbbVie Teams Up with Hidradenitis Suppurativa Patients Around the World to Raise Awareness About the Disease AbbVie, a research-based global biopharmaceutical company, today announced the launch of Voices of HS Unite, a global social media effort to connect...
NORTH CHICAGO, Ill. , June 4, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced the launch of Voices of HS Unite, a global social media effort to connect and inspire those impacted by hidradenitis suppurativa (HS), a painful, chronic,
Read more →ABBVAbbVie Announces Final Results of Tender Offer AbbVie (NYSE: ABBV) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City...
NORTH CHICAGO, Ill. , June 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . AbbVie has accepted for purchase 72,815,534 sha
Read more →ABBVPhase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study...
NORTH CHICAGO, Ill. , June 3, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA ® (ibrutinib) in combination with VENCLEXTA ® (venetoclax) i
Read more →ABBVPhase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE...
NORTH CHICAGO, Ill. , June 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA ® (ibrutinib) plus RITUXAN ® (rituximab) in
Read more →ABBVAbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from clinical trials across multiple...
NORTH CHICAGO, Ill. , May 31, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data from clinical trials across multiple blood cancers evaluating venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-
Read more →ABBVAbbVie Announces Preliminary Results of Tender Offer AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York...
NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . Based on the preliminary count by Compute
Read more →ABBVAbbVie Announces Updated Preliminary Results of Tender Offer AbbVie (NYSE: ABBV) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York...
NORTH CHICAGO, Ill. , May 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018 . This update replaces the preliminary resu
Read more →ABBVAbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39th Annual Global Healthcare...
NORTH CHICAGO, Ill. , May 29, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 . Richard A. Gonzalez , chairman and chief executi
Read more →ABBVIMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary ...
NORTH CHICAGO, Ill. , May 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluate
Read more →ABBVAbbVie dona 100 millones de dólares para reforzar el acceso a la atención médica y a la vivienda en Puerto Rico, devastado por el huracán AbbVie, una compañía biofarmacéutica global basada en la investigación, anunció hoy una donación de 100 millones de dólares a Puerto Rico, que se...
NORTH CHICAGO, Illinois , 22 de mayo de 2018 /PRNewswire-HISPANIC PR WIRE/ -- AbbVie, una compañía biofarmacéutica global basada en la investigación, anunció hoy una donación de 100 millones de dólares a Puerto Rico , que se utilizaran en proyectos específicos a través de dos org
Read more →ABBVAbbVie to Present at the Jefferies 2018 Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Jefferies 2018 Global Healthcare Conference on...
NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 . Bill Chase , executive vice president and chief financial o
Read more →ABBVAbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to two organizations, Direct Relief and Habitat ...
NORTH CHICAGO, Ill. , May 22, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to two organizations, Direct Relief and Habitat for Humanity International, to strengthen access to healthcare and housing in P
Read more →ABBVAbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data about the company's portfolio of...
NORTH CHICAGO, Ill. , May 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced it will present data about the company's portfolio of investigational oncology medicines during the American Society of Clinical Oncology (A
Read more →ABBVAbbVie to Present at the UBS Global Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 22,...
NORTH CHICAGO, Ill. , May 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 22, 2018 . Bill Chase , executive vice president and chief financial officer, will p
Read more →ABBVAbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 2018 Bank of America Merrill Lynch Health Care...
NORTH CHICAGO, Ill. , May 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 2018 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 . Richard A. Gonzalez , chairman and chief execu
Read more →ABBVAbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a marketing authorization application (MAA)...
NORTH CHICAGO, Ill. , May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational inter
Read more →ABBVAbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock AbbVie (NYSE: ABBV) announced today that it has commenced a modified Dutch auction tender offer to purchase for cash up to $7.5 billion of its...
NORTH CHICAGO, Ill. , May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that it has commenced a modified "Dutch auction" tender offer to purchase for cash up to $7.5 billion of its common stock at a price not less than $99.00 per share and not more than $114.00 per
Read more →ABBVAbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology AbbVie, a research-based global biopharmaceutical company, and Rice University today announced they have entered into a joint research collaboration...
NORTH CHICAGO, Ill. and HOUSTON , April 30, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, and Rice University today announced they have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. The research
Read more →ABBVAbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today...
NORTH CHICAGO, Ill. , April 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced that data for elagolix, an investigational, orally administered gonadotr
Read more →ABBVAbbVie Reports First-Quarter 2018 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2018. AbbVie is off to an excellent start in 2018, delivering...
NORTH CHICAGO, Ill., April 26, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2018. "AbbVie is off to an excellent start in 2018, delivering first quarter revenue and EPS growth well ahead of expectations," said Richar
Read more →ABBVAbbVie Reports First -Quarter 2018 Financial Results Reports First -Quarter Diluted EPS of $1.74 on a GAAP Basis; Adjusted Diluted EPS of $1.87 Reflects Growth of 46.1 Percent Delivers First -Quarter Net Re
AbbVie Reports First-Quarter 2018 Financial Results NORTH CHICAGO, Ill., April 26, 2018 - AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2018. "AbbVie is off to an excellent start in 2018, delivering first quarter revenue and EPS growth wel
Read more →ABBVAbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b/3 SELECT-SUNRISE...
NORTH CHICAGO, Ill. , April 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b /3 SELECT-SUNRISE clinical trial, showing that at 12 weeks, all doses of upadacitinib (7.5 mg,
Read more →ABBVAbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43rd Annual Health Care Conference on ...
NORTH CHICAGO, Ill. , April 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43 rd Annual Health Care Conference on Wednesday, May 9, 2018 . Bill Chase , executive vice president and chief fi
Read more →ABBVAbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , April 10, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced notification by the U.S. Food and Drug Administration (FDA) tha
Read more →ABBVUpadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE...
NORTH CHICAGO, Ill. , April 9, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial showing that after 12 weeks, upadacitinib (15 mg, once-daily) met
Read more →ABBVAbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis NORTH CHICAGO, Illinois, April 5, 2018 /PRNewswire/ – AbbVie (NYSE: ABBV) announced today global resolution of all intellectual property-related...
NORTH CHICAGO, Illinois , April 5, 2018 /PRNewswire/ – AbbVie (NYSE: ABBV ) announced today global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie
Read more →ABBVAbbVie is Now Accepting CF Scholarship Applications from Students with Cystic Fibrosis for 2018-2019 Academic School Year AbbVie, a global research and development-based biopharmaceutical company, today announced that the 2018 AbbVie CF Scholarship program is now...
NORTH CHICAGO, Ill. , March 28, 2018 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the 2018 AbbVie CF Scholarship program is now accepting applications for the 2018-2019 academic school year. Undergraduate and grad
Read more →ABBVAbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma AbbVie (NYSE: ABBV), a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today...
NORTH CHICAGO, Ill. and NORTH HOLLYWOOD, Calif. , March 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to condu
Read more →ABBVAbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , March 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met
Read more →ABBVJulianne Hough Encourages Women to Speak Up for Endo during Endometriosis Awareness Month AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, announced that actress, dancer and Emmy Award-winning...
NORTH CHICAGO, Ill. , March 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development based global biopharmaceutical company, announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is encouraging women to discuss symptoms of endometriosi
Read more →ABBVAbbVie to Present at the Barclays Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Thursday, March 15, 2018. Bill Chase, executive vice president...
NORTH CHICAGO, Ill. , Feb. 26, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Barclays Global Healthcare Conference on Thursday, March 15, 2018 . Bill Chase , executive vice president and chief financial officer, will present at 8 a.m. Central time . A live au
Read more →ABBVAbbVie to Present at the Cowen and Company 38th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018. Bill Chase, executive...
NORTH CHICAGO, Ill. , Feb. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 . Bill Chase , executive vice president and chief financial officer will present at 7:00 a.m. Central
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , Feb. 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met it
Read more →ABBVAbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company, today...
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass. , Feb. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strat
Read more →ABBVAbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ...
NORTH CHICAGO, Ill. , Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety a
Read more →ABBVAbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b...
NORTH CHICAGO, Ill. , Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-s
Read more →ABBVAbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced new results from the double-blinded extension ...
NORTH CHICAGO, Ill. , Feb. 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced new results from the double-blinded extension phase of the Phase 2 CELEST study, showing that many patients treated with up
Read more →ABBVAbbVie Increases Dividend and Announces New Stock Repurchase Program The board of directors of AbbVie (NYSE: ABBV) increased the company's quarterly cash dividend by 35 percent from $0.71 per share to $0.96 per share...
NORTH CHICAGO, Ill. , Feb. 15, 2018 /PRNewswire/ -- The board of directors of AbbVie (NYSE: ABBV ) increased the company's quarterly cash dividend by 35 percent from $0.71 per share to $0.96 per share and authorized a new $10 billion stock repurchase program. The cash dividend i
Read more →ABBVAbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data...
NORTH CHICAGO, Ill. , Feb. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA ® (adalimumab) at the 2018 American Aca
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results Reports Full-Year Diluted EPS of $3.30 on a GAAP Basis; Adjusted Diluted EPS of $5.60 Reflects Growth of 16.2 Percent Delivers Full-Year Ne
AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results NORTH CHICAGO, Ill., January 26, 2018 - AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December 31, 2017. "2017 reflects another year of top-tier performance, demonstrating the stron
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results AbbVie (NYSE:ABBV) announced financial results for the fourth quarter ended December 31, 2017. 2017 reflects another year of top-tier performance,...
NORTH CHICAGO, Ill., Jan. 26, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter ended December 31, 2017. "2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonzalez ,
Read more →ABBVAbbVie to Host Fourth-Quarter 2017 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter 2017 financial results on Friday, Jan. 26, 2018, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , Jan. 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter 2017 financial results on Friday, Jan. 26, 2018 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eas
Read more →ABBVAbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA)...
NORTH CHICAGO, Ill. , Jan. 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the investigational, once-daily ora
Read more →ABBVAbbVie to Present at the 36th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018. Richard A. Gonzalez,...
NORTH CHICAGO, Ill. , Dec. 20, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 . Richard A. Gonzalez , chairman and chief executive officer, will present at 10:30 a.m. Central time . A
Read more →ABBVAbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from the Phase 3...
NORTH CHICAGO, Ill. , Dec. 20, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. This ongoing study evaluated upadacitinib (AB
Read more →ABBVAbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 4, 2018....
NORTH CHICAGO, Ill. , Dec. 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 4, 2018 . Richard A. Gonzalez, chairman and chief executive officer, will present at 10
Read more →ABBVAbbVie Anuncia Estudo de Fase 3 com Venetoclax, em Combinação com Rituximabe, Atinge Objetivo Primário para Tratamento da Leucemia Linfoide Crônica - Resultados do estudo MURANO, Fase 3, foram apresentados pela primeira vez, durante o 59o Encontro Anual da Sociedade Americana de Hematologia (ASH...
- Resultados do estudo MURANO, Fase 3, foram apresentados pela primeira vez, durante o 59 o Encontro Anual da Sociedade Americana de Hematologia (ASH – American Society of Hematology), realizado em Atlanta , EUA (9-12 de dezembro, 17) - A sobrevida livre de progressão da doença
Read more →ABBVAbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety ...
NORTH CHICAGO, Ill. , Dec. 12, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Ph
Read more →ABBVIMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib)...
NORTH CHICAGO, Ill. , Dec. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib) in patients with chronic graft-versus-host disease (cGVHD), a potentially life-
Read more →ABBVIMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's...
NORTH CHICAGO, Ill. , Dec. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory (R/R) mantle cell lympho
Read more →ABBVIMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the Phase 3 iNNOVATE (PCYC-1127) trial evaluating IMBRUVICA® (ibrutinib) in...
NORTH CHICAGO, Ill. , Dec. 5, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the Phase 3 iNNOVATE (PCYC-1127) trial evaluating IMBRUVICA® (ibrutinib) in combination with rituximab in patients with treatment-naïve and previously-trea
Read more →ABBVRisankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from IMMhance, the...
NORTH CHICAGO, Ill. , Dec. 4, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced positive top-line results from IMMhance, the fourth pivotal Phase 3 clinical trial evaluating risankizumab (150 mg) for the
Read more →ABBVPhase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology (ASH) ...
NORTH CHICAGO, Ill. , Nov. 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets
Read more →ABBVAbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference AbbVie (NYSE: ABBV) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. Bill Chase,...
NORTH CHICAGO, Ill. , Nov. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017 . Bill Chase , executive vice president and chief financial officer, will present at 7 a.m. Centra
Read more →ABBVHackathon, na Campus Party™ Minas Gerais, Premia Soluções Inovadoras em Saúde em Benefício de Toda Sociedade A biofarmacêutica global AbbVie patrocina, em parceria com a Campus Party™, o Hackathon O Cidadão como Protagonista da Saúde . O Hackathon acontece...
SÃO PAULO, 3 de novembro de 2017 /PRNewswire/ -- A biofarmacêutica global AbbVie patrocina, em parceria com a Campus Party™, o Hackathon "O Cidadão como Protagonista da Saúde". O Hackathon acontece nos dias 3 e 4 de novembro, em Belo Horizonte , e a meta é incentivar os participa
Read more →ABBVAbbVie to Present at the Jefferies 2017 London Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Nov. 3, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017 . Bill Chase , executive vice president and chief financial officer, will present at 3:20 a.m. Central time . A
Read more →ABBVAbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , Nov. 1, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced detailed results from two replicate Phase 3 extension studies eva
Read more →ABBVAbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , Oct. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced that the U.S. Food and Drug Administration (FDA) has grant
Read more →ABBVAbbVie Reports Third -Quarter 2017 Financial Results Reports Third -Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41 , Reflecting Growth of 16.5 Percent Delivers Third -Quarter Ne
AbbVie Reports Third-Quarter 2017 Financial Results NORTH CHICAGO, Ill., October 27, 2017 - AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2017. "We are pleased with the significant progress we have made with our strategic priorities, i
Read more →ABBVAbbVie Increases Quarterly Dividend by 11 Percent The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 11 percent from $0.64 per share to $0.71 per...
NORTH CHICAGO, Ill. , Oct. 27, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) increased the company's quarterly cash dividend by 11 percent from $0.64 per share to $0.71 per share. The cash dividend is payable February 15, 2018 to shareholders of record
Read more →ABBVAbbVie Reports Third-Quarter 2017 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2017. We are pleased with the significant progress we have...
NORTH CHICAGO, Ill., Oct. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2017. "We are pleased with the significant progress we have made with our strategic priorities, including the recent settlement of our HU
Read more →ABBVRisankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal...
NORTH CHICAGO, Ill. , Oct. 26, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleuki
Read more →ABBVAbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that data from 38 abstracts of HUMIRA®...
NORTH CHICAGO, Ill. , Oct. 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced that data from 38 abstracts of HUMIRA ® (adalimumab) and the company's portfolio of investigational immunology medicines wi
Read more →ABBVAlector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease AbbVie (NYSE:ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, today announced a global strategic...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, today announced a global strategic collaboration to develop and commercialize medici
Read more →ABBVAbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have en
Read more →ABBVAbbVie to Present at the 2017 Credit Suisse Health Care Conference AbbVie (NYSE: ABBV) will participate in the 2017 Credit Suisse Health Care Conference on Wednesday, November 8, 2017. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Oct. 18, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 2017 Credit Suisse Health Care Conference on Wednesday, November 8, 2017 . Bill Chase , executive vice president and chief financial officer, will present at 12 p.m. Central time . A
Read more →ABBVAbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017 AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating...
NORTH CHICAGO, Ill. , Oct. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating MAVYRET™ (glecaprevir/pibrentasvir), its once-daily, ribavirin-free treatment for
Read more →ABBVAbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, today announced a...
NORTH CHICAGO, Ill. and OTTAWA, Ontario and NEW YORK , Oct. 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, today announced a research, option and license agreement whereby AbbVi
Read more →ABBVAbbVie to Host Third-Quarter 2017 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2017 financial results on Friday, Oct. 27, 2017, before the market opens. AbbVie will host a live ...
NORTH CHICAGO, Ill. , Oct. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2017 financial results on Friday, Oct. 27, 2017 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 am Easter
Read more →ABBVAbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen AbbVie (NYSE: ABBV) announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar...
NORTH CHICAGO, Ill. , Sept. 28, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie will
Read more →ABBVAbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour...
NORTH CHICAGO, Ill. , Sept. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved MAVIRET™ (glecaprevir/pibrentasvir), a once-daily
Read more →ABBVAbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of...
NORTH CHICAGO, Ill. and NEW YORK , Sept. 22, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol
Read more →ABBVAbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of...
NORTH CHICAGO, Ill. , Sept. 18, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in combination with Rituxan ® (rituximab) met
Read more →ABBVAbbVie Announces 25th Annual Cystic Fibrosis Scholarship Program Including 2017 Thriving Student Scholarship Contest and Blogger's Choice Award AbbVie, a research and development based global biopharmaceutical company, today announced the launch of the 2017 Thriving Student Scholarship...
NORTH CHICAGO, Ill. , Sept. 13, 2017 /PRNewswire/ -- AbbVie, a research and development based global biopharmaceutical company, today announced the launch of the 2017 Thriving Student Scholarship contest and the Blogger's Choice Award. These scholarships will each award a total o
Read more →ABBVAbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 3...
NORTH CHICAGO, Ill. , Sept. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigatio
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Nov. 15, 2017...
NORTH CHICAGO, Ill. , Sept. 8, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Nov. 15, 2017 to stockholders of record at the close of business on Oct. 13, 2017 . Since
Read more →ABBVAbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year AbbVie, a global biopharmaceutical company, achieved the top biotech industry sector ranking on the Dow Jones Sustainability Index (DJSI). Since...
CHICAGO , Sept. 7, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, achieved the top biotech industry sector ranking on the Dow Jones Sustainability Index (DJSI). Since AbbVie's founding in 2013, the company has been listed on both DJSI World and DJSI North Americ
Read more →ABBVAbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 2b...
NORTH CHICAGO, Ill. , Sept. 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 2b randomized, placebo-controlled, dose-ranging study of upadacitinib (ABT-494), a
Read more →ABBVAbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 15th Annual Global Health Care Conference on Tuesday, Sept. 12, 2017. Richard A. Gonzalez, ...
NORTH CHICAGO, Ill. , Sept. 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley 15 th Annual Global Health Care Conference on Tuesday, Sept. 12, 2017 . Richard A. Gonzalez , chairman and chief executive officer, will present at 10:10 a.m. Central t
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...
NORTH CHICAGO, Ill. , Sept. 6, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced that it has submitted a New Drug Application (NDA) to the U.S. F
Read more →ABBVAbbVie e Sociedades Médicas lançam campanha para incentivar diagnóstico dos quase 1,5 milhão de brasileiros que não sabem que têm Hepatite C Com objetivo de aumentar o diagnóstico de hepatite C, e encaminhamento dos pacientes com a doença para tratamento adequado, a companhia...
SÃO PAULO, 28 de agosto de 2017 /PRNewswire/ -- Com objetivo de aumentar o diagnóstico de hepatite C, e encaminhamento dos pacientes com a doença para tratamento adequado, a companhia biofarmacêutica AbbVie, em parceria com as Sociedades Brasileiras de Infectologia e de Hepatolog
Read more →ABBVAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™...
NORTH CHICAGO, Ill. , Aug. 3, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chron
Read more →ABBVAbbVie Reports Second-Quarter 2017 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2017. We are pleased with the continued strength of our...
NORTH CHICAGO, Ill., July 28, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2017. "We are pleased with the continued strength of our business. Our second quarter financial results reflected strong commercial and opera
Read more →ABBVTratamento para Hepatite C da AbbVie Estará Disponível pelo SUS O tratamento para Hepatite C da AbbVie, que combina os agentes antivirais ombitasvir, veruprevir/ritonavir e dasabuvir, estará disponível pelo SUS...
SÃO PAULO, 28 de julho de 2017 /PRNewswire/ -- O tratamento para Hepatite C da AbbVie, que combina os agentes antivirais ombitasvir, veruprevir/ritonavir e dasabuvir, estará disponível pelo SUS –Sistema Único de Saúde, de acordo com o anúncio feito ontem pelo Ministério da Saúde
Read more →ABBVAbbVie Reports Second -Quarter 2017 Financial Results Reports Second -Quarter Diluted EPS of $1.19 on a GAAP Basis; Adjusted Diluted EPS of $1.42 , Reflecting Growth of 12.7 Percent Delivers Second -Quarter
AbbVie Reports Second-Quarter 2017 Financial Results NORTH CHICAGO, Ill., July 28, 2017 - AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2017. "We are pleased with the continued strength of our business. Our second quarter financial results
Read more →ABBVEuropean Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for...
NORTH CHICAGO, Ill. , July 28, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for MAVIRET® (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adult
Read more →ABBVAbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
NORTH CHICAGO, Ill. , July 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adali
Read more →ABBVAbbVie to Host Second-Quarter 2017 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2017 financial results on Friday, July 28, 2017, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2017 financial results on Friday, July 28, 2017 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 am East
Read more →ABBVAbbVie é a companhia farmacêutica com melhor reputação, segundo estudo do Reputation Institute Reputation Institute, com sede em Boston e mais de 20 anos em pesquisa de reputação corporativa em todo o mundo, apurou a biofarmacêutica AbbVie como ...
SÃO PAULO, 28 de junho de 2017 /PRNewswire/ -- Reputation Institute, com sede em Boston e mais de 20 anos em pesquisa de reputação corporativa em todo o mundo, apurou a biofarmacêutica AbbVie como a companhia com melhor reputação, no setor farmacêutico, no mundo. A pesquisa (Glob
Read more →ABBVFuncionários da AbbVie Doam Mais de 26.000 Horas de Trabalho em uma Única Semana em Benefício de Comunidades ao Redor do Mundo Hoje, a biofarmacêutica global AbbVie celebra sua quarta edição anual da Semana de Possibilidades , em que mais de 6.000 colaboradores em mais de 50 ...
- AbbVie Brasil se junta aos seus colegas ao redor do mundo para fazer a diferença na vida de pessoas menos assistidas - Mais de 6.000 funcionários AbbVie em mais de 50 países irão doar mais de 26.000 horas de serviços, para fazer a diferença para comunidades onde se localizam, d
Read more →ABBV6,000 Employees in More Than 50 Countries Join Together as #AbbVieGivesBack AbbVie, a global biopharmaceutical company, and its key partners celebrate the launch of the fourth annual Week of Possibilities, with more than...
NORTH CHICAGO, Ill. , June 26, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and its key partners celebrate the launch of the fourth annual "Week of Possibilities," with more than 6,000 employees expected to volunteer 26,000+ hours in the communities where they
Read more →ABBVAbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of...
"MAVIRET represents a new generation of HCV therapy and has the potential to be a shorter, 8-week option for patients living with this serious, chronic illness," said Michael Severino , M.D., executive vice president, research and development and chief scientific officer, AbbVie.
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Aug. 15, 2017...
NORTH CHICAGO , Ill. , June 22, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Aug. 15, 2017 to stockholders of record at the close of business on July 14, 2017 . Since
Read more →ABBVAbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced ...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , June 13, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration
Read more →ABBVAbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial...
NORTH CHICAGO, Ill. , June 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor,
Read more →ABBVLong-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease Long-term follow-up results from the pivotal Phase 3 RESONATE™ trial (PCYC-1112) showed continued survival rates in patients with relapsed/refractory ...
NORTH CHICAGO, Ill. , June 5, 2017 /PRNewswire/ -- Long-term follow-up results from the pivotal Phase 3 RESONATE™ trial (PCYC-1112) showed continued survival rates in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) treated
Read more →ABBVNew Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients IMBRUVICA (ibrutinib) reduced cells that may play an important role in the survival and proliferation of chronic lymphocytic leukemia (CLL), without...
NORTH CHICAGO, Ill. , June 5, 2017 /PRNewswire/ -- IMBRUVICA (ibrutinib) reduced cells that may play an important role in the survival and proliferation of chronic lymphocytic leukemia (CLL), without negatively impacting non-cancerous immune system cells, through one year of trea
Read more →ABBVCerca de 25 Milhões de brasileiros têm dor de barriga frequente. Para tratar, a maioria se automedica, revela pesquisa DATAFOLHA, patrocinada pela AbbVie Cerca de 25 milhões de brasileiros, com mais de 16 anos, têm dor de barriga ou diarreia frequente (várias vezes ao ano), que tentam tratar com...
SÃO PAULO, 2 de junho de 2017 /PRNewswire/ -- Cerca de 25 milhões de brasileiros, com mais de 16 anos, têm dor de barriga ou diarreia frequente (várias vezes ao ano), que tentam tratar com medicamentos caseiros (38 por cento do total), no posto de saúde mais próximo (27 por cento
Read more →ABBVAbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Tuesday, June 13, 2017. Bill Chase, executive...
NORTH CHICAGO, Ill. , May 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 38 th Annual Global Healthcare Conference on Tuesday, June 13, 2017 . Bill Chase , executive vice president and chief financial officer, will present at 10 a.m. Central t
Read more →ABBVAbbVie to Present at the Jefferies 2017 Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , May 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017 . Bill Chase , executive vice president and chief financial officer, will present at 1:30 p.m. Central time . A l
Read more →ABBVAbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data about the company's portfolio of approved and...
NORTH CHICAGO, Ill. , May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced it will present data about the company's portfolio of approved and investigational oncology medicines during the 53 rd Annual Meeting of the American Socie
Read more →ABBVAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data...
NORTH CHICAGO, Ill. , May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced that data from two replicate Phase 3 studies evaluating the efficacy and safety of elagol
Read more →ABBVIMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results from an analysis of data pooled from three Phase 3 studies...
NORTH CHICAGO, Ill. , May 14, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced results from an analysis of data pooled from three Phase 3 studies evaluating IMBRUVICA® (ibrutinib) use in patients with high-risk chronic lymphocytic leu
Read more →ABBVAbbVie to Present at the UBS Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 22, 2017. Richard A. Gonzalez, chairman of the board and...
NORTH CHICAGO, Ill. , May 5, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the UBS Global Healthcare Conference on Monday, May 22, 2017 . Richard A. Gonzalez , chairman of the board and chief executive officer, will present at 7 a.m. Central time . A live audio w
Read more →ABBVAbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week® AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data from 20 abstracts in gastroenterology and hepatology programs will ...
NORTH CHICAGO, Ill. , May 4, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that data from 20 abstracts in gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW) 2017, May 6 – 9, in Chicago . "A
Read more →ABBVAbbVie Reports First-Quarter 2017 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2017. AbbVie delivered strong first quarter results, with...
NORTH CHICAGO, Ill., April 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2017. "AbbVie delivered strong first quarter results, with double-digit EPS and operational revenue growth, exceeding our guidance for the q
Read more →ABBVAbbVie Reports First-Quarter 2017 Financial Results Reports First-Quarter Diluted EPS of $1.06 on a GAAP Basis; Adjusted Diluted EPS of $1.28, Reflecting Growth of 11.3 Percent Delivers First-Quarter Net Re
AbbVie Reports First-Quarter 2017 Financial Results NORTH CHICAGO, Ill., April 27, 2017 - AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2017. "AbbVie delivered strong first quarter results, with double-digit EPS and operational revenue gro
Read more →ABBVAbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017. William Chase, executive vice ...
NORTH CHICAGO, Ill. , April 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Deutsche Bank 42 nd Annual Health Care Conference on Wednesday, May 3, 2017 . William Chase , executive vice president and chief financial officer, will present at 7:40 a.m. Central
Read more →ABBVEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates were achieved with 8 weeks of treatment with its...
AMSTERDAM , April 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced high SVR 12 rates were achieved with 8 weeks of treatment with its investigational, once-daily, ribavirin-free, pan-genotypic regimen of glecaprevir/pibrentasvir (
Read more →ABBVAbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected...
AMSTERDAM , April 20, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A) achieved su
Read more →ABBVAbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine...
NORTH CHICAGO, Ill. , April 19, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primar
Read more →ABBVAbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids AbbVie (NYSE: ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced detailed...
NORTH CHICAGO, Ill. , April 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced detailed results from a Phase 2b clinical trial evaluating the efficacy and safety of ela
Read more →ABBVAbbVie to Host First-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2017 financial results on Thursday, April 27, 2017, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , April 6, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2017 financial results on Thursday, April 27, 2017 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.
Read more →ABBVAbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced a supplemental New Drug Application (sNDA) was accepted for review by the...
NORTH CHICAGO, Ill. , April 4, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced a supplemental New Drug Application (sNDA) was accepted for review by the U.S. Food and Drug Administration (FDA) for ibrutinib (IMBRUVICA®) in chronic gr
Read more →ABBVU.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of...
NORTH CHICAGO, Ill. , March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) presc
Read more →ABBVAbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the...
NORTH CHICAGO, Ill. and TAMPA, Fla. , March 28, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network ® (ORIEN) Avatar R
Read more →ABBVJulianne Hough Empowers Women to Get in the Know About Endometriosis AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to...
NORTH CHICAGO, Ill. , March 23, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to raise awareness about endometriosis through a campaign called "Get in the Know a
Read more →ABBVAbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health,...
NORTH CHICAGO, Ill. , March 14, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-fre
Read more →ABBVAbbVie to Present at the Barclays Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017. William Chase, executive vice...
NORTH CHICAGO, Ill. , March 1, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017 . William Chase , executive vice president and chief financial officer, will present at 8 a.m. Central time . A liv
Read more →ABBVAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
NORTH CHICAGO, Ill. , Feb. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for a shorte
Read more →ABBVAbbVie to Present at the Cowen and Company 37th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017. William Chase,...
NORTH CHICAGO, Ill. , Feb. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 . William Chase , executive vice president and chief financial officer, will present at 8:20 a.m. Cent
Read more →ABBVU.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...
NORTH CHICAGO, Ill. , Feb. 2, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for its investigational, pan-genot
Read more →ABBVAbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2016. The fourth quarter was a continuation...
NORTH CHICAGO, Ill. , Jan. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the fourth quarter and full year ended December 31, 2016 . "The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since w
Read more →ABBVAbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an...
NORTH CHICAGO, Ill. , Jan. 25, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease and pro
Read more →ABBVEuropean Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that its marketing authorization application (MAA) has been validated and is ...
NORTH CHICAGO, Ill. , Jan. 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that its marketing authorization application (MAA) has been validated and is now under accelerated assessment by the European Medicines Agency (EMA) for t
Read more →ABBVU.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib)...
NORTH CHICAGO, Ill. , Jan. 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lym
Read more →ABBVAbbVie to Host Fourth-Quarter 2016 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its Fourth-Quarter 2016 financial results on Friday, January 27, 2017. AbbVie will host a live webcast of the...
NORTH CHICAGO, Ill. , Jan. 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its Fourth-Quarter 2016 financial results on Friday, January 27, 2017 . AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern). It will be acc
Read more →ABBVAbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators...
NORTH CHICAGO, Ill. , Jan. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and im
Read more →ABBVEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates with 8 weeks of treatment with its investigational,...
NORTH CHICAGO, Ill. , Jan. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced high SVR 12 rates with 8 weeks of treatment with its investigational, pan-genotypic, ribavirin (RBV)-free regimen of glecaprevir (ABT-493)/pibrentasvir (AB
Read more →ABBVAbbVie to Present at the 35th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017. Richard A. Gonzalez, chairman...
NORTH CHICAGO, Ill. , Dec. 22, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017 . Richard A. Gonzalez , chairman and chief executive officer, will present at 10 a.m. Central time . A live
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
NORTH CHICAGO, Ill. , Dec. 19, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company's investigational, pan-genotypic regimen of gl
Read more →ABBVLate-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib...
NORTH CHICAGO, Ill. , Dec. 6, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib (IMBRUVICA ® ) in patients with chronic graft-versus-host-disease (cGVHD), a serious
Read more →ABBVAbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Northwestern University today announced they signed a five-year collaboration agreement...
NORTH CHICAGO, Ill. and CHICAGO , Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and Northwestern University today announced they signed a five-year collaboration agreement with the goal of advancing research and discovery in oncology. Toge
Read more →ABBVAbbVie and Johns Hopkins to Collaborate on Cancer Research AbbVie (NYSE: ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a...
NORTH CHICAGO, Ill. and BALTIMORE , Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a five-year collaboration agreement with the goal of advancing medical o
Read more →ABBVFavorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies...
NORTH CHICAGO, Ill. , Dec. 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies evaluating ibrutinib (IMBRUVICA®) as a combination therapy in two of the most common typ
Read more →ABBVIMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA®...
NORTH CHICAGO, Ill. , Dec. 3, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA® (ibrutinib) use in patients with chronic lymphocytic leukemia/small lymphocytic lymph
Read more →ABBVAbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease - Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of...
- Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases[1] - Risankizumab is an investigational treatment being evaluated in immunological disorders, including Crohn's disease
Read more →ABBVCâncer é a Doença Mais Temida por Mais de Dois Terços da População Brasileira Revela Pesquisa DATAFOLHA O câncer é a maior preocupação de saúde para cerca de 65% dos brasileiros – com predominância entre mulheres (68%), enquanto as doenças...
SÃO PAULO, 17 de novembro de 2016 /PRNewswire/ -- O câncer é a maior preocupação de saúde para cerca de 65% dos brasileiros – com predominância entre mulheres (68%), enquanto as doenças cardiovasculares são a preocupação de 21% dos brasileiros, principalmente entre homens (23%).
Read more →ABBVAbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients...
NORTH CHICAGO, Ill. , Nov. 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response
Read more →ABBVAbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
NORTH CHICAGO, Ill. , Nov. 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimum
Read more →ABBVEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates with 8 weeks of treatment with its investigational,...
NORTH CHICAGO, Ill. , Nov. 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced high SVR 12 rates with 8 weeks of treatment with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) across a
Read more →ABBVAbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
NORTH CHICAGO, Ill. , Nov. 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an oral poly (adenosine diphosphate [ADP]-ribose) polyme
Read more →ABBVAbbVie to Showcase Growing Oncology Portfolio and Commitment to Treating Blood Cancers at the 2016 American Society of Hematology Annual Meeting AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data from 25 abstracts evaluating an important variety of...
NORTH CHICAGO, Ill. , Nov. 3, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that data from 25 abstracts evaluating an important variety of investigational uses of the company's portfolio of blood cancer medicines will be presented
Read more →ABBVAbbVie Announces European Fixed Income Investor Meetings AbbVie (NYSE: ABBV) today announced that it has mandated Barclays, BofA Merrill Lynch, Deutsche Bank, J.P. Morgan and Morgan Stanley (Global...
NORTH CHICAGO, Ill. , Nov. 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has mandated Barclays, BofA Merrill Lynch, Deutsche Bank, J.P. Morgan and Morgan Stanley (Global Coordinator) to organize a series of European fixed income investor meetings, commencin
Read more →ABBVAbbVie to Present at the 25th Annual Credit Suisse Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 25th Annual Credit Suisse Healthcare Conference on Tuesday, November 8, 2016. Richard Gonzalez, chairman...
NORTH CHICAGO, Ill. , Oct. 31, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 25 th Annual Credit Suisse Healthcare Conference on Tuesday, November 8, 2016 . Richard Gonzalez , chairman of the board and chief executive officer, will participate in a question an
Read more →ABBVAbbVie Reports Third-Quarter 2016 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2016. We delivered another strong quarter, with EPS growth...
NORTH CHICAGO, Ill. , Oct. 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2016 . "We delivered another strong quarter, with EPS growth ahead of our expectations. Year-to-date, we've driven strong commercial, op
Read more →ABBVAbbVie Increases Quarterly Dividend by 12.3 Percent The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 12.3 percent from $0.57 per share to $0.64 per...
NORTH CHICAGO, Ill. , Oct. 28, 2016 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) increased the company's quarterly cash dividend by 12.3 percent from $0.57 per share to $0.64 per share. The cash dividend is payable February 15, 2017 to stockholders of reco
Read more →ABBVAbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced detailed...
NORTH CHICAGO, Ill. , Oct. 19, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the effica
Read more →ABBVAbbVie to Host Third-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2016 financial results on Friday, October 28, 2016, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , Oct. 10, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2016 financial results on Friday, October 28, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.
Read more →ABBVAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that new...
NORTH CHICAGO, Ill. , Oct. 6, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced that new data from two replicate Phase 3 studies evaluating the efficacy and safety of El
Read more →ABBVAbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
NORTH CHICAGO, Ill. , Sept. 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of gle
Read more →ABBVAbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline AbbVie (NYSE: ABBV), a global biopharmaceutical company, today strengthened its manufacturing capabilities by opening the small molecule active...
SINGAPORE , Sept. 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site. This facility
Read more →ABBVAbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine...
NORTH CHICAGO, Ill. , Sept. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine risankizumab (formerly BI 655066), an IL-23 inhibitor, will be presented at the 25 th
Read more →ABBVAbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX®...
NORTH CHICAGO, Ill. , Sept. 23, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) treatm
Read more →ABBVAbbVie Launches 2016 Thriving Student Scholarship Contest to Award Two Inspirational Students with Cystic Fibrosis $24,000 Each in Educational Funds AbbVie, a global biopharmaceutical company, today announced the launch of the 2016 Thriving Student Scholarship Contest designed to grant $24,000 in...
NORTH CHICAGO, Ill. , Sept. 13, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the launch of the 2016 Thriving Student Scholarship Contest designed to grant $24,000 in educational funds to two exceptional students with cystic fibrosis (CF). Earli
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share. The cash dividend is payable Nov. 15, 2016...
NORTH CHICAGO, Ill. , Sept. 9, 2016 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.57 per share. The cash dividend is payable Nov. 15, 2016 to stockholders of record at the close of business on Oct. 14, 2016 . Since
Read more →ABBVAbbVie to Present at the Morgan Stanley Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Aug. 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer
Read more →ABBVAbbVie Reports Second-Quarter 2016 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016. AbbVie continues to deliver on our long-term strategy, as ...
NORTH CHICAGO, Ill. , July 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2016 . "AbbVie continues to deliver on our long-term strategy, as demonstrated by our sixth consecutive quarter of double digit sales and ea
Read more →ABBVAbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy...
NORTH CHICAGO, Ill. , July 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients wit
Read more →ABBVAbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability...
NORTH CHICAGO, Ill. and NEW YORK , July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific anti
Read more →ABBVAbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug...
NORTH CHICAGO, Ill. , July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritona
Read more →ABBVCHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
NORTH CHICAGO, Ill. , July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the use of 12
Read more →ABBVWorld-Renowned Soccer Player Brandi Chastain Partners with AbbVie to Raise Awareness about Inflammatory Bowel Disease and Share Personal Story World-renowned soccer player Brandi Chastain today announced her partnership with AbbVie, a global biopharmaceutical company, on the new educational...
NORTH CHICAGO, Ill. , July 19, 2016 /PRNewswire/ -- World-renowned soccer player Brandi Chastain today announced her partnership with AbbVie, a global biopharmaceutical company, on the new educational program, My IBD Game Plan. The program is designed to help individuals living w
Read more →ABBVAbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric...
NORTH CHICAGO, Ill. , July 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC)
Read more →ABBVAbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company, today will present findings of a Phase 3 study of patients with moderate to severe psoriasis ...
PARIS , July 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today will present findings of a Phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with HUMIRA® (adalimumab) achieved
Read more →ABBVAbbVie to Host Second-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2016 financial results on Friday, July 29, 2016, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 1, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2016 financial results on Friday, July 29, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eas
Read more →ABBVAbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA®...
NORTH CHICAGO, Ill. , June 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuvei
Read more →ABBVAbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fourth...
NORTH CHICAGO, Ill. , June 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fourth Breakthrough Therapy Designation (BTD) for ibrutinib (IMBRUVICA ® ) as a potential treat
Read more →ABBVAbbVie Teams Up with Leading Nonprofit Organizations to Give Back to Underserved Local Communities AbbVie, a global biopharmaceutical company, and its partners today launched the third annual Week of Possibilities, a volunteer program that involves ...
NORTH CHICAGO, Ill. , June 20, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and its partners today launched the third annual Week of Possibilities, a volunteer program that involves more than 5,500 employees volunteering more than 25,000 combined hours to help
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share. The cash dividend is payable Aug. 15, 2016...
NORTH CHICAGO, Ill. , June 16, 2016 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.57 per share. The cash dividend is payable Aug. 15, 2016 to stockholders of record at the close of business on July 15, 2016 . Since
Read more →ABBVAbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology...
NORTH CHICAGO, Ill. , June 16, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology Scholarship. These scholarships provide financial support for exceptional student
Read more →ABBVNew AbbVie Global Campaign Aims to Provide Educational Resources for Millions Living with Painful, Chronic Skin Disease AbbVie, a global biopharmaceutical company, today announced the launch of What's Your Sore Spot?, a disease education campaign to connect people...
NORTH CHICAGO, Ill. , June 7, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the launch of What's Your Sore Spot? , a disease education campaign to connect people impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin di
Read more →ABBVAbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced longer-term follow-up results from Phase 3 studies of IMBRUVICA®...
NORTH CHICAGO, Ill. , June 6, 2016 /PRNewswire/ -- Today, AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced longer-term follow-up results from Phase 3 studies of IMBRUVICA® (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Fin
Read more →ABBVAbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 – an...
NORTH CHICAGO, Ill. , June 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 – an investigational antibody drug conjugate (ADC) for epidermal growth factor recepto
Read more →ABBVResults of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 ...
NORTH CHICAGO, Ill. , June 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overal
Read more →ABBVAbbVie to Highlight its Innovative Pipeline to the Investment Community At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present an overview of its...
NORTH CHICAGO, Ill. , June 3, 2016 /PRNewswire/ -- At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV ), a global biopharmaceutical company, will present an overview of its innovative pipeline that reinforces AbbVie's strategy of delivering new therapies
Read more →ABBVAbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016) AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research,...
NORTH CHICAGO, Ill. , June 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients
Read more →ABBVAbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Thursday, June 9, 2016. Bill Chase, executive...
NORTH CHICAGO, Ill. , May 31, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 37 th Annual Global Healthcare Conference on Thursday, June 9, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question an
Read more →ABBVEuropean Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission (EC) approved IMBRUVICA® (ibrutinib) as a...
The broadened indication is based on data from the Phase 3 RESONATE™-2 (PCYC-1115) trial, which also served as the basis for the March 2016 U.S. approval in the first-line CLL/SLL treatment setting and the May 2016 update to the U.S. Prescribing Information to include positive ov
Read more →ABBVBiogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis The U.S. Food and Drug Administration (FDA) approved ZINBRYTA™ (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for...
CAMBRIDGE , Mass. and NORTH CHICAGO, Ill. , May 27, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved ZINBRYTA™ (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BII
Read more →ABBVAbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1] AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the...
NORTH CHICAGO, Ill. , May 27, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA ® (adalimum
Read more →ABBVAbbVie to Present at the Jefferies 2016 Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and ...
NORTH CHICAGO, Ill. , May 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session a
Read more →ABBVIL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn's disease with...
INGELHEIM, Germany , and NORTH CHICAGO, Ill. , May 24, 2016 /PRNewswire/ -- Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn's disease with investigational biologic, risankizumab (formerly BI 655066), a co
Read more →ABBVAbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present 13 abstracts across inflammatory bowel diseases including adult and pediatric...
NORTH CHICAGO, Ill. , May 19, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, will present 13 abstracts across inflammatory bowel diseases including adult and pediatric Crohn's disease, and ulcerative colitis at the Digestive Disease Week (DDW) Annu
Read more →ABBVAbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present data from multiple clinical trials evaluating the company's portfolio of...
NORTH CHICAGO, Ill. , May 18, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, will present data from multiple clinical trials evaluating the company's portfolio of approved and investigational oncology medicines during the 52 nd Annual Meeting of th
Read more →ABBVAbbVie to Present at the UBS Global Health Care Conference AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief...
NORTH CHICAGO, Ill. , May 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at 1:00
Read more →ABBVAbbVie submete à aprovação da ANVISA, Venetoclax, o primeiro inibidor da proteína BCL-2, para tratamento de Leucemia Linfocítica Crônica A companhia biofarmacêutica global AbbVie (NYSE: ABBV) anuncia a submissão à aprovação da ANVISA - Agência Nacional de Vigilância Sanitária de seu...
SÃO PAULO, 11 de maio de 2016 /PRNewswire/ -- A companhia biofarmacêutica global AbbVie (NYSE: ABBV ) anuncia a submissão à aprovação da ANVISA - Agência Nacional de Vigilância Sanitária de seu novo composto venetoclax, para tratamento de pacientes com leucemia linfocítica crônic
Read more →ABBVU.S. FDA Expands IMBRUVICA® (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA®...
NORTH CHICAGO, Ill. , May 9, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA® (ibrutinib) Prescribing Information (PI) to include new data from two Phase 3 trials supp
Read more →ABBVAbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2016 Global Health Care Conference on Thursday, May 12, 2016. Bill Chase,...
NORTH CHICAGO, Ill. , April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Bank of America Merrill Lynch 2016 Global Health Care Conference on Thursday, May 12, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a
Read more →ABBVEuropean Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
NORTH CHICAGO, Ill. , April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IM
Read more →ABBVAbbVie Reports First-Quarter 2016 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2016. AbbVie delivered strong first-quarter results, including...
NORTH CHICAGO, Ill. , April 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2016 . "AbbVie delivered strong first-quarter results, including significant revenue and EPS growth, and margin expansion," said Richard A.
Read more →ABBVAbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab...
NORTH CHICAGO, Ill. , April 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (S
Read more →ABBVAbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental ...
NORTH CHICAGO, Ill. , April 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK® (ombitasvir, paritap
Read more →ABBVAbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates AbbVie (NYSE: ABBV) and CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that they have entered into a collaboration to co-develop and...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and CytomX Therapeutics, Inc. (Nasdaq: CTMX ) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against
Read more →ABBVAbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on...
NORTH CHICAGO, Ill. and BREDA, The Netherlands and GHENT, Belgium , April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differe
Read more →ABBVAbbVie to Present at the Deutsche Bank 41st Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , April 20, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Deutsche Bank 41 st Annual Health Care Conference on Wednesday, May 4, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and an
Read more →ABBVAbbVie, University of Chicago collaborate to advance cancer research The University of Chicago and AbbVie (NYSE: ABBV), a global biopharmaceutical company, have entered into a five-year collaboration agreement designed ...
CHICAGO and NORTH CHICAGO, Ill. , April 20, 2016 /PRNewswire/ -- The University of Chicago and AbbVie (NYSE: ABBV ), a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in
Read more →ABBVAbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that with eight weeks of treatment, 97-98 percent of genotype 1-3 (GT1-3)...
BARCELONA , April 16, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that with eight weeks of treatment, 97-98 percent of genotype 1-3 (GT1-3) chronic hepatitis C virus (HCV) infected patients without cirrhosis treated with AbbVie's
Read more →ABBVAbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus...
BARCELONA , April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) ac
Read more →ABBVAbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients...
BARCELONA, Spain , April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patien
Read more →ABBVAbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus...
BARCELONA, Spain , April 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX® (ombitasvir/par
Read more →ABBVAbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...
NORTH CHICAGO, Ill. , April 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta™ (venetoclax) tablets for patients diagnosed with chronic lymph
Read more →ABBVAbbVie to Host First-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , April 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.
Read more →ABBVAbbVie CF Scholarship Now Accepting Applications from Students with Cystic Fibrosis for 2016-2017 Academic School Year AbbVie today announced that the 2016 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher...
NORTH CHICAGO, Ill. , April 6, 2016 /PRNewswire/ -- AbbVie today announced that the 2016 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now accepting applications. Undergraduate and graduate students can
Read more →ABBVAbbVie Partners with Nutrition Expert Joy Bauer to Launch New Resource for People with Often Under-Recognized GI Condition AbbVie today announced a partnership with celebrity dietitian Joy Bauer to raise awareness about the importance of a healthy diet and lifestyle for...
NORTH CHICAGO, Ill. , April 5, 2016 /PRNewswire/ -- AbbVie today announced a partnership with celebrity dietitian Joy Bauer to raise awareness about the importance of a healthy diet and lifestyle for people with a little-known gastrointestinal (GI) condition called exocrine pancr
Read more →ABBVAbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
NORTH CHICAGO, Ill. , April 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adali
Read more →ABBVAbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International...
NORTH CHICAGO, Ill. , March 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain , April 13-17 , including real-
Read more →ABBVAbbVie to Present at Barclays Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016. Bill Chase, executive vice president...
NORTH CHICAGO, Ill. , March 8, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer sessio
Read more →ABBVAbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal...
NORTH CHICAGO, Ill. and INGELHEIM, Germany , March 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis.
Read more →ABBVAbbVie Announces New Dermatology Research from More Than 35 Presentations on HUMIRA® (Adalimumab), Long-Term and Real-World Data at the American Academy of Dermatology 2016 Annual Meeting AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that more than 35 abstracts on HUMIRA® (adalimumab) and dermatologic...
NORTH CHICAGO, Ill. , March 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that more than 35 abstracts on HUMIRA® (adalimumab) and dermatologic diseases will be presented at the upcoming 74 th Annual Meeting of the American Acade
Read more →ABBVAbbVie to Present at Cowen and Company 36th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016. Richard A. Gonzalez,...
NORTH CHICAGO, Ill. , Feb. 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen and Company 36 th Annual Health Care Conference on Wednesday, March 9, 2016 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and answ
Read more →ABBVAbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation to...
NORTH CHICAGO, Ill. , Feb. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for t
Read more →ABBVAbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in Europe AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
NORTH CHICAGO, Ill. , Feb. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use
Read more →ABBVAbbVie Launches Scholarship to Support Students Living with Rheumatologic Diseases AbbVie, a global biopharmaceutical company, announced the launch of the AbbVie Rheumatology Scholarship, designed to provide financial support for...
NORTH CHICAGO, Ill. , Feb. 11, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, announced the launch of the AbbVie Rheumatology Scholarship, designed to provide financial support for exceptional students living with a rheumatologic disease as they pursue higher ed
Read more →ABBVAbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis AbbVie (NYSE:ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line results from the second of two...
NORTH CHICAGO, Ill. , Feb. 10, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced positive top-line results from the second of two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of E
Read more →ABBVAbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results AbbVie (NYSE: ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2015. AbbVie delivered strong performance...
NORTH CHICAGO, Ill. , Jan. 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2015 . "AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projection
Read more →ABBVVenetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...
NORTH CHICAGO, Ill. , Jan. 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the investigational agent venetoclax in combination with hyp
Read more →ABBVAbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of the first of two planned...
NORTH CHICAGO, Ill. , Jan. 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or
Read more →ABBVMD Anderson, AbbVie Connect to Advance Cancer Immunotherapy The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie (NYSE: ABBV) will...
HOUSTON and NORTH CHICAGO, Ill. , Jan. 21, 2016 /PRNewswire/ -- The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie (NYSE: ABBV ) will join forces to find new ways to unleash the immune system's potential
Read more →ABBVAbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...
NORTH CHICAGO, Ill. , Jan. 20, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for venetoclax in combination with rituximab for the treatment o
Read more →ABBVU.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted AbbVie's New Drug...
NORTH CHICAGO, Ill. , Jan. 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted AbbVie's New Drug Application (NDA) granting priority review for venetoclax for the treatment of
Read more →ABBVAbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety...
NORTH CHICAGO, Ill. , Jan. 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepat
Read more →ABBVAbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the start of a large Phase 3 clinical trial program to study the use of...
NORTH CHICAGO, Ill. , Jan. 8, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the start of a large Phase 3 clinical trial program to study the use of ABT-494, an investigational, once-daily, oral selective JAK1 inhibitor for the trea
Read more →ABBVFDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
NORTH CHICAGO, Ill. , Jan. 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) and granted priority review for VIEKIRA PAK ® (o
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2015 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2015 financial results on Friday, Jan. 29, 2016, before the market opens. AbbVie...
NORTH CHICAGO, Ill. , Jan. 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter and full-year 2015 financial results on Friday, Jan. 29, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central tim
Read more →ABBVAbbVie to Present at the 34th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016. Richard A. Gonzalez, chairman...
NORTH CHICAGO, Ill. , Dec. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 34 th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016 . Richard A. Gonzalez , chairman and chief executive officer, will make a formal presentation on the company
Read more →ABBVIMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients Today AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced results from the Phase 3 RAY (MCL3001) trial, which showed IMBRUVICA®...
NORTH CHICAGO, Ill. , Dec. 7, 2015 /PRNewswire/ -- Today AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced results from the Phase 3 RAY (MCL3001) trial, which showed IMBRUVICA ® (ibrutinib) significantly prolonged progression-free survival (PFS; the primary endp
Read more →ABBVCombination Ibrutinib (IMBRUVICA®) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymphoma Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced Phase 2 data demonstrated that the combination of ibrutinib (IMBRUVICA®)...
NORTH CHICAGO, Ill. , Dec. 7, 2015 /PRNewswire/ -- Today, AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced Phase 2 data demonstrated that the combination of ibrutinib (IMBRUVICA ® ) plus rituximab was well tolerated and associated with an overall response rate
Read more →ABBVAbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound...
NORTH CHICAGO, Ill. , Dec. 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia
Read more →ABBVIbrutinib (IMBRUVICA®) Improves Survival in Treatment-Naive Chronic Lymphocytic Leukemia Patients in the Phase 3 RESONATE™-2 Trial Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which...
NORTH CHICAGO, Ill. , Dec. 6, 2015 /PRNewswire/ -- Today, AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced the results of RESONATE ™ -2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA ® ) significantly decreased the risk of progression or de
Read more →ABBVAbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of Medicine...
NORTH CHICAGO, Ill. , Dec. 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of Medicine (NEJM) showing some patients with relapsed/refractory chronic lymphocytic leukemi
Read more →ABBVIbrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting...
NORTH CHICAGO, Ill. , Dec. 6, 2015 /PRNewswire/ -- Today, AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA ® ) plus carfilzomib with or without
Read more →ABBVAbbVie Launches Crohn's & Colitis Scholarship to Support Students Living with Inflammatory Bowel Disease AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the launch of the AbbVie Crohn's & Colitis Scholarship, designed to provide...
NORTH CHICAGO, Ill. , Dec. 4, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced the launch of the AbbVie Crohn's & Colitis Scholarship, designed to provide financial support for exceptional students living with inflammatory bowel disease (IB
Read more →ABBVAbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug...
NORTH CHICAGO, Ill. , Dec. 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components
Read more →ABBVAbbVie Launches Good Morning Hypothyroidism to Help Hypothyroid Patients Manage their Life-Long Condition through Education and a Sense of Community AbbVie, is introducing Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long...
NORTH CHICAGO, Ill. , Nov. 30, 2015 /PRNewswire/ -- AbbVie, is introducing Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long condition of hypothyroidism. When and how patients take their medication can affect th
Read more →ABBVAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493,...
NORTH CHICAGO, Ill. , Nov. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high r
Read more →ABBVAbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK®...
NORTH CHICAGO, Ill. , Nov. 14, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), with or withou
Read more →ABBVAbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S....
NORTH CHICAGO, Ill. , Nov. 13, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for labeling considerations based on safety an
Read more →ABBVAbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers AbbVie (NYSE: ABBV), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology portfolio during...
NORTH CHICAGO, Ill. , Nov. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology portfolio during the 57 th American Society of Hematology Annual Meeting (ASH), December 5-8 , in
Read more →ABBVAbbVie to Present at Jefferies Autumn 2015 Global Healthcare Conference in London AbbVie (NYSE: ABBV) will participate in the Jefferies Autumn 2015 Global Healthcare Conference on Thursday, Nov. 19, 2015. Bill Chase, executive vice ...
NORTH CHICAGO, Ill. , Nov. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies Autumn 2015 Global Healthcare Conference on Thursday, Nov. 19, 2015 . Bill Chase , executive vice president and chief financial officer, will participate in a question and an
Read more →ABBVAbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall ...
NORTH CHICAGO, Ill. , Nov. 3, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall impact of rheumatologic diseases from more than 40 abstracts, including three
Read more →ABBVAbbVie to Present at Credit Suisse 24th Annual Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Credit Suisse 24th Annual Healthcare Conference on Wednesday, Nov. 11, 2015. Richard A. Gonzalez,...
NORTH CHICAGO, Ill. , Nov. 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Credit Suisse 24 th Annual Healthcare Conference on Wednesday, Nov. 11, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and answer ses
Read more →ABBVAbbVie Reports Third-Quarter 2015 Financial Results AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2015. We are pleased with our outperformance in the third...
NORTH CHICAGO, Ill. , Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the third quarter ended September 30, 2015 . "We are pleased with our outperformance in the third quarter and our progress year-to-date. We've driven strong commercial, opera
Read more →ABBVAbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance AbbVie (NYSE:ABBV) today outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial...
NORTH CHICAGO, Ill. , Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial metrics over its long-range plan, through 2020. "AbbVie is well-positioned to
Read more →ABBVIMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that IMBRUVICA® (ibrutinib) was awarded the prestigious Prix Galien 2015...
NORTH CHICAGO, Ill. , Oct. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that IMBRUVICA ® (ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent. IMBRUVICA won this distinction out of 24 ca
Read more →ABBVAbbVie apresenta primeiros resultados de estudo inédito no Brasil, que avalia a qualidade de vida dos pacientes com psoríase Estudo inédito com pacientes brasileiros com psoríase indica que 63.7 por cento dos participantes têm a qualidade de vida impactada negativamente...
SÃO PAULO, 28 de outubro de 2015 /PRNewswire/ -- Estudo inédito com pacientes brasileiros com psoríase indica que 63.7 por cento dos participantes têm a qualidade de vida impactada negativamente pela doença; destes, 63,1 por cento apresentam sintomas associados à dor e mal estar
Read more →ABBVAbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™ In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and...
NORTH CHICAGO, Ill. , Oct. 22, 2015 /PRNewswire/ -- In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and TECHNIVIE™ (ombitasvir, paritaprevir, an
Read more →ABBVAbbVie revela resultados de estudo que demonstra impacto da Artrite Reumatoide na qualidade de vida e produtividade de pacientes no Brasil e América Latina Entre os 309 pacientes avaliados em centros de reumatologia de quatro países (Brasil, Argentina, Colômbia e México), os brasileiros com artrite...
SÃO PAULO, 7 de outubro de 2015 /PRNewswire/ -- Entre os 309 pacientes avaliados em centros de reumatologia de quatro países (Brasil, Argentina , Colômbia e México), os brasileiros com artrite reumatoide são os mais afetados pela doença, no que diz respeito à qualidade de vida e
Read more →ABBVAbbVie to Host Third-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2015 financial results on Friday, Oct. 30, 2015, before the market opens. AbbVie will host a live ...
NORTH CHICAGO, Ill. , Oct. 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2015 financial results on Friday, Oct. 30, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. East
Read more →ABBVAbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that 26 abstracts on HUMIRA® (adalimumab) and hidradenitis suppurativa (HS), ...
NORTH CHICAGO, Ill. , Oct. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that 26 abstracts on HUMIRA ® (adalimumab) and hidradenitis suppurativa (HS), psoriasis and psoriatic arthritis will be presented at the European Academy o
Read more →ABBVAbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical...
NORTH CHICAGO, Ill. , Oct. 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical development program have been accepted for presentation at The Liver Meeting®, the A
Read more →ABBVAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
NORTH CHICAGO, Ill. , Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved VIEKIRAX ® (ombitasvir/paritaprevir/ritonavir), as a new interferon and ribaviri
Read more →ABBVAbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational...
NORTH CHICAGO, Ill. , Sept. 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a
Read more →ABBVAbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational...
NORTH CHICAGO, Ill. , Sept. 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either
Read more →ABBVAbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical trial...
NORTH CHICAGO, Ill. , Sept. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), today announced the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add
Read more →ABBVAbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S....
NORTH CHICAGO, Ill. , Sept. 14, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-l
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.51 per share. The cash dividend is payable Nov. 14, 2015...
NORTH CHICAGO, Ill. , Sept. 11, 2015 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.51 per share. The cash dividend is payable Nov. 14, 2015 to stockholders of record at the close of business on Oct. 15, 2015 . About
Read more →ABBVAbbVie to Present at 2015 Morgan Stanley Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 2015 Morgan Stanley Global Healthcare Conference on Friday, Sept. 18, 2015. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 2015 Morgan Stanley Global Healthcare Conference on Friday, Sept. 18, 2015 . Bill Chase , executive vice president and chief financial officer, will participate in a question and ans
Read more →ABBVAbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA®...
NORTH CHICAGO, Ill. , Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA ® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HU
Read more →ABBVCast Your Vote for the 2015 Thriving Undergraduate and Graduate Scholars to Help Grant Two $20,500 AbbVie Scholarships to Students with Cystic Fibrosis AbbVie today announced the launch of the voting contest phase of its annual AbbVie CF Scholarship program. The public is encouraged to visit...
NORTH CHICAGO, Ill. , Sept. 9, 2015 /PRNewswire/ -- AbbVie today announced the launch of the voting contest phase of its annual AbbVie CF Scholarship program. The public is encouraged to visit www.AbbVieCFScholarship.com today through September 22, 2015 to help determine who will
Read more →ABBVAbbVie Reports Second-Quarter 2015 Financial Results AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2015. We are pleased with the high level of performance we've...
NORTH CHICAGO, Ill. , July 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the second quarter ended June 30, 2015 . "We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to
Read more →ABBVTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
NORTH CHICAGO, Ill. , July 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) in combination with
Read more →ABBVIMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the first treatment...
SUNNYVALE, Calif. , July 10, 2015 /PRNewswire/ -- Today AbbVie (NYSE: ABBV ) announced the European Commission (EC) granted marketing authorization for IMBRUVICA ® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treat
Read more →ABBVAbbVie apresenta resultados de estudos para Hidradenite Supurativa, doença inflamatória crônica da pele e ainda sem tratamento disponível A AbbVie, companhia biofarmacêutica global, anuncia resultados de seus dois estudos clínicos pivotais de Fase III, PIONEER I e PIONEER II, realizados ...
SÃO PAULO, 7 de julho de 2015 /PRNewswire/ -- A AbbVie, companhia biofarmacêutica global, anuncia resultados de seus dois estudos clínicos pivotais de Fase III, PIONEER I e PIONEER II, realizados com pacientes com hidradenite supurativa, de moderada a grave, tratados por 12 seman
Read more →ABBVAbbVie to Host Second-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2015 financial results on Friday, July 24, 2015, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2015 financial results on Friday, July 24, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eas
Read more →ABBVHUMIRA (Adalimumabe) da AbbVie é aprovado no Brasil para tratamento de Espondiloartrite Axial Não Radiográfica A agência regulatória brasileira ANVISA aprovou HUMIRA® (adalimumabe) para o tratamento de adultos com espondiloartrite axial não radiográfica grave...
SÃO PAULO, 1 de julho de 2015 /PRNewswire/ -- A agência regulatória brasileira ANVISA aprovou HUMIRA® (adalimumabe) para o tratamento de adultos com espondiloartrite axial não radiográfica grave sem evidência de dano estrutural em exame de raios-X. HUMIRA é a primeira e única med
Read more →ABBVAbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario Common Drug Review grants positive recommendation for HOLKIRA PAK Ontario is the second province in Canada to reimburse HOLKIRA PAK In Phase 3...
MONTREAL , June 29, 2015 /CNW/ - AbbVie, a global biopharmaceutical company, today announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)'s positive recommendation 1 of HOLKIRA PAK for listing with provincial drug formularies. HOLKIRA PAK
Read more →ABBVAbbVie anuncia resultados de Fase 3b de estudo com pacientes crônicos com Hepatite C, Genótipo 1b, e Cirrose Hepática Compensada A AbbVie, companhia biofarmacêutica global, anunciou os resultados do estudo TURQUOISE-III, que demonstrou que 100% (n=60/60) dos pacientes adultos...
SÃO PAULO, 29 de junho de 2015 /PRNewswire/ -- A AbbVie, companhia biofarmacêutica global, anunciou os resultados do estudo TURQUOISE-III, que demonstrou que 100% (n=60/60) dos pacientes adultos com o vírus da Hepatite C (HCV) crônica, Genótipo 1b, com cirrose hepática compensada
Read more →ABBVAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
NORTH CHICAGO, Ill. , June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR 12 ) in genotype 1b (GT1b) ch
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.51 per share. The cash dividend is payable Aug. 14, 2015...
NORTH CHICAGO, Ill. , June 18, 2015 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.51 per share. The cash dividend is payable Aug. 14, 2015 to stockholders of record at the close of business on July 15, 2015 . About
Read more →ABBVAbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees globally...
NORTH CHICAGO, Ill. , June 8, 2015 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees globally volunteering more than 14,000 service hours to transform schools and communities
Read more →ABBVAbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy...
NORTH CHICAGO, Ill. , June 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy medicines at the 20 th European Hematology Association Annual Congress (EHA), June 11-
Read more →ABBVAbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Bill Chase, executive...
NORTH CHICAGO, Ill. , June 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 36 th Annual Global Healthcare Conference on Tuesday, June 9, 2015 . Bill Chase , executive vice president and chief financial officer, will participate in a question and
Read more →ABBVAbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015 AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that data from more than 30 abstracts on HUMIRA® (adalimumab), investigational...
NORTH CHICAGO, Ill. , June 4, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced that data from more than 30 abstracts on HUMIRA® (adalimumab), investigational medicines and rheumatologic diseases will be presented at the 16 th European Leagu
Read more →ABBVAbbVie to Present at Jefferies 2015 Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015. Richard A. Gonzalez, chairman and chief...
NORTH CHICAGO, Ill. , June 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and answer session at 8:30 a
Read more →ABBVAbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib...
NORTH CHICAGO, Ill. , June 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an im
Read more →ABBVAbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel...
NORTH CHICAGO, Ill. , May 31, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in par
Read more →ABBVAbbVie apresenta estudos sobre novos tratamentos em pesquisa para câncer no 51o encontro da Sociedade Americana de Oncologia Clínica (ASCO) No 51o Encontro Anual da Sociedade Americana de Oncologia Clínica (ASCO), 29 de maio a 2 de junho, Chicago, AbbVie apresenta 17 estudos sobre...
SÃO PAULO, 28 de maio de 2015 /PRNewswire/ -- No 51 o Encontro Anual da Sociedade Americana de Oncologia Clínica (ASCO), 29 de maio a 2 de junho, Chicago , AbbVie apresenta 17 estudos sobre tratamentos em pesquisa para diferentes tipos de câncer, entre os quais, resultados com Ve
Read more →ABBVAbbVie Completes Acquisition of Pharmacyclics AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing...
NORTH CHICAGO, Ill. , May 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader i
Read more →ABBVAbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis AbbVie (NYSE: ABBV) presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, ...
NORTH CHICAGO, Ill. , May 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir a
Read more →ABBVAbbVie Announces Offer Consideration for Acquisition of Pharmacyclics AbbVie (NYSE: ABBV) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding...
NORTH CHICAGO, Ill. , May 21, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics, Inc. ("Pharmacyclics") for a mix of cas
Read more →ABBVAbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. AbbVie Inc. ( AbbVie ) (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire ...
NORTH CHICAGO, Ill. , May 15, 2015 /PRNewswire/ -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m.
Read more →ABBVAbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS) AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the...
NORTH CHICAGO, Ill. , May 15, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) ( Hurl
Read more →ABBVAbbVie to Present at UBS Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Wednesday, May 20, 2015. Bill Chase, executive vice president and...
NORTH CHICAGO, Ill. , May 13, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the UBS Global Healthcare Conference on Wednesday, May 20, 2015 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at 9
Read more →ABBVAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW)...
NORTH CHICAGO, Ill. , May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW) 2015, May 16 – 19, in Washington, D.C. The abstracts feature results from studies
Read more →ABBVAbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV) announced 17 abstracts from studies of the company's oncology pipeline are being presented at the 51st Annual Meeting of the...
NORTH CHICAGO, Ill. , May 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced 17 abstracts from studies of the company's oncology pipeline are being presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 - June 2 , in Chicago . Notabl
Read more →ABBVAbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015. Richard A....
NORTH CHICAGO, Ill. , May 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and ans
Read more →ABBVInvestigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation AbbVie (NYSE: ABBV) today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being...
NORTH CHICAGO, Ill. , May 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough The
Read more →ABBVAbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis AbbVie (NYSE: ABBV) announced results from VISUAL‑I, a Phase 3 study investigating the efficacy and safety of HUMIRA® (adalimumab) in adult patients...
NORTH CHICAGO, Ill. , May 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced results from VISUAL‑I, a Phase 3 study investigating the efficacy and safety of HUMIRA® (adalimumab) in adult patients with active non-infectious intermediate, posterior, or panuveitis who still expe
Read more →ABBVAbbVie to Present at Deutsche Bank 40th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 40th Annual Health Care Conference on Wednesday, May 6, 2015. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , April 29, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Deutsche Bank 40 th Annual Health Care Conference on Wednesday, May 6, 2015 . Bill Chase , executive vice president and chief financial officer, will participate in a question and an
Read more →ABBVAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015 AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is...
VIENNA , April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tab
Read more →ABBVU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority...
NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antivir
Read more →ABBVAbbVie Reports First-Quarter 2015 Financial Results AbbVie (NYSE: ABBV) announced financial results for the first quarter ended March 31, 2015. AbbVie had an exceptional first quarter, delivering on...
NORTH CHICAGO, Ill. , April 23, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2015 . "AbbVie had an exceptional first quarter, delivering on our projection of top-tier EPS growth, as well as robust sales growth and si
Read more →ABBVAnvisa aprova VIEKIRA PAK, da AbbVie, para o tratamento de pacientes brasileiros com Hepatite C crônica, Genótipo 1 A Anvisa (Agência Nacional de Vigilância Sanitária) aprovou, em processo de análise prioritária, VIEKIRA PAK (comprimidos de...
SÃO PAULO, 23 de abril de 2015 /PRNewswire/ -- A Anvisa (Agência Nacional de Vigilância Sanitária) aprovou, em processo de análise prioritária, VIEKIRA PAK (comprimidos de ombitasvir/veruprevir/ritonavir e de dasabuvir), novo tratamento da AbbVie, de curta duração, totalmente ora
Read more →ABBVAbbVie to Host First-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2015 financial results on Thursday, April 23, 2015, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , April 15, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2015 financial results on Thursday, April 23, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m.
Read more →ABBVAbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan AbbVie (NYSE: ABBV) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for its...
NORTH CHICAGO, Ill. , April 15, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavi
Read more →ABBVAbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015 AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation...
NORTH CHICAGO, Ill. , April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation during The International Liver Congress TM (ILC) 2015 in Vienna, Austria from A
Read more →ABBVAbbVie CF Scholarship Application for Students with Cystic Fibrosis Now Available for 2015-2016 Academic School Year AbbVie today announced that the 2015 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher...
NORTH CHICAGO, Ill. , April 1, 2015 /PRNewswire/ -- AbbVie today announced that the 2015 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now open to undergraduate and graduate students. Students can apply
Read more →ABBVAbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein...
NORTH CHICAGO, Ill. , March 19, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that it has entered into an exclusive worldwide license agreement with C 2 N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize
Read more →ABBVAbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting AbbVie (NYSE: ABBV) announced that data from 22 abstracts on HUMIRA® (adalimumab) and dermatological diseases will be presented at the upcoming 73rd...
NORTH CHICAGO, Ill. , March 17, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that data from 22 abstracts on HUMIRA® (adalimumab) and dermatological diseases will be presented at the upcoming 73rd Annual Meeting of the American Academy of Dermatology (AAD), March 20 – 24, i
Read more →ABBVAbbVie inicia, no Brasil, estudos clínicos com novo tratamento para hepatite C, totalmente oral e livre de Interferon Os pacientes elegíveis para o estudo Topázio III serão os primeiros brasileiros a ter acesso ao tratamento de curta duração da AbbVie (Viekira Pak),...
SÃO PAULO, 17 de março de 2015 /PRNewswire/ -- Os pacientes elegíveis para o estudo Topázio III serão os primeiros brasileiros a ter acesso ao tratamento de curta duração da AbbVie (Viekira Pak), para pacientes adultos com infecção crônica pelo vírus da hepatite C, Genótipo1. Es
Read more →ABBVAbbVie to Present at Barclays Global Health Care Conference AbbVie (NYSE: ABBV) will participate in the Barclays Global Health Care Conference on Thursday, March 12, 2015. Richard A. Gonzalez, chairman and...
NORTH CHICAGO, Ill. , March 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Barclays Global Health Care Conference on Thursday, March 12, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will participate in a question and answer session at 8
Read more →ABBVAbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise AbbVie (NYSE:ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its...
NORTH CHICAGO, Ill. and SUNNYVALE, Calif. , March 4, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Pharmacyclics (NASDAQ: PCYC ) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® (ibrutinib), a highly effective
Read more →ABBVAbbVie Launches SigueElGuion.com to Educate Spanish-Speaking Americans about Hypothyroidism and the Importance of Dialogue between Patient and Healthcare Professional To further awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of Americans, AbbVie...
NORTH CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ -- To further awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of Americans, AbbVie (NYSE: ABBV ) launched the Spanish-language website SigueElGuion.com . The websi
Read more →ABBVAbbVie lanza SigueElGuion.com para instruir a los estadounidenses de habla hispana acerca del hipotiroidismo y la importancia del diálogo entre el paciente y el profesional de la salud Para aumentar la concientización sobre la importancia de diagnosticar y tratar el hipotiroidismo, una afección de la tiroides que afecta a millones...
NORTH CHICAGO, Illinois , 26 de febrero de 2015 /PRNewswire-HISPANIC PR WIRE/ -- Para aumentar la concientización sobre la importancia de diagnosticar y tratar el hipotiroidismo, una afección de la tiroides que afecta a millones de estadounidenses, AbbVie (NYSE: ABBV ) lanzó el s
Read more →ABBVAbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting AbbVie (NYSE: ABBV) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for...
NORTH CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for presentation during the 67 th American Academy of Neurology annual meeting in Washing
Read more →ABBVAbbVie to Present at Cowen 35th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen 35th Annual Health Care Conference on Wednesday, March 4, 2015. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Feb. 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen 35 th Annual Health Care Conference on Wednesday, March 4, 2015 . Bill Chase , executive vice president and chief financial officer, will make a presentation on the company and
Read more →ABBVResults from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) AbbVie (NYSE: ABBV) today announced that results from part one of the Phase 2 portion of its Phase2/3 open-label study, TURQUOISE-I, in genotype 1...
NORTH CHICAGO, Ill. , Feb. 23, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that results from part one of the Phase 2 portion of its Phase2/3 open-label study, TURQUOISE-I, in genotype 1 chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co
Read more →ABBVAbbVie Increases Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 4 percent from $0.49 per share to $0.51 per...
NORTH CHICAGO, Ill. , Feb. 19, 2015 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) increased the company's quarterly cash dividend by 4 percent from $0.49 per share to $0.51 per share. The cash dividend is payable May 15, 2015 to stockholders of record at th
Read more →ABBVAbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the...
NORTH CHICAGO, Ill. , Feb. 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 1
Read more →ABBVAbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014. AbbVie delivered exceptional...
NORTH CHICAGO, Ill. , Jan. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014 . "AbbVie delivered exceptional performance in 2014 with sales and earnings well above our original projections for
Read more →ABBVAbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan AbbVie (NYSE: ABBV) released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment...
- 95 percent SVR 12 rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and with a high viral load - Regulatory filing in Japan planned for the first quarter of 2015 NORTH CHICAGO, Ill. , Jan. 30, 2015 /PRNews
Read more →ABBVAbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment...
NORTH CHICAGO, Ill. , Jan. 16, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV ) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is ad
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2014 financial results on Friday, Jan. 30, 2015, before the market opens. AbbVie...
NORTH CHICAGO, Ill. , Jan. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter and full-year 2014 financial results on Friday, Jan. 30, 2015 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central ti
Read more →ABBVEuropean Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C AbbVie (NYSE: ABBV) announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free...
NORTH CHICAGO, Ill. , Jan. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX ® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA ® (da
Read more →ABBVAbbVie Issues Strong Outlook for 2015 AbbVie (NYSE: ABBV) today issued earnings-per-share guidance for the full-year 2015. AbbVie expects diluted earnings per share of $4.25 to $4.45 on...
NORTH CHICAGO, Ill. , Jan. 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today issued earnings-per-share guidance for the full-year 2015. AbbVie expects diluted earnings per share of $4.25 to $4.45 on an adjusted basis, and $3.99 to $4.19 under Generally Accepted Accounting Princ
Read more →ABBVAbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line results from the first of two...
NORTH CHICAGO, Ill. , Jan. 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV ), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), announced positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of el
Read more →ABBVAbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Dec. 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation on the
Read more →ABBVAbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, Jan. 6, 2015. Richard A. Gonzalez,...
NORTH CHICAGO, Ill. , Dec. 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, Jan. 6, 2015 . Richard A. Gonzalez , chairman and chief executive officer, will take part in a question and answer sess
Read more →ABBVAbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without...
NORTH CHICAGO, Ill. , Dec. 19, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV ) VIEKIRA PAK ™ , an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1)
Read more →ABBVAbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting AbbVie (NYSE: ABBV) presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2...
NORTH CHICAGO, Ill. , Dec. 7, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) presented during an oral presentation at the American Society of Hematology's 56 th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with a
Read more →ABBVCHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's...
"The CHMP positive opinions mark an important milestone in our HCV development program and recognize the potential our treatment brings to people in Europe living with this chronic condition," said Michael Severino , M.D., executive vice president, research and development and ch
Read more →ABBVAbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting AbbVie (NYSE: ABBV) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American...
NORTH CHICAGO, Ill. , Nov. 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting (ASH), December 6-9 , in San Francisco . D
Read more →ABBVAbbVie to Present at Jefferies 2014 Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive...
NORTH CHICAGO, Ill. , Nov. 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation o
Read more →ABBVAbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive ...
NORTH CHICAGO, Ill. , Nov. 14, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and
Read more →ABBVAbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will...
NORTH CHICAGO, Ill. , Nov. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that data from 37 abstracts related to HUMIRA ® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annu
Read more →ABBVAbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1)...
BOSTON , Nov. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014. New,
Read more →ABBVAbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4)...
BOSTON , Nov. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylat
Read more →ABBVAbbVie to Present at Credit Suisse 2014 Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2014 Healthcare Conference on Thursday, Nov. 13, 2014. Bill Chase, executive vice president ...
NORTH CHICAGO, Ill. , Nov. 5, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Credit Suisse 2014 Healthcare Conference on Thursday, Nov. 13, 2014 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation on the company
Read more →ABBVAbbVie Reports Third-Quarter 2014 Financial Results AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014. Our third-quarter results reflect the strong...
NORTH CHICAGO, Ill. , Oct. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the third quarter ended Sept. 30, 2014 . "Our third-quarter results reflect the strong performance of our business with double-digit growth from HUMIRA and several othe
Read more →ABBVAbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than...
NORTH CHICAGO, Ill. , Oct. 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that Science / Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than 5,000 respondents in the biotechnology, pharmaceutical and biopharmaceutical in
Read more →ABBVAnnouncement Of Termination Of Proposed AbbVie And Shire Transaction AbbVie Inc. ( AbbVie ) and Shire plc ( Shire ) have agreed to terminate their proposed merger following the decision by AbbVie's Board to withdraw...
The Company conducted a thorough review of the September 22, 2014 notice to explore available options to preserve the transaction. This review included the advice of external tax, legal, and financial advisors in both the U.S. and the U.K. The executive management team ultimately
Read more →ABBVAbbVie Announces New $5 Billion Stock Repurchase Program and Increases Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized a new $5 billion stock repurchase program and increased the company's quarterly...
NORTH CHICAGO, Ill. , Oct. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) today authorized a new $5 billion stock repurchase program and increased the company's quarterly cash dividend by nearly 17 percent. The authorization allows for the repurchas
Read more →ABBVAnnouncement Of Notice To Shire Of AbbVie Board Intention To Reconsider Recommendation AbbVie Inc. ( AbbVie ) announces it has notified Shire plc ( Shire ) of its Board of Directors' intention to reconsider the recommendation made on...
NORTH CHICAGO, Ill. , Oct. 14, 2014 /PRNewswire/ -- AbbVie Inc. ("AbbVie") announces it has notified Shire plc ("Shire") of its Board of Directors' intention to reconsider the recommendation made on July 18, 2014 that AbbVie stockholders adopt the merger agreement needed to compl
Read more →ABBVAbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing...
AMSTERDAM , Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), spec
Read more →ABBVAbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and Older AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the HUMIRA indication for...
NORTH CHICAGO, Ill. , Oct. 6, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to redu
Read more →ABBVAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
NORTH CHICAGO, Ill. , Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of
Read more →ABBVAbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with...
NORTH CHICAGO, Ill. , Sept. 27, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free su
Read more →ABBVAbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and...
NORTH CHICAGO, Ill. , Sept. 25, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA ® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's di
Read more →ABBVAbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be...
NORTH CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Ann
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share. The cash dividend is payable Nov. 17, 2014...
NORTH CHICAGO, Ill. , Sept. 19, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.42 per share. The cash dividend is payable Nov. 17, 2014 to stockholders of record at the close of business on Oct. 15, 2014 . About
Read more →ABBVAbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common...
COPENHAGEN, Denmark , Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA ® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS),
Read more →ABBVAbbVie to Present at Morgan Stanley Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Sept. 5, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation on the co
Read more →ABBVInfinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to...
CAMBRIDGE, Mass. and NORTH CHICAGO, Ill. , Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) and AbbVie Inc. (NYSE: ABBV ) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's or
Read more →ABBVRevised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance Following the announcement of the collaboration agreements with Calico Life Sciences LLC (Calico) and Infinity Pharmaceuticals Inc (Infinity), AbbVie ...
NORTH CHICAGO, Ill. , Sept. 3, 2014 /PRNewswire/ -- Following the announcement of the collaboration agreements with Calico Life Sciences LLC (Calico) and Infinity Pharmaceuticals Inc (Infinity), AbbVie is amending its earnings guidance on a GAAP basis for the year ending December
Read more →ABBVAbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new...
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, i
Read more →ABBVAbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate...
NORTH CHICAGO, Ill. , Aug. 18, 2014 /PRNewswire/ -- AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholars
Read more →ABBVAbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug...
NORTH CHICAGO, Ill. , Aug. 4, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth
Read more →ABBVAbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program AbbVie (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional habits in the...
NORTH CHICAGO , Ill. and PALO ALTO, Calif. , Aug. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional habits in the cystic fibrosis (CF) community through the CF Chef Shares
Read more →ABBVAbbVie Reports Second-Quarter 2014 Financial Results NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
NORTH CHICAGO, Ill. , July 25, 2014 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Read more →ABBVAbbVie to Host Second-Quarter Earnings Conference Call NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
NORTH CHICAGO, Ill. , July 23, 2014 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Read more →ABBVAbbVie Announces Inaugural Week of Possibilities Volunteer Program to Support Six Schools in North Chicago, Ill., and Worcester, Mass. AbbVie today announced its first Week of Possibilities, an employee volunteer program to support educational improvement projects in local...
NORTH CHICAGO, Ill. , July 16, 2014 /PRNewswire/ -- AbbVie today announced its first Week of Possibilities, an employee volunteer program to support educational improvement projects in local communities where AbbVie is based. As part of the inaugural program, more than 1,300 AbbV
Read more →ABBVAbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound,...
NORTH CHICAGO, Ill. , June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherap
Read more →ABBVNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION On June 25, 2014, AbbVie issued the following supplementary information about the company: AbbVie Facts at a Glance AbbVie Supplementary Information...
NORTH CHICAGO, Ill. , June 25, 2014 /PRNewswire/ -- On June 25, 2014 , AbbVie issued the following supplementary information about the company: A copy of these materials will be available on AbbVie's website at: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-discla
Read more →ABBVNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV) today raised the midpoint of its full-year 2014 earnings-per-share guidance by six cents and now expects a full-year diluted...
NORTH CHICAGO, Ill. , June 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today raised the midpoint of its full-year 2014 earnings-per-share guidance by six cents and now expects a full-year diluted earnings-per-share range of $3.06 to $3.16 on an adjusted basis, or $2.69 to $2.79
Read more →ABBVNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie Inc. ( AbbVie ) notes the recent press speculation and confirms it made an indicative approach to Shire plc ( Shire ) with a merger proposal...
LONDON , June 19, 2014 /PRNewswire/ -- AbbVie Inc. ("AbbVie") notes the recent press speculation and confirms it made an indicative approach to Shire plc ("Shire") with a merger proposal which was rejected by the Board of Shire. There can be no certainty that any firm offer will
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share. The cash dividend is payable Aug. 15, 2014...
NORTH CHICAGO, Ill. , June 19, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.42 per share. The cash dividend is payable Aug. 15, 2014 to stockholders of record at the close of business on July 15, 2014 . AbbVie
Read more →ABBVEuropean Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen...
NORTH CHICAGO, Ill. , June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C v
Read more →ABBVU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment...
NORTH CHICAGO, Ill. , June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infect
Read more →ABBVAbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory...
PARIS , June 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF
Read more →ABBVAbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive ...
NORTH CHICAGO, Ill. , June 10, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Goldman Sachs 35 th Annual Global Healthcare Conference on Wednesday, June 11, 2014 . Bill Chase , executive vice president and chief financial officer, will take part in a question a
Read more →ABBVAbbVie to Present at Jefferies 2014 Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, ...
NORTH CHICAGO, Ill. , June 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 . Scott Brun , M.D., vice president, pharmaceutical development, will take part in a question and answer session
Read more →ABBVAbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2)...
NORTH CHICAGO, Ill. , May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an
Read more →ABBVAbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR)...
NORTH CHICAGO, Ill. , May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four
Read more →ABBVAbbVie to Present at 2014 UBS Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president...
NORTH CHICAGO, Ill. , May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014 . Bill Chase , executive vice president and chief financial officer, will take part in a question and answer session at
Read more →ABBVAbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the...
NORTH CHICAGO, Ill. , May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA ® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chron
Read more →ABBVAbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer....
NORTH CHICAGO, Ill. , May 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) has named Michael Severino , M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns wi
Read more →ABBVAbbVie to Present at Bank of America Merrill Lynch 2014 Health Care Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase,...
NORTH CHICAGO, Ill. , May 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 . Bill Chase , executive vice president and chief financial officer, will take part in a question an
Read more →ABBVAbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C AbbVie (NYSE: ABBV) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's...
NORTH CHICAGO, Ill. , May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult pat
Read more →ABBVAbbVie Reports First-Quarter 2014 Financial Results AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2014. AbbVie delivered strong first-quarter results, with sales ...
NORTH CHICAGO, Ill. , April 25, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced financial results for the first quarter ended March 31, 2014 . "AbbVie delivered strong first-quarter results, with sales and earnings per share above our original guidance, significant margin ex
Read more →ABBVAbbVie to Present Data on Investigational Compounds at the 2014 American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented...
NORTH CHICAGO, Ill. , April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50 th Annual Meeting of the American Society of Clinical Oncol
Read more →ABBVAbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's...
NORTH CHICAGO, Ill. , April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patie
Read more →ABBVApplication Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship,...
NORTH CHICAGO, Ill. , April 16, 2014 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can
Read more →ABBVAbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, ...
NORTH CHICAGO, Ill. , April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced
Read more →ABBVAbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver...
LONDON , April 12, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress TM (ILC) 2014. Data from a pivotal phase III study, TURQUOISE-II, featured in the
Read more →ABBVAbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™ AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver...
LONDON , April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress ™ (ILC) 2014 and featured in the ILC press conference. Results from the pivotal p
Read more →ABBVAbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress™ AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in...
NORTH CHICAGO, Ill. , March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London , April 9-13 . Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III
Read more →ABBVAbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a...
NORTH CHICAGO, Ill. , March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA ® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic pla
Read more →ABBVLargest Global Survey Of People With Rheumatoid Arthritis Reveals Need For Increased Education RA: Join the Fight today is convening a panel of rheumatology experts at the Pan-American League of Associations for Rheumatology (PANLAR) Congress...
PUNTA DEL ESTE, Uruguay , March 18, 2014 /PRNewswire/ -- RA: Join the Fight today is convening a panel of rheumatology experts at the Pan-American League of Associations for Rheumatology (PANLAR) Congress to unveil findings from a global survey of more than 10,000 people with rhe
Read more →ABBVAbbVie Supports Educational Initiatives in Latin America to Impact Standards of Care and Research for Rheumatic Diseases AbbVie today announced its support for two educational initiatives aiming to impact standards of care and research for rheumatic diseases at the...
PUNTA DEL ESTE, Uruguay , March 12, 2014 /PRNewswire/ -- AbbVie today announced its support for two educational initiatives aiming to impact standards of care and research for rheumatic diseases at the XVIII Pan-American League of Associations for Rheumatology (PANLAR) Congress.
Read more →ABBVAbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on...
BOSTON , March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV ) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as
Read more →ABBVAbbVie to Present at Barclays Global Healthcare Conference 2014 AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Wednesday, March 12, 2014. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Feb. 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Barclays Global Healthcare Conference 2014 on Wednesday, March 12, 2014 . Bill Chase , executive vice president and chief financial officer, will take part in a question and answer se
Read more →ABBVAbbVie Increases Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 5 percent from $0.40 per share to $0.42 per...
NORTH CHICAGO, Ill. , Feb. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) increased the company's quarterly cash dividend by 5 percent from $0.40 per share to $0.42 per share. The cash dividend is payable May 15, 2014 to stockholders of record at th
Read more →ABBVAbbVie Announces New Art Gallery Designed To Provide Perspectives On The Impact Of Chronic Inflammatory Diseases AbbVie today announced the launch of 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current...
NORTH CHICAGO, Ill. , Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of ' Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact
Read more →ABBVAbbVie to Present at Cowen 34th Annual Health Care Conference AbbVie (NYSE: ABBV) will participate in the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive...
NORTH CHICAGO, Ill. , Feb. 19, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Cowen and Company 34 th Annual Health Care Conference on Wednesday, March 5, 2014 . Bill Chase , executive vice president and chief financial officer, will take part in a question and
Read more →ABBVAbbVie Expands Manufacturing Presence with US$320 Million Investment in Singapore AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule...
NORTH CHICAGO, Ill. , Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV ) announces a US$320 million [approximately S$400 million ] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will
Read more →ABBVAbbVie Reports Fourth-Quarter and Full-Year 2013 Financial Results AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013. We are pleased with AbbVie's...
NORTH CHICAGO, Ill. , Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013 . "We are pleased with AbbVie's performance in our first full year as an independent biopharmaceutical company," sa
Read more →ABBVAbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess...
NORTH CHICAGO, Ill. , Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy with and without ribav
Read more →ABBVAbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound,...
NORTH CHICAGO, Ill. , Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with ear
Read more →ABBVAbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens. AbbVie...
NORTH CHICAGO, Ill. , Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central ti
Read more →ABBVAbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 32 nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014 . Bill Chase , executive vice president and chief financial officer, will make a formal presentation on the
Read more →ABBVAbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in...
NORTH CHICAGO, Ill. , Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 6
Read more →ABBVAbbVie to Present at Credit Suisse 2013 Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013. Bill Chase, executive vice president ...
NORTH CHICAGO, Ill , Nov. 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013 . Bill Chase , executive vice president and chief financial officer, and Scott Brun , M.D., vice president, pharmaceu
Read more →ABBVNew Survey Reveals More than Half of Americans are Living with Gastrointestinal Symptoms and Not Seeking Care from a Doctor According to a new, national survey of more than 2,000 U.S. adults, 72 percent said they have experienced at least one of the following...
NORTH CHICAGO, Ill. , Nov. 6, 2013 /PRNewswire/ -- According to a new, national survey of more than 2,000 U.S. adults, 72 percent said they have experienced at least one of the following gastrointestinal (GI) symptoms a few times a month or more: diarrhea, gas, bloating, stomach
Read more →ABBVCanadian Psoriasis Network launches on World Psoriasis Day National organization will advocate for the one million Canadians who live with psoriasis ST. JOHN'S, Oct. 28, 2013 /CNW/ - The Canadian Psoriasis...
National organization will advocate for the one million Canadians who live with psoriasis ST. JOHN'S , Oct. 28, 2013 /CNW/ - The Canadian Psoriasis Network (CPN), a Canadian-based patient network for those living with psoriasis and psoriatic arthritis will launch on World Psoria
Read more →ABBVAbbVie Reports Third-Quarter 2013 Financial Results Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60 Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP...
NORTH CHICAGO, Ill. , Oct. 25, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the third quarter ended Sept. 30, 2013 . "Our third-quarter performance demonstrates the strength and durability of our product portfolio and the continued execution o
Read more →ABBVAbbVie Named a Science Top Employer The journal Science named AbbVie as one of its 2013 Top Employers. AbbVie ranked fourth in its first year on the annual list, as surveyed by more...
NORTH CHICAGO, Ill. , Oct. 24, 2013 /PRNewswire/ -- The journal Science named AbbVie as one of its 2013 Top Employers. AbbVie ranked fourth in its first year on the annual list, as surveyed by more than 3,000 respondents. "We are honored to be regarded highly among our peers in
Read more →ABBVAbbVie to Host Third-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its third-quarter 2013 financial results on Friday, Oct. 25, 2013, before the market opens. AbbVie will host a live ...
NORTH CHICAGO, Ill. , Oct. 4, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its third-quarter 2013 financial results on Friday, Oct. 25, 2013 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. East
Read more →ABBVAbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in...
NORTH CHICAGO, Ill. , Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA ® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS)
Read more →ABBVAbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and...
NORTH CHICAGO, Ill. and MECHELEN, Belgium , Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cy
Read more →ABBVAbbVie Declares Quarterly Dividend The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.40 per share. The cash dividend is payable Nov. 15, 2013...
NORTH CHICAGO, Ill. , Sept. 19, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ) declared a quarterly cash dividend of $0.40 per share. The cash dividend is payable Nov. 15, 2013 to stockholders of record at the close of business on Oct. 15, 2013 . AbbVi
Read more →ABBVNew Treatment Option Available for Canadian Children Living with Severely Active Pediatric Crohn's Disease AbbVie's HUMIRA® is the First Subcutaneous Biologic Approved in Canada for the Treatment of Pediatric Crohn's MONTREAL, Aug. 27, 2013 /CNW/ - AbbVie...
AbbVie's HUMIRA ® is the First Subcutaneous Biologic Approved in Canada for the Treatment of Pediatric Crohn's MONTREAL , Aug. 27, 2013 /CNW/ - AbbVie announced today that Health Canada has approved HUMIRA ® (adalimumab) for reducing signs and symptoms and inducing and maintaini
Read more →ABBVVote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education AbbVie has selected 40 exceptional undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 AbbVie CF...
NORTH CHICAGO, Ill. , Aug. 19, 2013 /PRNewswire/ -- AbbVie has selected 40 exceptional undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 AbbVie CF Scholarship for the 2013-2014 school year based on their academic excellence, extracurric
Read more →ABBVAbbVie to Host Second-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its second-quarter 2013 financial results on Friday, July 26, 2013, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , July 8, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its second-quarter 2013 financial results on Friday, July 26, 2013 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eas
Read more →ABBVStacy London Launches Uncover Your Confidence™ Campaign to Empower People Living with Psoriasis Stacy London, style expert and co-host of TLC's What Not to Wear, today announced her partnership with AbbVie (NYSE: ABBV) on a new psoriasis...
NORTH CHICAGO, Ill. , July 8, 2013 /PRNewswire/ -- Stacy London, style expert and co-host of TLC's "What Not to Wear," today announced her partnership with AbbVie (NYSE: ABBV ) on a new psoriasis campaign called Uncover Your Confidence. The campaign features educational resources
Read more →ABBVAbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2)...
NORTH CHICAGO, Ill. , June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocy
Read more →ABBVLargest Global Survey of Rheumatoid Arthritis Patients Shows Opportunity for Increased Collaboration Between Doctors And Patients And Further Education About Disease Progression RA: Join the Fight today presented at a launch event in Madrid the findings from the largest global rheumatoid arthritis (RA) patient survey, which...
MADRID , June 11, 2013 /PRNewswire/ -- RA: Join the Fight today presented at a launch event in Madrid the findings from the largest global rheumatoid arthritis (RA) patient survey, which included 10,171 patients across 42 countries. Findings show that while a majority of RA patie
Read more →ABBVAbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 34th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013. Bill Chase, executive...
NORTH CHICAGO, Ill. , June 5, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 34 th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13 , 2013. Bill Chase , executive vice president and chief financial officer, and Scott Brun , M.D., vice pres
Read more →ABBVAbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for...
NORTH CHICAGO, Ill. , June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (
Read more →ABBVAbbVie Announces Market Availability of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON® (pancrelipase) Delayed-Release Capsules is commercially available in...
NORTH CHICAGO, Ill. , May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that a new, higher-dose capsule of CREON ® (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration (FDA) recently approved
Read more →ABBVAbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment...
NORTH CHICAGO, Ill. , May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Br
Read more →ABBVAbbVie to Participate in 2013 Jeffries Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the 2013 Jeffries Global Healthcare Conference on Tuesday, June 4, 2013. Bill Chase, executive vice president ...
NORTH CHICAGO, Ill. , May 28, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the 2013 Jeffries Global Healthcare Conference on Tuesday, June 4 , 2013. Bill Chase , executive vice president and chief financial officer, and Scott Brun , M.D., vice president, pharmace
Read more →ABBVAbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess ...
NORTH CHICAGO, Ill. , May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today the initiation of a Phase 3 clinical study called SONAR ( S tudy O f Diabetic N ephropathy with A t r asentan) to assess the effects of the investigational compound atrasentan - when added to
Read more →ABBVAbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include...
NORTH CHICAGO, Ill. and MECHELEN, Belgium , May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2
Read more →ABBVAbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at...
NORTH CHICAGO, Ill. , May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Ma
Read more →ABBVAbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease AbbVie (NYSE: ABBV) and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a...
NORTH CHICAGO, Ill. and SAN CARLOS, Calif. , May 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a global collaboration to develop a novel oral treatment for
Read more →ABBVAbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013. Bill Chase, executive ...
NORTH CHICAGO, Ill. , May 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will participate in the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14 , 2013. Bill Chase , executive vice president and chief financial officer, and John M. Leonard , M.D., senio
Read more →ABBVAbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the...
NORTH CHICAGO, Ill. , May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year. Previously known as the CFCareForward Scholarshi
Read more →ABBVAbbVie Reports First-Quarter 2013 Financial Results AbbVie (NYSE: ABBV) today announced financial results for the first quarter ended March 31, 2013. In our first quarter as an independent company,...
NORTH CHICAGO, Ill. , April 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced financial results for the first quarter ended March 31, 2013 . "In our first quarter as an independent company, AbbVie delivered earnings per share above our original guidance," said Richar
Read more →ABBVNew Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 (NYSE: ABBV) – Results from Aviator, AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of...
AMSTERDAM , April 23, 2013 /PRNewswire/ -- (NYSE: ABBV ) – Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral respons
Read more →ABBVSofia Vergara Encourages Individuals with Hypothyroidism to Follow the Script (NYSE: ABBV) – Emmy-nominated actress Sofia Vergara is helping to raise awareness about the importance of diagnosing and treating hypothyroidism, a...
NORTH CHICAGO, Ill. , April 17, 2013 /PRNewswire/ -- (NYSE: ABBV ) – Emmy-nominated actress Sofia Vergara is helping to raise awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of Americans, through a new campaign c
Read more →ABBVSofía Vergara alienta a las personas con hipotiroidismo a Seguir el guión (NYSE: ABBV) – La actriz Sofía Vergara, nominada al Emmy, está ayudando a generar conciencia sobre la importancia del diagnóstico y el tratamiento...
NORTH CHICAGO, Illinois , 17 de abril de 2013 /PRNewswire-HISPANIC PR WIRE/ -- (NYSE: ABBV ) – La actriz Sofía Vergara, nominada al Emmy, está ayudando a generar conciencia sobre la importancia del diagnóstico y el tratamiento del hipotiroidismo, una afección de la glándula tiroi
Read more →ABBVAbbVie to Host First-Quarter Earnings Conference Call AbbVie (NYSE: ABBV) will announce its first-quarter 2013 financial results on Friday, April 26, 2013, before the market opens. AbbVie will host a...
NORTH CHICAGO, Ill. , April 8, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will announce its first-quarter 2013 financial results on Friday, April 26, 2013 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Ea
Read more →ABBVAbbVie to Present at Barclays Global Health Care Conference AbbVie (NYSE: ABBV) will present at the Barclays Global Health Care Conference on Wednesday, March 13, 2013. Bill Chase, executive vice president and ...
NORTH CHICAGO, Ill. , Feb. 27, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present at the Barclays Global Health Care Conference on Wednesday, March 13 , 2013. Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session
Read more →ABBVAbbVie to Present at Cowen and Company 33rd Annual Health Care Conference AbbVie (NYSE: ABBV) will present at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013. Bill Chase, executive vice...
NORTH CHICAGO, Ill. , Feb. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) will present at the Cowen and Company 33 rd Annual Health Care Conference on Wednesday, March 6 , 2013. Bill Chase , executive vice president and chief financial officer, will make a formal presentation on t
Read more →ABBVAbbVie Issues Inaugural Full-Year Outlook for 2013 AbbVie today confirmed it delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of...
NORTH CHICAGO, Ill. , Jan. 30, 2013 /PRNewswire/ -- AbbVie today confirmed it delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent
Read more →ABBVAbbVie Named to S&P 500 Dividend Aristocrat Index AbbVie (NYSE: ABBV), a global biopharmaceutical company, has been named to the S&P 500 Dividend Aristocrat Index for 2013. The Dividend Aristocrat...
NORTH CHICAGO, Ill. , Jan. 21, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a global biopharmaceutical company, has been named to the S&P 500 Dividend Aristocrat Index for 2013. The Dividend Aristocrat Index measures the performance of dividend-paying companies within the S&P 500
Read more →ABBVAbbVie Declares Inaugural Dividend The board of directors of AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, today declared the Company's first quarterly cash dividend of ...
NORTH CHICAGO, Ill. , Jan. 4, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV ), a global biopharmaceutical company, today declared the Company's first quarterly cash dividend of $0.40 per share. The cash dividend is payable Feb. 15, 2013 to stockholders o
Read more →ABBVAbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients...
NEW YORK , Jan. 2, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchan
Read more →Competitive Position
How ABBV ranks across every disease it competes inCompetitive Position is a premium feature
See how ABBV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial